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Abstract 
This thesis examines the utility of temporal studies of cancer in practice, particularly from the 
perspective of analyses of the three underlying time components, age, period of event and 
birth cohort. This enquiry encompasses a review of temporal studies and routine data 
sources, as well as a more critical appraisal of the strategies available for APe analysis and 
presentation. Specific methods are then applied to trends in cancer incidence and mortality 
in Europe. 
The central aims of the thesis are: 
1) to comprehensively review the graphical and analytical approaches available, 
particularly in relation to APe modelling and their usage in current practice; 
2) on the basis of 1), to provide broad but sensible guidelines for the analyses of time 
trends; 
3) on the basis of 2), to practically demonstrate the utility of time trends and the APe 
model; 
4) to consider the benefits and limitations of systematic approaches applied to time 
trend studies. 
The recommended strategies are used as guiding principles for a detailed analysis of trends 
in incidence and mortality rates of three cancers (cervix, endometrium and testis) in 
European populations. The analyses of these neoplasms - purposely selected given their 
differing temporal and aetiological profile as well as their means of prevention - provides a 
platform to demonstrate the utility of APe analyses and the specified recommendations in 
practice. This motivates a discussion of the difficulties inherent in such studies and the 
consequences of introducing systematic approaches to the analyses of cancer trends. 
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1 Introduction to topic and rationale for thesis 
Investigations of the changing temporal patterns of incidence of, and mortality from, 
particular diseases are standard tools in epidemiological science and public health 
surveillance. Long-term data from vital sources enables a quantification of the evolution of 
population-based rates over time and may provide clues as to the underlying determinants. 
Trend analyses may establish novel hypotheses or provide confirmatory evidence of existing 
ones. In keeping with epidemiological inferences in general however, systematic 
measurement errors, potential confounders and the role of chance must be investigated as 
plausible explanations for a particular temporal pattern. Changing rates over time lend 
supporting evidence to inferences regarding causality should the temporal patterns relate, 
allowing for a sufficient time lag, to the (suspected or known) distribution and prevalence of 
one or several risk factors [1]. Time trends studies at the population level are an essential 
component in the implementation and evaluation of preventative strategies aimed at the 
primary, secondary and tertiary level. 
There has been a transformation in the range and sophistication of the techniques applied to 
temporal data during the last few decades and some of these developments are discussed 
in this chapter. Historically, graphical inspections of disease rates often emphasised 
variations according to age and calendar time only. Temporal analyses broken down by a 
third component, the birth cohort, have become a conventional and standard mode of 
analysis only relatively recently - this in spite of origins dating back to the 19th century (in 
actuary and demography) - and the publication of several breakthrough mortality studies in 
the early and mid-20th century. 
The emerging importance of generation-specific analyses has certainly been aided by 
theoretical developments of the age-period-cohort (APC) model and knowledge of the inbuilt 
mathematical limitations of the methodology. The use of statistical models to augment visual 
approaches to trends in disease rates from vital sources can be traced back to several key 
papers in the 1920s and 1930s. However, the methodological developments that began in 
the early-1970s were to be the major force for numerous applications in many areas of 
research. The generalisation of a family of linear models that provided maximum likelihood 
estimates via a weighted least squares algorithm [2] provided important practical 
applications to disease counts via the use of log-linear modelling approaches [2-4]. 
Complementing the theoretical developments was the availability of software [5,6] dedicated 
to fitting such models on computers powerful enough to handle the intensive computations. 
In the study of temporal patterns of cancer, the increasing availability (and accumulation) of 
incidence and mortality data from vital sources has been a major driver in demonstrating the 
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validity of such techniques. The combined efforts of cancer registries in standardising 
procedures and data definitions have been particularly important in establishing the quality 
and comparability of cancer incidence data. 
This thesis considers the study of time trends of cancer in the context of epidemiological and 
preventative research, outlining the specific complexities that may obscure interpretation at 
the data collection, analysis and presentation phases, both in theory and in practice. In 
section 1.1 of this introductory chapter, the specific objectives of the thesis are set out. The 
rationale of trends analyses and their application to cancer control is discussed in 1.2. Some 
preliminary comments on the data sources, the analysis and the presentation of trends is 
given in 1.3 and the properties of trends according to age, period and cohort dimensions of 
time outlined in 1.4. The history of age-period-cohorl, or generation studies, is sketched in 
1.5. The final section provides a preamble to the forthcoming chapters and their specific 
objectives in relation to the objectives of this research. 
1.1 Objectives of thesis 
This thesis examines the utility of temporal studies of cancer in practice, particularly from the 
perspective of analyses encompassing the three underlying time components, age, period of 
event and birth cohort. A primary aim is to provide some recommended procedures for 
temporal analyses and to gauge to what extent a systematic approach can be adopted in 
studies involving numerous populations and/or cancer sites. A truly systematic study could 
be considered one that takes a unified approach to data preparation, analysis and 
presentation of the results, so enabling a comparison and interpretation of results in an 
objective and parsimonious manner, potentially leading to insights into the disease derived 
from the variability in trends between and within subgroups. 
In this thesis, trends in cancer incidence and mortality are investigated using data obtained 
from European population-based cancer registries and the WHO mortality databank data, 
respectively. The objectives are to: 
o review methods available for the study of cancer trends and provide guidelines on 
this basis, particularly in relation to the use of APe models, informed by a review of 
current practice in the literature; 
o demonstrate the practical utility of temporal analyses in monitoring cancer trends in 
terms of providing clues as to the factors that drive them, informing the debate 
surrounding prevention strategies; 
o describe the benefits and limits to systematic approaches in practice. 
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In order to fulfil these objectives, some basic recommendations will be made on reviewing 
the graphical and modelling strategies available in the analysis of time trends. On the basis 
of these, a detailed analysis of European trends in three cancers motivates discussion of the 
utility of the APC model in practice, as well as some consideration of the role of systematic 
approaches in temporal studies of cancer. 
1.2 Review of temporal investigations 1: applications to cancer control 
Time trends of cancer rates provides an opportunity to measure how the risk of cancer in 
defined populations is changing, and more fundamentally, give pointers to the underlying 
determinants of the observation and a means to formulate, implement and further develop 
preventative strategies. Changes in the evolution of cancer incidence rates over time allow, 
in the absence of artefacts, consideration of plausible mechanisms of, and changes in, 
environmental exposures, time-lagged by an approximation of the latency period. 
Hypotheses may be more readily generated when changes in trends are observed over a 
relatively short timeframe rather than over a number of decades [7], although a rapid 
detection of changing trends is not easily achieved for most cancers [8]. 
Genetic factors only have a minor impact on time trends of cancer, unless there are 
sufficiently large migrational influxes and exoduses in the population under investigation [7]. 
Such demographic events would be readily identified, and in addition, would impact on the 
trend rather slowly relative to environmental determinants [9]. 
As discussed in more detail below, there are several approaches to cancer control [10]: the 
removal of the causes themselves before cancer develops either by general or specific 
measures (primary prevention); the detection of pre-invasive lesions or cancers at an early 
stage that are amenable to treatment (secondary prevention); therapy and care directed at 
preventing death from the disease (treatment) and alleviating pain and suffering (tertiary 
prevention / palliative care). The monitoring of secular trends plays a direct role in assessing 
the need for cancer control measures, and in continually evaluating implemented 
programmes. 
Situation analyses of mortality trends have been exploited as a means to critically assess 
progress against cancer in recent decades [11,12]; the ensuing debate regarding the 
relative merits of different approaches to cancer control has remained at the top of the 
health agenda, particularly in the U.S. Predictions of future cancer burden have also 
become established as tools in the planning of health policy and the strategic allocation of 
future resources, and in measuring the success (or failure) of specific interventions [13]. 
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1.2.1 Primary prevention 
Primary prevention in a general sense is the protection of health by personal or communal 
means [14]. There are numerous applications of this level of prevention in controlling 
cancer, and indeed they embody the third revision of the European Cancer Code, a set of 
recommendations for the individual designed to reduce cancer occurrence in the community 
(in this case, the member states that collectively make up the European Union). The code 
advocates the avoidance of smoking, obesity and excessive sun exposure, prudent 
consumption of alcohol, the undertaking of daily physical exercise and increasing fruit and 
vegetable consumption, while reducing animal fat intake [15]. Primary prevention also 
includes the field of chemotherapy for which well-designed randomised trials may be utilised 
to demonstrate the effect of chemical substances on cancer risk [16]. 
Secular analyses of cancer trends in rates offer inferences regarding the possible 
introduction or removal of causes of cancer over time within a defined population, and as 
such have direct application to consideration of the longer-term impact of primary prevention 
strategies. The incidence rate is the correct indicator for measuring the impact of prevention, 
although mortality can be used as a surrogate for cancers where (often poor) survival rates 
have remained largely unchanged over time. Lung cancer is one such example, and further 
represents an important example of the promise of primary prevention. Not only is the 
disease the most common form of cancer worldwide [17], with cumulative risk approximately 
10% in males in certain Eastern European countries and among black men in the U.S. [18], 
lung neoplasms are among the most preventable - at least 90% and 50% of lung cancer 
male and female cases respectively are attributable to tobacco smoking in Europe [19]. 
Time trends of lung cancer incidence and mortality have played a crucial role in validating 
smoking as the primary cause of the disease [20]. The recorded rise in rates and 
subsequent fall in some populations has reflected the maturity of the smoking epidemic in 
different countries. As has been noted by Lopez however, there are limitations to inferences 
in relating the impact of tobacco consumption to lung cancer trends [21]. The lack of 
availability of comparable information on tobacco smoking (in terms of data coverage and 
the methodology applied in its collection), and insufficiency of detail (e.g. by age and sex) 
hampers examinations of the interrelationships. 
Yet the relation between tobacco consumption and lung cancer probably represents the best 
"cause to effect" example in cancer epidemiology, while reasonably comparable datasets on 
various characteristics of tobacco consumption trends are becoming increasingly available 
[22]. Most neoplasms have a multifactorial aetiology with very few single associations as 
powerful as the effects of smoking on lung cancer. Moreover, there is frequently insufficient 
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comprehension (and quantification) of the contribution of individual factors in explaining 
temporal observations, while data on the established determinants are often unavailable or , 
lack the requisite level of detail. Therefore, assessing the impact and prospects for 
prevention via the inspection of incidence trends is, for most cancers, often at best an 
informed speculation. 
Nevertheless, there are some informative examples that relate the changes in putative risk 
factors to corresponding cancer trends in England and Wales. A general monograph on 
cancer incidence and mortality trends included a comprehensive chapter on trends in 
putative and known risk factors for cancer [23], while a recent article on trends in female 
cancers interrelated trends in several risk determinants, in an attempt to better explicate the 
trends in breast, endometrial and ovarian cancer occurrence [24]. The prospects of primary 
prevention of cervical, endometrial and testicular cancer will be revisited in Chapters 4 
through 6, respectively. 
1.2.2 Early diagnosis and screening 
Cancer screening is the application of a test or enquiry, to identify individuals at sufficient 
risk of mortality (or serious morbidity) to benefit from further investigation or direct 
preventative action among those who have not sought medical attention on account of 
related symptoms. It is considered an effective strategy in reducing cancer mortality as 
neoplasms often undergo several pre-invasive changes before they become biologically 
relevant and clinically detectable. The monitoring of screening effects via trends analyses of 
incidence and mortality rates is of major importance for cervical, breast and prostate cancer 
for which screening has, for differing reasons, become commonplace in some countries. 
Monitoring trends of colorectal cancer incidence and mortality rates will become increasingly 
important as supporting evidence from randomised trials emerges as to which method (or 
methods) to apply in the test, as organised programmes are implemented, and there is a 
need to evaluate their effectiveness. The evaluation of screening in relation to trends in 
breast and prostate cancer are briefly described below. A thorough analysis of cervical 
cancer trends in relation to screening in Europe comprises Chapter 4. 
1.2.2.1 Breast cancer 
An international working group recently considered that there was sufficient evidence for the 
efficacy of screening women aged S0-69 by mammography in reducing breast cancer 
mortality [2S]. The bulk of the evidence came from a number of large scale randomised trials 
showing that, in women aged SO-64, the early detection of invasive lesions via 
mammography at regular intervals could reduce breast cancer mortality by around 30% [2S]. 
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Supporting empirical evidence of its effectiveness came from time trends studies - declines 
in mortality were observed where screening had been introduced. 
The main evidence that decreases were partially attributable to screening were studies in 
Northern Europe and Australia describing the anticipated increases in the incidence of early 
stage and in situ breast cancers, followed by decreases in advanced cancers, leading to 
subsequent reductions of mortality. Quantification of the contribution of screening has been 
notoriously problematic for breast cancer however. It has been estimated that about one-
third of the overall 21 % reduction in breast cancer mortality in the U.K. was due directly to 
screening by 1998 [26], although some have considered this an insufficient time lag for the 
benefits of screening to emerge [27]. Further, the observed declines in mortality in the U.K 
(a 25% reduction by 2000) started in 1986, before screening was introduced. In addition to 
mammography, a number of improvements in combination have probably led to the 
observed declines [28], and include the establishment of treatment protocols, improved 
chemotherapeutic options and better therapeutic guidelines [26]. 
1.2.2.2 Prostate cancer 
Incidence rates of prostate cancer are influenced by the diagnosis of latent cancers both by 
prostate specific antigen (PSA) screening of asymptomatic individuals, and by detection of 
latent cancer in tissue removed during prostatectomy operations, or at autopsy. Where PSA 
testing has been prevalent, recorded incidence is very high, as seen in the U.S and several 
Nordic countries. The distribution of mortality rates is less affected by early diagnosis of 
asymptomatic cancers. Mortality is affected by case fatality as well as incidence, and 
survival is significantly greater in high-risk countries - five-year relative survival rates for 
men diagnosed 1995-2001 is 99.8% in the U.S. [29], a figure probably affected by lead and 
length time biases reflecting the upsurge in latent cancers that PSA has detected. 
In evaluating the effectiveness of PSA using temporal analyses, the prostate cancer 
mortality rates in the U.S. have been historically of most interest, given the large underlying 
male population and the extent to which PSA testing has become prevalent. Based on 
current data from the SEER program, the overall all-race mortality rates based has been 
steadily declining from 1993 up to the latest year available, 2002 [29]. While there are 
promising leads, no risk factors are established [30], and these, in any case, could not 
account for the mortality declines. That the decrease might reflect advances in treatment in 
combination with PSA-related early detection has been the subject of much debate [31]. 
Supportive of a partial screening effect were the PSA-associated characteristics of the 
incidence trends of late-stage prostate cancer after 1992 [32] and the initial decline in the 
death rate due to a decline in late-stage cancers [33]. However a simulation of the effects of 
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lead time found the observed decrease were better explained by factors other than 
screening [34]. Other doubts come from mortality data in areas where PSA testing has been 
uncommon, where declines in prostate cancer death rates in such countries have been 
observed [35]. Two randomised clinical trials currently underway in Europe [36] and the U.S. 
[37] will provide additional information, within the next five years. These include the benefits 
and harms of screening, and will possibly answer whether PSA (and digital rectal 
examination) can reduce prostate cancer mortality. 
1.2.3 Treatment and cancer care 
As discussed above, the beneficial effects of treatment on breast and prostate cancer have 
made quantification of the respective effects of screening via mammography, and the PSA 
test in reducing mortality at the population level, very difficult to ascertain. The mortality rate 
is considered the appropriate measure for such an enquiry, as comparisons of survival rates 
over time may be less meaningful in this context, given that improvements in survival may 
be a result of early diagnosis and treatment in combination [38]. 
Trends in cancer mortality rates have also been the focus in determining the impact of 
cancer treatment relative to cancer prevention. As is discussed in the next section, an 
interpretation of the U.S. cancer mortality trends has led to a widely-publicised view that 
treatment, as a form of cancer control has been failing. Yet there have been a number of 
pivotal breakthroughs in oncology in recent decades [39], particularly with regards therapy 
for several forms of cancer that commonly affect younger persons aged under 45 [40]. The 
favourable trends in mortality following the introduction of novel therapies has lent support to 
their efficacy at the population level [41]. The examples of time trends studies below 
describe, in a European context, the need for adequate resources and effective 
management in providing optimal care. 
Hodgkin lymphoma (HL) is considered one of the most curable forms of cancer. As with 
other haematological malignancies, survival has improved markedly with time [42], in 
response to the continued development of more effective chemotherapy in the last three 
decades [43]. Time trends of mortality reflect these improvements, and while incidence 
tends to be stable or decreasing in many populations [8], mortality trends have been falling 
since the 1960s in most European countries [44]. The exception is Eastem Europe, where a 
considerable delay in the decline of mortality from HL, and a lesser order of magnitude of 
the rate of decrease, is clearly observed, pointing to insufficient resources in the recent past, 
as well as inefficiencies in the organisation and management of the disease [44]. 
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The treatment of acute leukaemias includes chemotherapeutic regimens which can cure up 
to 80% of childhood, and 40% of adult cases of acute lymphoblastic leukaemia [45]. The 
death rates from all types of leukaemia in Europe in younger age groups are similar to those 
of HL, both in terms of the trends and their interpretation. Declines in death rates are 
observed in most countries since the 1960s, although the corresponding falls in Eastern 
Europe declines are of a lower order of magnitude, and seen later than elsewhere [46]. 
Another success story, the introduction and development of chemotherapeutic regimens for 
the treatment of testicular germ cell tumours is examined in detail in Chapter 6 in relation to 
its impact on trends in testicular cancer mortality in Europe. 
1.2.4 Assessing progress against cancer 
Since Nixon signed the U.S. National Cancer Act in 1971 to provide "a total commitment of 
Congress and the president to provide the funds for the conquest of cancer" in the U.S., 
cancer control, metaphorically at least, has been on a war footing. Establishing whether a 
society is "winning" or "losing" the "battle" against cancer, and the relative merits and 
prioritisation of primary, secondary and tertiary prevention, have received much attention (in 
the U.S. in particular). Trends in cancer mortality rates have been at the forefront of the 
debate; the direction of trend has been considered by some as the indicator of progress, 
pointing towards success or failure in controlling cancer, and informing the need to redress 
the balance of allocation of funding to preventative and treatment-orientated research. 
Bailar and Smith's paper in the New England Journal of Medicine in 1986 [11], an 
assessment of the "progress against cancer", based on trends in cancer mortality in the 
U.S. 1950-82, may be considered as igniting the debate. Their report was a somewhat 
pessimistic assessment of cancer control in the U.S., highlighting the failure of cancer 
control strategies to reduce the long-term mortality burden, and specifically, the need to shift 
research efforts away from treatment - given its perceived lack of impact on the mortality 
trend - to prevention. The conclusions were largely drawn from the fact that the overall age-
adjusted mortality rates for all cancers combined had not changed appreciably over three 
decades. As the authors concluded: "by making deliberate choices among the measures, 
one can convey any impression from overwhelming success against cancer to disaster." 
Indeed, several authors were critical of some aspects of the study and a number of 
subsequent papers sought to readdress the issue. Sir Richard Doll, in his assessment of 
progress in Europe, indicated that while mortality from all cancers was the correct outcome, 
the use of the all-age adjusted rate was "profoundly wrong", in that it outweighs the effect of 
recent progress with the "prevalence of carcinogenic agents in the distant past, which are 
irrelevant" [40]. Any progress among young people, therefore, as would have been seen in 
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the age-specific rates, would have been masked on combining age groups, and the notable 
successes (in high resource settings) of therapeutic improvements for several relatively 
uncommon cancers, as discussed above, largely ignored. 
A decade later in the same journal, Bailar and Gornik, using mortality data from 1970-94, 
and including this time a stratification of the trends into younger (0-54) and older age groups 
(55+) - concluded with a not dissimilar message to previously - that the favourable trends in 
the most recent years were largely through means of primary prevention and early detection 
rather than treatment [12]. Such an interpretation was vociferously challenged by Kramer 
and Klausner of the U.S. National Cancer Institute, who suggested theirs was a defeatist 
approach to progress. Further, they commented that Bailar's paper failed to allow for future 
breakthroughs in treatment or the variable prospects for cancer prevention, the difficulties in 
implementation of primary prevention, and the heterogeneity of cancer as a disease [47], 
claims refuted subsequently by Bailar and Gornik [48]. Deliberations on progress against 
cancer, and the capability of different strategies to control the disease on the basis of past, 
present and anticipated future mortality trends will undoubtedly continue in both scientific 
and political arenas well into the future, as witnessed by several recent news reports in the 
cancer literature [49-51]. 
1.2.5 Predicting future cancer burden 
The planning of services is an integral component of cancer control programmes [52]. 
Predictions may inform us of the extent to which the determinants of the disease, and 
interventions, planned or unplanned, are likely to impact on the frequency of cancer in the 
years that follow. The specific objectives of predicting future cancer burden are dependent 
on the users of the information [13,53]. Health care providers need accurate and routinely-
updated estimates of the future number of cancer patients in allocating finite resources to 
prevention, treatment and palliative care. Investigation of the root determinants of the 
underlying trends is critically important in translating predictions to policy evaluation. 
Artefacts related to the data source and coding issues, the possible effect of interventions, 
and the aetiological profile of the cancer type all need to be investigated. 
Incorporating exposure data in making predictions may be considered amongst the best 
approaches; these are difficult to implement however, given the present lack of 
understanding of the factors that drive most cancer trends, as well as a lack of availability of 
such data where determinants are established. This necessitates the use of more simple 
techniques that usually involve simple extrapolations of trends in the recent past into the 
future. Projections can include supplementary data where available, and have been applied 
in predicting future lung cancer mortality on the basis of various scenarios regarding future 
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smoking habits [S4,SS]. Where necessary, predictions may also include information on 
specific interventions, such as screening activity: projections of breast cancer incidence in 
the Nordic countries in 2010, for instance, incorporated information on the impact of national 
mammographic screening programmes [S6]. 
1.3 Introduction to the components of time 
1.3.1 Data collection, analysis and presentation 
As Esteve notes, each of the stages of data collection, analysis and presentation bring their 
own set of problems to the study of cancer trends [S7]. The appropriate measures for such 
analyses often come from existing sources of data, such as population-based cancer 
registries, which collect, store, and analyse information on all new cases of cancer in well-
defined populations. National offices are responsible for the collation of information on the 
causes of death of its inhabitants, compiled, for instance, at the international level in the 
WHO mortality databank. Incidence and mortality relate to the frequency of the disease -
other attributes can also be studied temporally, and survival rates measure the impact of 
cancer on patients, while prevalence, a more complex function of occurrence and duration 
of the disease, estimates the number of persons alive and requiring some aspect of care 
within a health system. 
The relative merits of cancer incidence or mortality data in time trends stUdies and their 
complexities in interpreting trends have been much debated [S8-60]. Changing 
completeness of registration, improving diagnostic methods, and inaccurate population 
estimates at the sub-national level may cause artefactual changes in incidence rates. 
Mortality data, though more extensive in availability than incidence, depends on the 
accuracy of the cause of death information, which may be subject to change with calendar 
time. In addition, mortality rates are poor measures of trends in risk (e.g. as surrogates of 
incidence) if there have been improvements in prognosis (case fatality) over time. Often the 
joint description of incidence, mortality and survival serves to confirm and clarify our 
understanding of the underlying disease processes. Comprehensive understanding of 
artefactual influences is a prerequisite however, and these are discussed in Chapter 2. 
1.3.2 Age, period and birth cohort 
Quantitatively, the most important time-related factor is age. Cancer incidence rates usually 
increase with age, and for epithelial cancers, the risk increases at approximately the Sth to 
6th power of age [61]. Ageing characterises the cumulative exposure of the body to 
carcinogens over time, and the accumulation of the series of mutations necessary for the 
unregulated cell proliferation leading to cancer [62]. 
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Rates may also differ over calendar time and between different generations (birth cohorts) of 
individuals. The modem Lexis diagram provides a graphical representation of the 
demographical relationship between age and chronological calendar time. In the diagram, 
the lifetime of a group of individuals can be represented by a third time dimension, a straight 
line beginning on the time axis at the time of the person's birth, and continuing diagonally 
upwards, ending at the age and time point representing the event of interest e.g. cancer 
diagnosis or death. Lexis diagrams trace the experience of a cohort within a particular age 
interval or the experience of a cohort over a lifetime. Cohort effects may relate to birth itself, 
or may approximate factors related to birth by exerting influences that are shared in the 
same group as they age together. 
An examination of cancer rates according to birth cohort may provide valuable insight into 
the nature and intenSity of disease-correlated exposures that vary across successive 
generations, and given that many forms of cancer have a rather long induction phase, plays 
a vital role in corroborating evidence of the role of putative aetiological factors from other 
types of epidemiological study. A changing distribution and prevalence of environmental risk 
factors would tend to affect particular generations of individuals in the same way as they age 
together, and in some instances, may exert particular influence on earlier stages of 
carcinogenesis development, given the causes of cancer may take several decades to 
emerge. 
Period effects are characterised by an immediate or fixed-delayed change in the incidence 
rates for all age groups [63], and thus may act as surrogate measures of events that quickly 
change rates with the same order of magnitude across all affected age groups under study. 
More frequently, they transpire from changes in classification criteria or the availability of 
new diagnostic tests, although the introduction of a powerful carcinogen or a screening 
intervention (affecting all study age groups) may also show up as a period effect. With 
respect to cancer mortality, the effect of interventions (e.g. advances in treatment affecting 
all study age groups) is likely observed as a period-related influence on mortality. However, 
as Hobcraft observes, the effects of period and cohort are weak proxies for events that we 
cannot measure directly [64]. 
While valuable information can be gleaned about temporal risk patterns from an analysis 
restricted to age-standardised rates over calendar time, strictly speaking, summary rates are 
only accurate as measures of risk in the absence of an interaction between age and 
calendar time, indicative of the presence of strong birth cohort effects [65]. Graphical 
descriptions of age-specific patterns according to period and cohort are an integral part of 
temporal analyses, and a careful visual inspection wi" usually provide some insight into the 
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importance of each time component, and possibly, its relative contribution to the observed 
temporal pattern. 
A more formal quantification of the relative importance of the three time effects involves 
statistical modelling via the APC model [63,66-68] (see Chapter 3). Despite its increasing 
use, there are inherent limits to the approach as a result of the identifiability problem - the 
fact that knowledge of any two factors implies knowledge of the third, making one of the 
factors redundant [69]. 
1.4 Review of temporal investigations 2: a short history of cohort analyses 
The analysis of disease events across the axes of calendar time and age has a long history 
in demography. Lexis described a graphical representation of the life history of subjects 
according to birth cohort (the abscissa) and age (the ordinate) [70]. The original diagram 
thus represented an age-cohort, rather than the age-period space to which the Lexis 
diagram represents today. The modern interpretation of the Lexis diagram, described in 
some detail by Case [71], displays subjects arranged by calendar year of event and age at 
time of event on the same unit scale, with each cell corresponding to a year of birth, the 
diagonal tracing the experience of subjects born in the same year, whom are under 
observation until either the end of follow-up, the event of interest occurs, or they are lost to 
follow-up. In the commonly tabulated system used for vital rates, a synthetic birth cohort 
over a 10-year range is derived from the combined experience of subjects in a five-year age 
group over a five-year period. Cohorts are identified by their central year of birth, with years 
other than the central year contributing to two overlapping cohorts. 
The first use of the term cohort is attributed to Frost in a letter written to a colleague in 1935 
[72]. The note was published posthumously alongside his landmark paper that discussed 
some insights that could be attained by visually examining age-specific death rates from 
tuberculosis according to cohorts, members of a community who share the same birth 
period, rather than simply in the usual cross-sectional way [73]. The present day usage of 
cohort extends beyond the closed or hypothetical sense of the term used by Frost. In 
modern epidemiology, a cohort study can be defined as "any study in which groups of 
people with defined characteristics are followed up to determine incidence of, or mortality 
from, some specific disease, all causes of death, or some other outcome" [72], and cohorts 
"closed populations defined and bound by their entry, often but not necessarily at birth" [74]. 
The term age-period-cohort analysiS is often used to describe temporal studies that include 
birth cohort analyses, to distinguish it from the generic usage of cohort in prospective 
studies [75]. 
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The arrival of birth cohort analyses however, preceded the work of Frost by a decade; two 
actuarial papers were published [76,77] stressing the importance of considering overall 
mortality rates that characterised generations born in a particular year rather than deaths 
occurring in a calendar year. The authors noted that rather similar age mortality curves were 
obtained on inspection of the diagonals in a cross tabulation of age and calendar year. An 
important study by Kermack and colleagues noted analogous observations by means of 
cohort analyses on all-cause mortality in Scotland and Sweden [78], hypothesising that 
early-life exposures had an impact on later adult mortality, particularly from birth to the age 
of 15. The paper has been described as innovative and of considerable importance in the 
deliberations as to whether environmental factors in early-life development materially 
influenced subsequent adult mortality [79]. 
Using data from the U.S., Frost's main contribution to promoting cohort analyses was to 
show that the peak in more recent cross-sectional age-mortality curves (in 1930) at later 
ages (50-60) compared to peaks in young children (0-4) previously (in 1880) and at the ages 
20-40 in (1910) was an illusion - an examination of the same age curves by cohort indicated 
subjects comprising the 1930 curve passed through greater risks in the previous decades -
the class of individuals whom were children in 1880 and who were aged 50-60 (if still alive) 
by 1930 [73]. In concluding, he noted that contemporary peaks of mortality in later life did 
not signify a postponement of maximum risk, but rather were the residuals of higher rates in 
early life. Frost acknowledges an earlier paper involving cohort analyses of tuberculosis 
mortality by Andvord [80], although generational influences on disease rates may have been 
known earlier [79,81]. Andvord's paper, published in a Norwegian journal using data from 
Denmark, Norway, Sweden and the U.S., suggested, not without some insight, that the age-
curve by cohort enabled one to extrapolate the trends in younger cohorts through to older 
ages, thus enabling a prediction of future mortality [80]. 
It was not until the 1950s that the birth cohort approach to trend analyses was applied to 
rates of non-communicable diseases, such as cancer. Korteweg convincingly showed that a 
cross-sectional view of age curves of lung cancer mortality led to an erroneous 
interpretation; the age curves were artificially pushed down by the increase in lung cancer in 
younger age groups [82]. The consistent pattern of declining rates at relatively early ages for 
five consecutive periods between 1911 and 1945 was therefore not an observation that 
required a biological explanation. 
Just as Frost and other researchers did before him, Korteweg argued that the correct way to 
view the mortality curves was in cohorts defined by date of birth: by doing so, the age-
curves of lung cancer came to resemble the monotonically increasing "all sites except lung" 
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curve which, during that era, remained largely unaffected by the extraordinary effects of 
smoking that would subsequently impact on lung cancer rates [82]. Conduding, he 
remarked that the decline in lung cancer rates amongst the older age group was a 
consequence of "irritative factors" - an adopted term that, according to Sir Richard Doll, 
avoided the controversy of linking smoking as the principal cause [72]. The mechanisms that 
promoted lung cancer, Korteweg observed, acted particularly (but not exclusively) in 
younger people [82]. 
A number of generational studies of cancer incidence were published in the 1950s. 
Clemmesen and colleagues examined lung cancer incidence and mortality in European 
countries using a similar methodology [83]. Dorn and Cutler described the monotonic 
increase in lung cancer incidence by birth cohort in every age group using U.S. national 
survey data [84], while MacMahon extended Korteweg's observations to incidence trends in 
breast cancer [85] and to cancers of the digestive tract [86]. Much of the use of the earlier 
cohort analysis was reviewed by Case in a paper published in 1956 [71], who was 
particularly articulate in defining the role of the three time dimensions in the Lexis diagram, 
extending the discussion as to how to characterise the age mortality curve, and the 
possibility that adult disease rates were a product of early life. 
Despite studies by Barrett, developing the cohort-based methods of earlier studies to 
descriptions of cancers of the cervix [87], bladder [69] and prostate [88], and applications 
such as the study of cohort trends in cervical cancer incidence trends in relation to rates of 
sexually-transmitted diseases [89], the techniques became largely neglected in the 1960s 
and 1970s [90]. In 1982, Muir suggested studies were needed that systematically examined 
trends, particularly by birth cohort [90]. It is interesting to note contrasting approaches to 
time trends compilations in that year - one volume of international time trends in cancer 
mortality contained only three chapters that applied cohort analyses [91], while in another 
volume on trends in incidence, they were included as part of the analyses in the majority of 
chapters [92]. 
A flurry of research arrived with the advent of theoretical and applied research into 
estimation of the independent effects of age, period and cohort via the APC model in the 
unavoidable presence of non-identifiability. It was Kermack and colleagues that first outlined 
the technical aspects of the estimation of relative mortality from tuberculosis using the 
decomposition of age and cohort effects in a multiplicative model [78]. In 1972, Barrett used 
a similar model in the study of cervical cancer mortality trends and discussed one arbitrary 
solution that incorporated all three effects, and the need to search beyond the linear trends 
[69,87,88]. From the 1980s, many novel solutions were offered as how should one present 
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the joint components in epidemiological settings [63,65-68,93-103], although much of the 
theoretical work had come earlier from workers in the sociological field [104-106]. A number 
of reviews and critiques of these techniques have been disseminated [107-112]. 
Two further compilations of international time trends of incidence and mortality were 
published in the early to mid-1990s [8,113]. The volumes varied in the editorial approach: 
Doll and colleagues documented and interpreted international trends in incidence and 
mortality by cancer site, allowing some flexibility in each site-specific chapter by leaving it to 
the expertise of the multiple authors to decide on the selection of data and the presentation 
format for a given cancer [113]. In contrast, the International Agency for Research on 
Cancer (IARC) monograph by Coleman and colleagues [8] was a strictly systematic attempt 
at the analysis of worldwide trends of the major cancers in four continents. The approach 
involved an algorithmic approach to APC modelling [57], and a fixed presentation style, with 
only a limited number of authors involved in the analysis and writing. 
Other large studies with a systematic approach to the presentation of cancer trends in one 
population include the monograph by Roush et at examining incidence trends in Connecticut 
in the U.S., and a more recent book documenting incidence and mortality trends in England 
and Wales [23]. In addition, incidence and mortality trends are comprehensively examined in 
the U.S. published online as part of the SEER reviews series [114], although only the Roush 
et at publication embraced APC modelling. 
Systematic overviews of cancer trends have also appeared in the medical and 
epidemiological literature, such as the series of articles examining mortality trends according 
to broad subgroups of cancer [115-119], for which a specific APC technique was used 
throughout [120]. The yearly updates of rates and trends in the U.S. in their "annual report to 
the nation" has recently involved the use of joinpoint analyses (see 3.2.3.2) to determine 
recent linear trends by calendar time [31]. Cohort analyses have not been a focus in this 
series however, although other reports on U.S. incidence trends have used a more 
sophisticated approach involving APC analyses [121]. 
1.5 Outline of subsequent chapters 
Following on from this introductory chapter, Chapter 2 appraises the routine sources of data 
and their usage in temporal studies. The availability, quality and characteristics of incidence 
and mortality data are reviewed, and the synergy between the measures examined. Chapter 
3 provides a critique of the numerous graphical and statistical methods available for 
analysing time trends of cancer data, with particular reference to the joint representation of 
age, period and cohort effects. The chapter rounds off with some observation and 
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recommendations with regards the analyses of time trends, and these techniques are 
employed in the study of trends in cervical cancer incidence (Chapter 4), endometrial cancer 
incidence and mortality (Chapter 5), and testicular cancer incidence and mortality (Chapter 
6) in Europe. These chapters have been developed into a series of six research articles as 
part of a collaborative time trends project (Appendix 1). A declaration of the level of 
involvement of the author of this thesis in the planning, analysis and interpretation stages is 
given separately, as is due acknowledgement of collaborators involved (Appendix 2). 
Finally, Chapter 7 discusses how the recommendations - based as they were following a 
review of the available methods - worked in practice. The Thesis ends with some 
concluding remarks on the role of the APC model and systematic approaches to analysis. 
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2 Routine sources of data: definitions, availability and data quality 
While temporal investigations of cancer have important applications both in the planning and 
evaluating of public health strategies and in epidemiological research, they are a complex 
phenomenon to study, having substantial limitations and potential errors associated with 
them. Asides from the problems of analysis and presentation, discussed in depth in the next 
chapter, researchers wishing to critically interpret time trends must be aware of the 
characteristics of the incidence and mortality dataset specific to the cancer and population 
under investigation. They must be aware that artefacts (e.g. inaccuracies related to 
diagnosis or reporting) may have impacted on trends in addition to specific interventions of 
interest or hypothesised changes in the population prevalence of aetiological factors. 
There are a number of artefacts associated with incidence rates that potentially affect trends 
should the extent of these biases change with time. Potential errors include: i) 
misclassification of a case as a resident or non-resident; ii) incorrect definition of an incident 
case of cancer; iii) duplicate registrations; iv) a failure to identify or diagnose true cancer 
cases; v) poor specification of diagnosis; vi) improvements in diagnostic procedures and vii) 
difficulties estimating populations at the national or sub-national level. 
Mortality data is prone to erroneous death certification and changes in coding practice. If 
mortality trends are used as a proxy of incidence rates (as they often are, given their more 
extensive availability), a further bias is introduced for cancers where prognosis has improved 
with time, given that case fatality would not be constant. 
The text that follows discusses the properties, availability and quality of cancer data from 
routine sources within Europe, and their utility (and limitations) in investigating time trends. 
The opening sections discuss incidence (2.1), mortality (2.2), and at a more cursory level, 
prevalence (2.3) and survival (2.4). Interrelationships between the indicators are discussed 
in 2.6. 
As well as data from existing systems in Europe, there are a limited number of datasets that 
contain relevant exposure information at the population level, either collected for particular 
studies in repeated surveys, or in some countries, routinely, e.g. in national household 
surveys. Their availability in Europe and their limitations in temporal analyses are discussed 
in 2.7. Finally, the primary data sources and minimum inclusion criteria for the trend 
analyses that comprise Chapters 4 through 6 are set out in the final section, 2.8. 
2.1 Incidence 
Cancer incidence is the frequency of occurrence of new cases of cancer in a defined 
population over a given period of time. It can be expressed as the absolute number of cases 
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and is often used in this form in planning and prioritising resources for cancer control. For 
comparative purposes however, the quantification and comparison of risk necessitates the 
computation of rates of cancer. Ideally, we would estimate a rate by ascertaining, for every 
individual in the population, the risk of being diagnosed with cancer at a given age and 
specific point in time. The rate is sometimes described as the force of incidence or the 
instantaneous incidence rate [122] and requires that the designated period of time is 
infinitely small, approaching zero. As cancer is a relatively rare disease however, we must 
estimate the average rate of occurrence of new cases of cancer in a sufficiently large 
population over a sufficiently long time period. In this formulation, the denominator is the 
underlying person-time at risk from which the cancer cases in the numerator arose. 
The term rate is often used interchangeably with the risk of developing a cancer, but, strictly 
speaking, risk is a proportion and describes the accumulation of the effect of rates over a 
given period of time e.g. the cumulative risk [123]. Cancer rates are nonetheless essential 
should we wish to make comparisons of risk in different groups. Observed changes in 
incident cases and deaths across time are particularly dependant on the ongoing 
demographic effects of ageing and population growth over time. 
2.1.1 Data availability 
Incidence data are produced by population-based cancer registries, whose remit is to collect 
and classify information on all new cases of cancer in a defined population, providing 
statistics on occurrence for the purposes of assessing and controlling the impact of cancer 
in the community [52,124]. The continuous recording of individuals with cancer followed 
several failed attempts at producing good quality cancer morbidity statistics. A series of 
cancer surveys between 1900 and 1910 in European countries based on questionnaires to 
physicians resulted in poor participation rates, while ad hoc analyses in the U.S. of ten 
metropolitan areas in 1937-38, 1947-48 and 1969-71 were eventually deemed undesirable, 
given that the outcome of the individual could not be followed [125]. Methodological 
enhancements in pilot studies in the 1930s brought about a more successful system that 
reported cases by name, eliminating multiple registrations and allowing the follow-up of 
individual patients. 
The first systematic collection of incident cases was undertaken in Hamburg, Germany, in 
the 1930s, and funded by the Hamburg Public Health Department. The Danish Cancer 
Society founded the Danish Cancer Registry in 1942 and is today the oldest operating 
registry covering a national population in Europe. The other Nordic countries launched 
national population-based registries in the 1940s and 1950s, with the Swedish Cancer 
Registry being the most recent, established in 1958. The support for cancer registration 
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activities was greatly enhanced in 1946 by the recommendations of 12 international experts 
in the field of cancer control who advised the World Health Organization (WHO) to establish 
cancer registries worldwide with a view to comparability of a set of common standards. In 
1966, the existing cancer registries formed the International Association of Cancer 
Registries (IACR) in order to uphold a common set of data definitions, as well as to promote 
communication and international collaboration between registries [126]. In a like manner, the 
European Network of Registries (ENCR) was established in 1989 to promote and coordinate 
the expanding cancer registration activities at the European level and to facilitate exchanges 
of ideas, cross-collaboration and research between registries. As of 2005, there were 
around 170 ENCR members (national or regional registries) in Europe collecting incident 
cases in 40 European countries. 
Registries may cover national populations (e.g. the Nordic countries, The Netherlands and 
Slovakia) or certain regions within a country (e.g. Italy, Spain and France). The founding of 
registries has been a rather indiscriminate process over the last half century, dependent on 
official policy to support and fund such activities, or through individual initiatives by research-
orientated clinicians and pathologists [35]. As a result, European cancer registries differ 
enormously with respect to the size of the population covered, the number of accumulated 
years of complete data available since the start of the endeavour, as well as, in the case of 
regional registries, their representativeness of the national profile of cancer burden and risk 
patterns. 
2.1.2 Data quality 
Population-based cancer registries produce timely information on the incidence of, and 
survival, from cancer in the community, and as such, form a unique and pivotal role in public 
health and epidemiological research. The effectiveness of registries relies profoundly on the 
quality control procedures in place, which can be broken down into three components: 
comparability, completeness and validity of the incidence data [127]. Comparability refers to 
the standardisation of practices concerning the classification and coding of new cases, and 
to the definition of incidence, such as rules for coding multiple primaries and incidental 
diagnoses. Completeness is the extent to which all of the incident cancers occurring in a 
target population are included in the registry database. There are numerous techniques 
used to evaluate registry completeness [127], including: 
• methods that evaluate the data sources themselves (number of sources/notifications 
per case, percentage of cases histologically verified (%HV), and methods based on 
death certificates); 
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• 
• 
methods that involve independent case ascertainment (rescreening of cases, 
capture-recapture methods, the mortality:incidence (M:I) ratio); 
historic data methods (stability of incidence over time, comparison of incidence in 
different populations, age-specific incidence curves). 
Finally, validity or accuracy refers to the proportion of cases in the registry with a given 
characteristic that truly have that attribute, and depends on the precision of source 
documents and the level of expertise in abstracting, coding, and recording [127]. Again there 
are a number of approaches to its evaluation: 
• diagnostic criteria methods (%HV), percentage of cancers for which no other 
information than a death certificate mentioning cancer can be obtained (%DCO); 
• assessment of level of missing information (percentage with primary site unknown 
(%PSU), age unknown, histology unknown); 
• re-abstracted record methods (comparison of recorded data with an 'gold standard' 
expert opinion e.g. for abstracted diagnosis, opinion of the clinician or pathologist 
that measures reproducibility between observers); 
• internal consistency methods (internal validity checks for invalid codes or 
combinations, or unlikely combinations using the IARC computer program Check 
[128]). 
Such analyses of registry performance are essential in providing credible time trends 
analyses in Europe, and a complementary local knowledge of the data collection procedures 
from the cancer registries themselves also minimise the likelihood of erroneous 
interpretation. The Cancer Incidence In Five Continents (CI5) series now in its eighth 
volume, and covering diagnoses of cancer 1993-97 in 186 registries in 57 countries [18], 
provides comparable data on the incidence of cancer in different geographical locations and 
distinct subpopulations (especially ethnic), as a source of reference for studies requiring 
information on international variations in cancer risk. It is also a good marker of the quality of 
an individual registry should it be included in the compilation, given that the editorial process 
includes the following quality assessments: stability of incidence over time, comparison of 
incidence in different populations, inspection of age-specific incidence curves including 
childhood cancers, %HV, M:I ratio, %DCO, % age unknown, and %PSU. Although CI5 has 
been more a publication focused more on geographical rather temporal comparability, 
inclusion of a registry in successive volumes is a reasonable indicator of consistency of high 
data quality over time. 
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More specifically, issues concerning data quality and other detectable artefacts in 
interpreting time trends have been comprehensively addressed by seminal papers by Saxem 
[59] and Muir et al [60], and more recently by Swerdlow et al [23]. The required provisos that 
ensure truly valid comparisons of cancer trends, as described by Muir et al [60], are worth 
repeating unabridged: 
i. The definition and content of the cancer site being studied have not changed; 
ii. The criteria of malignancy have not changed; 
iii. The likelihood that a cancer will (ever) be diagnosed has not changed; 
iv. The progress of cancer from inception to diagnosis is not modified by early detection 
or screening programmes; 
v. Ascertainment of incident cases and deaths has been equally efficient throughout the 
period of study; 
vi. Indexing in the International Classification of Diseases (ICD) has not changed; 
vii. Accuracy and specificity of coding is consistent over time; 
viii. Statistics are available at the level of detail required. 
As the authors note, few, if any, data series would meet all of the above criteria, although 
the situation is perhaps not as discouraging as one might initially imagine. The influences of 
the above conditions differ appreciably according to the neoplasm under study, but in most 
instances, specific problems with a given site are recognised and the effects on the time 
trend, at least in terms of its likely consequence on the true underlying trend, reasonable 
well understood. Some factors that complicate assessments of incidence of certain cancer 
sites over time are discussed in brief below. 
2.1.2.1 Changes in ICD classification 
Changes in the content of the ICD rubric in consecutive revisions have had considerable 
effects on the evaluation of time trends; particularly affected have been cancers of the lung, 
pleura and liver. Others, such as rubrics for breast and laryngeal cancer have remained 
unchanged in the last four revisions [60]. The demand for a greater provision of detail in 
classification at the level of subsite in each successive volume has led to some problems 
with lack of comparability. Notably affected are cancers of the oral cavity and kidney, where, 
for example, subsites in the 9th revision are irretrievable from the less comprehensive codes 
in lCD-B. 
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2.1.2.2 Changes in the ICD index 
Changes in the ICO index, the instructions used by coders to assign the correct code, have 
brought about the possibility of artefactual changes in the corresponding time trends. The 
assignments of carcinoids, neuroblastomas and sarcomas have all been affected. In the 
case of the index for mesotheliomas, mesothelioma of the peritoneum or pleura was 
assumed malignant in ICOB and IC09, while mesothelioma of unspecified malignancy was 
coded to 'neoplasm, connective tissue, benign' in ICD-7. 
2.1.2.3 Changes in the definition of malignancy 
The definition of what constitutes a tumour may change over time. The classification system 
of cancer is based on histomorphology, but malignancy is a clinical notion [59]. There has 
been an increasing likelihood of pathologists seeing evidence of malignancy in tissue 
samples through improving technology. For example, the rapid increase in cancers of the 
thyroid may, at least in part, be due to an increasing tendency to interpret papillary change 
as malignant. Benign neoplasms of the bladder have always been included in successive 
revisions of lCD, but with a better understanding of the biology of papilloma, some changes 
in the classification of tumour behaviour have emerged. Registry practices regarding the 
coding of invasiveness of bladder tumours have shifted accordingly. 
2.1.2.4 latent carcinoma 
There is an increasing likelihood of incidental diagnoses of tumours that may not have 
progressed to invasion. The ICD does not make any provision for such cancers, and 
interpretation of the likes of prostate cancer incidence over time should be particularly 
guarded. Latent carcinomas of the prostate that are coded as malignant are substantially 
influenced by the frequency of transurtheral resections of the prostate (TURP) and more 
recently, opportunistic screening for prostate cancer via the PSA test. 
2.1.2.5 Effects of screening programmes 
Screening programmes modify the stage of progression at which cancer or pre-cancerous 
lesions are detected. Slow-growing tumours are therefore more likely to be diagnosed than 
under normal conditions. In the case of organised breast screening programmes, the 
classical model involves a temporary, artificial, increase in the observed incidence due to a 
prevalence round, as a result of the early diagnosis of malignancies that would have 
become clinically manifest in time [129]. This is subsequently followed by a reversion of the 
trend to its former state. Cervical screening should also induce a temporary increase in the 
observed incidence due to an amassing of prevalent cases, but there should, in the long-
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term, also be a lasting reduction in rates of invasive cancer, as screening involves detection 
of pre-invasive disease. 
2.1.2.6 Changes in medical practice 
Changes in the tendency of patients to present for diagnosis, the availability and capability 
of medical services and the ability of the doctor to make diagnoses (based on their 
diagnostic efforts, aptitude and technological advances) can influence the likelihood of a 
cancer being diagnosed, as well as the accuracy and specificity of the recorded information 
[23]. Examples include an increasingly aggressive investigation of illness in the elderly, e.g. 
for brain tumours, a tendency towards greater specialisation in medicine, increasing use of 
treatment guidelines, networks and specialist referral. 
2.1.2.7 Changes in population denominators 
Age and sex-specific cancer incidence rates are obtained from the number of stratum-
specific observed cases in a defined population and period, divided by the corresponding 
person-time (by convention, expressed in years), usually taken from population estimates. 
That these persons would have been counted as incidence cases if affected with the 
neoplasm in question is an assumption not strictly met using such crude demographic data 
as denominators, although its is waved for most cancers. There are some exceptions 
however, where an adjustment to the person-time would be desirable. An important example 
is the need for adjustment for prevalence of hysterectomy in the female population in the 
study of uterine cancer trends. An increasing proportion of women in some European 
countries have undergone a hysterectomy in the last thirty years and are consequently are 
at minimal risk of certain cancers, particularly endometrial cancer [130]. Unadjusted trends 
may therefore be attenuated relative to a more accurate temporal description that accounts 
for the prevalence of hysterectomy in each population. 
2.1.2.8 Changes in registration efficiency and practice 
As the registration process becomes more efficient, improving completeness of registration 
with time alongside a greater accuracy and specificity of data may produce artefactual 
changes in the incidence trends. Registries may vary in the rules adopted regarding the 
inclusion of neoplasms, for sites where there is difficulty in distinguishing between 
malignant, benign and unspecified tumours. The major concerns involve tumours of the 
brain and central nervous system as well as the bladder, although trends in melanoma of 
the skin and thyroid may also be affected. Trends in bladder cancer incidence are very 
difficult to interpret without precise information on how registries have dealt with papillomas 
over time. Saxem has shown that, on exclusion of papillomas of the bladder, much of the 
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variation in bladder cancer incidence rates in the Scandinavian countries was removed [59]. 
In general, changes in registry procedures are more likely to affect comparisons between 
registries, rather than trends in a single registry over time, provided such practices do not 
alter over time [113]. 
2.1.2.9 Changes in histological specification 
The study of incidence trends according to histological subtypes is a relatively recent 
activity. The potential for insight over and above the traditional topography-only analyses is 
undeniable, given the evidence of heterogeneity in aetiology, screen detection and 
prognosis among histologies of certain tumours. Parkin et al put together a set of 
histological groups for 15 common cancers with an aim to reach some consensus between 
registries in classifying subtypes [131]. The main difficulties in comparing trends in 
histological groups between and within populations occur when the proportion of cases with 
unspecified histology is large, and has been observed to be changing over time; in such 
instances, the unspecified proportion usually decreases with time, as the specificity of 
known subtypes improves. The utility of trend analyses of histological subtypes, and the 
interpretational difficulties associated with their use, is revisited in Chapter 4, in the temporal 
study of the main histological subtypes of cervical cancer. 
2.2 Mortality 
Mortality provides a measure of the impact of cancer, and is expressed either as number of 
deaths occurring, or as a mortality rate: the number of deaths per 100,000 persons per year. 
Mortality data derive from vital registration systems, where usually a medical practitioner 
certifies the fact and cause of death. The International Classification of Diseases (ICD) 
provides a uniform system of nomenclature and coding, and a recommended format for the 
death certificate. Mortality is a product of the incidence and the case fatality ratio of a given 
cancer. Death rates estimate the average risk to the population of dying from a specific 
cancer, while fatality, the inverse of survival, represents the probability that an individual with 
cancer will die from it. Thus for stable trends over time, a case fatality ratio of 0.25 (equal to 
a survival of 0.75) would yield a mortality rate one-quarter that of incidence. 
2.2.1 Data availability 
Mortality data is usually available by year of death, five-year age group and sex, but its 
relative advantage over incidence stems from its more comprehensive availability at the 
national level; the WHO mortality databank holds mortality data for most countries in 
Europe, and for more extensive periods than that of incidence. Partly for this reason, 
temporal analyses of cancer mortality tend to be more common than those of incidence in 
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the medical and epidemiological literature. There are some potential difficulties interpreting 
mortality rates for some cancers, as discussed below. 
2.2.2 Data quality 
Mortality statistics are produced according to the underlying cause of death; although this 
may not equate with the presence of a particular tumour. Asides from artefacts related to 
registration practices, many of the factors that affect incidence apply equally to mortality 
data given that they both rely on the accuracy of the initial cancer diagnosis [132]. 
Comprehensive mortality statistics require that diagnostic data are available on decedents, 
which are transferred in a logical, standardised fashion to death certificates, which are then 
accurately and consistently coded, compiled and analysed. Death registrations require that 
the correct diagnosis is written on the death certificate and further that this diagnosis is then 
certified as the underlying cause of death [132]. 
Many stUdies have investigated the accuracy of death certificate diagnoses in vital statistics 
data, comparing cause of death entered on the death certificate with a reference diagnosis 
derived from autopsy reports [133], detailed clinical records [134], or cancer registry data 
[135]. Such studies have shown that the level of accuracy of the stated cause of death 
declined as precision in the diagnosis increased; although the total number of deaths from 
cancer of all types was only slightly underestimated, the distribution by site of cancer may 
be incorrect. A tendency to over-record non-specific diagnoses instead of the correct 
location (e.g. large intestine instead of rectum) has been noted, and accuracy is often lower 
in those dying at older ages. Grulich et al on analysing cancer trends in England and Wales 
1970-90 in the age group 75-84 found the rise in all-cancer mortality in the elderly was in 
part due to increasing lung cancer mortality, but data artefacts were responsible for much of 
the increase in the other common specified cancers [136]. 
Percy et al [135] compared death certificates mentioning cancer as the underlying cause of 
death for almost 50,000 incidence cases, contrasting detection rates (proportion of death 
certificates conveying the same diagnosis as that made in life) and confirmation rates 
(proportion of cancer deaths for which the underlying cause was confirmed by hospital 
diagnosis). Over-reporting on death certificates was indicated when the detection rate was 
high relative to the confirmation rate, as was the case for neoplasms of the larynx and colon, 
and unspecified cancers of the uterus. Conversely, underreporting was observed 
(confirmation high relative to detection rates) for cancers of the cervix and corpus uteri, and 
rectal cancers. For melanoma and breast cancer, death certification was deemed more or 
less correct. There were also quite marked differences between different countries in the 
allocation of lCD-codes to death certificate diagnoses [137]. 
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2.2.3 Impact of changing case fatality rate 
Mortality data have been a useful surrogate for incidence patterns in aiming to describe 
changes in population risk. To be interpreted as such, one must assume a case fatality that 
is constant over the study period, and, where treatment has improved sufficiently to affect 
mortality rates, observed incidence and mortality trends may be at considerable variance. 
Mortality rates are therefore not a good representation of incidence rates for cancers where 
prognosis has improved over the study period. 
2.3 Survival 
The survival of a cancer patient is defined as the time that elapsed between diagnosis and 
death. The most basic measure of patient survival is the observed survival, with the five-year 
observed survival being the percentage of patients alive five years after the date of 
diagnosis. Not all deaths among cancer patients will however be due to the primary cancer 
in question. Deaths from other causes lower the observed survival rate and predude 
comparison between groups where the probabilities of death in the general population vary. 
Relative survival avoids this problem of comparability, and is the observed survival in a 
patient group divided by the expected survival of a comparable group in the general 
population, usually with respect to age, sex and calendar period of investigation. 
As with statistics on incidence, survival estimates are produced by cancer registries. To do 
so, they require follow-up of registered cancer cases, either actively or by matching death 
certificates against cancer notifications and assuming that unmatched cases are still alive. 
Population-based figures are becoming increasingly routinely available from registries and 
included in their annual reports. Survival comparisons at the European level have been 
made available through the EUROCARE studies. The most recently published 
(EUROCARE-3) was based on submitted data on patients diagnosed between 1990 and 
1994 from 67 cancer registries in 22 European countries [138]. 
2.4 Prevalence 
Unlike incidence, mortality and survival, which are established indicators in the cancer 
domain, an appropriate definition of prevalence is not universally accepted. Prevalence is a 
more complex measure of cancer incidence, fatality, and other influences operating in 
affected individuals prior to death or "cure". Total (or complete) prevalence is the number of 
persons in a defined population alive at a given time who have had cancer diagnosed at 
some time in the past. However, the resource requirements for treating newly diagnosed 
patients are very different from those for supporting long-term survivors. Thus, overall 
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prevalence is not particularly useful for health care planning purposes, especially as a large 
proportion of long-term survivors can be considered cured. 
Partial prevalence, which limits the number of patients to those diagnosed during a fixed 
time in the past, is therefore a more useful measure of cancer burden. Prevalence for cases 
diagnosed within a certain number of years are likely to be of relevance to the different 
stages of cancer therapy, namely, initial treatment (within one year), clinical follow-up (two to 
three years) and cure (four to five years) [139]. There are some exceptions, primarily that of 
female breast cancer, for which the risk of death remains higher than the general population 
for many more years. 
2.5 Staging information 
Staging refers to the extent of disease in terms of an established and well-defined set of 
rules. It is an essential variable in clinical practice, both in the planning and evaluating 
cancer treatments, and in assessing likely prognosis. In epidemiology and public heath 
research, it is especially relevant in the evaluation of cancer control. Population-based 
cancer registries with adequate resources strive to record such information on every case, 
although in practice, there is often inadequate or inconsistent information in the records for 
staging in a proportion of the cases. The situation is broadly improving, although a tendency 
towards a declining proportion with unknown stage with time, may distort the stage-specific 
trends. 
Where staging data may be considered of reasonable quality, an example of their 
fundamental importance has been in evaluating breast cancer mortality trends at the 
population level. An important aim in the U.K and the U.S., for example, has been to 
establish the underlying reasons for the observed drop in mortality that began during the 
1980s and has subsequently continued [28]. Staging data may be used as a means to 
disconnect the main components of the period effect on mortality, mammographic screening 
and treatment, given screening should bring about an increase in early stage incidence 
among the screen-targeted age group, and a corresponding decline in the number of late-
stage breast cancers. 
The difficulties in deciphering breast cancer trends in populations where early diagnosis and 
treatment may both playa role serves as an example of the need for the co-evaluation of 
trends in mortality, incidence, and survival, stratified, where available, by stage. Although, 
one would ideally be informed by stage- and treatment-specific mortality rates of breast 
cancer, these are seldom complete and available in each of the periods under investigation 
[140]. There has been much debate surrounding inference of survival from breast cancer, 
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given the shift towards earlier diagnosis in some populations. The consequence is an 
increase in incidence and a survival time that is artificially prolonged by lead time; survival is 
improved by advancing the date of diagnosis without necessarily postponing the date of 
death. Mortality is not affected by such a bias. 
There are however numerous examples where a joint analysis of the indicators has been 
instructive. In the U.S, Chu et al have evaluated trends in stage- and age-specific breast 
cancer incidence and survival alongside mortality in white females, concluding that 
screening and treatment were both implicated in the temporal pattern [141]. Significant 
decreases in both mortality and incidence in the age group 40-79 were observed, although 
modelling implied the large drop in mortality between 1989 and 1993 could not be entirely 
due to increasing screening activity. Localised incidence rates increased rapidly from 1982-
87 but were stable or less rapidly rising thereafter. Regional disease rates decreased after 
1987, suggested as a result of increasing use of mammography in the prior period. In 
contrast, the authors commented that improvements in therapy were likely responsible for 
the increasing three-year survival rates observed in cases diagnosed 1980-89 for both 
localised and regional disease, and in all age groups. 
2.6 Incidence versus mortality 
As has been noted above, there has been considerable deliberation on the relative merits of 
incidence, mortality and survival rates in cancer research generally, and in time trend 
analyses specifically [28,57,58,132,142-145]. The importance of determining artefacts and 
considering their contribution to observed cancer incidence and mortality trends have been 
comprehensively addressed by the papers by Saxem [59] and Muir et al [60], while many 
studies have investigated the accuracy of death certificate diagnosis [135,137,146,147] 
Analysing trends in incidence may allow some insight into the possible changes in the 
prevalence and distribution of risk factors that drive the trend. Given its coverage and 
availability, the mortality rate has historically been a useful surrogate for incidence. The 
assumption of constancy over time in the fatality ratio may not hold for cancers where 
prognosis has been improving and novel effective therapies for a number of cancers were 
introduced from the 1960s. Mortality rates are certainly the best measure of disease 
outcome; in determining the beneficial effects of a specific treatment regimen at the 
population level, for example. 
In the same epoch that survival was improving, so cancer incidence was sufficiently accrued 
(in Connecticut and the Nordic countries, for example) to allow detailed analyses of secular 
trends [113]. However, in their landmark study of environmental causes of cancer in the U.S. 
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published in 1981, Doll and Peto utilised mortality rather than incidence data, citing that 
incidence was the more complex to interpret and that two factors were largely responsible 
for their concern. In addition to the artefacts associated with changing efficiency of the 
registration process, Doll and Peto considered the effects of changing practice in 
classification of cancers associated with different rates of fatality and the spread of 
screening tools that detect cases earlier as having had a large impact on the record 
incidence of many cancer types. This neglect of available incidence data drew some 
criticism [148,149] although Doll et al have since reiterated their viewpoints [113]. 
There is a general consensus (including that of Doll and Peto) that a combined description 
of trends in incidence, mortality and survival often serves to confirm and clarify 
understanding of the underlying biological and epidemiological processes, as well as restate 
the relative strengths and weaknesses of each measure in interpretation [58,60,132,149]. 
Doll et al comment that incidence, while of great value, has not removed the need for 
mortality data, necessary - in combination with incidence - to detect improvements in 
therapy, and partly to verify the validity of incidence trends [58]. 
Asides from cancer occurrence data from vital sources, there are a limited number of 
datasets collected on risk factors that may be of some utility in elucidating cancer trends or 
clarifying epidemiological evidence. These are briefly discussed below. 
2.7 Supporting data from health surveys 
Increasing rates in lung cancer mortality in men in the last century were shown to closely 
approximate the upsurge in smoking prevalence in the underlying population several 
decades before. The relation between tobacco consumption and lung cancer is of course 
beyond doubt - the majority of cases would be avoided on elimination of cigarette smoking 
- particularly in countries where the habit has long been established [150,151]. Rather than 
being attributed to specific carcinogens however, many common cancers have a more 
complex, multifactorial aetiology. Moreover, there is often a lack of information on important 
population exposures for a given cancer, either in specific populations or over time. 
Where such data are available, in sufficient detail and of reasonable quality, trends in 
exposure data may be compared to trends in disease to ascertain which are credible as risk 
factors in the study population. To better understand incidence and mortality trends in 
breast, endometrial and ovarian cancer in England and Wales, Dos Santos Silva et al 
presented the cancer-specific trends alongside changes in fertility and oral contraceptive 
use [152]. Increases in breast cancer incidence rates were rapid among successive 
generations up to the end of the 19th century, mirroring dedining fertility. Slower increases 
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were observed for cohorts thereafter, with declines seen in consecutive generations born 
after 1920. On the basis of the exposure trends, it was speculated, among other 
possibilities, that the introduction and increasing use of oral contraceptives may have 
produced a long-lasting protective effect. 
Comparisons of changing risk factors among several populations has the advantage that it 
is less prone to confounding than with a single population, given that unmeasured factors 
related to both exposure and changes in trends are less probable in several different 
populations, than would be the case be in just one [153]. More generally, ecological 
comparisons provide only weak evidence of associations, are potentially misleading, and 
are susceptible to certain problems and biases. One issue is the imposition of an 
appropriate time lag between exposure and cancer occurrence, which may be rather 
arbitrary. Furthermore, exposure information may not be available for the relatively distant 
past, and, where it is, the corresponding population data may comprise different individuals, 
given a wide enough interval between exposure and cancer. The main problem involves the 
weak assumption that trends in a particular exposure apply to all members in that 
population. There may be differences in the relationship at the individual level (within 
groups) and the group level (between groups) [153]. 
Several monographs on temporal trends have included chapters that describe available 
trends in common risk factors in the population of interest. Thus Rouch et aI, in describing 
incidence of common cancers in Connecticut, U.S., provide tabular and graphical 
descriptions of trends in tobacco and alcohol consumption, as well as a number of dietary, 
reproductive hormonal and occupational factors state- or nationwide. Swerdlow et al 
presented an introductory chapter corresponding to an A-Z of trends in almost 60 risk 
factors to complement their study of cancer incidence and mortality trends in England and 
Wales [23]. 
In Europe, the availability of collections of risk factor data is rather limited. Data on trends in 
tobacco consumption is however well-covered by the reference volume International 
Smoking Statistics which comprises historical data from 30 developed countries, based on 
sales data from the Tobacco Research Council supplemented by survey data on smoking 
habits by age and sex [22]. A number of lifestyle factors have been collated at the European 
and international level and made available as online databases. Several risk factor surveys 
have provided valuable trends in exposures. The WHO MONICA Project (Multinational 
MONitoring of Trends and Determinants in CArdiovascular Disease) was established to 
monitor trends and determinants of cardiovascular diseases [154]. Population surveys for 
the main risk factors were conducted in geographically defined populations in 21 
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predominantly European countries. The related Health for All software package contains 
temporal data covering a number of maternal and child health indicators [155]. The WHO-
CINDI Programme (Countrywide Integrated Noncommunicable Disease Intervention) was 
initiated in 1982 by the WHO Regional Office for Europe [156]. CINDI surveys have been 
conducted in defined regions in 26 European countries and include risk factors that are 
common to a number of chronic noncommunicable diseases, and include smoking and 
excessive alcohol consumption. Detailed data on dietary factors are available in the 
European Prospective Investigation into Cancer and Nutrition (EPIC) study, a cohort study 
of over 500,000 healthy, middle-aged men and women in 23 centres in 10 countries [157]. 
2.8 Data sources used in this thesis 
A critical review of APC methods in Chapter 3 is put in practice in Chapters 4 to 6 using data 
available at the national or regional level for incidence, obtained with permission from 
members of the European Network of Cancer Registries (ENCR), the population-based 
cancer registries in Europe. Mortality data was extracted from the WHO Mortality Databank. 
Chapter 4 provides an analysiS of trends in cervical cancer incidence by histological 
subtype; Chapter 5, an analysis of endometrial cancer incidence and mortality trends and 
Chapter 6 analyses trends in testicular germ call cancer incidence (by main histological 
subtype) as well as testicular cancer mortality. 
Incidence and mortality analyses were carried out using Stata [158]. Details of the inclusion 
criteria are listed below; further details, additional inclusion and exclusion criteria, and 
pointers to data quality concerns are contained within the specific chapters under the 
heading Data Sources. The data were analysed and presented according to the United 
Nations (UN) classification of Europe; this definition classifies 38 countries into one of four 
areas [159], as shown in the map of Figure 2.1. 
2.8.1 Incidence 
ENCR members are asked to make regular submissions of incidence, mortality and 
population data to a central EUROCIM data bank held at the IARC [160]. The incidence data 
from each registry are converted to ICD-O-2 and subjected to a set of validity checks. No 
attempt is made however to impose any inclusion restrictions on the basis of quality, and all 
submitted registry datasets are included in the final EUROCIM database. 
For the purposes of the analyses detailed in Chapter 4-6, incidence data was extracted from 
the EUROCIM by registry, topography (ICD-O-2), histology (ICD-O-2), year of diagnosis, 
and five-year age group. Corresponding data on person-years at risk, derived from 
population estimates supplied by each registry were also available in EUROCIM by year, 
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age and sex. To confine the analyses to data considered to be of high quality, a minimum 
requirement for a registry's inclusion in the analysis was their consecutive compilation in the 
last three volumes (VI-VIII) of CIS [18,161,162]. This criterion was chosen as a general 
marker of each registry's data quality over time, given the editorial process involves a 
detailed assessment of the comparability, completeness and validity of the submitted 
incidence datasets. 
For eight countries, a number of regional registries were aggregated to obtain an estimate of 
the national incidence trends. It was therefore assumed that the regional characteristics 
accorded with the national population profile, in terms of socioeconomic status, customs, 
and urban/rural mix, and so forth. 
As the span of data available from regional registries varied, the aggregation aimed to 
maximise the registration period, while ensuring as many of the regional registries were 
involved in the national estimation. An attempt was made to ensure the same registries were 
used throughout the elected time period, although in practice, some registries did not cover 
the whole span. The possible systematic error induced by the sudden inclusion or removal 
of a registry with a shorter period of coverage than the designated study period was 
considered to be of less concern than the loss of that registry's contribution of data in its 
entirety. 
A minimal span of recent data was required in order to apply the main statistical techniques 
in practice: each dataset was required to span at least 11 years to allow join point regression 
(see 3.2.3.2), and a minimum of 15 years was required for APC analyses (see 3.3.1). The 
European countries involved, the area covered by cancer registration, and the years of 
registration available, are summarised in Table 2.1. Due to computation difficulties in dealing 
with small numbers, Iceland was not included in the APC analyses. 
2.8.2 Mortality 
National mortality data were extracted from the WHO mortality databank, which contains 
death data officially reported by WHO Member States, by topography (lCD-g), five-year age 
band, sex, and year of death. Population data were extracted from the same source. The 
only rules for inclusion were that countries were listed in the UN classification of European 
countries, and as for incidence, the span of data was at least 11 years (for joinpoint 
regression) and 15 years (for APC analyses). The countries and years for which national 
data were available are presented in Table 2.2. 
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Figure 2.1: Map showing the four European areas studied, as defined by the UN 
[159] 
NORTHERN EUROPE 
Denmark, Estonia , Finland, Iceland, 
Ireland, Latvia , Lithuania, Norway, 
Sweden, United Kingdom 
Belarus . Bulgaria, Czech Republic , 
Hungary, Poland, Republic Of 
Moldova, Romania , Russia, Slovak ia, 
Ukraine 
Albania, Croatia , ~Yf<?!!1 (Macedonia), 
Greece, Italy , Malta, Portugal, 
Slovenia , Spain 
WESTERN EUROPE 
Austria , Belgium, France. Germany. 
Luxembourg , Netherlands, 
Switzerland 
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Table 2.1: Cancer incidence by registration status, where data were available for a 
span of years ~ 11 (for joinpoint analyses) and ~15 (for APC analyses) 
European Country Joinpoint: Registration status APC: 
Area Period available {years available where regional} Period available 
{year span} (# fIVe-year 
periods) 
Northem Denmark 1978-1998 (21) National 1979-1998 _(4) 
Estonia 1968 - 2000 (33) National 1971-2000 (6) 
Finland 1953 -1999 (47) National 1955-1999 (9) 
Iceland 1955 - 2000 (40) National N/A 
Norway 1953 - 1997 (45) National 1953-1997 (9) 
Sweden 1960 - 1998 (39) National 1 964-1 998 (7) . 
England (1978-1997) 
United Kingdom 1981 -1997 (17) Scotland (1978-1997) 1978-1997 (4) 
Eastem Czech Republic 1985-1999 (15) National 1985-1999 (3) 
Cracow City (1978-1997) 
Lower Silesia (1987-1997) 
Poland 1986 - 1996 (11) Warsaw City (1978-1997) N/A 
Slovakia 1968 - 1997 (30) National 1968-1997 (6) 
Florence (1985-1997) 
Varese Province (1983-1997) 
Parma Province (1983-1997) I I 
Ragusa Province (1983-1997) i 
Southem Italy 1983 - 1999 (17) Turin (1985-1997) 1983-1997 (3) 
Slovenia 1980 -1997 (18) National 1985-1999 (3) 
Tarragona (1980-97) 
Granada (1985-97) 
Murcia (1984-96) 
Navarra (1978-97) 
Spain 1978 - 1997 (20) Zaragoza (1 981-95) 1983-1997 (3) 
Bas-Rhin (1975-1997) I 
Calvados (1978-1997) 
Doubs (1978-1997) 
Isere (1979-1997) 
Somme (1982-1997) 
Westem France 1978 - 1997 (20) Tam (1982-1997) 1978-1997 (4) ! 
Germany 1981 -1997 (17) Saarland (1981-1997) N/A 
Basel (1983-1997) 
Geneva (1983-1997) I 
Neuchatel (1983-1996) 
St.Gall-Appenzell (1983-1997) 
Vaud (1988-1996) 
1983-1997 (3) Switzerland 1983 1997 (15) Zu rich (1983-1996) 
Eindhoven (1958-1997) N/A I 
The Netherlands 1974 - 1997 (24) Maastricht (1 986-1998) ! 
N/A: not applicable. Either there was <15 years available in the data series or, for the cancers analysed in this thesis, the underlying numbers were 
too sparse to provide reliable results on fitting the APe model. 
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Table 2.2: Cancer mortality data available for a span of years ~ 11 (for joinpoint 
analyses) and ~15 (for APC analyses) 
European Area Country Joinpoint: APC: 
Period available Period available 
, (year span) (# five-year periods) 
Northem Denmark 1969 - 1999 (31) 1969-1998 (6) 
Estonia 1981 - 2002 (20) N/A 
Finland 1969 - 2002 (34) 1970-1999 (6) 
Iceland 1969 - 2002 (34) N/A 
Ireland 1969-1999 (31) 1969-1998 (6) 
Latvia 1969 - 2000 (32) N/A 
Lithuania 1980 - 2002 (23) N/A 
Norway 1981 - 2002 (20) 1969-1998 (6) 
Sweden 1969 - 2001 (33) 1969-1998 (6) 
United Kingdom 1969-1999 (31) 1970-1999 (6) 
Eastem Belarus 1981 - 2001 (19) N/A 
Bulgaria 1970 - 2002133) 1970-1999 (6) 
Czech Republic 1986 - 2001 (16) 1986-2000 (3) 
Hungary 1970 - 2002 (33) 1971-2000 (6) 
Poland 1970 - 1996 (27) 1980-1994 (3) 
Republic of Moldova 1981 - 2002 (20) N/A 
Romania 1970 - 2002 (32) 1981-2000 (4) 
Russia 1980 - 2002 (23) N/A 
Ukraine 1981 - 2000 (18) N/A 
Southem Croatia 1972 - 2000 (29) 1986-2000 (3) 
Greece 1969 - 1990 (22) 1969-1998 (6) 
Italy 1972 - 2002 (31 ) 1969-1998 (6) 
Malta 1972 - 1997 (26) N/A 
Portugal 1972 - 1999 (28) 1980-1999 (4) 
Slovenia 1983 - 2001 (19) N/A 
Spain 1972 - 2002 (31 ) 1974-1998 (5) 
Westem Austria 1985 - 2002 (18) 1971-2000 (6) 
Belgium 1972 - 1999 (28) 1971-1995 (5) 
France 1972 - 2000 (29) 1969-1998 (6) 
Germany 1972 - 2002 (31) 1985-1999 (3) 
Luxembourg 1972 - 2000 (29) N/A 
Switzerland 1985 - 2002 (18) 1970-1994 (5) 
The Netherlands 1969 - 2001 (33) 1970-1999 (6) 
N/A: not applicable. For the cancers analysed in this thesis, the underlying numbers were too sparse to provide reliable results on 
fitting the APe model. 
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3 Methodological approaches to analyses of cancer trends 
This chapter presents a summary and critique of the various approaches at a researcher's 
disposal in analysing time trends of cancer occurrence. In putting forward some 
recommendations for an appropriate analysis, emphasis is put on the need for approaches 
to data collection, analysis and presentation that maximise comparability, and a description 
of trends that makes full use of any a priori knowledge regarding the biology and 
epidemiology of the cancer under investigation in the study population. The review covers 
the following areas: 
• The use of graphical descriptions as exploratory analyses: 
o Graphical depictions are a key fixture of temporal analyses. They necessarily 
involve choices regarding the form of the rate (e.g. standardised or stratified) 
and the particular time component (age, period or cohort) to plot against it. 
The selection of scale (e.g. arithmetic versus a log-transformation of the Y 
axis) and the dimensions of the graph (ratio of the Y to X axes) are often 
considered trivial matters; scaling however can accentuate or attenuate 
particular observations and some advocated rules for presentation are 
discussed. 
• The use of models to quantify temporal change: 
o Simple methods that estimate relative and absolute changes over time are 
standard, but the magnitude of change depends on the form of model and the 
period of time considered. The degree of linearity in the underlying data will 
dictate how informative relative changes are. Recently, methods (and 
dedicated software) have become available for determining abrupt linear 
changes in the trend, which remove, to some extent, the arbitrariness 
involved in selecting an appropriate time period. 
• The APC model: characteristics, the identifiability problem, and approaches to 
presenting the parameter estimates: 
o The relative straightforwardness of fitting APC models is at odds with the 
difficulties in providing an informed presentation of the model parameters, 
given the irresolvable issue of non-identifiability. Statisticians and 
epidemiologists have taken a keen interest in developing methods to 
circumvent non-identifiability since the late-1970s, and as a result, a wide-
range of methods are presently available and used in practice. A critical 
review requires a suitable classification of approaches, and each method is 
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considered in terms of its degree of arbitrariness (and the extent to which a 
strategy connects to external knowledge available) and its complexity (in 
terms of both the method and its interpretation). 
• A review of the application of APe models to cancer trends 2000-2004: 
o APe modelling has also become an established tool in practice. A thorough 
search and description of relevant articles in medical and epidemiological 
journals in recent years provides an opportunity to review current practices 
regarding the analysis of cancer trends. 
The following text therefore assimilates and appraises the various techniques proposed, 
from graphical presentations (3.1) and the estimation of the rate of temporal change from 
simple linear models (3.2), through to more sophisticated analytic techniques using the APe 
model (3.3) and in particular, the various approaches to dealing with the non-identifiability 
problem (3.4). A review and critique of current literature is outlined in 3.5. 
The broad aim of this chapter is to provide some recommendations for a researcher wishing 
to perform an analysis of temporal variations in cancer rates, and these are given in 3.6. The 
value of these guidelines in practice - obtained as they were from a mainly methodological 
perspective - will be put to test in later chapters. 
3.1 Graphical presentation of trends and their attributes 
As reviewed in the introductory chapter, early approaches to analysing time trends mainly 
focussed on graphical or tabular approaches that related age patterns to existing knowledge 
of disease biology. Despite the use of mathematical modelling of age and cohort as early as 
1927 [78], general usage of APe models began during the last decades, and in the study of 
cancer, mainly since the 1970s, an early example being Barrett's analysis of cervical cancer 
[87]. 
Despite a shift of emphasis towards a modelling framework, graphical approaches remain 
an intrinsic part of good data analysis [163]. Exploratory data analysis (EDA), as originally 
set out by Tukey [164], is a philosophy as to how best to dissect a dataset; what should be 
investigated, how it should be undertaken, and how it is then interpreted. EDA uses mainly 
graphical techniques to analyse the dataset, as its main role is to open-mindedly explore. 
Graphs may often reveal the structural characteristics of the dataset, as well as open the 
possibility of gaining new or unsuspected insight into the data. In combination with the 
pattern-recognition skills that humans naturally possess, graphical descriptions thus provide 
unparalleled power to carry this out. 
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Unquestionably no statistical tests or estimations should commence without a thorough 
understanding of the underlying relationships between the variables in the dataset. Pre-
analysis strategies may find coding errors or outliers in the raw dataset. Given the lack of a 
unique set of age, period and cohort parameters in the APC model, interpretation is aided by 
an understanding of the basic features of the observed trend data that graphical approaches 
provide. These relations may establish hypotheses regarding the nature of the trends, and 
may lend support to a particular approach to APC modelling that is more informative and 
less arbitrary. 
Although some authors have offered some guidance in visually depicting trends in disease 
rates [165], such displays are usually heterogeneous in the literature, possibly reflecting the 
fact that the technical issues involved are not given high priority, leaving the graphical 
depiction a matter of individual preference. In consequence, there can be difficulties 
comparing results across studies; some guidelines towards a more systematic 
representation of trends may therefore be of some value in this respect, acting as a pointer 
for future temporal analyses. 
The following sections consider what underpins a good graphical presentation, making 
some minimum recommendations to improve comparability and aid interpretation of 
temporal studies. The type (and level of detail) of the statistical measures portrayed is 
discussed in 3.1.1, and some of the key technical properties of the graph itself, the scale 
and ratio of the axes, are described in 3.1.2 and 3.1.3, respectively. The various ways to 
summarise rates plotted against, or stratified by age, period and cohort are reviewed in 
3.1.4. 
3.1.1 Age-adjusted rates 
There are powerful reasons for adjusting for the effects of age when comparing cancer risk 
in populations over time. Age is a strong determinant of cancer risk. In general terms, the 
risk of epithelial cancers, which comprise nine-tenths of all human cancers worldwide, 
increase approximately as a fifth power of age [166], representing about a 1000-fold 
difference in cancer rates between young (aged 20) and old persons (aged 80). In addition, 
the demographic effects of ageing and population growth will continue to have a major 
impact in European countries, particularly within the next two decades [159]. Direct 
standardisation procedures yield the age-standardised rate [167] and cumulative risk [123], 
both of which absorb the schedule of age-specific rates, allowing comparisons of cancer risk 
over time in the same population using a single summary measure. In the former, a 
standard population with a fixed age distribution - such as the World standard of Segi [168], 
later modified by Doll [169] or the European standard [170] - is applied to the age-specific 
55 
rates to obtain an expected summary rate if the population of interest had the same age 
distribution as the standard. 
Trends in age-adjusted rates are often not the best way to examine cancer risk either 
geographically or temporally [123]. Strictly speaking, trends in this measure are only 
accurate in the absence of an interaction between age and calendar time. Trends in age-
standardised rates by calendar period may thus mask important changes in the age-specific 
rates, particularly in the presence of strong birth cohort effects [171]. 
Figure 3.1 presents annual trends in lung cancer mortality rates in women in England 1971-
1997 using three rate measures, the all-ages age-standardised rate, age-truncated rates 
(age groups 30-49, 45-64 and 65 or over) and five-year age-specific rates. The age-adjusted 
rate conveys the idea of a levelling off of lung cancer rates in all women by the late 1980s, 
but fails to give an accurate picture of the underlying trends for certain age groups. 
According to the truncated rates, there have been substantial dedines in younger women 
aged 50-64 since this time, while rates in the youngest age group have been decreasing 
throughout the 30-year period. Generation-specific decreases become more evident when 
the mortality rates are plotted versus period by five-year age band, as depicted in the right-
hand diagram of Figure 3.1 (see 3.1.4). 
There can be no substitute to an inspection of age-specific rates in temporal analyses, as 
these serve to validate the use of age standardisation and provide valuable background 
information in interpreting results from more complex modelling procedures [171]. Trends in 
age-adjusted rates may be informative if they are used to facilitate a summary of the trends 
allowing a comparison across several populations, with the understanding that the 
underlying trends in age-specific rates form the foundation of the analysis. Valuable 
information can be gleaned from visual descriptions of the age-standardised rates over time 
across populations, such as the portrayal of incidence and mortality trends of various 
cancers in different countries with regions worldwide [35]. Age-truncated rates used in 
accordance with the epidemiological profile of the cancer under study, may succinctly 
summarise the major changes in the trends, with diverging trends by age group, suggestive 
of birth cohort effects and the need for a more detailed analysis of the time components. 
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Figure 3.1: Lung cancer mortality in women in England and Wales 1971-97. AlI-
ages. and truncated ASR (Europe) vs. calendar year (left diagram); five-year age-
specific rates (30-84) vs. calendar year (right diagram) (source: WHO) 
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Graphical descriptions may be ambiguous if the rates are associated with excess random 
variation. In such instances, it is common practice to aggregate the number of events and 
person-years at risk over several years (commonly aggregates of 3 or 5 years). 
Alternatively, moving or rolling averages can be calculated, with the advantage of retaining 
(with the exceptions of the first and last point) single-year rates that are aggregated mean 
estimates centred around their midpoint, although disadvantaged by the fact that the 
average rates are no longer independent of each other. Aggregated rates tend to be 
smoother than the rolling mean alternative, and given they retain more information regarding 
the trend, may be the preferred option. 
Indirect standardisation is used seldom in time trends studies, although age-standardised 
cohort ratios have been favoured by some epidemiologists investigating temporal studies of 
cancer mortality in England and Wales [23,89,172]. The approach requires age-specific and 
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birth year-specific data, and therefore the individual records of events. The age-
standardised cohort mortality ratio (SCMR) summarises the risk of death in each birth cohort 
at the age they have attained in the study period relative to the expected mortality at the 
same ages in the population overall, adjusting for population structure between cohorts [23]. 
3.1.2 Semi-log vs. arithmetic displays 
Two types of scale are in general use in plots of rates over time: the arithmetic (no 
transformation of either axis) and semi-logarithmic (logarithmic transformation of the 
ordinate). Both transformations are regularly applied in epidemiological literature to 
graphically portray disease rates over time. 
Arithmetic scales are appropriate where absolute rather than relative changes in magnitude 
are the main point of interest, for example when temporal trends of greater magnitude are 
considered to be of greater consequence when the absolute values are large. Examples in 
public health include the evaluation of operating costs for a vaccination programmes over 
time, the number of interval cancers in a screened population, or the predicted number of 
breast cancer cases as an indication of the resources required for treatment. The slopes of 
the trend line reflects absolute changes in the rate over time, and can be estimated by fitting 
a simple linear regression to the rate with time fitted as a continuous covariate (see 3.2.2). 
There are two reasons why the semi-log display may be of greater utility in studies 
investigating changes in rates with time. Firstly, rates of very different order of magnitude 
may be plotted and visually interpreted. A visual interpretation of rates associated with few 
events alongside those with many is enabled, such as trends in five-year age-specific rates 
of lung cancer incidence in men aged 30-74, or the comparison of trends in rates of a rare 
versus a common cancer. Secondly, it should be considered important in epidemiological 
research to identify proportional changes in rates among populations where the baseline 
rates differ [165]. The semi-log display is particularly effective at depicting relative changes 
in risk over time in low risk relative to higher risk groups, providing evidence of similarities or 
differences in the trends between groups. Figure 3.2 illustrates the arguments by contrasting 
the use of the arithmetic and semi-log displays in portraying trends in age-adjusted female 
breast cancer mortality in five populations. The large and uniform increases in Japan 
(relative to the U.S., for example) are played down by the use of arithmetic scaling of the Y-
axis, given the lower baseline rate. On a log scale, the two-fold increase in death rates in 
Japan is readily apparent, a much larger increase than observed in high-risk areas but 
similar to the rate of increase that was seen among Spanish women. 
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It remains true that both semi-log and arithmetic scales have interpretational advantages in 
certain circumstances; it has been argued, for instance, that use of the log scale may 
conceal important period or cohort effects, primarily in the older age groups when the rates 
are of a large magnitude [109]. In the temporal analysis of rates however, the log-
transformed plot should generally be preferred, given its interpretational link with log-linear 
modelling, and the concept of multiplicative effects for which relative changes in rates with 
time for all ages can be viewed as a series of parallel lines. 
Sufficiently detailed labelling of a log-transformed ordinate may also be important, in order 
that absolute changes over time can also be calculated and evaluated. The log-scaled 
ordinate may be labelled (or ticked) as deciles of each cycle e.g. from 0.1 to 1, 1 to 10,1 to 
100, and so forth. If the rate of change is constant, the observed time trend will be a straight 
line on a semi-log display. Quantification of this regular trend, often described as the 
estimated annual percentage change (EAPC), can be obtained (together with an estimate of 
its precision) via log-linear modelling (see 3.2.2). 
Figure 3.2: Age-standardised (World) mortality rates of female breast cancer in 
five countries 1960-97 examined on an arithmetic and a semi-log scale 
respectively (source: WHO) 
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3.1.3 Ratio of Y:X axis 
Devesa et al [165] describe the potential differences in interpretation of the magnitude and 
direction of the time trend on altering the ratio of the Y - to X-axis. Fundamental is the degree 
to which a time-related increase or decrease will be evident. One sensible rule, the authors 
propose, allows a 1 % change in the rate per annum to be detected by a 10° change in the 
slope. To determine the Y:X ratio, the span of the abscissa must be considered in relation to 
the range of values for the rate described on the ordinate. Assuming a semi-log 
transformation, the proposal works for a one-cycle ordinate (e.g. 1 to 10) and a 40-year 
abscissa plotted giving a Y:X ratio of 1:1 and a square graph. Alternatives such as a 2-cycle 
40-year graph (Y:X ratio of 2:1) and a 3-cycle 20-year (Y:X ratio of 6:1) would visually 
represent the slope of the trends equivalently. The adoption of uniform scaling rules in 
recent stUdies by its proponent and collaborators has led to a degree of comparability 
among these studies not seen elsewhere in the trends literature (see also 3.5.3). 
3.1.4 Graphical displays by age, period and cohort 
3.1.4.1 Line charts: Korteweg's approach 
The demonstration of the importance of the birth cohort phenomenon (when compared with 
cross-sectional trends on the same graph) is often attributed to Korteweg's study of lung 
cancer mortality trends in England and Wales [72,82]; but its roots are in earlier work such 
as Frost's examination of tuberculosis mortality in the U.S. [73], as discussed in Chapter 1. 
The lung cancer graph associated with Korteweg, connected, as solid lines, the age-specific 
rates by period, and as broken lines, the rates in each cohort. This conveyed in a single 
diagram the idea that cohort influences were a more plausible explanation for the rising lung 
cancer rates than period of diagnosis. Given the strong tendency for risk of lung cancer to 
increase with age, the description of rates declining in later ages in each successive period 
seemed implausible and an effect produced by artefact. The cohort-specific representation 
however provided a more rationale explanation for the observed lung cancer trend, with 
rates uniformly increasing in successive generations regardless of age, therefore explaining 
the potential for an erroneous interpretation with the period display. 
In an interview looking back at his career, Sir Richard Doll recently described the need to 
persuade the medical community of the causal link between smoking and lung cancer even 
after publication (with Sir Austin Bradford Hill) of their landmark report in 1950 [173]: "If 
smoking is the cause, we ought to find that wherever the disease was common, smoking 
should be common, and vice versa ... And that's what we found when we looked round the 
world" [174]. The realisation of a regular age relationship and sharply rising death rates with 
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each generation and in successive generations would have helped to convince the 
unconverted of the carcinogenicity of tobacco [74]. 
3.1.4.2 Line charts: rates versus age by period, cohort 
Portraying rate versus age by period and birth cohort in a single graph demonstrated both 
the importance of generational changes and the misrepresentation of the period curve as an 
indicator of an inconsistent degree of immunity at different ages, when applied to 
tuberculosis infection [73]. Rates at older age were artificially pulled down due to this age 
group passing through greater risk earlier in life (as picked up by birth cohort trends). The 
graphical display of lung cancer trends in this fashion is cited as a textbook example of 
temporal relations and differences between period and cohort [65,71,82], though for many 
other neoplasms, the relationships are less clear, and by necessity, graphs are usually 
plotted separately by period and cohort. 
The first- and second-left graphs of Figure 3.3 depict observed (logarithm of) female breast 
cancer rates versus age by period (A by P) and versus age by cohort (A by C) respectively, 
based on mortality data from Japan [68]. When examining such period or cohort curves, 
there are a number of features that alert us to a particular interpretation [175]. Curves that 
appear to be placed on top of each other indicate that there is no increase in the regular 
time trend, with fluctuations the result of random variation. If there are steady increases in 
incidence by period or cohort, the lines wi" be relatively para"el, with the most recently 
diagnosed or the most recently-born generations, respectively, experiencing the highest 
rates. 
A lack of para"elism in such curves however - indicative of increases or decreases affecting 
some age groups more than others - can lead to difficulties in interpretation of the temporal 
patterns. In Figure 3.3, the A by P and A by C plots display such characteristics, although 
some parallelism can be seen in younger age groups at diagnosis e.g. among those aged 
under 65 and more recent generations e.g. among those born after 1900. The 
interpretational difficulties with these displays leads to more informative plots of logged-rates 
versus cohort by age (C by A) and versus period by age (P by A), as discussed below. 
3.1.4.3 Line charts: rates versus period and cohort, by age 
The rate versus age graphs were perhaps more commonly utilised in early temporal studies, 
where interest was focused mainly on interpreting cross-sectional age curves to better 
understand the known biology of disease. More recent practice favours comparisons of plots 
of rates versus period and birth cohort, with lines connecting each age group, given that 
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interest is directed primarily at how rates vary temporally, rather than how they may differ by 
age. 
The centre-right and extreme-right graphs in Figure 3.3 show the Japanese female breast 
cancer mortality rates as C by A and P by A plots. Uniform changes in the rates in specific 
periods or birth cohorts can be more readily identified when the period and cohort lines are 
connected by their respective age group. 
Period effects are evident if there is a sudden change in the slopes in each of the studied 
age groups at a given period of time, for example, following the introduction of screening or 
a new diagnostic tool that leads to a similar change in the rates among all affected age 
groups. Period effects often indicate possible artefacts that may affect all age groups 
similarly, such as would result following a change in classification. 
Cohort effects are established if a sudden change affects a particular generation 
(irrespective of their age at diagnosis). Often, such changes in rates among a particular 
generation are followed by the continuation of the trend in successive generations, 
symptomatic of the introduction or removal of a highly carcinogenic agent (changes in 
tobacco consumption or in sexual behaviour are well-known examples). The C by A plots in 
Figure 3.3 illustrate its value - uniform increases in rates of breast cancer are seen in 
successive generations of Japanese women born since the tum of the twentieth century. 
The use of equivalent time scales for period and cohort forces the length and basic shape of 
the lines to be the same for both period and cohort, and in doing so, provides a first 
indication of the nature of the identifiability problem in applying APC models; while the 
regular trend corresponds to both period and cohort, changes in the rates at specific points 
on either time axis (the non-linear components) are identifiable (see 3.3). 
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Figure 3.3: Representations of rates by time. left to right: rates vs. age by period (A by P); rates vs. age by cohort (A by C); 
rates vs. cohort by age (C by A); rates vs. period by age (P by A). Breast cancer, Japan 1953-77 (Source: [68]) 
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3.1.4.4 Other graphical methods 
The graphical depictions conveyed thus far project the three-dimensional response surface 
onto a two-dimensional plane via the use of line charts. A difficulty in interpretation in the 
isolation of one of the time factors has led to the advocacy of more complex multi-
dimensional methods. One display attempts to simultaneously depict the effects of age, 
period and cohort using a 'contour' plot, and such displays may have certain applications 
when the temporal patterns are complex. Ultimately however, the need to concurrently 
control for all three factors in a graphical analysis leads aptly to the use of a modelling 
framework, set out below. 
The disentangling of the age-specific rates for many neoplasms is not as straightforward as 
the classic lung cancer example above. Boyle and Robertson use the latter example to 
show the benefits of a 'surface' or 'perspective' plot, where age, time (period or cohort), and 
the rate are the X, Y and Z-axes, respectively [109]. In certain instances the surface plot 
conveys information that could not be gleaned from the traditional line plot; although as 
Holford points out, such a representation is often complex to interpret [110]. The magnitude 
of a specific effect is difficult to assess, and given that only two of the three axes are 
displayed in anyone graph, it remains unclear as to how the rates in one axis change at a 
predetermined point of the other time axis. 
Other methods have attempted to simultaneously graph the age, period and cohort 
attributes by creating a diagram consisting of equilateral triangles, the three sides of which 
represent the effects of age, period and cohort. Contour plots describe the response curve 
in terms of a set of projected lines that are constant on the two-dimensional plane (e.g. age 
vs. period or age vs. cohort). These graphs are considered particularly useful for more 
complex situations where multiple disease aetiologies are considered likely. Following the 
parallel lines on either axis enables one to gauge how fast rates are changing according to 
how rapidly contours are crossed. Regions where contours are parallel on the period axis 
indicate no temporal trend in the rate by calendar time. Conversely, if they cross, there is 
evidence of a period effect. The diagonal lines indicate constant changes in cohort and, in 
the same way, generational effects can thus be simultaneously evaluated according to 
whether the contours are parallel or cross on the diagonal axis. Such representations have 
largely been attributed to Weinkam and Sterling [176], although, as Keiding point outs 
[177,178], activity in this area stem back at least to the 19th century demography in 
Germany, including such an equilateral representation by Lexis in the context of marriage-
death models [70]. 
Graphical displays may also exploit multivariate techniques including biplots and 
correspondence analysis. Robertson and Boyle comprehensively review various graphical 
approaches to APC analysis [109]. In general, the usage of more elaborate graphical 
methods than the standard line charts described in 3.1.4, has been rather minimal. 
3.2 Descriptive measures of temporal change 
3.2.1 The role of statistical modelling 
Conclusions based on graphical means are often not straightforward and may not by 
themselves provide satisfactory levels of inference. It is in these situations that our 
understanding of the evolution of cancer risk can be greatly enhanced by the use of more 
formal statistical procedures. Models offer quantitative and comparable estimates of trend 
based on objective criteria for choosing the best description of the data, and statistical tests 
to decide whether the trends may be real or due simply to chance [57]. The consequences 
of subjective judgments based exclusively on graphical descriptions are thus avoided. The 
interpretation of cancer trends is however often complex and statistical models will not 
provide definitive answers. When used skilfully they may however aid interpretation of the 
observed temporal patterns. 
Time trend data should be analysed according to the problem under investigation, and the 
structural characteristics of the data. In cancer monitoring, the goal might be to quantify 
recent trends in cancer, making statements as to the needs for future health priorities on the 
basis of anticipated future trends. The EAPC provides a summary of the magnitude and 
direction of the trend, and is obtained from log-linear modelling (see 3.2.2). This procedure 
has an arbitrary element however, in that the trend estimate will depend on the extent of log-
linearity in the selected period. Alternatively, one may wish to determine the EAPC for 
periods of time between statistically significant abrupt changes in the linear trend, as 
discussed in 3.2.3. 
3.2.2 Estimated Annual Percentage Change 
Assuming the background age-specific rates over time are proportional on an arithmetic 
scale, and constant on a log scale, the EAPC of the age-standardised rate can be estimated 
from the slope parameter on fitting a log-linear model to the summary rate and including the 
time axis as a covariate: 
E[logrjJ = J1 + 5· j {3.1} 
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The log-transformed age-adjusted rate rj in period j is assumed to be normally distributed 
with mean Aj' J is the slope over j, f.1 is the intercept. The EAPC is the value e6 -1 :::: J 
if J is small. If however there is a degree of curvature in the trend on a log-scale, the model 
is likely to be inadequate and the EAPC not interpretable. Alternative models that allow 
polynomial terms for time may be explored. Models with quadratic and cubic terms (or if 
necessary higher order terms could be added to {3.1} to determine the extent of curvature 
over and above the fitted linear slope: 
{3.2} 
{3.3} 
The models are hierarchically nested so comparisons of model {3.2} with {3.1} and model 
{3.3} with {3.2} may be tested for second and third-order curvature respectively. 
Alternatively (and as a test of the proportionality assumption required above), the mean rate 
of change in the age-specific rates can be estimated on assuming the number of cancer 
cases dij is distributed as a Poisson random variable with rate rij = dij /Yij where r;j is the 
number of person-years in age group i and period j , assumed fixed and known, and Q j is 
the effect of age group i, J the linear slope when period is fitted as a continuous covariate 
over calendar time j . 
The model is then: 
E[log rij ] = f.1 + Q j + J. j {3.4} 
In statistical packages, the model is implemented by specifying dij as the response variable 
and the log(Yij) as an offset. Estimation of the parameters using Poisson regression is 
preferable to methods which assume the cases are normally distributed, as the precision of 
the estimates is optimal (as measured by the standard error) using the Poisson distribution 
[179]. 
The log-linear model of {3.4} is unlikely to be a sensible model if, as is common, there are 
different proportional changes in different age groups [180]. One might consider testing for 
this by fitting an age-period interaction of the form: 
{3.5} 
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Thus, in estimating the EAPC based on the overall trend in the age-adjusted or age-specific 
rates, one should strictly first test the assumption of proportionality in the age-specific rates. 
Certainly, the EAPC as an overall descriptive measure is useful and commonly applied in 
practice (see 3.5). The calculation of a 95% confidence interval (95% CI) for the slope is an 
indication of whether the trend is real or random. Simple models such as {3.5} have also 
been used for making short-term predictions of cancer rates [180]. 
Cohort effects can be considered as a special form of an age-period interaction with a single 
observation in each cell [181]. A lack of proportionality in age-specific trends by period may 
suggest important (non-linear) cohort effects, and one might bypass the above modelling 
procedure in favour of a more sophisticated APC analysis. The concept of a regular trend 
being ascribed to calendar period is an assumption that cannot be tested, and for a 
sufficient span of data, the APC framework that reports the regular time trend or net drift ( g 
in {3.4}), may be a more practical and sensible approach (see 3.4.1.1.3). 
Estimation of the mean annual absolute change can be easily accommodated in the 
framework of models {3.4} and {3.5} by specifying an identity rather than a log link, and 
fitting the rate directly with no offset. In an attempt to balance the overall age-adjusted 
estimate according to the underlying structure of the population, it is common to weight by 
the person-years at risk rather than give equal weighting to all age groups. Alternatively, 
weighting by the number of cases effectively minimises the influence of age curves with 
substantial random errors while providing more weight to age groups considered more 
influential (and important) in view of having more cases associated with them. 
3.2.3 Automated procedures 
In estimating the rate of change, there is an assumption of log-linearity in the cancer rates 
over time, but if there are elements of curvature in the trend, the EAPC will give incorrect 
and imprecise estimates of the average unit change. Moreover, if one wishes to describe 
only recent short-term trends, the particular time base for which to estimate the slope is 
often arbitrary and, in the absence of highly stable rates over time, the EAPC will differ 
appreciably according to the period of time nominated. One proposal involves modelling that 
identifies sudden changes in the trend, and on that basis, estimates the direction and 
magnitude of the slope for each epoch of time where rates are relatively stable. 
Interrelated methods have been devised by Chu et al [182] and by Kim et al [183], and the 
latter implemented in a specially written (and freely available) statistical software package 
entitled Joinpoint [184]. While both techniques involve fitting of a piecewise model to the 
time trend, the techniques used to determine the unknown joinpoints differ somewhat. 
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3.2.3.1 The stepwise method 
According to the method of Chu et al [182], the predictor variables 55 represent each of the 
possible linear slopes from year j to J , where j ~ 1 and J is the most recent year in the 
analysis. The baseline model includes an intercept term and a slope ~ over the whole 
period. Weighting by the total annual number of cancer events, the selection procedure then 
identifies which of the tSs causes the most significant change in the overall trend. A 
Bonferroni correction for multiple comparisons is applied to the p-value so that p < 0.05/ J is 
considered a significant contribution. If none of the tSs are significant, then the procedure 
ends and the two-factor model denoting a simple linear trend across the whole period is 
accepted. Otherwise, the most significant 5s is added to the model. The stepwise procedure 
continues in this fashion, testing for significant changes in the slope defined by 5s . At each 
stage, the terms already included in the model are re-tested and eliminated if they are no 
longer statistically significant. A final model is reached when no further significant changes 
in the trend are observed. 
3.2.3.2 The joinpoint method 
As with the above method, the idea behind the joinpoint regression model is that linear 
trends should be derived over a few continuous linear phases. The procedure is motivated 
by the problem of determining joinpoints, the points in time for which significant changes in 
the trend are detected, and in doing so, estimate the linear trend between each set of 
jOinpoints (or segments, as they have been described). The maximum number of joinpoints 
is user-specified rather than obtained via the stepwise procedure above. To determine up to 
two joinpoints, for example, a model indicating no change is compared against the model 
containing two joinpoints. If the null hypothesis of no joinpoints is rejected, then the 
procedure is applied to test the null hypothesis of one joinpoint against the alternative of two 
joinpoints. Otherwise, the test for the null hypothesis of no change is considered against the 
alternative of one joinpoint. Another consideration on identifying the final joinpoint model is 
to estimate confidence regions for the parameters. The test statistic is obtained by the grid 
search method suggested by Lerman [185] and its p-value is computed using the 
permutation procedure. 
The Joinpoint program fits the simplest piecewise model according to the user-specified 
minimum and maximum number of joinpoints [184]. The program starts with the minimum 
number of joinpoints (e.g. 0 joinpoints, a straight line) and tests whether more joinpoints are 
statistically significant and must be added to the model (up to that maximum number). This 
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enables the user to test whether an apparent change in trend is statistically significant. The 
tests of significance utilise a Monte Carlo Permutation method described by Kim et al [183]. 
The models may incorporate an estimate of the variation for each time point (e.g. when the 
responses are age-adjusted rates) or use the standard Poisson model for counts or rates. 
Given the automated nature of the search for linear trends, particular focus on recent 
temporal patterns, and the fact that cancer data from vital sources in different populations 
are often available for variable spans of time, the program has obvious applications to 
descriptive analyses of multiple regions or countries. One concern refers however to the 
plausibility of a procedure that exclusively identifies only abrupt changes in trends that act 
linearly. The merits of the technique are further discussed in Chapter 5, where it is 
systematically applied to endometrial cancer incidence and mortality trends across Europe. 
3.3 The age-period-cohort model 1: components of the dataset and notation 
To provide the epidemiologist with clues to the aetiology of disease, time trends are often 
jointly considered using age, time of event and date of birth. The approach, outlined in detail 
below, involves the fitting of age, period and cohort as explanatory variables in a log-linear 
Poisson regression model of the number of disease events, offset by the corresponding 
person-years. APC modelling [63,66-68,87] has become a standard technique for the 
temporal analysis of disease rates, and applications to cancer trends regularly appear in the 
peer-reviewed medical and epidemiological literature. 
3.3.1 The age-period tabulation of rates 
Data from vital statistics systems are often made available at an aggregated level, usually 
by five-year age group and single calendar period. While APC methods that deal with 
unequally spaced intervals are available [66,106], they introduce further complexities, and 
typically, APC analyses proceed using equally-spaced five-year age and five-year period 
groupings (the so-called quinary-quinquennial estimates), as initially described by Case [71]. 
The Lexis diagram in Figure 3.4a gives the midpoints of the birth cohorts for each of the 
cells in an age-period classification for which the age groups are 30-34,35-39, ... ,65-69 and 
periods 1960-64, 1965-69, ... ,1995-99. 
The central value of birth cohort is easily derived on subtracting the midpoint of each age 
category from the midpoint of the corresponding period. Moving diagonally in the Lexis 
diagram from bottom left to top right identifies cells and the cohort midpoints, with the 
earliest cohort in the oldest age group (top left cell) and the most recent cohort in the 
youngest age group (bottom right cell). The number of rates associated with each cohort 
varies from one to eight as one moves from the extreme cells towards the middle diagonal. 
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Figur~ 3.4a: Lexis diagram depicting midpoints of birth cohorts for each of the 
cell.s In an age-period classification for five-year age classes 30-69 and five-year 
penods 1960-99 
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Complete sets of age groups and periods are available, but earlier and later birth cohorts 
are underrepresented however, with only the midyear cohort (1930) complete. Given the 
crude tabulation of age and period, the cohorts are synthetic; each cohort represents a 10-
year span that overlaps with every other cohort by exactly five years. The cohort identified 
as 1930 in Figure 3.4a within the two diagonal lines travelling from bottom left to bottom right 
of the table represents the experience of a generation born between 1 January 1925 and 31 
December 1934. Adjacent 10-year cohorts to the left and right overlap and they therefore 
also partially represent the cohorts born 1925-29 and 1930-34 respectively (Figure 3.4b). 
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Figure 3.4b: Lexis diagram for five-year age classes 30-69 and five-year periods 
1960-99. The .10-year cohort with midpoint 1930 is identified as well as adjacent 
and overlapping cohorts 
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Often the main focus of interest is the evaluation of trends occurring among more recently-
born cohorts, as the impact of recent carcinogens may show up more clearly in this group 
[113]. Trends in younger generations also naturally lend themselves to a future prediction; 
these birth cohorts will, in time, enter the age groups associated with the greater part of the 
cancer burden. Unfortunately, as has been clarified already, young cohorts are represented 
by rather few age-period cells that contain relatively few cases. Approaches to cancer 
predictions involving the APC model are briefly discussed in 3.4.6. Before turning in detail to 
the statistical aspects of APC analysis, some general comments are provided on selecting a 
suitable age, and usage of finer resolutions than that afforded by a quinary-quinquennial 
grouping. 
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3.3.1.1 Selection of age range for APe analysis 
Some restriction on the age range considered is usually necessary. The oldest age groups 
are often excluded on the grounds that the quality of mortality statistics in the elderly is 
particularly affected by a lack of precision and coding of the death certificate, as well as by 
erroneous decisions regarding the underlying cause of death [23,136]. For incidence data, 
case ascertainment is less effective in the very old, in part due to inaccuracy in the 
abstraction and coding of diagnostic information, and in part due to competing causes of 
death, with a result that a neoplasm is either not recorded as the underlying cause of death, 
or is not recorded at all. In addition, trends in the elderly are more likely to be affected by the 
extent to which diagnostic investigations have been sought [23]; the intensity of 
examinations has likely increased over time, as technology develops. 
Most epithelial tumours are rare below the age of 30, and it is common practice to exdude 
this age group from an analysis of adult cancers; the numerators of the age-specific rates, 
associated as they are with few events, will provide little extra information. Prostate cancer, 
primarily a disease of the elderly, is uncommon in men aged under 50, so a temporal 
analysis that restricts attention to an older age range, more representative of the burden, 
may be appropriate. 
For testicular germ cell cancer, most incident cases occur in the 15-54 age range, and an 
analysis that focuses the investigation on such a restricted age group has been proposed 
[186]. A bimodal age curve of HL incidence has been observed in some populations, 
stratified analyses reflecting the possibility of a multiple aetiology might be considered. 
Menopausal changes notably affect the risk of women developing certain cancers 
associated with hormonal control (e.g. breast, endometrial and ovarian cancer) and further 
stratification by age may be necessary, e.g. according to menopausal status. 
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3.3.1.2 Five-year groups versus finer classifications of age and/or period 
The use of narrower intervals for age and period may permit a more detailed analysis of 
temporal patterns. For example, an analysis at the individual level enables the description of 
temporal curvature with greater precision and resolution via the use of spline regression 
[187-189] (see 3.4.5.5). A focus on methods based on a five-year age-period classification is 
in part a convention laid down by the availability of incidence and mortality data from vital 
sources, and corresponding population data from official statistics in five-year age intervals. 
Some registries have both one-year incidence & population data, and it is constructive to 
contrast the relative utility of trend analyses using data at higher and lower levels of 
resolution (see 3.4.5.5). 
Interpolation techniques are however often required to estimate the populations estimates 
that correspond to the resolution of age and period, such as Beer's method that preserves 
five-year totals [190]. Tarone and Chu [102,103] have consistently used APC models based 
on two-year age and period spans in analysing cancer trends in the U.S.(see 3.4.3.2 and 
3.4.5.4). 
3.3.2 The role of statistical modelling 
Given the limited number of variables that require our attention in conventional APC 
analyses, graphical analyses of time trends have often been considered adequate 
descriptions of temporal data. As Kupper et al conclude [67], such a display avoids the 
potential for errors associated with "researcher bias" in presenting one solution from the 
many available from APC modelling (see 3.4 below). Yet the interpretation of time trends of 
many neoplasms is often unclear, and deciding whether trends can be attributed to period or 
cohort on the basis of graphical descriptions is itself somewhat arbitrary. Modelling has 
shown its value over and above purely graphical methods, particularly on consideration of 
biological or epidemiological information that lends itself to a particular presentation and 
interpretation of the model effects. 
3.3.3 Notation 
The APC log-linear model involves additive contributions of the three time effects on the 
logarithm of the rate, and is given by: 
{3.6} 
where as above r.. = d.. /r:. is the rate of cancer occurrence with Y. the number of person-
, 'lJ lJ lJ lJ 
years in age group i and period j, assumed fixed and known, a, is the effect in age group 
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indexed i for i = 1, 2, .. , I, /3j the effect of period indexed j (j = 1,2, .. , J) , and Y
k 
the 
effect of birth cohort with index k = 1, 2, .. , K linearly dependent on period and age as 
k = I - i + j . The number of cancer events, Y i} are assumed to be distributed as a Poisson 
random variable with mean Ai}. In its multiplicative form the model is: 
{3.7} 
where Ai} is the untransformed rate, M the baseline rate, and Ai' ~ , and C
k 
are the 
antilogs of the age, period and cohort effects. The model can be estimated readily in 
statistical packages using maximum likelihood techniques, with the numbers of events fitted 
as a generalised linear model assuming Poisson errors and a log link function relating the 
mean to the linear component of the model [191]. Given log(rij) = log(Yij) -log(nij) , the 
logarithm of the corresponding person-years can be declared as an offset, an added 
constant set to unity for which estimation is not required. 
The goodness-of-fit is determined by the deviance, D, the ratio of likelihoods from the 
currently fitted model LF and the saturated model LG respectively, with: 
{3.8} 
The fit of the model can be tested by comparing D with the X2 distribution on the residual 
degrees of freedom (d.f.). The goodness-of-fit of submodels (see 3.4.1.1) can be tested in 
the same way, with the contribution of the individual effects assessed by comparing 
differences in the deviance of two nested models with the X2 distribution on the 
corresponding difference in the degrees of freedom. 
3.3.4 What is the identifiability problem? 
Intrinsic to recognising the inherent limitations of the APe model is the fact that knowledge 
of any two factors implies knowledge of the third, making one of the factors redundant 
[69,87,106]. As mentioned above, the index of cohort is defined by the corresponding 
indexes of age and period, and hence the three factors are exactly linearly dependant on 
each other. 
Although submodels are not free from potential biases, they at least are identifiable. 
Subjecting {3.6} to a common set of constraints, such as fixing the first level of each of the 
effects to zero so that a1 = /31 = Y1 = 0, or applying the so-called usual constraints whereby 
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the sum of the effects of each is zero i.e. Ijaj = Ii f3j =Ik Yk = 0, does not realise a 
unique set of parameters; rather, there are an infinite number of them [68]. It is an 
inescapable fact that identification of any two of age, period and cohort identifies the third; in 
modelling terms, this signifies that the linear components of each factor cannot therefore be 
identified. One further linear constraint must be imposed to ensure a unique solution, but the 
crux of the problem is that the choice of model constraint and the resulting parameter 
estimates are completely arbitrary in the absence of compelling external information that 
one can bring to bear in making the selection. The follOwing text critically explores the many 
choices open to the researcher wishing to derive and interpret results from the APC model 
in the unavoidable presence of non-identifiability. 
3.4 The age-period-cohort model 2: advocated approaches 
The main techniques are classified into four groups that, though not mutually exclusive, 
serve to highlight the relative capacity of each method to provide an honest representation 
of the trends as well as an informative solution, given concerns regarding their degree of 
conservativeness, arbitrariness, and complexity. 
o Simple (potentially arbitrary) approaches - specifying an additional constraint on 
the parameters in an APC model, or dropping one of the factors altogether; 
o Conservative (potentially arbitrary) approaches - using an estimable function 
(curvature) but adding a specified slope of one factor (based on external information 
or otherwise) to provide a unique solution; 
o Conservative (never arbitrary) approaches - restricting summary to a 
reformulation of the APC model parameters that identifies an estimable function e.g. 
invariant to the constraint imposed; 
o Complex (entirely arbitrary) approaches - mathematical solutions proposed by 
observing particular mathematical relationships between the time components. 
A fifth miscellaneous group includes (often more complex) approaches that do not easily fit 
into one of the above categories. 
It is appropriate to start with simple, commonly applied strategies for dealing with 
identifiability, for which the potential for arbitrariness is often overlooked (see 3.4.1). Clayton 
and Schifflers' logical ordering of nested models and their introduction of the net drift is 
fundamental to understanding the difficulties, and is introduced here. 
Holford's approach forms the next section, and provides further insight into the nature of 
identifiability, as well as a sensible (and potentially informative) method. The main strategy 
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involves explicit quantification of the magnitude of the slope for one of the factors, which 
once specified, immediately quantifies the remaining slopes. Addition of the linear 
component to the corresponding curvature provides the solution - its implementation and 
function is discussed in 3.4.2. 
Estimable functions are parameterisations that offer summaries that are identical for a given 
arbitrary set of APC parameters. More conservative approaches based solely on such 
functions steer clear of any imposition of arbitrary statements and are discussed in 3.4.3. A 
number of quantifies can be derived that are estimable and may fulfil the investigative 
objectives of a temporal study [110]. 
Other more technical approaches are discussed in the remaining two sections. Methods that 
ensure identifiability through particular mathematical formulations are examined in 3.4.4. 
Section 3.4.5 describes miscellaneous techniques that include extensions to the three-factor 
model, non-linear models for which parameters are identifiable and non-parametric 
methods. A final section (3.4.6) relates the utility of results from the APC model to the 
prediction of future cancer burden. 
3.4.1 Simple constraints on the model parameters 
3.4.1.1 Dropping one factor 
Perhaps the easiest way to circumvent identifiability is to ignore the three-factor model. In 
the study of time trends of cancer, certain conditions lend themselves to a logical choice of 
the age-period (AP) or age-cohort (AC) model. Indeed, this practice is incorporated in the 
definition of the "age-period-cohort model" in Everitt's Cambridge Dictionary of Statistics in 
the Medical Sciences: "various methods have been suggested for disentangling the 
dependence of the factors, although most commonly one of the factors is simply not 
included in the modelling process" [192]. 
Other than avoiding the necessity to deal with the identifiability problem explicitly, adoption 
of two-factor models is often made on the basis of goodness-of-fit. Often this involves 
securing the observation that one of these models yields a reasonably good fit, or at least 
fits better than the other two-factor model; the AP and AC models are not directly 
comparable, as they are not nested within each other. 
The root of the problem with the two-factor approach stems from the fact that there will be 
an inherent bias in the resulting estimates should one of the three effects be wholly linear 
[67]. The inability to quantify or test the linear part of the effects of age, period and cohort is 
encapsulated in Clayton and SchiffJers adoption of a net drift term to quantify a function of 
slopes that is both estimable and interpretable (as the regular time trend). The logical 
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ordering of models, with the nested age-drift (AD) model examined prior to the two-factor 
models, forces acceptance that tests for period or cohort effects only involve tests of their 
respective non-linear components (see 3.4.1.1.3). 
Given its apparent simplicity relative to methods dealing with the full APC model however, 
two-factors models are commonly applied in the cancer epidemiology literature. Before 
bringing AD models into the discussion, some characteristics of the AP and AC models are 
examined. 
3.4.1.1.1 Age-period models 
An AP model may reasonably describe quasi-parallelism of age-specific curves by calendar 
period on a semi-log display. Clayton and Schifflers specify two features that may yield such 
an observation: 1) when there are immediate (or delayed but predetermined) effects on the 
log-transformed rates; 2) when there are constant increases or decreases of the same 
quantity over calendar time across all age groups [63]. Using the same notation as above, it 
can be written: 
{3.9} 
The model may provide an acceptable description should the period effects over and above 
age explain a significant amount of variation and {3.9} does not suffer from a significant lack-
of-fit. In the absence of cohort influences, one might consider adopting the AP model, 
although if cohort also provides a significant improvement to the age-only model, the 
adoption of {3.9} as the sole representation of the observed data is unjustified. 
Certainly there are many examples where strong period effects are present in disease 
trends. The introduction of an intervention affecting trends irrespective of age at a fixed point 
in calendar time will produce period effects. Rapid changes in the prevalence and 
distribution of one or more risk factors in the population at a single point in time may also 
give rise to period effects, with the abrupt decline in the risk of cardiovascular disease in the 
U.S. [65], a commonly cited example. 
Period effects may be observed in cancer trends where effective screening programmes 
have been implemented, and a reduction in rates is seen across all age groups invited to 
participate. Where such a test detects pre-invasive malignancies, both incidence and 
mortality rates will decrease; tests that detect cancer at an early stage will, in theory, only 
reduce mortality trends. The introduction of national cervical screening programmes in 
several of the Nordic countries led to rapid period-specific declines in cervical cancer 
incidence and mortality in all screened age groups, notably in Finland, where an 82% 
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decline in mortality was observed from its peak in the late 1960s to its nadir in the early-
1990s [193]. The importance of examining period effects in asseSSing the effectiveness of 
cytological screening is revisited in Chapter 4. 
More often, period effects point to a rtefactual changes (e.g. changes in coding, in diagnostic 
practices, and in ascertainment) that act on rates in a likewise fashion across all affected 
age groups. MacMahon and Trichopoulos, in discussing the complexities of interpreting 
temporal variation, state that "most difficult to deal with are those components of trends 
relating to the effect of changes in clinical concepts, diagnosis and terminology, because 
such changes evolve gradually" [194]. Gradual changes in cancer rates over calendar time 
across all age groups would strongly imply a linear effect of period, although linear trends 
cannot and never will be detected by AP models, or indeed any other class of APC model 
(see 3.4.1.1.3). This link between non-identifiability and artefactual changes in cancer trends 
is perhaps overlooked in APC studies; steady and ongoing improvements in diagnostic 
ability, for instance, will go undetected in APC models, and the interpretation of cohort 
parameters, for instance, may be substantially altered on identifying a true linear increase 
with calendar time. The difficulties in quantifying these artefactual changes can at least be 
explored by modelling the impact of a plausible range of period slopes on the resultant 
cohort trends. This strategy is discussed in 3.4.2.1.3. 
3.4.1.1.2 Age-cohort models 
AC models may be represented by quasi-parallelism of age-specific curves according to 
birth cohort on a semi-log display, indicating constant increases or decreases in rates seen 
within a particular generation irrespective of their age at diagnosis, that is, within a specific 
birth cohort equally throughout life [63]. The model is of the form: 
{3.10} 
The model can be established as providing a reasonable fit using tables of deviances, as 
above. The lack of ability to detect linear slopes of any of the time components of course 
remains, yet one of the most frequent means of summary of APC data seen in the literature 
involves the presentation of results from the AC model. Why? Other than on statistical 
grounds (e.g. if the model yields a reasonable fit), or an obvious route to avoid the non-
identifiability issue, it is well founded that exposures to strong risk factors often follow 
generational patterns. The root causes of many cancers are related to lifestyle factors, and 
the protracted exposure required before the development of a neoplasm implies that 
cancers will occur two or more decades later, and rather than affecting all groups 
simultaneously, will show up in certain cohorts whom have had greater exposure than 
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others. The changing distribution and prevalence of smoking, sexual behaviour, and diet, for 
instance, may be heavily related to societal or peer-related influences which put men and 
women at higher (or lower) risk in successive generations [195]. Further, exposures that 
occur within a relatively narrow age range, such as those that occur early in life, should also 
manifest themselves as cohort effects [195]. 
3.4.1.1.3 The problem with two-factor models: Clayton and Schifflers net drift 
In 1987, Roush and colleagues (with Holford as second author), considered the following 
models to systematically describe incidence data in Connecticut for 20 cancer sites [196]: 
i. Models with age, period and cohort (as {3.6}); 
ii. Models with age and period (as {3.9}); 
iii. Models with age and cohort (as {3.10}); 
iv. Models for which choice between AP and AC was ambiguous. 
Notably absent was the AD model incorporating regular trend which Clayton and Schifflers 
[63] introduced in the same year. The net drift parameter represents the average annual 
change in the rates over time, the passage of time that is common to calendar period and 
birth cohort, a quantity that cannot be disentangled between them, given the algebraic 
relationship that identifies cohort as the difference of period and age. The AD model can 
describe a situation whereby the two-factor models {3.9} and {3.1 O} fit the data equally well, 
and for which models in iv. of Roush and colleagues' above categorisation [63] might better 
be described by: 
E[log rij ] = J1 + ai + t5 . j {3.11} 
Model {3.11}, already stated as {3.4}, implies the same linear change in the logarithm of the 
rates over time in each age group. Given the linear component over time is identifiable but 
cannot be allocated in any way to period or cohort, t5 can be estimated by either specifying 
period or cohort as a continuous covariate, with the EAPC estimated as (eJ -l)xlOO, 
expressed in terms of the unit of origin. 
Holford [66] and others had already shown that several functions of the three slopes were 
estimable (see 3.4.2.1), however it was Clayton and Schifflers who suggested that the net 
drift, as the sum of the period and cohort slopes, should become an integral part of the APC 
modelling strategy, as an estimate of the rate of change of the regular trend [63], and as a 
means to partition first order and curvature effects [68]. The net drift obtained from a data 
series spanning decades includes observations in the distant past, and may not provide a 
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good indication of recent trends. One sensible modification would be to estimate the trend 
for the whole study period and for the 15 years (say) of most recent data, enabling a 
comparison of the relative magnitude and direction of long-term vs. contemporary trends. 
The Clayton and Schifflers papers [63,68] established a formal modelling strategy that 
forced age in all models and prioritised a test of the significance of the regular trend, and in 
doing so brought the concept of (non-identifiable) linear and (identifiable) non-linear effects 
down to the level of the two factor models. Specifically, the authors recommend fitting a 
hierarchy of models (Figure 3.5), starting, given its importance on carcinogenic processes, 
with a baseline model including age but no temporal trend. 
Figure 3.5: Clayton and Schifflers' logical order of APe model fitting [68] 
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The relative contribution of each effect in the hierarchy is determined by comparing the 
change in the deviance and degrees of freedom in two sequentially-fitted models with the 
appropriate X2 statistic. A comparison of an age-only model with {3.11} is a one d.f. test for 
the net drift; a comparison of models {3.9} versus {3.11}, and model {3.1 O} versus {3.11} 
provides P - 2 and K - 2 tests for the effects of non-linear period and non-linear cohort, 
respectively. Comparing model {3.6} versus {3.10} tests for the effects of non-linear cohort 
effects, with a further loss of K - 2 degrees of freedom adjusting for net drift and non-linear 
period. Finally, the comparison of model {3.6} versus {3.9} tests the P - 2 effects of non-
linear period, adjusting for net drift and non-linear cohort. 
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Such a modelling framework asks the researcher to acknowledge the inherent problem in 
both two-factor models as well as the APC model; that the linear component of each of the 
effects are neither identifiable nor statistically testable, being hopelessly entangled due to 
the algebraic relationship that identifies birth cohorts. The model-fitting procedure has 
become standard in APC studies, but a number of related difficulties in APC modelling, as 
discussed by its authors [63,68] are perhaps less well appreciated (see 3.5). 
A graphical display of the fitted rates from the APC model and submodels provides a simple 
but effective demonstration of both the identifiability problem and the characteristics of each. 
Figure 3.6a shows the observed rates (aged 30-64) of breast cancer incidence data from 
Sweden, 1964-98, and the estimated rates from each of the models (Figure 3.6b) in the 
same logical ordering as Clayton and Schifflers recommended [68]. The fitted rates from the 
age model (A) depict horizontal lines (no time trend) and represent the mean rates for each 
age group. Rates from the AD model represent linear trends for period and cohort that 
necessarily are of the same order of magnitude, given that the cohort lines differ from the 
period lines only in terms of a simple subtraction of the age group represented. Rates from 
the AP model impose period curvature over and above the net drift to all age groups; the 
sharp increases in diagnosis are the result of a prevalence round of screening in Sweden -
primarily affecting women aged 50-64. Fitted rates from the AC model reflect the possible 
attenuation of rates in breast cancer incidence in younger generations, noted by Persson et 
al [197], although mammography may have also had a recent impact among peri-
menopausal women. Finally, the fitted rates of the APC model impose both non-linear 
period and cohort curvature over and above the net drift. 
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Figure 3.6a: Observed rates of breast cancer incidence vs. cohort and period by 
age, Sweden, 1964-98 
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Perhaps unsurprisingly given the complexity of the trends, none of the models fit in the 
above example; the APe model is a rather blunt instrument for summarising such temporal 
patterns. More generally, maximum likelihood estimates for parameters assuming Poisson 
errors often leads to a situation where none of the candidate models adequately fit the data, 
due primarily to the large number of events than any systematic departure from the model 
[66]. Several established methods for dealing with the effects of overdispersion are available 
[191,198]. 
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Figure 3.6b: Graphical depiction of fitted rates by birth cohort obtained on fitting the APC model and its submodels according 
to Clayton and Schifflers' procedure [68] 
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Day and Charnay have suggested a consideration of the factors across several registries 
(see 3.4.5.3) to improve the possibility of detecting period or cohort effects [65]. As Holford 
comments however, such an approach may still miss important trends if the effects of period 
or cohort are relatively linear [107]. 
3.4.1.1.4 Two-factor models in practice 
Given the direct interpretation afforded by their use, few researchers have dwelled on 
potential biases with two-factor models. Their use is more justified when selected on the 
grounds of goodness-of-fit and where there is some rationale for the adoption of a specific 
model. In practice, this is not always the case, and there may be difficulties gleaning insight 
without succumbing to over-interpretation. 
Hermon and Beral describe long-term trends (1950-92) in breast cancer mortality rates by 
calendar period and birth cohort in 20 countries using AP and AC models respectively, 
linking these to trends in several reproductive variables [199]. The authors graphically 
depicted the trends in period and cohort effects as rate ratios in each country (obtained from 
the respective two-factor models), suggesting these "are comparable to a relative risk 
estimate and can be interpreted in a similar manner" [199]. 
The problem of interpretation comes down to the placement of drift. A focus on period 
effects will place the drift with period, likewise with cohort, and an honest interpretation 
would confine discussion to changes in the slopes. Given the magnitude of the slopes are 
necessarily arbitrary, a particular choice will affect the values of the rate ratios. 
In the study, the results were not generally over-interpreted, but in the discussion the 
difficulty obtaining insight with this approach emerged: "in [several countries] mortality rates 
are either constant or have recently levelled off or have began to decline. The decline 
appears in part due to birth cohort effects and in part due to period effects although it is 
sometimes difficult to separate these effects using mathematical models" [199]. No observed 
data were presented, nor was the goodness-of-fit of either model established; it therefore 
remains unclear as to whether period and cohort effects (or both) impacted on the reported 
trends. This is important as much of the discussion centred on concomitant generational 
changes in nulliparity, age at first birth and completed family size. 
Baron et al also attempted to avoid the identifiability problem by presenting both AP and AC 
models of trends in non-epithelial cancer incidence in Denmark, Finland and Sweden 1961-
90, by sex [200]. Although the analysis of deviances of the APC model and submodels was 
displayed, they also presented relative risk estimates derived from both two-factor models. 
The authors state: ''we could not justify a priori assumptions regarding the rates to allow 
unique estimation in the full APC models, and chose not to present multiple estimates, 
based on different allocations of the non-unique linear drift effect. Therefore we present 
results from the basic AP and AC models, although in certain cases, none of the partial 
models adequately represent the data" [200]. 
Indeed, of the six populations, only for Finnish males did the two-factor (AC) model fit the 
data. For four of the populations, the APC model best described the data. Quite why 
estimates of the trends were derived from the AP and AC models rather than the APC 
model is not clear as no justification of the approach is given. Further, the authors (from the 
abstract) note that modelling "suggested that the dominant factor in the underlying increases 
were birth cohort effects" [200], although both non-linear period and cohort effects 
significantly improved the fit in all six populations. Only rate ratios from the AC model were 
presented, and the "increasing" cohort effects described as "relatively strong", with a 
comparison between countries, indicating "trends were most pronounced for Finland, and 
somewhat less marked in Sweden" [200]. 
One problem illustrated in this example is the assertion of cohort influences without 
particular justification. Non-epithelial cancers (the majority of which are haematological 
cancers) are particularly susceptible to artefactual increases as a result of improving 
diagnostic ability that should show up as period effects (linear if gradual, non-linear if 
sudden). Adjusting the cohort effects to simultaneously allow for the possibility of uniform 
increases in successive periods (e.g. that gradual improvements in diagnostic ability may be 
largely responsible for the increasing trends) would radically alter the interpretation of the 
generational influences. 
Kupper and colleagues state that "adoption of a two-factor model based on standard 
goodness-of-fit criteria is invalid when the population effects for one of the factors (age, 
period or cohort) follow a non-horizontal linear pattern" [67]. Some studies in the literature 
have also bypassed the use of deviances in adopting a particular model on the basis of its 
non-linear effects, instead preferring a priori beliefs to inform the selection process (see 3.5). 
Interestingly, the use of AC models has been advocated by Clayton and Schifflers for 
systematic studies across many populations [68], although the authors do not offer 
guidelines or a justification of this statement. Perhaps the authors would have cited the 1985 
study by Roush et al as a good example of their use. In the study AP, AC and APC models 
were systematically fitted to incidence for 25 adult cancers, with cohort a Significant factor in 
34 of 44 datasets [201]. Certainly, comparisons of birth cohort trends in different populations 
may help establish or confirm hypotheses regarding differences in the underlying distribution 
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and prevalence of risk factors, and such an approach is taken in the analysis of trends of 
cancers of the cervix, endometrium and testis using the APC model in Chapters 4 through 6, 
respectively. 
3.4.1.2 Equating two or more parameters 
Given the problems with two-factor models, it is logical to consider the full APC model as the 
primary option. Moreover it also often provides the best fit: Roush et aI, in their systematic 
study of incidence data in Connecticut by cancer site and sex, found APC analyses led to a 
choice of APC model in 20 of the 44 datasets: there were 14 AC models, seven AP models 
and three for which there was "no clear choice of model" [201]. 
An alternative to limiting inference to the two-factor model is to equate two, rather than all of 
the parameters of one of the effects. A unique set of parameters for age, period and cohort 
can be obtained by assuming, for instance, that the first and last, or two neighbouring 
effects, are equal. The main problem relates to the difficulty in securing a sensible 
preference as to which two effects to equate. There is rarely an example of a trend for which 
one can assume the effect of two age groups, period or cohorts are equal; the solution is 
thus arbitrary in the absence of compelling information regarding the underlying nature of 
the trends. 
Two approaches may ensure some level of plausibility and are discussed below. The first 
involves the presentation of one or more solutions on equating two effects of one factor that 
reflect the researcher's a priori beliefs regarding a feature or features of the temporal trend 
(see 3.4.1.2.1). A more general proposal, as advocated by Clayton and Schifflers is to 
equate the first and last effects of one factor (either period or cohort) in an attempt to force 
attribution of the drift to the other factor (see 3.4.1.2.2). As will be seen, neither method is 
without problems however, lending support for an explicit quantification of one of the slopes 
(see 3.4.2). 
3.4.1.2.1 Selecting constraints from plausible scenarios 
Achieving a credible interpretation of time trends on assuming that two levels of one factor 
are equal requires knowledge of the epidemiology of the disease in the study population. 
Plausible scenarios may be explored using several alternative sets of estimates, as in 
Hamajima and Lee's 1987 study [202] described below. 
Several constraints were used to represent age, period and cohort trends in gastric cancer 
mortality in Japan 1955-80 [202]. On acknowledging different constraints led to widely 
varying trends in age, period and cohort, the authors introduced several constraints on the 
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period parameters such that a) /31 = /32 produced long-term declines in mortality risk; b) 
/32 = /33 introduced a peak period-wise around 1960 and c) /33 = /36 (in men) or /34 = /36 (in 
women) allowed risk to level off in more recent periods. 
Figure 3.7 presents cohort and period effects for stomach cancer trends in men for 
scenarios a) and c), as described in tabular form in the original paper [202]. Clearly, the 
period effects are very different. Scenario a) involves early period-related increases in the 
1960s and a constant trend in the 1970s. Corresponding cohort declines are largely 
constant in successive generations born since 1900. Scenario c) indicates constant period-
specific declines from the 1960s, but successive cohort declines only in generations born 
between 1900 and the late-1920s, cohort trends being relatively flat elsewhere. The authors 
suggest that the true period effect might be found somewhere between a) and c), 
interesting, as Figure 3.7 would suggest an underlying slope for period of approximately 
zero, a general method proposed implicitly by Clayton and Schifflers [68] in the same year 
and explicitly by Holford [66] some years earlier. 
Figure 3.7: Stomach cancer mortality trends by birth cohort and period in Japan 
on equating two period effects based on plausible assumptions; dotted line 
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This way of circumventing non-identifiability was used earlier by Barrett in 1972 in the study 
of cervical cancer mortality rates [87]. Two solutions, one based on equating the last two 
cohorts, the other the last two periods, were selected more on a posteriori grounds in that 
they provided sensible parameter estimates rather than an a priori preference for a 
particular constraint. His later mortality stUdies of bladder [69] and prostate cancer trends 
[88] were based on a single set of parameters on equating the first and last period effects 
(see 3.4.1.2.2). Each of Barrett's stUdies emphasised the importance of interpreting the 
deviations from linearity of each factor, rather than their unidentifiable linear slopes. 
Insight is therefore possible with such a technique, provided a range of constraints is used 
to present the trends, and the particular choices of constraints justified. It is difficult however 
to escape the arbitrary nature of such a parameterisation; often there is an insufficient level 
of understanding of the cancer trends to set two effects to equality, and differences in 
opinion between observers will certainly exist. 
3.4.1.2.2 Clayton and Schifflers' suggestion: mean first differences 
Clayton and Schifflers proposed a solution involving the de-trending of the adjacent effects 
of one factor so that the corresponding overall slope is equal to the mean of the successive 
first differences [68]. For the period effects these are: 
{3.12} 
By imposing J31 = J3J ' the period line is forced to return to the baseline value (assuming the 
default reference category is J3j = 0 ), effectively achieving an underlying slope that 
approximate a horizontal slope of gradient zero. In this parameterisation, the cohort effects 
contain all of the net drift and can be examined and interpreted under the hypothesis that 
the linear trend is entirely attributable to generational influences. 
Likewise, setting 1I = YK attempts to eliminate the linear component of cohort, thereby 
sending the net drift to the period effects. On constraining the extreme cohort effects to zero 
however, a problem emerges. Clayton and Schifflers advocated the method due to its 
relative simplicity - most statistical software programs will automatically alias the first and 
last effects of the last-entered variable - but refrained to discuss the possible errors such an 
approach may introduce. 
The random error associated with small numbers in the single cell occupied by the youngest 
cohort in the age-period table, as discussed in 3.3.1, can often lead to wide fluctuations in 
the corresponding model parameter. It may be of a large enough positive or negative 
magnitude to have the effect of tilting the drift upwards or downwards, respectively. In such 
88 
cases, the constraint ~ = YK will poorly serve its function as a means to allocate the entire 
drift to period, potentially leading to erroneous interpretation. 
Tarone et al examined breast cancer mortality trends by period and cohort in the U.S. and 
Canada [203]. The authors acknowledge that the cohort effects from the APC model that 
appeared in their paper (their Fig.1), and reproduced here as Figure 3.8a, cannot be 
interpreted as relative risk estimates, while the main emphasis of their paper is quantification 
in the changes in the slopes (see 3.4.3.2). Nevertheless, such a parameterisation is not 
uncommon in the recent literature (see 3.5), and several papers have included a citation to 
their paper (and others) as a justification for its use e.g. [204]. 
Further, it is worth considering the particular interpretation that is served by their choice of 
constraints (the zero cohort slope in Figure 3.8a joins those parameter estimates that are 
set to equality for U.S. whites, the first and last effects). The negative linear trends indicates 
that the U.S. cohort slope would have taken on a very different trend and direction if the 
second and second-last effects had been constrained to be equal. Had the latter 
parameterisation been adopted, the U.S. cohort effects would have undergone a counter-
clockwise rotation similar to the crude display in Figure 3.8b. 
The chosen constraints are particularly important in interpreting the period trend, which 
would have experienced an equal but opposite (clockwise) rotation, that is, equating first 
and last effects would have had the effect (in the above example) of attenuating the period 
trends relative to those obtained on equating the second and second-last parameters. Both 
choices of constraints for cohort purport however to be approaches that approximately yield 
a cohort slope of zero. 
Alternatives to Clayton and Schifflers' suggestion have been described by M011er [205] and 
include a refitting of the model on removing the youngest cohort, or computation of the 
mean first differences following exclusion of the first and last cohorts. More generally, 
Kupper et al have shown that when one of the age, period and cohort effects follows a 
straight line pattern, equating any two effects in {3.6} will lead to that effect being deemed 
unimportant according to the usual goodness-of-fit measures, with the consequence that the 
particular constraint will rotate the estimated linear pattern to a horizontal position [67]. A 
better understanding of the linear relation between the factors may be obtained by thinking 
in terms of the individual rotations of the effects of each factor on changing the slope of one, 
a concept introduced in 3.4.2. 
Insufficient information on which to base the equating of two effects effectively reduces the 
viability of the method in analysing most cancer trends. However, a presentation and 
89 
interpretation that examines the parameters on allocation of drift to cohort by equating the 
first and last periods can be seen as an honest approach, and where appropriately used, not 
without some interpretative value. 
Assuming such a slope for period may be less appropriate if gradual artefactual changes 
have occurred. Adami et aI, for instance, reported in an article published in The Lancet, 
uniform increases in total cancer risk in successive cohorts in Sweden and "suggest a 
worrying pattern of increasing population exposure to carcinogenic influences" [206]. The 
solution obtained, on setting the first and last periods to zero in an APe model, naturally 
placed the drift with cohorts. Interpretation of regular trends as purely birth cohort could 
have been interpreted - on suitably allocating the drift to cohort - as period effects, hence 
their strong conclusions were somewhat unjustified, as remarked upon by Bonneux et al in a 
subsequent correspondence to the journal [207]. The difficulty allocating the drift estimate 
precisely, coupled with more general difficulties with interpretation, brings us to a related but 
more flexible approach advocated by Holford [66]. 
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3.4.2 Holford's approach to non-identifiability 
Holford suggests that given the large number of parameters included in {3.6}, for simplicity it 
is sensible to highlight the non-identifiability in terms of two sets of parameters [66], one 
representing a linear function of the three slopes, and the other the identifiable curvature of 
each effect such that: 
( . I +IJ a j = 1--2- xaL +({Jj {3.13) 
{3.14) 
{3.1S) 
where aL, PL and YL represent the linear terms for age, period and cohort, and ({Ji' ({Jj and 
({Jk the respective elements of curvature. The linear dependency k = I - i + j generates 
slopes that are wholly arbitrary and inestimable, while the curvature terms are invariant to 
any set of constraints imposed [66-68,107,108]. 
There are a number of ways in which curvature can be represented in a model. Rogers 
noted that for any random pair of numbers (x,y) the linear function: 
{3.16} 
is invariant to any particular specific set of constraints enforced, in other words, it is an 
estimable function. Thus setting x = y = 1 implies aL + PL is estimable, while x = O,y = 1 
designates that, as has already been seen, the sum of the period and cohort PL + YL is also 
estimable (see 3.4.1.1.3). This term will be denoted Holford's drift as it is obtained from the 
full APC model. It is however usually a close approximation of the Clayton and Schifflers' net 
drift J obtained from {3.11}. 
Equation {3.16} implies that although the overall slopes are unrestricted, they do not vary 
independently. Holford [107,108,110] showed that fixing the value of anyone slope leads to 
estimation of the other two: 
{3.17} 
{3.18} 
{3.19} 
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Here a~ , /3~ ,and Y~ are biased representations of the respective slopes of age, period 
and cohort generated on fitting the APe model, with v is an indeterminate constant that 
may result in increasing or decreasing trends of each slope. aL , /3L' and YL then 
correspond to the true (non-identifiable) values of age, period and cohort. If one is prepared 
to make particular assumptions on one of the slopes, specifying the magnitude of the trend, 
or restricting the values that the slope can take, the values of the other two slopes, or the 
range of values, are immediately estimable, respectively. To ensure this, postulation as to 
the direction and magnitude of a slope should be ideally founded on biological or 
epidemiological evidence; otherwise, if erroneous, a bias in all of the effects is incurred. 
Holford and colleagues have mainly discussed plausible assumptions that restrict the values 
of the period slope (see 3.4.2.1). 
The unique curvature terms for the three components can be determined by linear contrasts, 
based on the residuals from a simple linear regression [110]. Alternatively, one can partition 
the effects of the linear and curvature components in a design matrix with independent 
columns that yield a unique linear combination of parameter estimates. The partitioned 
design matrix X is: 
{3.20} 
where A L , PL , CL are the linear components and Ac ' Pc' Cc and the curvature 
components of the age, period and cohort effects respectively. The regression parameters 
that correspond to X are denoted by the vector: 
{3.21} 
To obtain the curvature terms of the design matrix, the curvature regression parameters are 
set to be orthogonal to the linear components, allowing a polynomial model of high order to 
be fitted in single variables for age, period and cohort. Holford's approach to generating 
such a matrix is given in an Appendix in his 1983 paper [66]. For I levels of age, the 
regressor variable defined in a matrix Z: has ith row and fth column are given by 
+ 1 ,i = j 
Z .. = -1 ,i=I 
IJ 
o ,otherwise 
The linear trend can be found for age as before with the column vector L denoted by 
{3.22} 
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L . 1 I 1 . =z-- --122 {3.23} 
The matrix orthogonal to L that provides the curvature elements is: 
{3.24} 
Of interest are the overall curvature components of age (rpi ), period (rpj) and cohort (rpk) 
rather than particular orders of curvature, and these may be obtained by multiplying the 
matrix orthogonal to the linear component with the vector containing the regression 
parameters: 
{3.25} 
{3.26} 
{3.27} 
Individual categories of age, period and cohort are calculated by adding together the 
corresponding linear and overall curvature components as in formulae {3.13}, {3.14} and 
{3.15} respectively. The method of assuming a slope (or slopes) for one factor and its 
implications to the study of cancer trends will now be discussed. 
3.4.2.1 Specifying an overall slope 
Holford [98] demonstrates that hypothesising as to the true gradient of one of the slopes in 
{3.17} through to {3.19} leads to fixed estimates of the slopes of the other two components 
(in terms of the identified constant v). This has an important application in APC analysis; if it 
is reasonable to utilise existing biological or epidemiological arguments to allocate a 
particular value, or range of values to one slope, the infinite set of possible values of the 
parameters of all three components will be limited to a range that is consistent with possible 
explanations regarding the temporal nature of the observed trends. 
If the particular specification of the slope is incorrect, the estimates of each slope are 
biased; selecting a range of slopes however leaves some margin for error, allowing the 
researcher to contrast the age, period and cohort effects, based on their particular 
preference(s) for the fixed slope, with other plausible specifications. The technique 
highlights the fundamental problem with APC modelling: while the departures from linearity 
for age, period and cohort are unique and local curvature identifiable, the slopes are not, so 
that the overall trend is entirely dependent on these unknown quantities that can take on an 
infinite range of values. As the three slopes are mathematically interrelated however, an 
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arbitrary specification of just one of them leads immediately to an identifiable but, 
necessarily, subjective solution. 
The most commonly applied technique involves making assumptions regarding the slope of 
the period component of the trends. Holford describes the justification of a procedure that 
imposes a zero period slope [110], as used in the systematic study of incidence trends in 
Connecticut 1940-79 [208]. The choice of restriction on period was motivated by: (1) the 
necessity to leave age in the model unaffected given its clear biological importance, leaving 
a choice of either period or cohort to be inconsequential; (2) of the two remaining effects, 
empirical evidence pointed to cohort effects being more important for trends in incidence; (3) 
assumptions on period slope at least allowed estimation of period curvature, and therefore 
the procedure were less restrictive than a two-factor modelling approach. The methods 
described below have been used extensively by Holford and colleagues, mainly in a series 
of articles describing trends in the incidence of various cancers in Connecticut (see 3.4.2.1.2 
and 3.4.2.1.4). 
3.4.2.1.1 Zero period slope 
The assumption of negligible (linear and non-linear) period effects in describing the AC 
model of {3.1 O}, and the equating of the first and last period effects of {3.6} in an attempt to 
obtain a negligible linear period effect, has been respectively discussed in 3.4.1.1 and 
3.4.1.2. In the current context, the requirement of f3L = 0 places no restriction on qJj' while 
the average linear trend should consistently provide a more accurate description of the 
underlying partition of a zero slope to period and a slope equalling Holford's drift to cohort. 
From {3.18}, v = f3L - f3~ and on assuming a true period slope of zero, v = -f3~, the 
negative of the linear term for period, obtained from the vector described in {3.21}. Imposing 
the respective value for v in {3.17} and {3.19} therefore provides unique estimates for the 
slopes for age such that a L = a~ - v and for cohort, YL = Y~ - v , where YL = f3~ + Y~ is 
Holford's drift. A program written by the author of this thesis in R [209] demonstrates the 
technique in practice, in the study of bladder cancer incidence in Italy [68] (Appendix 3). 
3.4.2.1.2 The zero period slope method in practice 
Zheng et al assumed a period slope of zero in studying adenocarcinoma of the cervix 
incidence using SEER data according to race [210]. An explanation for the preference is not 
given, although it would presumably be related to the birth cohort phenomenon driven by 
changing sexual behaviour and the prevalence and distribution of oncogenic types of HPV, 
alongside a relative inability to detect cervical adenocarcinoma using cytological screening 
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(see Chapter 4). The authors concluded that the trends were cohort-driven, starting in 
generations born in the mid-1920s, an observation seen in blacks and whites, although the 
increase was considered stronger in white women. 
Zheng et al applied the same constraint in studying bladder cancer incidence between 1935 
and 1992 in Connecticut, justifying the assumption on the grounds of strong birth cohort 
effects in previous findings of incidence trends in bladder and other tobacco-related cancers 
[211]. The authors observed that cohort effects were increasing in generations born before 
the mid-1930s, but for generations born thereafter, a levelling or dedine in rates was 
apparent in both men and women. Although an increasing period slope (e.g. via an 
increasing diagnosis of benign tumours) may have altered the interpretation, such an effect 
was dismissed, on the grounds that it could not explain the long-term increases in the 
regular trend. 
3.4.2.1.3 Restricted ranges of period slopes 
If a specific identification of one slope is considered of insufficient plausibility, an obvious 
extension imposes a constraint on the range of possible values for one of the slopes, with 
the range determined, where possible, by existing biological or epidemiological knowledge. 
As with the zero slope method, period effects are most often considered for restriction, as it 
is considered the least influential of the three effects. The method is however a less arbitrary 
solution given that it draws attention to the lack of identifiability - the overall cohort trends 
often adopt very different courses even with relatively minor adjustments to the magnitude of 
the linear period slope. 
3.4.2.1.4 The range of slopes method in practice 
Effects obtained on specifying a choice of possible slopes are derived in the same way as 
the zero slope procedure. In proceeding, possibilities regarding the choice of slopes are 
dependent on the availability and degree of persuasiveness of background knowledge that 
one can bring to bear to provide explanations for the characteristics of the trend. The more 
precise the specification of the range, the stronger the assumptions regarding one or more 
of the slopes must be. 
Holford et al in studying incidence trends of Non Hodgkin lymphoma (NHL) in Connecticut 
1935-89 anticipated that the increases were partly related to diagnostic practices, and thus 
trends in age, period and cohort were examined according to various period slopes that took 
account of the extent of the artefact: slopes of 0, +0.1, +0.2, and +0.3 were considered 
[212]. The magnitude of a given slope relates to the unit of time of the period effect, five 
years in this study, and hence a slope of +0.1 represents a 2% increase in gradient per 
96 
annum. The level of inference of the subsequent effects is dependent on the degree of belief 
that the increases in the drift are due to gradual period increases. The method generates 
hypotheses depending on a particular choice of slope and may reveal interesting cohort-
specific observations irrespective of extent of attribution of drift to period. 
For some cancers, one may wish to assume that an overall negative trend by period or 
cohort is not feasible and bound the range of the slopes accordingly. Wickramaratne et al in 
a temporal study of the trends in major depression in the U.S. showed that the joint 
assumptions of period-specific increases PL ~ 0 and cohort-specific increases Y;?' 0 can be 
addressed [213]. Adding YL to both sides of the first inequality gives PL + YL ~ YL ~ 0 where 
PL + YL ' as already shown, is Holford's version of drift and therefore estimable. Similarly, 
P L + YL ~ PL ~ 0 and aL + P L ~ aL ~ aL - YL specify the age and period slopes respectively, 
with a L + PL and a L - YL also estimable functions. The authors suggested that the method 
could be considered for investigating trends in cancer, where it is known a priori that time 
trends are biased upwards due to improving medical care and diagnosis. Trends in thyroid 
cancer, melanoma and NHL are obvious candidates for such statistical treatment, yet the 
method has been rarely put into practice. 
Otherwise, less certainty as to particular attributes of the linear trend for period, leads to a 
safer tactic whereby one adopts a family of curves that encompasses the possibility of 
negative, zero and positive slopes for one of the factors (usually period). In a number of 
stUdies examining histological trends of cancer incidence in Connecticut by Zheng et al 
[214-216], the authors obtained identifiable solutions by fixing the period slopes through the 
range -0.2 (+0.1) +0.2 for investigating the age, period and cohort effects for oesophageal 
cancer [216], and the range -0.2, 0.0, +0.2 for similar enquiries regarding the trends of 
stomach and lung cancer [214,215]. 
3.4.2.1.5 Other possible restrictions 
One option not addressed by Holford's group involves utilising a slope for age that satisfies 
what is known regarding the age structure of some cancers. From the 1950s, characteristic 
curves for different forms of cancer have been established [61,166,217-222]. Prior to 
screening, the age-specific incidence rates of invasive cervical cancer for instance, have 
been shown to be similar in shape irrespective of the international population examined 
[221]. In Chapter 4, estimates of age, period and cohort effects of cervical squamous cell 
carcinoma incidence are obtained on assuming a slope for age that mimics this unique age 
structure. Fixing age "frees" period and cohort - slopes of these effects are not dependant 
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on a priori assumptions - an independent assessment of the impact of cytological screening 
against a background of changing generation-specific risk can be made. 
For hormone-dependant cancers in women, Pike has related the rate of change in the age-
specific incidence rates to effective tissue age [220,222,223], and has shown the 
correspondence in age curves of breast, endometrium and ovarian cancers on setting the 
rate of tissue ageing to a different constant level according to the period of a woman's 
reproductive life [220]. Consequently, there is potential for seeking solutions that assume a 
particular slope in keeping with what is known regarding the underlying age structure in 
terms of the disease processes. This approach is partially applied in Chapter 5, whereby the 
age curves of endometrial cancer incidence are fixed within a postmenopausal age range in 
order to assess the period and cohort trends in European countries. 
3.4.2.2 Attaching confidence limits to Holford's estimates 
There is no easy way of obtaining standard errors using the above modelling approach. The 
regressions on age, period and cohort are complex functions of the underlying dataset and 
the resulting parameters therefore have virtually intractable standard errors. One might 
follow the suggestion of Carstensen and Keiding who advocate a method that fits period to 
the residuals of an age-cohort model [224]. Their method therefore prioritises time scales, 
ranking period lowest, but does allow the standard errors to be readily obtained. 
A relatively simple way to gauge the variability in Holford's estimates is to obtain confidence 
intervals based on bootstrapping percentiles [225]. The bootstrap is now a common 
procedure for estimating the sampling distribution of an estimator by resampling with 
replacement from the original sample [226]. To illustrate how the approach works in practice, 
a 95% confidence interval for the period and cohort effects obtained from Holford's method 
is shown in Figure 3.9 using testicular cancer mortality data from Norway 1965-99. The 
success of treatment from the early-1970s on certain forms of testicular cancer would 
suggest that period effects should dominate the mortality trends and a cohort slope of zero 
is assumed in this example (see Chapter 6 for further exploration). 
The bootstrap interval was constructed in R [209] assuming that each cell followed a 
binomial distribution for which the rate and the number of person-years at risk represented 
the probability of success and number of trials, respectively. The original mortality data were 
resampled 1000 times and the 2.5 and 97.5 percentiles of each of the curvature 
components of the 1000 sets of estimates of qJj and qJk were selected to obtain the 
percentile interval depicted in the Figure. 
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Figure 03.9: Period an~ c?hort effects, based on Holford's approach (solid line) 
and 95 Yo confidence limits, based on bootstrap percentiles (dashed lines) 
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3.4.3 Restriction to estimable functions 
Several authors, notably Holford [66,98,107,108,110] and Clayton and Schifflers [68] have 
stressed the importance of solutions that reveal the mathematical dichotomy of overall 
slopes that cannot be uniquely determined, and their deviations, estimates of the curvature 
that can. Each factor is characterised by a slope that may take on a wide range of values, 
while maintaining a set of identical deviations. Clayton and Schifflers, after discussing briefly 
two sensible parameterisations (Holford's zero period slope method (discussed in 3.4.2.1.1) 
and their own simpler (but potentially imprecise) mean first differences approach (3.4.1.2.2), 
propose a final preference, a reparameterisation that provides unique estimates of each 
effect, regardless of the particular set of constraints imposed. This ensures identifiability by 
focusing solely on a summary of estimable curvature and in doing so, avoids the need to 
make arbitrary statements regarding the linear trend. The approach leans to the 
conservative side with regards interpretation - trends are not informed by possible values of 
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the slopes. Certainly the proposal remains however one of the more statistically valid 
solutions to the problem [227]. 
3.4.3.1 Second differences 
A unique set of age, period and cohort parameters can be obtained by utilising the fact that 
on an antilogarithmic scale, non-linear effects can be expressed as relative risks between 
adjacent age, period or cohort levels [68]. Using cohort parameters from an APC model as 
an example, second-order effects identify changes in the magnitude of trends by comparing 
the position of a particular cohort relative to the preceding and subsequent cohort. Second 
differences have the useful property that the estimated cohort values are affected only by 
neighbouring data [68]. On an additive scale, for k = 2,3, ... , K -1 the c; are the second 
differences: 
{3.28} 
{3.29} 
{3.30} 
On a multiplicative scale the Y; thus represent adjacent relative risks: 
I / Y3 i Y2 Y4 Y3 YK YK-l 
, , ... , 
Y21YI Y31Y2 YK-li YK-2 
{3.30} 
Decelerations in the trend (y; < 1, concave curvature) provide evidence that increasing 
rates are slowing down with time, or declining rates are decreasing more rapidly with time. 
Conversely, accelerations ( Y; > 1 , convex curvature) indicate either a reduction in the pace 
of the decreasing rates, or the speeding-up of increasing rates. Y; approximating unity 
indicate that local trends are unchanging, or relatively linear. Abrupt increases or decreases 
should be considered most important, with values close to unity indicative of regular linear 
increases or decreases. 
Second differences may be interpreted more readily when graphically presented alongside 
the observed and fitted rates - indications of local departures from linearity, acceleration or 
decelerations in the cohort trend can be substantiated on inspection of a cohort graph 
depicting trends in cohorts as they reach the same age. 95% CI based on the calculation of 
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the standard errors serve to indicate the precision of the model parameters, and in 
particular, the considerable caution required in interpreting estimates of trend curvature 
representing the youngest cohorts. 
Despite their advocacy by Clayton and Schifflers, few examples of their application occupy 
the cancer trends literature (e.g. [228,229]). Certainly the concept of second differences is 
somewhat difficult to grasp, given that they constitute the relative risk of first-order relative 
risks based on two adjacent cohorts. Perhaps the main problem is the low level of insight 
that can be gleaned from such a conservative approach, particularly if interpreted without 
prior knowledge of the observed rates or possible sets of model effects. Figure 3.10 shows 
the second differences and sets of model estimates for cohorts using the breast cancer data 
example in Japan from the second of the APC articles by Clayton and Schifflers [68]. The 
accelerations in risk in successive cohorts born since the turn of the century are detected by 
the second differences (abrupt increase around 1900, y; > 1), although a display of possible 
model estimates aids interpretation. The observed trends in the C by A plot shown in Figure 
3.3 suggest the possibility of cohort-specific increases from 1900. A deceleration around 
1920, and a further acceleration in 1935 is implicated in the model effects in Figure 3.10. 
This observation, if real, may be related to a time window between the wars for which risk 
was not increasing in pre-menopausal women. 
More generally, a presentation that is restricted to curvature effects without knowledge of 
the linear trends is considered by some to be of limited use, given the obvious lack of basic 
information regarding even the direction of the trend [67]. Tango and Kurashina however 
demonstrated that by focusing on estimable curvature, some insights into trends in mortality 
from major diseases in Japanese men were possible [101], particularly the accelerations in 
risk of diabetes, liver cirrhosis and ischaemic heart disease in cohorts born 1925-40, the 
same cohorts for which an acceleration in breast cancer mortality was noted by Clayton and 
Schifflers using the same approach [68]. Tango and Kurashina also suggested examining 
the mean of the adjacent second differences so as to detect changes that may have 
occurred within the five years that overlap between two successive cohorts [101]. 
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Figure 3.10: Second differences and three sets of APC model estimates 
de~endent on choice of constraint, as presented by Clayton and Schifflers' in 
their second APC paper, 1987. Breast cancer, Japan 1953-77 (Source: [68]) 
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3.4.3.2 User-defined identifiable contrasts 
Tarone and Chu extend the use of contrasts offered by Clayton and Schifflers [68], 
developing a method that allows a priori hypotheses to be tested [103]. The authors define 
YLI and YL2 to be the slopes of the linear trend in two epochs such that for cohort indices 
c1 < c2 ' such that: 
{3.31} 
{3.32} 
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where 8} and 82 are the intercepts of the two cohort lines. They show that while the slopes 
for the transformed parameters may not be identifiable, the difference in the slopes p} - P2 
is an invariant function. Any comparison of the slopes between two groups of cohort is 
estimable, but relies on a sound basis of specific epidemiological enquiries to construct 
hypotheses a priOri, that avoid merely data dredging and multiple testing. 
Tarone and Chu [103] examine the slopes of the linear trends in breast cancer mortality in 
the U.S. in terms of evaluating pre-defined contrasts. In particular the contrast: 
{3.33} 
is analogous to the local curvature obtained using the second differences [68]. Similarly, in 
an approach analogous to an earlier study involving non parametric methods [102] (see 
3.4.5.4), all relevant cohorts make a contribution to the linear contrast comparing the slopes 
in two blocks of eight cohorts: 
C2 =7rk+7 +5rk+6 +3rk+5 +rk+4 -rk+3 -3rk+2 -5rk+l -7rk 
-(7rh+7 +5rh+6 +3rh+) +rh+4 -rh+3 -3rh+2 -5rh+1- 7rh) {3.34} 
Similar contrasts can be constructed for determining the change in age and period slopes. 
Robertson and Boyle applied the method (and the same cohort contrast C2 ) to compare 
breast cancer incidence and mortality trends in Scotland [230]. They showed that cohort 
effects post-1900 were similar for both incidence and mortality, and that increases in birth 
cohort mortality after 1925 match those seen in the previous study of the U.S. and Japan. 
Robertson and Ecob recently used the method to compare overall cancer mortality in men 
and women in later versus earlier periods of death, and in cohorts defined by their dates of 
birth, before or after World War II, stratified by U.K. region. They demonstrated that there 
were no substantial differences across regions in terms of the curvature of the three effects, 
with evidence of decelerating mortality rates in both period and cohort-specific terms in 
women, but not in men [231]. 
3.4.4 Mathematical solutions 
The approaches to circumventing identifiability considered in the last two sections have 
involved either the bringing to bear of external information to provide a solution or range of 
solutions (3.4.2), or a reparameterisation that is strictly invariant to any proposed solution 
(3.4.3). Both methods have their merits: the former at least removes some of the 
arbitrariness in selecting solution(s), should the method have groundings in biological or 
epidemiological plausibility, the latter focuses attention and interpretation only on what is 
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identifiable. Two methods are outlined below that employ mathematical approaches to 
obtain unique estimates of the linear slopes of age, period and cohort, thus solving, or 
appearing to solve, the identifiability problem. 
3.4.4.1 Penalty function approach 
The approach proposed by Osmond and Gardner uses an identifiability constraint obtained 
by finding the best agreement between two-factor models and the full model [96]. The 
authors find values for the age, period and cohort slopes a~, f3;, and r~, by estimating v , 
the unknown constant introduced in equations {3.17}-{3.19} estimated in this method on 
minimising the penalty function, the sum of the squares of the differences between the 
parameters of each of the three two-factor models and the full three-factor model weighted 
by a goodness-of-fit measure, such as the deviance [112]. Clayton and Schifflers describe 
the Osmond-Gardner method as a partition of the drift between period and cohort in a ratio 
that depends on the relative magnitude of the non-linear effects [68]. The value of v 
obtained is used to "correct" an arbitrary three-factor model, much in the same way as the 
imposition of an assumed slope identifies all effects (see 3.4.2.1). 
The solution obtained depends on the number of levels of each factor, the parameters in the 
two-factor models and their relative goodness-of-fit [107], and both Clayton and Schifflers 
[68] and Holford [107] have argued that the solution obtained remains an entirely arbitrary 
one, given the failure to allow for biological plausibility. Clayton and Schifflers also note that 
in situations where both the AP and AC models fit the data (and for which the AD model 
may be a better realisation), much of the drift will be sent to the cohort effects, simply 
because it has more parameters. 
Decarli and La Vecchia proposed a similar procedure to the penalty function approach -
they minimised a weighted sum of the squared distances - and also provided a routine for 
implementation in GUM [120]. Perhaps as a result of the availability of a ready-made 
program, the method has found numerous applications in cancer studies in the last 20 years 
[232-234]. The ability to find a single solution appears inviting, although justification of the 
method is not always apparent. Authors of a study of trends in six European countries 
indicate the approach was chosen because of "its applicability to large numbers of routinely 
produced datasets and due to ease of interpretation" [234]. One might however argue that 
the arbitrary partition of drift is disadvantageous in making meaningful comparisons of 
trends between populations. 
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3.4.4.2 Individual records approach 
Robertson and Boyle describe a method that exploits the additional information available 
from individual records (lacking in grouped data) to solve the identifiability problem [100]. By 
forming a two-way table of age and period based on individual data rather than aggregates, 
the cohorts minimally overlap, as one may assign each case to their year of birth. Each cell 
of a five-year age by period classification can be split into two birth cohorts spanning five 
years. The 10-year overlapping cohort identified with midpoint 1930 in Figure 3.4 can be 
diagonally partitioned into unique cohorts with all cases in the lower triangle of Figure 3.11, 
born between 1925 and 1929, and all cases in the upper triangle born between 1930 and 
1934. Cases on the diagonal are still overlapping, but divided equally between the two 
triangles [100]. 
Using the same notation for age and period above, the indices for cohort, k· , are now 
almost free of overlap, being represented in age group i and period j by j - i + 1 in the 
lower triangles and j - i + 1 + 1 in the upper triangles. The method provides a unique set of 
parameters when fitted in any statistical package, as the identifiability problem has been 
solved given i, j and k * break the linear dependency between the three factors [107]. 
The errors in the approach were rapidly forthcoming after its publication, taken up by 
numerous authors including Clayton and Schifflers [68], Osmond and Gardner [235], Tango 
[236] and others [107,108,110,224,237], and acknowledged by the original authors 
themselves [111,112,238]. The problem lies in the indices being unrepresentative of their 
respective times [107]; assuming age and period are uniformly distributed across a single 
cell, the 10-year cohort will in upper triangles disproportionately represent older ages 
diagnosed towards the start of the period, and in lower triangles, younger ages diagnosed 
later in the period. For a uniform age distribution across the age-period cell represented by 
mean age index i, Holford [107] has shown that the mean ages for the two triangles (as 
depicted in Figure 3.11) are i - ~ (lower) and i + ~ (upper); for period j + ~ (lower) and 
j - ~ (upper); and cohort k + ~ (lower) and k - ~ ( upper). In APC modelling, the mean 
values of age, period and cohort therefore must be used, since in any part of the Lexis 
diagram, k must equal j - i + I . On refitting the model with unbiased indices for all three 
factors, the identifiability problem re-emerges. In Figure 3.11, the correct mean values for 
the three factors in the lower triangle of the lower left age-period cell are given. 
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Figure 3.11. Lexis ~iagrams depicting near non-overlapping birth cohorts for 
u~per and lower triangles of each age-period cell; the central values in the lower 
triangle of the bottom cell are 31 X, 1963}j and 1931 % , for age, period and 
cohort, respectively. 
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3.4.5 Other statistical approaches 
1970 
Calendar time 
1980 
There a number of other methods that do not correspond to the four categories listed in the 
beginning of section 3.4. These are briefly described below. 
3.4.5.1 Non-linear models 
The APe model of {3.6} does not take account of the possibility of interactions between the 
factors, for example, where period effects are dependant in some way on level of age, 
unrelated to the special form of interaction that constitutes a cohort effect. 
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A prime example relates to time trends in mortality from multiple myeloma, a cancer for 
which diagnosis is largely dependant on the availability of medical facilities and the intensity 
of laboratory testing [239,240]. Velez et al observed that in England and Wales, 1953-1977 
[240] (updated and extended to international populations by Cuzick [241-243]), increases in 
death rates were steepest in the 1950s, the period in which diagnostic advances were 
greatest. Further, the most rapid increases were observed in men and women aged over 70; 
rates were less rapidly increasing in younger age groups in England and Wales, and rather 
stable in other Western countries [240-243]. Cuzick considered this observation an example 
of an age-dependant period effect masquerading as a cohort effect [243]; artefactual forces 
acting near the time of death (such as diagnostic improvements and greater access to 
medical care among the elderly) were a more plausible explanation than a generational 
effect whereby some exposure or exposures exdusively affected older persons [242]. 
Studies in the late-1970s and early-1980s by Moolgavkar et al [93] established that various 
interactions over and above the AC model were estimable and in some instances could be 
given a biological interpretation. In particular, the model introduced by Moolgavkar et al and 
used by James and Segal in the study of prostate cancer mortality [95] extended the APC 
model to the form: 
{3.35} 
The effect of age a i is included as multiplicative factor with period denoted as Jj , with the 
period and cohort effects as in {3.6}. This is a non-linear model that does not suffer from 
non-identifiability; the interaction enables the age curves across periods to vary by a fixed 
multiplicative factor [68]. 
The drawbacks are the obvious difficulty in interpretation, the possibility of introducing 
unrealistic assumptions, and the computational difficulties in obtaining convergence that are 
sometimes associated with such models. Further, if {3.6} provides a reasonable fit i.e. 
J. "'" I, {3.35} reduces to {3.6} and the identifiability problem re-materialises [68,108]. Tango } 
and Kurashina [101] and Lee and Lin [244] have used similar approaches to the above, 
although the former authors focused on curvature effects, and the latter introduced a more 
complex interaction in the APC model such that E[log rij] = J1 + (aj + Yk .Jj ).jJj . 
Fienberg and Mason have studied possible extensions to the full model with polynomials 
and outlined those interactions that do not suffer from the identifiability problem [106]. As 
Holford states however, interpreting interactions from higher-order models in light of the 
identifiability problem usually leads to quite a complex interpretation [108]. 
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3.4.5.2 Using external data 
Holford has reviewed approaches that introduce external information to achieve an 
identifiable solution without the need for arbitrary constraints [108]. One tactic is to specify 
the functional form of age using the multistage models introduced by Armitage and Doll 
[166]. In its multiplicative form, the effect of age has the same distributional form as the 
Weibull hazard such that ~ ex: t' , where 1] represent the number of stages minus one. In 
log-linear terms a j = 1] log(i) , and 1] is unknown, requiring estimation from the data. The 
factors are no longer linearly dependant, but the usefulness of the model will be dictated by 
its ability to correctly specify the functional form of age [108]. 
Although many cancer types were observed to conform to the simple patterns described by 
the Armitage-Doll model, systematic departures soon emerged for certain cancers, and a 
number of modifications reflected this, such as the two-mutation model, have been 
proposed [245,246]. Holford applied the model and some of the proposed extensions to lung 
cancer trends in Connecticut 1935-88 [247]. Models that included polynomials for age and 
allowed the age effects to differ according to susceptibility fitted well. 
More recently, Luebeck and Moolgavkar fitted multistage models to colorectal cancer in the 
U.S. by fitting the age-specific incidence as a two- to five-stage clonal expansion model 
[245] that mathematically incorporated the sequence of genetic events that define the main 
pathway to colorectal cancer occurrence. Adjusting for period and cohort effects, the authors 
suggested trends in colon cancer could be attributed mainly to the effect of calendar period 
[248]. The models were also informative regarding the prospects for prevention - the 
administration of nonsteroidal anti-inflammatory drugs was reported to be very efficient at 
lowering colon cancer risk substantially - even when the intervention began later in life. 
Trends in risk factors have been used as a more direct measure of time than the surrogate 
measures of period and cohort. Brown and Kessler predicted lung cancer mortality in the 
U.S. to 2025 by incorporating changes in the composition of cigarettes - average tar 
exposure over each calendar period allowing for a sufficient time lag - adjusting for age and 
cohort [55]. Holford points out that the successful use of external data in this model relied on 
the non-linear nature of the period effects; had levels of tar changed with calendar time in a 
linear fashion, a dependency with age and cohort would have once again arisen [108]. 
Stevens and Moolgavkar derived estimates of the relative risk of lung and bladder cancer 
due to smoking in England and Wales, by incorporating a function of the proportion of 
smokers and the cumUlative number of cigarettes smoked, as a cohort effect, adjusted for 
period and age [249]. Such approaches have the potential to produce a unique set of 
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parameters that are plausible, although the effects of the two 'free' factors will be 
determined by the underlying accuracy of the data used to fix the third. 
3.4.5.3 Fixing age curves across populations 
Day and Charnay proposed an analysis involving several registries and fixing the age-
specific curves in order to separate the effects of period and cohort [65]. Should common 
age curves give a good representation - the adequacy of the assumption can be tested _ 
the authors recommend inclusion of registries considered to have either minimal period or 
cohort effects. By doing so, period and cohort factors can be uniquely identified in other 
registry areas where both effects are deemed important, and for which a plausible solution is 
reached on assuming a fixed biological age curve. 
In studying trends in lung cancer in Slovenia and Finland, Day and Charnay assumed that 
period effects were negligible in Slovenia and fitted a common age curve to the data from 
the two countries, thereby enabling period and cohort effects to be examined in Finland [65]. 
Clayton and Schifflers were critical of an approach that fixed the age structure across 
registries however, citing the likelihood that populations in different localities may have 
experienced differing exposure profiles and subsequently, a heterogeneity in their respective 
age patterns [68]. 
Boyle et al extended Day and Charnays' approach, exploring incidence trends in malignant 
melanoma in a national registry area (Norway) but allowing for sex and subsite as well as 
age, period and cohort factors [94]. Of particular interest was the lack of statistical 
associations in the interactions between age and the other factors, enabling the fixing of age 
curves across such strata, thus ensuring identifiability. The authors suggested two possible 
interpretations: one that involved a common age curve but different cohort trends for each 
subsite for both sexes, and another for which there was a common cohort curve that varied 
by age, sex and subsite. 
3.4.5.4 Non-parametric methods 
Tarone and Chu described a method that allowed them to examine mortality trends of breast 
cancer mortality in the U.S., without the need for a formal model specification [102]. The 
non parametric approach compares age-specific rates between adjacent effects of cohort (or 
the other factors), on the basis of the sum of the negative decreases, constructing a 
permutation test of the null hypothesis that there is no cohort trend. The exact mean and 
variance for n comparisons in the same age group is n / 2 and (n + 2) / 12 , respectively. 
The expected number must take into account the range of possible comparisons in any 
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particular diagonal, given the number of rates associated with each cohort varies from the 
extreme cohorts to their maximum number along the middle diagonals (see 3.3.1). 
3.4.5.5 Splines and curvature 
Most analytic strategies, from Case's article in 1956 [71] onwards, have focused on an age-
period table with equally-spaced five-year age and five-year period groupings, at least in 
part reflecting the availability of the data from vital sources. The categorical approach has a 
certain amount of flexibility; but where there are small numbers involved, it may be desirable 
to smooth the curvature either by the use of polynomials or splines [110]. Heuer cited the 
loss of information at the aggregated level and the lack of possibilities in examining 
interactions as motivation to analyse the data at a more detailed level, for example in one-
year intervals, using regression splines [250]. The possibilities to implement such an 
approach is dependant on the resolution of data available. Unequally-spaced analyses of 
trends, for example using single calendar periods and five-year age group are feasible 
approaches to data pertaining from vital sources, so long as the indices of age, period and 
cohort are corrected to represent their respective times [66]. 
Spline functions are functions that represent polynomials that are joined together at knots 
(pre-defined points), with continuous derivatives at the knots. Carstensen and Keiding have 
reviewed the various forms of splines available [224]. They often take the form of cubic 
splines, but modifications of cubic splines such as restricted cubic splines and natural 
splines, force the trends to be linear outside the outer knots. The authors noted the need to 
specify the knots a priori and recommended the use of natural splines, as they are 
considered most stable. 
To compare an APC analysis involving a 5-year quantisation of age and period with one 
based on single year data, an application to testicular cancer incidence in Norway 1954-
2003 is provided in Figure 3.12. In the figure, the smoothed cohort effects based on the 1-
year data are obtained via an implementation of natural splines in R [209]. The allocation of 
knots at cohort values of 1920, 1930, ... , 1970, as well as the boundary knots, were specified 
a priori. The APC analyses of the higher and lower resolutions of the data was based on 
identical procedure, whereby the period effects were conditional on the estimated age and 
cohort effects, and the drift term was explicitly allocated to cohort (see 4.5.2.2.2). The 
reference cohort is 1954-55 and 1950-59 for the 1- and 5-year analyses respectively. 
Given the 5-year tabulation of age and period generates synthetic cohorts over 10-year 
spans compared to 2-year cohorts in the single year analysis, the former is less able to 
accurately identify important short-term effects and may tend to wash out weaker ones. In 
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Figure 3.12, a short-term wartime effect in Norway, involving an attenuation of increasing 
risk of testicular cancer in men bom 1940-5 is evident in both curves, as has been 
demonstrated previously [251]. The additional information conveyed by the single year 
analysis is the more precise identification of a minimum risk in the generation bom around 
1940. 
There are a number of prior examples of the use of splines in APC modelling of cancer 
rates. Sasieni and Adams examined trends in cervical cancer incidence and mortality using 
natural cubic splines, citing justification on the grounds that the method enabled flexibility in 
the modelling of the fluctuating cohort trends [189]. Zheng et a/ examined rates of cervical 
adenocarcinoma rates in the U.S. using cubic splines to smooth the trends given the relative 
rarity of the histology [210]. An example of the application of natural cubic splines to 
incidence trends of cervical adenocarcinoma is given in Chapter 4. 
Figure 3.12. Comparison of cohort effects from an APC model based on a 5-year 
versus 1-year quantisation of age and period. The vertical line denotes the risk 
ratios for the cohort born in 1940 
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3.4.5.6 APC models and cumulative risk 
1960 1980 
Cumulative risk has certain advantages over age standardisation as a form of direct 
standardisation; the weights of the standard population equal the width of each age group, 
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and are therefore no longer entirely arbitrary. Further, the cumulative risk is directly 
interpretable as a measurement of lifetime risk, assuming no other causes of death are in 
operation. 
Coleman et al in a comprehensive analysis of incidence and mortality trends of 23 cancers 
worldwide used an approach that systematically presented trends in each population 
according to lifetime risk defined by their birth cohort [8,57]. As the youngest and oldest 
cohorts were not entirely represented in the age-period table, the method had a prediction 
component; the authors extrapolated the smoothed cohort effects from an APC model 
backwards and forwards in time. To obtain efficient smoothing, polynomials of each factor 
were continually added until polynomials of order two levels above the present best-fitting 
model failed to significantly improve the fit. Several studies have applied this approach, 
including papers examining international trends in cervical squamous cell [252] and cervical 
adenocarcinoma incidence, respectively [253]. 
3.4.6 Predicting future cancer burden 
Making provision for health services for cancer requires not only knowledge of the current 
pattern of occurrence, but also an estimate of the likely evolution in the future. MacMahon 
states, in an introductory text to temporal studies of cancer incidence, that "[predictions] if 
accurate, are clearly of great value for planning purposes. But it is a tricky business and it is 
a courageous epidemiologist who enters it - particularly if he or she is of an age to see the 
prediction evaluated by the passage of time" [254]. Predicting cancer occurrence is rightly 
considered a hazardous exercise: for some cancers in some populations, we can be 
reasonably confident that trends observed in the past will not hold in future. 
Much of the contemporary work on making predictions of cancer incidence, from both a 
theoretical and practical perspective, stems from scientists working at the Finnish Cancer 
Registry. Their first report, which involved predictions of the 12 most common forms of 
cancer in Finland for 1980, was published in 1974, based on the linear extrapolation of 
trends from 1957--68 [255]. Key to further developments of methods over the next three 
decades has been a continued validation of prior attempts at prediction. A recent study 
provided an empirical comparison of 15 different prediction methods in predicting the 
incidence of 20 cancer sites in the five Nordic countries [256]. 
Predictions, according to Hakulinen, can be divided into those made for administrative and 
scientific purposes [13]. Accurate predictions can aid health planners attempting to optimise 
resources (e.g. for prevention, early detection, treatment, rehabilitation and palliative care), 
and explanations for deviations between the observed rates and those predicted are often 
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useful to establish in order to understand why predictions fail (e.g. a failure of the method vs. 
shift in trends following prediction). In a more scientific setting, cancer predictions may give 
advanced warning (and impetus) for the need for action, particularly where unfavourable 
trends are potentially modifiable by intervention. 
It is important to note that predicted numbers are a composite of population growth and 
ageing, as well as changing risk. Demographic changes substantially alter the expected 
number of future cases, and ageing will continue to have major consequences on the 
burden of disability and chronic diseases projected over the next 50 years, particularly in the 
developing world. 
The extrapolation of trends of cancer rates into the future is a necessary proxy for the 
changing prevalence and distribution of risk detenninants, given that risk factors for most 
cancers, where established, are neither singularly powerful enough to model directly, nor 
available at the prerequisite level of detail required. 
Changes in the size and particularly in the ageing of the population often constitute a larger 
component of predicted increases in burden than corresponding changes in risk [257]. 
Indeed, predicted increases in the absolute numbers might arise from demographic changes 
even when existing trends are stable or declining. It is therefore important that the potential 
for misinterpretation is minimised by focusing on the impact of risk and the reduction of risk 
through prevention [257]. 
3.4.6.1 Predictions using the APe model 
The potential of the cohort method in predicting future disease burden dates back to 
Andvord and his study of tuberculosis mortality published in 1930 [80]. He discusses the 
extrapolation of (the favourable) trends in younger generations into later ages as a way of 
estimating future mortality. Frost's riposte to this echoes both the utility and inherent 
difficulties in making predictions, citing the idea as "both tempting and encouraging but 
perhaps dangerous" [73]. 
Osmond was one of the first to advocate the APC model for predictions and details the 
methodology that projects the underlying age-, period-, and cohort-specific trends into future 
time periods [258]. The APC model can be written as Rij = exp(ai + tS.} + /3j + Yk)' where 
R .. is the incidence rate in age group i in calendar period} with tS the net drift parameter. 
I) 
As the three components are mutually dependent, it is possible to estimate only the regular 
trend and its deviations, not whether period or cohort-specific factors are responsible for the 
slope. Holford showed that the change in time between a projected rate and the rate within 
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the study period was an estimable function, and therefore predictions did not suffer from a 
lack of identifiability. In closing their APC paper, Clayton and Schifflers however state "in 
recent years there has been several attempts to use an APC model fitted to past data to 
forecast rates ... Unfortunately [Holford's assertion [98]] ... is a strong assumption that will 
rarely be justified in practice" [68]. 
That drift will remain constant in future periods is a major assumption. Several studies of 
prediction in the Nordic countries have aimed to address the issue by "damping" the 
projected trend on the aforementioned belief that rates will not continue to increase forever. 
The most recent study systematically predicted the number of cases up to 2020 of 20 types 
of cancer for each sex in the Nordic countries [257]. The prediction involved the APC model 
but one that allowed for an increasing reduction in the projection of drift with future time. 
Variations in the method (50% reduction in drift after 10 years, gradual reduction in drift 
every five years) have been shown empirically to perform favourably [256]. 
The other difficulty stems from the use of the exponential function in predicting from log-
linear models, giving rise to predictions that grow exponentially over time, and for some 
cancer types, unrealistically high predictions [180]. A power model such as 
Rij = (ai + tS.j + /3j + rk f has been proposed to reduce the growth in the predicted rates. 
M011er and colleagues found that the model improved predictions, as did methods that 
emphasised trends in the last decade [256]. Some or all of these conditions (power model, 
dampening of drift, emphasis on recent trends) have been incorporated in a number of 
recent prediction studies [257,259,260]. 
Berzuini and Clayton have developed a Bayesian approach to smooth the effects of age, 
period and cohort groups, taking a second differences approach (see 3.4.3.1) that prevents 
the rate estimates for adjacent groups from differing too much from each other [261]. The 
model originates from the APC model, using the exponential function between the rate and 
the effect variables, and thus for some cancers has given rather extreme predictions. 
Where a lesser data span is available, simpler models that contain only the age and the drift 
component of the APC model have been developed in Finland [179,180,262]. Such models 
have been applied to annual data 1990-2000 rather than over consecutive five-year periods. 
To avoid the exponential growth over time, models that were linear with time were applied to 
cancers with increasing trends [262]. The disadvantage of the approach is that it does not 
incorporate cohort-specific patterns. Nevertheless, it has been shown to perform well 
compared with other prediction methods [256]. 
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Past experience of exposure to causative or preventive factors, or the availability of 
preventive and therapeutic procedures, is not a sure guide to the future. For this reason, or 
simply on the grounds of insufficient data, future scenarios are sometimes confined to 
consideration of the effects of probable demographic changes, assuming that future rates 
remain constant at the present level. It is often considered that such simple methods would 
not produce any less accurate predictions than those assuming a projection of this drift into 
the future. However, an empirical study of cancer incidence in the Nordic countries showed 
that projecting current trends resulted in predictions closer to the rates observed 10 years 
later than the constant rate approach [256], although the latter performed reasonably well. In 
GLOBOCAN 2002 [263], future numbers of cancer cases and deaths can be calculated by 
this means for 2005 to 2050, and can incorporate specifications of the likely future EAPC in 
five age groups. 
The innovative Cancer Scenarios project in Scotland has gone beyond the simple provision 
of predicted numbers and rates, soliciting the expertise of specialists to discuss future 
preventative and treatment-based interventions in terms of their capacity to modify incidence 
and mortality trends, projected up to and including the period 2010-2014 [264]. Predictions 
of cancer are also now commonplace in peer-reviewed medical and epidemiological articles; 
calculating the future course of epidemics of lung cancer in relation to smoking [54,55,265-
267], and mesothelioma in men exposed to asbestos [268-271] have been particularly 
intensively researched. 
3.5 The age-period-cohort model 3: review of APe studies 2000-2004. 
To ascertain the extent to which the strategies considered above were applied by 
researchers in recent practice, this section of the thesis involves a review of peer-reviewed 
statistical, medical and epidemiological journals publishing relevant articles over the five-
year period 2000 to 2004. The final list of articles for review was assembled over several 
stages. 
A list of candidate papers was established on the basis of a merge from three independent 
sources. Papers published 2000-04 that cited one of 16 key references on APe analyses 
were identified using the citation search facility in Web of Science's Science Citation Index 
Expanded database. After a further restriction to articles in English, 188 articles were found, 
and upon review, 112 were relevant to the study of cancer. 
A parallel step involved an individual search of papers in PubMed that contained any of the 
fields (age*, period*, cohort*, trend*) in combination with (cancer* OR neoplasms* OR 
tumor* OR tumour*) and a publication date 2000-04, for which 220 articles were retrieved 
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and, of which, 93 considered relevant. The third component was a search of relevant articles 
in a bibliographical database over the same period held by the author on a time trends 
database of 22 cancers. The three sets of articles were then merged in Reference Manager 
to obtain a final list of 256 papers. 
The final stage involved a necessity to moderate the number of papers to those that were 
directly relevant and appeared in journals that regularly publish such studies, so as to allow 
a broad examination of editorial policies regarding their inclusion. A restriction to journals 
that published five or more articles on the topic during the five years was imposed, which 
reduced the number of studies to 100 (Table 3.1), about two-fifths of the previous total. The 
top seven of the nine Journals (Int J Cancer, Eur J Cancer Prev, Cancer, Cancer Causes 
Control, Br J Cancer, Eur J Cancer, and JNCI) were specific to cancer research. 
Of these, 40 were studies investigating cancer data that presented an analysis involving 
age, period and cohort effects using the APC model. Two papers that focussed exclusively 
on future predictions and one that assessed the impact of screening were excluded, and the 
final list therefore included 37 papers [204,252,272-307]. Table 3.2 presents details of the 
papers. All journals were represented by at least three articles, with the largest number 
published in The International Journal of Cancer (1 0 studies). The exception was The 
Lancet where none of the articles were of relevance (being either letters, commentaries, or 
not directly involving APC approaches). 
Table 3.1: Journals publishing one or more time trends studies per year on 
average, 2000-04, according to the criteria set out in 3.5 
Number of 
Journal articles 2000-04 
Int J Cancer 24 
Eur J of Cancer Prey 14 
Cancer 12 
Cancer Causes Control 11 100 articles = 39.1 % of total Brit J Cancer 10 number found 
Eur J Cancer 9 
J Natl Cancer Inst 8 
Int J Epidemiol 7 
Lancet 5 
Other journals 156 
Total number of articles 256 
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Table .3.2: Finalised list of studies utilising APe modelling approaches to 
describe cancer trends in one or more populations 
Journal 
Int J Cancer 
Eur J Cancer 
Brit J Cancer 
Cancer 
Eur J Cancer Prey 
Int J Epidemiol 
Cancer Causes Control 
J Natl Cancer Inst 
Total number of articles 
Number of 
articles 2000-04 
10 
5 
4 
4 
4 
4 
3 
3 
37 
The following methodological elements were examined: 
o Presentation of observed trends; 
o APC methodology adopted; 
o Specific technique used to circumvent identifiability where applicable; 
o Tabular presentation of the model fit and parameters; 
o Graphical presentation of the model fit and parameters. 
It was anticipated that the results of the review would inform the guidelines developed in this 
chapter, potentially shedding some light on the rationale for a particular approach to time 
trends analysis and APC modelling. Table 3.3 provides some brief notes on the main 
features of the methods employed in each of the 37 papers reviewed. The following text 
attempts to encapsulate the main points arising from these findings. 
3.5.1 Aims of the studies 
The objectives of the studies were diverse. Typically, the papers described the time trends 
of a specific cancer in a single population, but specific aims over and above a broad 
synthesis of the trends were sometimes given, e.g. an examination of lung cancer related to 
observed trends in the tar yield of cigarettes [274] or adolescent smoking [301] in Australia 
and Norway respectively, or mesothelioma trends in the U.S. in relation to SV40 
contamination at birth [302]. 
Most commonly studied were trends in lung cancer (8 articles), malignant melanoma and 
breast cancer (6 articles each). 22 papers focussed on incidence-based trends, 11 on 
mortality, and the remaining four analysed both. Only two papers dealt with more than one 
distinct cancer site (one examining trends in four common cancers [297], the other within 
diagnostic groups of childhood solid tumours [293]). The majority of incidence studies did 
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however include sub-analyses of trends in defined histological groups or anatomical 
subsites. Only five studies analysed trends of a particular cancer across populations from 
more than one country, either at the intemational [252,253,299] or European level [284,307]. 
3.5.2 Tabular presentation of observed trends 
Some basic form of tabulation of trends data was provided in most studies, the commonest 
approach being an age-period tabularisation with cells representing either cases or rates. 
The grouping of age and period was commonly five- or 10-year, but other ranges were also 
applied, particularly for age. Person-years at risk or percentages, the latter as a proportion 
of the marginal totals, were also provided in some studies, as was a tabular presentation of 
trends in age-standardised rates. A further breakdown by histology, subsite, stage etc was 
commonly presented in more detailed studies. A handful of studies did not include a 
tabulation of the basic information, but only in one study was there no provision of observed 
data in either tabular or graphical form. 
3.5.3 Graphical presentation of observed trends 
Study approaches to the visual display of observed trends were quite heterogeneous, an 
indicator of the multiple options available in producing them (see 3.1). Over half of the 
reviewed articles did not provide graphical depictions of the observed trends, opting for a 
tabulation as the sole means of providing basic information. Where a visual approach was 
provided, one of the most frequent displays involved a plot of the age-standardised rates 
(either for all ages or truncated over one or more age ranges) versus calendar period. A 
number of standard populations were utilised in their production; by far the most commonly-
used were the World and European standard - although standards local to the study 
population were also applied to the study of trends in Hong Kong, Sweden and the u.s. In 
plotting the trends, the abscissa was usually represented by period either annually or as 
five-year aggregates, but other groupings (two-year aggregates, three-year moving 
averages) were also employed among the 37 papers reviewed. There were no clear 
preferences of scale for the ordinate, although there was perhaps a tendency for studies to 
use an arithmetic scale where age-adjusted rates were plotted. 
The other main approach was a more detailed breakdown of rates according to age, period 
and cohort (see 3.1.4.3). Most commonly applied were C by A plots (in 11 studies) while P 
by A and A by P plots were also depicted (in five and four studies respectively). Again, there 
was no clear convention to providing either a semi-logarithmic or arithmetic scaling, with 
some authors (possibly a prion) having preferences for arithmetic or logarithmic scales, 
irrespective of the trend measure being plotted. Few studies explicitly considered the 
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principles regarding either the size of the graph in terms of the ratio the of Y:X axis 
(dependant on the range of values presented on each axis) or the labelling of the axes (see 
3.1). Exceptions were several U.S. studies [285,291,302] (one of the co-authors in all three 
studies was the first author of the paper providing guidelines for presentation for rates [165], 
as was described in detail in 3.1.3). 
3.5.4 APe methodology used to present model estimates 
The numerous approaches adopted in these articles in presenting the effects from APC 
modelling reflect the wide range of choices of solution presently available, as reviewed in 
3.4. The papers by Clayton and Schifflers were among those cited as standard references to 
APC modelling in the majority of the 37 articles. Nevertheless, the rather few methods 
advocated by Clayton and Schifflers in their 1987 paper [68] is at odds with the 
heterogeneity of methods used to reach a solution (or solutions) in the reviewed articles 
2000-04: eight studies used a two-factor approach (six papers adopted the AC model only); 
five studies presented the effects by taking the first and last effect of cohort and/or period 
effects; a further three used a constraint that equated two levels of one factors; drift was 
attributed to period or cohort (or both) in five papers; linear contrasts were used to compare 
birth cohort slopes in four; cumulative risk based on polynomial expansions of the AC or 
APC model were estimated in three studies, and miscellaneous other methods were also 
practiced (penalty function approach; fitted rates; SCMR). Seven studies did not explicitly 
present effects from the APC model, while in six articles where modelled trends were 
presented, it was not clear as to the method used to reach the solution. 
3.5.5 Tabular presentation of the model fit I parameters 
Close to half (16) of the 37 studies explicitly provided some form of tabulation of the 
deviance of the APC model and/or submodels in order to examine (with the corresponding 
degrees of freedom) the goodness-of-fit of the APC model and/or submodels, and the 
variation explained by each factor. The Clayton and Schifflers modelling approach illustrated 
in Figure 3.5 was utilised in many of these articles, although the age-drift model was not 
fitted in several. In studies where numerous subgroup analyses were undertaken, it was 
more common to present the deviance for the best-fitting model only. In the remaining 
studies without tabulation of the goodness-of-fit, several provided details of the deviance of 
the models presented in the text; others provided no information on model fits. 
The EAPC was explicitly presented in 15 of the studies reviewed, in 11 as a separate table, 
but in those remaining, as part of a tabulation of the observed data. In the majority of 
studies, the EAPC was derived not from the net drift, but from a log-linear model of the form 
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outlined in 3.2.2. 95% CI were almost always provided. Joinpoint regression was used in 
only one study and the results were not shown. Tables of parameter estimates were 
incorporated rarely, with the presentation usually carried out via graphical means (see 3.5.6 
below). 
3.5.6 Graphical presentation of the model fit I parameters 
Only eight of the studies failed to provide some form of visual presentation of the model 
effects. Of the 29 studies including graphics, all but one included a cohort representation of 
the effects. Five studies showed effects for all three factors, and 11 studies showed effects 
for period and cohort. Only one study exclusively presented modelled trends versus 
calendar period. 
14 of the 29 studies provided antilog estimates as rate ratios, whereas eight produced 
trends effects based on the untransformed maximum likelihood estimates. Calculation of the 
effects as rates and as cumulative risk were other forms of presentation of the model results, 
as was the description of trends using the fitted rates from the APC model. 95% CI were 
included in some studies, but not in the majority. 
3.5.7 Other relevant methodological considerations 
In a few of the reviewed studies, trends in risk factors directly related to the cancer being 
investigated were included in the analysis and/or interpretation. Thus in three temporal 
studies of lung cancer, trends in smoking patterns in the study population were also 
presented [274,301,307]. Similarly, two temporal studies of mesothelioma [302,304] 
provided risk factor patterns relevant to the study aims (import of raw asbestos in Norway, 
SV40-contaminated poliovirus vaccine in the U.S.). Two studies of female cancer (breast 
and cervix) included data on local trends in reproductive factors and historical patterns of 
rates of tested positive serum syphilis, respectively [290,298]. 
3.5.8 Trends in citation numbers of major APe articles 
To get an indication of the consensus with regards the key APC papers, Figure 3.13 
provides a graphical description of the numbers of citations in scientific journals for each of 
nine selected papers since their year of publication. 
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Figur~ 3.13: !rends in number of ~itations vs. year of publication for nine original 
or ~evle~ artl~les on .AP~ models In the scientific literature (Source: Web of 
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Clearly, the Clayton and Schifflers' papers have been increasingly cited from their 
publication date in 1987, with more than 20 citations per year 2000-04. Most of the other 
studies varied from 1-10 citations annually with no real trends discernible (possibly some 
peaks in popularity of, or output using, a particular method are observed). Holford's original 
1983 paper combined with his later reviews 1991 and 1992 would be the only serious 
challenger to the papers by Clayton and Schifflers, representing an approximate total of 15 
citations annual in recent years. 
3.5.9 Concluding remarks 
Some interesting findings were obtained following the mini-review of methods that presently 
comprise an APC analysis of cancer trends. It was clear that there was some adoption of 
Clayton and Schifflers' (and to some extent Holford's) principles of APC analysis beyond 
merely being an appropriate citation, as might have been implied in the results in 3.5.8; in 
general terms, a majority of the papers reviewed could be considered technically competent 
in terms of the analytic strategies employed, with some demonstrating both an 
understanding of the identifiability problem in practice and due caution in interpretation of 
the APC effects. 
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However, there remained tremendous inconsistency with regards the method selected to 
present formal estimates via APC modelling. Among the 37 papers, nine methods were 
employed in presenting the model effects. Further, there was rather little exposition 
surrounding the basis of this choice. In some, but not all studies, the choice of model was 
dictated by the goodness-of-fit of model according to Clayton and Schifflers' framework [68], 
but justification for a particular choice of APC model effects (or exclusive representation 
using a two-factor model) was less apparent. One common rationalisation was reference to 
the use of the chosen method in previous studies; few articles, however, discussed their 
particular solution in terms of biological or epidemiological plausibility. 
Presentation of observed data leading to the more formal APC analyses was considerably 
heterogeneous among the 37 studies, both in terms of tabular and graphical 
representations. The importance of tabulated data at this level has not received much 
emphasis in this chapter, yet an important aspect of temporal studies is the provision of 
basic information such as number of cases and person-years at risk. These provide some 
indication of the impact of the trends (in public health terms), and the degree of variability 
represented in the underlying data. 
The graphical methods used to examine the time trends were as diverse as the wide array 
of choices to consider in their composition. For the purposes of comparability across studies, 
some level of standardisation of output would however seem appropriate. In producing the 
age-standardised rates for instance, at least three standards were used other than the 
World and European standards (conventionally used for international and European 
comparisons respectively). Despite sensible guidelines regarding the use of arithmetic or 
logarithmic scales for the rates axis, and recommendations regarding the dimension of plots 
[165], such features of the graphs appear to largely reflect the preferences of the 
researcher( s ). 
A number of methods were applied in practice in presenting the APC effects. That almost 
one-quarter utilised a two-factor approach (six papers adopted the AC model only) is in spirit 
with Everitt's definition of the APC technique [192] (see 3.4.1.1). Goodness-of-fit tests were 
not uniformly applied among the papers, though in some they informed the choice of 
presentation. Few studies provided a rationale for a particular solution, either in terms of 
biological or epidemiological evidence, or otherwise. 
Cohort (rather than period) effects predominated in the graphical presentation of the APe 
analysis, to be expected given that the analysis (as opposed to simpler age-calendar period 
approaches to trends) implies particular attention to generational influences. This 
observation, and the common tendency towards adoption of the AC model in some studies, 
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may point to a priori beliefs in the importance of cohort effects among researchers, and in 
some instances explain the bypassing of goodness-of-fit tests and the detailed consideration 
of period effects. 
The statistical measure used to convey the trends may have depended on the method 
utilised. For example, graphics depicting rate ratios were more often obtained from two-
factor model analyses on an antilog transformation of the effects; papers utilising Holford's 
method and the APC model were often presented as the logarithm of the effects, and for 
which the sum of the effects presented all add to zero, a presentation style used invariably 
by Holford himself in the numerous collaborative studies of cancer trends in Connecticut 
(see 3.4.2). The EAPC was used in almost half of the studies, yet only in the minority was 
this calculated within the APC framework, based on estimation of the drift. More commonly, 
a separate log-linear modelling exercise was performed to obtain the measure. 
Interestingly, from the perspective of assessing systematic approaches, very few studies 
examined more than one cancer by topography. Many of the reviewed studies of incidence 
trends did however provide further APC analyses by histology or topography. 
123 
Table 3.3: Summary description of methodological characteristics of 37 retrieved papers examining cancer trends using the 
APe model in eight peer-reviewed journals 2000-04 
r# Journal Reference Cancer site (data type), Presentation of observed ~PC methodology (as a Tabular presentation of Graphical presentation Comments 
population (period data means to present model model results of model results 
studied), effects) 
aim of study 
1 BJC Blizzard and Lung (mortality), Australia Graphics: A by P (both 10-yr) ~C model only None Cohort effects as rate Prevalence of smoking and age 
Dwyer (1965-98). Aim was to by sex. A by C by sex (both log ratios (AC model with at starting smoking, both 
determine whether lung scale). effects relative to presented by birth cohort 
cancer mortality trends were cohorts with highest nationally and regionally. Strange 
related to reductions in the rates) cohort constraint to use for 
'tar' yields. presentation. 
2 BJC Leung et al Breast (incidence), Hong Table of 5-yr rates (+ ~PC model, assumed first and EAPC by 5-yr age 1973- Cohort effects as rate 
Kong (1973-99). Aim was to population) for 5-yr ages and last PIC effects equal to zero. 99 + sign of 2nd-order ratios (APC model with 
describe long-term trends, periods 1975-99. Graphics: A term. Total deviance, constraint that first and 
distinguishing between time by P (5-yr) + ASR (World) (log adjusted R2 for 5 APC last periods = 0). 
period and birth cohort. scale). C by A (5-yr) (arithmetic models. Period and 
scale) . cohort effects from APC 
model 
3 BJC Liu et al Thyroid (incidence), Canada Graphics: aggregated APC model, assumed first and EAPC for 4 age groups+ Age, period and cohort Cite Tarone and Chu (1996) 
(1970-96). Aim was examine Incidence ASR (World) by last cohort effects equal to zero. all ages 1970-96. effects as logarithmic regarding use of particular 
incidence trends by age, three-year period by sex 1970- effects (APC model with constraint to achieve 
period and cohort. 96 (arithmetic scale). cohort constraints). identifiability. 
f4~. BJC Severi et al Melanoma (mortality), 9 Graphics: TASR (World APC model, assume: (1) the None Cohort effects as rates 
countries/regions (1960-94), standard) by period 1973-99 for entire drift is period effect. (2) (APC model with 3 
Aim was to investigate each sex and country drift is cohort effect. (3) drift is different constraints) for 
whether decreases has been (arithmetic scale). shared between period and each sex and country. 
recently observed in long- cohort. 
term mortality data. 
~ 
5 Cancer Chu et al Prostate (mortality), U.S. Graphics: ASR (U.S. Standard Linear contrasts characterising None Period and cohort 
SEER by race (1969-99). 2000) by single year 1969-99 slope of period effects 1991-97, effects presented as 
Aim was to investigate the (arithmetic scale) for each race. and 1985-91. APC model, logarithmic effects for 
recent decrease in mortality assumed first and last cohort each histology (APC 
in white by examining effects equal to zero. model with cohort 
incidence, survival, and constraints such that 
mortality rates by race. Itjrst and last effects = 
I 
-
0). 
-II ~ournal Reference Cancer site (data type). Presentation of observed jApc methodology (as a Tabular presentation of Graphical presentation Comments 
population (period data means to present model model results of model results 
studied). effects) 
aim of study 
6 Cancer Cohn- Melanoma (mortality), Graphics: ASR (Sweden 1970) AP model only, on basis of EAPC by period and sex Period effects as rate Not clear which model used to 
Cedermark et Sweden (1970-96). Aim was by period 1970-96 (arithmetic goodness-of-fit. and cancer type, ratios for each sex present period effects. 
al to describe trends and scale). TASR (four age groups) nationally and within (possibly AP model but presumably AP - cohort effects 
investigate potential impact by period 1972-96 and sex and selected regions 1972- not clear). NS when added to AP model. 
of primary prevention. cancer type, nationally and 96,1977-86 and 1987-
within selected regions 96. Total deviance for 5 
(arithmetic scale). APC models. 
7 Cancer McGlynn et al Testicular germ cell Graphics: aggregated ASR APC model, assumed first and Change in rates in each Period and cohort Not clear what parameterisation 
(incidence), U.S. SEER by (World) by five-year periods last P or C effects were equal to successive five-year effects as logarithmic yields period and cohort effects. 
race (1973-98). Aim was to 1973-98 by age and histology zero in presenting the other (not period 1973-78 to 1994- effects for each 
examine whether rates (log scale). A by P (5-yr) for clear). 98 by race and histology. histology (APC model 
among white men have each histology. P by A (5-yr) for with cohort and period 
recently stabilised and each histology (all logarithmic constraints 
whether rates among black scale). respectively). 
men remain remained low. 
8 Cancer McNallyetal Solid childhood tumours Table of incidence and rates for iApc models were fitted with Relative risk of diagnosis None Relative risk based on a model 
(incidence), NW England ages <1,1.4,5-9,10-14 and 0- aim to detect significant period with CNS and non-CNS involving sex and age only. 
(1954-98). Aim was to 14 by diagnostic group and sex and cohort curvature adjusted and in the latest period 
determine whether for CNS and non-CNS tumours Itor other factor. Significant non- vs. in previous periods. 
diagnostic improvements or for period 1954-98. TASR linear period effects reported for 
reporting changes explained (World standard) of CNS certain groups in text. Not 
increasing trends. Tumours by Diagnosis and five- explicitly presented. 
year periods 1954-1998. 
-- --- - --
9 CCC Myrdal et al Lung (incidence), Sweden Tables of number of cases by AC model used to display Total deviance for 5 APC Cohort effects as rate 
(1958-94). Aim was to 10-yr age group and 5-yr period cohort effects. models. Period effects ratios for each sex 
estimate age, period and 1958-94. from AP model. 
cohort effects with an Graphics: ASR (Sweden 1970) 
emphaSis on sex-specific and TASR (Sweden 1970 10-
I 
trends by histological yr.) by period, histology and sex 
I 
--
subtype. 1958-94 (all logarithmic scale). 
--------------
------- --- - -
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# Uournal Reference Cancer site (data type), Presentation of observed ~PC methodology (as a Tabular presentation of Graphical presentation Comments 
population (period data means to present model model results of model results 
studied), effects) 
aim of study 
10 CCC Pompe-Kim et Breast, cervix, lung, mouth None ~P or APC or "modified" Total deviance for 3 APC Age, period and cohort Not clear if zero period slope 
al and pharynx (incidence), models that incorporated models (APC vs. AP vs. effects as rate ratios. methods was used to present the 
Slovenia (1965-94). Aim was effects of different smoking and Modified APC) by cancer effects. Study focussed on 
to evaluate age, period and drinking habits in different age and sex. predictions up to 2009. 
cohort trends and predict groups. Age, period and cohort Smoking/drinking effects appear 
cancer-specific incidence up effects obtained assuming zero to be added as an interaction witt1 
to 2009. period slope? the additive effects of age, period 
and cohort. Not clear where 
external data derive from, nor 
what assumptions of the 
"calculated age effect typical for 
Slovenia" meant when effects 
from APC model presented. 
11 CCC Strand et al Lung (incidence), Norway Table of incident cases by sex, Fit of APC models inspected. None None Smoking prevalence on the right 
(1954-98). Aim was to age, and period 1954-98. 5-yr effects not reported or Y-axis of observed trends. Age-
describe the national trends age-spec. rates by sex and displayed. adjusted (world) incidence rates 
in lung cancer incidence period. Graphics: P by A (5-yr of lung cancer by period + 
among young adults and the for 3 age groups) 1954-98 smoothed lines by a locally 
relationship to adolescent stratified by sex (arithmetic weighted least-squares curve-
smoking. scale). fitting method (loess). 
12 EJC Bray et al Lung (mortality), 15 EU Table of ASR (European Observed and fitted rates of Direction and magnitude Fitted rates shown vs. Trends in % prevalence of 
countries (1967-99). Aim standard) + ranking by sex and best-fitting model shown. of most recent change In observed rates by smokers by country and sex also I 
was to estimate current country 1975, 1985 and 1995. second differences used to trends from year where country and sex. given. 
stage of lung cancer SMR by country and sex. identify local departures from recent changes was 
epidemic in 15 EU countries Graphics: TASR vs. period by period and cohort regular observed. 
by sex and relate period and age group (30-64 and 65+) trends. 
cohort effects to smoking (European standard) 
prevalence. (logarithmic scale). 
--
13EJC Colonna et al Thyroid (incidence), French Table of ASR (World standard) lAC model with a smoothing Assessment of the Cohort effects 
registries (1978-97). Aim and distribution of cases for spline. recent rate of increase presented as rate ratios 
was to study time trends each histological type by and geographical (in women). 
using data from 5 registries period, sex and age. Regional homogeneity tested 
with complete data and SIR by sex and histological according to deviance 
geographical variation in 8 type. tables by time x registry 
registries for a shorter interaction. EAPC 1982-
period. 96 by region and 
I t1istological type 
I 
I 
-- --
----
-- ----
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'# ~ournal Reference Cancer site (data type), Presentation of observed ~PC methodology (as a Tabular presentation of Graphical presentation Comments 
population (period data means to present model model results of model results 
studied), effects) 
aim of study 
14 EJC de Vries et al Melanoma (incidence and Table of age-specific incidence !APC models fitted according to Coefficients from None Best-fitting APC described in text 
mortality), Netherlands rates 1989-97 by histological Clayton and Schifflers method. Poisson model inc. only. 
(1989-98 and 1950-99). Aim subtype and anatomical site Not explicitly presented. region and period only. 
was to determine incidence two age groups (35.64, 65+). 
and mortality trends and test ASR (European standard) by 
for birth cohort effects on histological subtype and 
mortality. anatomical site and sex. Stage 
distribution by sex. 
Graphics: Incidence and 
mortality ASR (European 
standard) vs. period (3-year 
moving average) by sex (EAPC 
for each trend given in legend). 
Incidence and mortality rates 
I 
vs. period (3-year moving 
average) in three age groups 
for each sex (EAPC for each 
trend given in legend). Trends 
in incidence ASR (European 
standard) vs. three-year I 
periods by region for each sex. 
- -----
Iiall arithmetic scalel 
15 EJC Gonzalez- Ovary (mortality), 15 EU Table of ASR (European Effects from APC model Total deviance for 5 APC Age, period and cohort 
Diego countries (1955-93). Aim Standard) by country for each estimated in 3 ways: 1) models for each country. effects presented as 
was to provide an in-depth five-year period 1955-93, rate Osmond-Gardner method 2) rate ratios by country 
analysis of mortality trends, ratios and EAPC by country for and allocation of drift to period assuming 1) Osmond-
characterise any differences 1955-93 and 1979-93 and 3) to cohort. Gardner method 2) and 
between countries, and separately for all ages and for allocation of drift to 
outline possible causes. 35-64. period and 3) to cohort. 
Graphics: mortality ASR 
(European standard) vs. five-
year period by country within 
region (arithmetic scale). 
16EJC Stang et al Melanoma (incidence), Tables of number of cases by IAPC models fitted according to EAPC by sex and Age, period and cohort Best-fitting APC described In text. 
German Democratic sex and anatomical site 1961- Clayton and Schifflers method. anatomical site 1961-89. effects presented as Not clear how P and C effects are 
Republic (1961-89). Aim was 89. Graphics: A by P (1 O-yr) Method used In presenting rate ratios by sex. obtained - possibly by adding 
to study differences In the according to sex and subsite. C effects not indicated. drift to each effect before Its 
magnitude of age, period by A (5-yr) stratified by sex presentation. 
and cohort effects between (both logarithmic scale). 
I sexes and subsltes. 
I 
I - ~ 
----- --------~ ---- ~-
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1# ~ournal Reference Cancer site (data type), Presentation of observed !APC methodology (as a Tabular presentation of Graphical presentation Comments 
population (period data means to present model model results of model results 
studied), effects) 
aim of study 
17 EJCP Alvarez-Riesgo Breast cancer (mortality), Table of incidence rates and Submodels up to and including Total and change in Period and cohort Exposition of method used to 
Asturias, Spain (1975-94). number of cases by five-year two-factor models fitted. deviance for 3 APC effects presented as present APC estimates not 
Aim was to describe trends age group and periods 1959-97 models (A, AP, AC). rate ratios obtained from entirely clear. appears to be use 
and in relation to screening. + ASR (European standard) Period and cohort effects AP and AC models of two-factor models. not clear 
and cumulative rate by period. presented as rate ratios respectively. Age effects whether age effects presented 
Mil ratio vs. 1-yr period. ASR obtained from AP and based on one of two- are cross-sectional or 
1994 by EU country (possibly AC models respectively. factor models? longitudinal. 
World standard but not stated). 
18 EJCP Bouvier et al Gastric (incidence), Cote ASR (World standard) by 5-yr Cumulative risk obtained from Cumulative risk (30-74) None 
d'Or, France (1976-95) Aim. period and age stratified by sex best-fitting AC model with by histological type and 
was to examine role of age, 1976-95. ASR (World standard) polynomials (as in Coleman et birth cohort stratified by 
period and cohort on by subsite and age stratified by al,1993). sex for best-fitting AC 
incidence trends by subsite sex 1976-95. model with polynomials. 
and histology. Graphics: C by A (10-year) 
(arithmetic scale) stratified by 
location and sex. C by A (10-
year) (logarithmic scale) 
stratified by histological type 
and sex. 
19 EJCP Mitry et al Colorectal (Incidence), Cote Table of ASR (World standard) ~PC models allowing for Table of total deviance Cumulative risk (30-74) I 
d'Or, France (1976-95). Aim by 5-yr period and subsite polynomials for each effect (as for best-fitting APC vs. birth cohort by 
was to present incidence stratified by sex 1976-95. in Coleman et ai, 1993). model with polynomials subslte stratified by sex 
trends by subsite. Tables of number of cases and Cumulative risk obtained from by subsite stratified by for best-fitting AC model 
% by 5-yr period and subsite best-fitting AC model with sex. with polynomials. 
stratified by sex 1976-95. polynomials. 
~O EJCP Svensson et al Colorectal (incidence), Graphics: cases and % by sex, APC models fitted. Method Total deviance for 5 APC Cohort effects as rate Not clear how C effects are 
Norway 1958-97. Aim was to age and subsite 1953-97. ASR used In presenting effects not models. ratios. obtained - possibly on adding 
examine colorectal trends by vs. 5-yr period 1953-97 (?World indicated (either from the AC drift or via AC model. 
sex and subsite via APC standard) by Nordic country model or assuming drift with 
modelling. (arithmetic scale) for each sex. cohorts - not clear). 
ASR vs. 5-yr period 1953-97 by 
subsite (arithmetic scale) for 
each sex. 
-
- --
211JC Arbyn and Cervix (mortality), Belgium Proportion of Uterine cancers Standardised cohort mortality EAPC by 5-yr age 1954- SCMR In successive Authors explicitly mention in the 
Geys (1954-94). Aim was to study by age and reference ratios (relative risk of cervical 94. Standardised cohort cohorts by correction Introduction that study of trends 
age, period and cohort population (table and graphic). cancer death for a given cohort mortality ratio (SCMR), status. based on APC models is part of 
trends. Graphics: number of deaths reiative to the average mortality with relative risk of ongoing work. 
and ASR (European standard) of all cohorts). cervical cancer death for 
in five-years periods by site, a given cohort relative to 
Belgium, 1954-1994. C by A, average mortality of all 
i, 
for corrected and uncorrected cohorts. 
cervical cancer (arithmetic 
I scale). 
I i - - .~.--~--- - -
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# ~ournal Reference Cancer site (data type), Presentation of observed ~PC methodology (as a Tabular presentation of Graphical presentation Comments 
population (period data means to present model model results of model results 
studied), effects) 
aim of study 
22 IJC Blizzard and Lung (mortality), Australia Table of number of cases by lAc model presented for Linear contrasts of Cohort effects as rate Study objective was to examine 
Dwyer (1982-95). Aim was to sex, histology and 1 O-year birth histological subsites for which parameter estimates to ratios for each sex. impact of filtered cigarettes on 
examine trends by cohort. the AC model fitted and period changes in trends in Australian population. 
histological subtype and effects did not significantly particular cohorts. 
impact of switch to filter-tip contribute. 
cigarettes in a setting where 
their tar yields remained 
unchanged for a decade. 
23 IJC Chirpaz et al Prostate (incidence and Graphics: Incidence and AP model for mortality. APC Total deviance for 5 APC Period and cohort 
mortality), French registries mortality ASR (European model for incidence, first and models. EAPC by five- effects presented as 
(1982-96). Aim was to standard) vs. period by French last cohort effects assumed year period 1982-7,87- logarithmic effects of 
examine incidence and area. Incidence and mortality equal to zero. Linear contrasts 93,93-5. Period effects in incidence (from APC 
mortality trends with special rate vs. P by A (various age to compare specified cohort mortality from the AP model with period 
emphaSis on population groups). C by A (all logarithmic slopes. model. constraints ). 
screening by PSA. scale). 
24 IJC Chiu et al Lung (incidence, females), Table of rates in five-year age ~P model used to display EAPC by 5-yr age group Period and cohort All models (including the APC) 
Hong Kong (1976-2000). groups and periods 1976-2000 period effects, AC model to 1976-2000 and 1991- effects as rate ratios indicated a significant lack-of-fit. 
Aim was to estimate age, with crude and ASR (Hong display cohort effects. 2000. Total deviance for from AP and AC models Graphic showing prevalence of 
period and cohort effects Kong 1990 standard). 4 APC models (did not respectively. daily smokers by age group in 
and explore underlying Graphics: ASR by single period include AD model). Hong Kong females, 1982-98 
reasons. 1976-2000 (arithmetic scale). C also given. 
by A (logarithmic scale). 
-
251JC Lambert et al Stomach (incidence and % with localised stomach lAC model used to display EAPC 1975-95 by Cohort effects as rate 
mortality), Japan, Slovenia, cancer by country and period. cohort effects. country and sex, ratios from AC model. 
U.S. SEER (1975-95). Aim Graphics: ASR Incidence and incidence vs. mortality. 
was to compare incidence Mortality by single calendar EAPC by country and 
and mortality trends by year 1975-95 (World standard) sex for each stage. 
period and cohort to assess by sex and stage for each Absolute change in 
relative contribution of country (arithmetic scale). overall and localised 
"unplanned prevention" vs. stomach cancer by age. 
mass screening policy. Total deviance of best-
ifitting APC model by 
country and sex and for 
incidence, mortality and 
localised cancers. 
-
-----
26 IJC Minami et al Breast (Incidence), Miyagi Table of incidence rates by five- APC model with cohort effects Total deviance and Period and cohort Overdispersion dealt with using a 
Prefecture, Japan 1959-97. year ages and periods 1959-97. estimated assuming a linear change in deviance for 5 effects as logarithmic quasi-likelihood approach. Table 
Aim was to examine period Graphics: ASR incidence vs. period effect of O. APC models. effects from APC model of risk factors (and local evidence 
! and cohort effects, with a five-year periods for main assuming zero period for their effect) and national i focus on the Importance of emale cancers 1959-97 slope. trends In prevalence of risk I cohort. (logarithmic scale). factors also given. I 
: . -- - .- . 
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# ~ournal Reference Cancer site (data type), Presentation of observed APC methodology (as a Tabular presentation of Graphical presentation Comments 
population (period data means to present model model results of model results 
studied), effects) 
aim of study 
27 IJC Ulvestad et al Mesothelioma (Incidence), Table of mesothelioma of the AC model used to display Total deviance and Cohort effects as rate Graph of import of raw asbestos 
Norway (1965-99). Aim was pleura incidence rates by 10- cohort effects. change in deviance for 5 ratios from AC model. to Norway after World War" and 
to analyse incidence trends year ages and periods 1965-99 APC models. numbers/rates of mesothelioma 
and study consequences of by sex. Graphics: ASR (World of the peritoneum also given. 
asbestos and the standard) vs. five-year periods 
effectiveness of the ban on by sex 1965-99. rates vs. five-
its use. year periods for three age 
groups 1965-99 (both 
logarithmic scale). 
28 IJC Verkooijen et al Invasive lobular breast Graphics: ASR (European fA.PC model used to test None 7 Fitted rates from APC Not clear from paper how APC 
(incidence), Geneva, standard) vs. five-year period importance of cohort effects. model shown as C by A. model was used and how the 
Switzerland (1976-99). Aim by histological subtype 1976- Possibly fitted rates from APC observation of significant cohort 
was to describe the trends in 1999 (EAPC also displayed). model, but not clear. effects in lobular cancer was 
breast cancer incidence by T ASR vs. five-year period, 5 established. Not clear whether 
histological subtype. age groups for ductal, lobular, Fig 4 displays fitted (from APC) or 
and other histologies. ASR vs. observed rates. 
five-year histology/stage (all 
arithmetic scale). 
29 IJC Vizcainio et al Cervical squamous cell Table of total number of cases Cumulative rates obtained from Total deviance for best- Cumulative rates vs. 
carcinoma (incidence), 32 and ASR (World standard) by best-fitting APC model with fitting APC model with birth cohort (25-49, 50-
intemational populations subtype and country. polynomials (as in Coleman et polynomials. EAPC 25- 74) by country and 
(1973-91). Aim was to ai, 1993) for age groups 25-49 49,50-74 and 25-74 region for best-fitting 
i present a detailed analysiS and 50-74. from net drift. APC model with 
of the time trends in diverse polynomials. 
settings. 
- _. 
30lJC Vizcainio et al Oesophagus (incidence by Data quality indices by country Used only to indicate the best- EAPC from net drift and None 
histology), 34 international and CI5 volume (5-yr periods). 'itting APC model. Not explicitly best-fitting APC model 
populations (1973-95). Aim Table of cases and ASR (World presented. for country and histology 
was to identify the relative standard) for each histology by by sex. 
Importance of components 0 country. 
birth cohort, period In Graphics: ASR (World 
determining trends by standard) vs. CI5 volume by 
histological type, and assess histological type stratified by 
contribution of changes in country (all logarithmic scale). 
the proportion of cases with 
specified histology. 
--------
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)# ~ournallReference 
3111JE 
3211JE 
3311JE 
Bulliard and 
Cox 
Li et al 
Liu et al 
Cancer site (data type), 
population (period 
studied), 
aim of study 
Melanoma (incidence and 
mortality), New Zealand 
(1969-93). Aim was to 
assess long-term incidence 
and mortality trends in a 
high-risk country in relation 
to sun exposure and 
behaviour. 
Presentation of observed 
data 
ITable of observed birth cohort 
'trends summarised by arrows 
denoting systematic increases 
or decreases in age-specific 
rates compared to previous 
generation for males and 
Ifemales. 
Graphics: ASR incidence and 
mortality (World standard) vs. 
one-year period by sex 1969-
1993. ASR incidence (World 
standard) vs. one-year period 
(3-year moving average) by sex 
and anatomical site 1969-
1993. C by A (logarithmic 
scal~ for males and females. 
JAPc methodology (as a 
means to present model 
effects) 
/Test of drift and non-linear 
effects reported in the text but 
no graphical or tabular 
presentations from APC model 
or submodels. EAPC reported 
using net drift. 
Cervix (mortality), Shan dong Table of ASR (World standard) PC model with age effects 
Province, China (1970-92). by survey area and five-year estimated assuming first two 
Aim was to describe time period. rates by 5-yr age group effects = 0, period effects 
trends of cervical cancer and and period in Province. estimated assuming first two 
elucidate reasons for the Graphics: P by C (arithmetic effects = 0, cohort effect age 
findings. scale). number of cases and assuming sixth and seventh 
Testicular germ cell 
(incidence), Canadian 
registries (1970-95). Aim 
was to examine differences 
in incidence pattems of 
seminoma and non-
seminoma. 
rates by 5-yr age group and effects = O. 
period in one county. 
Table of number of cases and 
% 1970-95, rates 1970-1 and 
1994-5, EAPC 1970-95 by 
histological type. 
Graphics: ASR incidence 
(World standard) vs. two-year 
period overall and by 
histological type 1970-1995. C 
by A (arithmetic scale for each 
histological type 1971-95. 
JAPC model with cohort effects 
lestimated assuming a linear 
period effect of O. 
Tabular presentation oflGraPhlCal presentatlonlComments 
model results of model results 
EAPC 1969-1993 INone 
(based on drift) by sex 
and anatomical site. 
Table of age, period and INone 
cohort effects as (log) 
rate ratios and (antilog) 
rate ratios. 
Test of deviance of non- Age, period and cohort 
linear period and cohort effects of each 
effects for each histological subtype as 
histological subtype. Testlogarithmic effects from 
of deviances of APC model assuming 
histology-curvature zero period slope. 
interactions for age, 
period and cohort. 
Significance of linear trends 
versus non-linear effects of A, P 
and C mentioned in the text. 
Rates of tested positive serum 
syphilis 1954-60 in Shandong 
also given. Putative risk factors in 
two age groups and rural/urban 
status also given. 
3411JE iRobertson et al Breast cancer (incidence), Graphics: P by A and C by A JAPC model assuming first and Total deviance for AP, None Demographic information on 
Slovenia (1971-93). Aim was (both logarithmic scale). last cohort effects equal to zero. and APC model + 7 reproductive factors by birth 
to Investigate cancer trends addition of available extensions of the AP cohort from official statistics and 
in relation to trends in risk demographic data on model incorporating case-control studies also 
I
factors in a population with reproductive factors by birth reproductive data at the presented and used to replace 
relatively little screening. cohort added to AP models. population level. cohort effects. 
Linear contrasts characterising 
eight cohorts bom 1900-14 with 
those bom after 1924. 
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~ Journal Reference Cancer site (data type), Presentation of observed APC methodology (as a Tabular presentation of Graphical presentation Comments population (period data means to present model model results of model results 
studied), effects) 
aim of study 
35 WNCI Jemal et al Lung (mortality), U.S. SEER Graphics: C by A (2-year Cohort effects estimated on None Cohort effects as In presenting cohort effects from 
(1970-97). Aim was to bands) for males and females assuming last and second last logarithmic effects APC model, authors 
evaluate recent trends. (logarithmic scale). cohort = O. Linear contrasts assuming last two acknowledge "different estimates 
used to compare specified cohort effects are equal will be obtained under different 
cohort slopes. (last effect not constraints", focus is on changes 
lQresented). in slopes. 
36 WNCI Jemal et al Melanoma (incidence), U.S. Graphics: ASR incidence (U.S. Linear contrasts used to Table of EAPC 1974-89 None JOinpoint regression used to 
SEER (1973-97). Aim was to Standard) vs. one-year period compare earlier and later birth and 1990-97 for all ages characterise overall trends in men 
examine incidence pattems 1973-97 by sex (logarithmic cohort effects. and in three age groups, and women. 
stratified by sex, age, tumour scale). C by A and P by A for stratified by sex. Table of 
stage, and tumour thickness males and females (logarithmic EAPC 1988-97 by age 
to detenmine whether scale). ASR incidence (U.S. and tumour thickness, 
increasing incidence is real Standard) vs. one-year period stratified by sex. 
or whether reflected 1973-97 by stage, stratified by 
improved diagnosis. sex (logarithmic scale). 
37 JNCI Strickler et al Pleural mesothelioma Graphics: ASR incidence (U.S. ~PC model assuming the 1890- 1 O-year slope contrasts Birth-cohort effects as The age-specific prevalence of 
(incidence), U.S. SEER Standard) vs. three-year period 91 and 1892-93 effects equal. from APC model by sex logarithmic effects from exposure to potentially SV40-
(1975-97). Aim was to 1977 -97 overall and by sex Linear contrasts for comparing APC model presented contaminated poliovirus vaccine 
examine pleural (logarithmic scale). P by A (6 birth cohort effects that 1) together with slope in the U.S. 1961 also given. In 
mesothelioma incidence age groups, logarithmic scale). spanned approximately 10 contrasts. Plot of setting adjacent cohorts to zero, 
trends among adults in by years covered periods during differences between authors rationale Is very low rate I 
age in relation to the which cohort- specific vaccine adjacent two-year birth- of exposure and low incidence In 
probability of their exposure prevalence curve was cohort effects and early birth cohorts. 
to potentially SV40- approximately linear (1894-99, differences in 
contaminated poliovirus 1900-07,1908-17,1918-27, prevalence of exposure 
vaccine 1955-61. 1928-35,1936-47,1948-57.2) to potentially SV40-
contrasted consecutive contaminated poliovirus 
differences of two-year birth vaccine. 
I 
cohorts (1900-01,1902-03, ... , 
1960-61 ). 
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3.6 Summary and recommendations 
This chapter has provided a broad overview and critique of the technical issues surrounding 
the analysis and presentation of cancer trends. It has mainly focussed on usage of the APC 
model, necessarily so, given its utility and emergence as the standard tool for such data, 
and the controversies that surround the identifiability problem and what may be described as 
a reasonable solution to the presentation of age, period and cohort effects. 
The diversity of graphical, tabular and model-based analyses applied in recent studies, as 
demonstrated in the last section, probably reflects the descriptive (imprecise) nature of this 
form of study and a lack of consensus - between both methodologists and practitioners _ 
regarding a suitable presentation of the model effects. The last point is not likely to be easily 
remedied given the inherent difficulties in obtaining satisfactory inferences from the full APC 
model. The present heterogeneity of methods used in APC analyses reinforces the need to 
address the major issues of concern to better serve future studies, and the following text is a 
compilation of key observations and recommendations from this chapter. Those items in 
bold are considered as SUbstantive points that will require attention in the study of trends in 
practice in Chapters 4-6: 
o No statistical tests should start without a thorough understanding of the 
observed trends. Graphical approaches can be informative, lending support to 
the relative importance of period versus cohort. They may also inform the 
APe modelling approach and interpretation of the subsequent parameters. 
o Although some guidelines for displaying trends in rates are available, basic 
characteristics of graphics displayed in publications are largely 
heterogeneous. Technical issues in producing graphs for peer-reviewed 
publication are not given sufficient priority at the author or editorial level, 
despite their demonstrated utility in aiding interpretation and improving 
comparability between studies: 
o Arithmetic and logarithmic scales on the y-axis are in general use in 
plots of rates over time. Arithmetic scales are appropriate where 
absolute rather than relative changes in magnitude are the main point of 
interest. Semi-log displays are of greater utility in trends studies 
however as they allow a visual description of rates of very different 
orders of magnitude, and identify relative changes in rates irrespective 
of baseline values. 
o Detailed labelling of the Y-axes enables identification of absolute as 
well as relative changes. The ratio of the Y to X-axis can affect 
interpretation, and scaling rules are available. The use of the same time 
scale for period and cohort forces the length and shape of the period 
and cohort lines to be equivalent, and highlights the relationship 
between the three time factors and the nature of the identifiability 
problem. 
o Trends in age-adjusted rates may mask important changes in the age-specific 
rates, notably the impact of changes in successive birth cohorts. Comparisons 
of plots of rates versus period by age and birth cohort by age are the most 
useful of the possible displays in gauging the relative importance and basic 
characteristics of trends by period and cohort, and also serve to aid 
interpretation of subsequent APC model output. 
o In quantifying recent trends in cancer, the EAPC provides a summary of the 
magnitude and direction of the trend. To circumvent the arbitrary choice of 
time period for estimation, joinpoint regression allows identification of sudden 
linear changes in the trend and estimation of the direction and magnitude of 
the slope within time segments for which rates are relatively stable. 
o Deciding whether period or cohort effects are important from graphical 
depictions of the observed rates is itself an arbitrary process, and 
interpretation of many cancers is too complex to rely solely on visual 
techniques. The APC model provides a framework for testing and quantifying 
the overall time trend and the non-linear effects of age, period and cohort, and 
indicates whether the graphed trends may be considered real or random. 
o Two-factor models are commonly used to present the effects. Justification of such a 
model is usually provided on the basis of one or more of the following: i) the model 
fits reasonably well; ii) there is external support that the model is appropriate; iii) the 
approach always provides a unique solution. The inherent problem of bias in the 
effects, should one factor primarily occur as a linear pattern, is usually left 
unchallenged. There is a further under-appreciation that artefactual changes may 
arise as linear (unidentifiable) period effects. 
o Clayton and Schifflers' net drift has become as an integral part of APC 
modelling. It provides an estimate of the rate of change in the regular trend, 
and enables a test of the relative contribution of period and cohort curvature 
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over and above the estimable linear component applicable to both. In doing so, 
the identifiability problem is seen to arise at the two- as well as the three-factor 
level. 
o Where trends convey minimal period or cohort curvature, the APC model may 
not provide useful information over and above the reporting of the net drift. 
o Net drift estimates obtained over several decades include trends seen 
in the distant past, and may not reflect recent trends. The relative 
magnitude and direction of the net drift for the whole study period as 
well as a more recent epoch may be compared. 
o The full APC model is often the point of departure for trends analyses. Many 
methods have been proposed: 
o One solution is to equate two effects of one factor, although this may be 
considered arbitrary, as often one parameterisation cannot be justified 
against another. 
o Taking the mean first differences of one factor forces the slopes of one effect 
to return to the baseline value, thereby placing drift with the other factor. 
While robust for period, the random variation associated with extreme cohorts 
can lead to resulting cohort slope of magnitudes that do not closely 
approximate zero, thus rendering the allocation of drift to period erroneous. 
o Holford introduced a flexible approach that explicitly sets the overall slope of 
one factor to a designated value. On specifying this magnitude, the values of 
the other two slopes are immediately estimable, and a unique solution 
emerges. 
o The period component of time trends is often considered the least 
influential of the three effects, and studies using Holford's method 
usually obtain unique solutions by estimating the period slope, 
assuming either a slope of zero or a range of values. Imposing a zero 
period slope puts no restriction on period curvature, which is estimable. 
o Postulation as to the direction of a slope founded on biological or 
epidemiological evidence may be considered amongst the least 
arbitrary approaches available, although an erroneous specification will 
create a bias in each of the effects. One possibility is to define the slope 
for age to conform to a known age pattern for a given cancer. 
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o Second differences identify changes in the magnitude of trends by comparing the 
position of a particular effect relative to preceding and subsequent ones. The 
approach is conservative given an absence of any linear information, and the 
estimates need to be interpreted alongside the observed rates and possibly against 
several arbitrary model parameterisations. Extensions that allow a comparison of the 
slopes of the linear trend in two epochs have been proposed. 
o The fitted values from the full APC model are seldom shown in studies, but often 
inform regarding any departures from the observed data. 
o Several mathematical approaches have been proposed, but can only provide 
arbitrary interpretations, given that they are informed purely by mathematical 
properties rather than biological principles. Other approaches including the 
introduction of identifiable interactions into the APC model and use of the multistage 
model to fix age effects have their merits but are in practice difficult to implement. 
o Often, particularly in analyses of a large population, the models suffer from 
overdispersion, whereby the variance in the counts is larger than that of the Poisson 
assumption. Such circumstances render statistical tests somewhat subjective, 
although methods are available that take overdispersion into account. 
o The potential of extrapolating trends in younger generations into later ages is long 
established. The APC model provides a framework for making predictions and the 
resulting estimates do not suffer from a lack of identifiability. 
o Several problem areas exist: the assumption that drift will remain constant in 
the future period; unrealistic predictions as a result of increase exponentially 
over time; the need for simple models and narrow prediction intervals. These 
issues have been explored and recent model specifications have been shown 
to provide reasonable predictions. 
As has become appreciated over the last decades, no single APC method can be 
considered as superior to all others. No definitive solution is available given that the 
identifiability problem arises from the simple algebraic relation that defines the three factors. 
With the aim of reaching an honest and informative solution it is reasonable to focus on what 
is identifiable from the model, and apply our current understanding of the biology and 
epidemiology of the cancer under investigation in the population under study. The next three 
chapters of the thesis aim to do this, by considering the recommended graphical and 
statistical techniques to trends in several cancers in multiple populations. Chapter 4 
describes an analysis of trends in the incidence of cervical squamous cell carcinoma and 
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cervical adenocarcinoma in 13 European countries, Chapter 5, an analysis of endometrial 
cancer incidence trends in the same 13 European countries, as well as corresponding 
mortality trends in 28 European countries. Finally, Chapter 6 includes an equivalent trends 
analysis of testicular germ cell cancer incidence and testicular cancer mortality, and a 
comparison of cohort-specific trends in the two main histological subtypes of germ cell 
tumours of the testis. 
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4 Analyses of temporal trends of cervical cancer in Europe 
4.1 Introduction to the chapter 
This broad aim of this chapter is a detailed description and evaluation of time trends of 
cervical cancer incidence in Europe. The focus is on the trends in the main histological 
subtypes of cervical cancer. The analysis takes advantage of the sufficient time span of high 
quality cancer registry data available in 13 countries on the continent. 
4.1.1 Why analyse trends in cervical cancer? 
Cervical cancer is the third most common cancer in women under 65 in Europe after breast 
and colorectal cancer, with almost one in 100 European women developing the disease 
before this age [263]. The monitoring of time trends of cervical cancer incidence and 
mortality in European populations is essential for two reasons. Firstly, the implementation 
and organisation of cytological screening programmes in Europe varies considerably from 
country to country [308], and temporal analyses of rates by calendar period among targeted 
age-groups is fundamental in the evaluation of the effectiveness of organised programmes, 
and may allow some assessment of the impact of opportunistic screening, where it is 
prevalent. Exposing contrasting trends in populations with longstanding and highly 
organised screening programmes with those where programmes have either not been 
implemented or are considered ineffective, provides compelling visual evidence for the need 
for immediate action to remedy the situation [309]. 
A second area of interest in the study of cervical cancer trends involves the changing 
prevalence of infection with HPV, established as the virtually necessary cause of cervical 
cancer [310,311]. The monitoring of disease rates among successive generations provides a 
means to examine changes in the central modifier of risk -levels of persistent infection with 
high-risk HPV types - as a result of changing patterns of sexual behaviour among birth 
cohorts [309]. 
4.1.2 Why analyse incidence? 
Incidence is an appropriate statistic for evaluating the impact of the screening test, as 
cytological screening can detect cervical cancer precursors and aims to reduce the 
incidence of invasive disease, leading to a subsequent reduction in mortality. While mortality 
may still have advantages over incidence in terms of longer time series and greater 
availability with larger population coverage (often national), these are offset by several 
difficulties associated with their use. 
Firstly, the quality of diagnostic information is a major hurdle: there has been a historical 
failure to distinguish cancers of the uterine cervix, instead they have often been assigned 
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the code "malignant neoplasm of the uterus, part not specified". These "unspecified" 
deaths, as a proportion of all uterine cancer mortality, vary considerably among European 
countries, and for some (such as Italy), they represent over 50% of all uterine cancer deaths 
[312]. Importantly for the study of time trends, there has been a tendency for the unspecified 
proportion to decrease over calendar time. The problem is exacerbated by the structure of 
the 8th revision of ICD and a differing precision of mortality data transmission at the national 
level, rendering a combined category of "corpus uteri and uterine cancer, unspecified" in the 
WHO mortality databank [312]. 
A second interpretational uncertainty with mortality trends stems from its characterisation as 
a function of both incidence and case fatality. Improving survival rates with time may distort 
trends in mortality and subsequent interpretation when used as a proxy for changing 
incidence. The favourable long-term trends in stage at diagnosis and survival as a result of 
better treatment - as observed in Sweden [313] - would indicate that such a characteristic is 
present in the cervical cancer mortality trends in several European countries. 
4.1.3 Why analyse trends by histology? 
Studying cervical cancer incidence allows examination of trends according to the main 
histological subtypes, cervical squamous cell carcinoma and cervical adenocarcinoma, 
important as they substantially differ in terms of screen detection and possibly their 
aetiology. Cervical squamous cell carcinoma is the main histological subtype, representing 
75-90% of cervical neoplasms in western countries [18]. Adenocarcinomas are rarer, but the 
proportion of cases with this histology is higher in low risk than in high risk countries [18], 
possibly as a result of screening. Susceptibility to detection by cytology has been considered 
much greater for cervical squamous cell carcinoma than for adenocarcinoma, as reported by 
Mitche" et al in a regional case-control study in Australia in 1995 [314]. More recently (in 
2003), Mitchell and colleagues have commented that such a distinction may be becoming 
less apparent, as an understanding of precursors to adenocarcinoma emerges, and 
methods for detecting endocervical lesions improves [315,316]. 
Persistent viral infection with the high-risk types of HPV is established as an almost-
necessary cause of both cervical cancer subtypes [310,311], although they may differ in the 
predominant HPV types involved. There is some evidence of heterogeneity in the cofactors 
associated with the two histological subtypes [317-321], particularly the effects of smoking 
for which risk is elevated for squamous cell carcinoma but not for adenocarcinoma 
according to several recent studies [319,321]. 
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4.1.4 Main objectives of the trends analyses 
Analyses of incidence trends of cervical squamous cell carcinoma and cervical 
adenocarcinoma in European women of screening age allows exploration of the varying 
impact of, and further need for, primary and early detection prevention strategies in each of 
the 13 countries examined. For each subtype, the main objective is an evaluation of trends 
related to: 
• the effectiveness of cytological screening in Europe, characterised at present by a 
broad range of screening policies and implementation strategies [308]; 
• changing risk patterns amongst European women, likely related to a changing 
population prevalence of high-risk HPV types. 
Before this work is presented and discussed, some background on the epidemiology and 
screening of cervical cancer and its histological subtypes is given below. 
4.2 Review of cervical cancer epidemiology and screening 
4.2.1 Descriptive epidemiology 
Cervical cancer, the second most common cancer amongst women worldwide, is 
responsible for almost 10% of all new female cancers. Almost half a million new cases of 
cervical cancer were estimated to have occurred worldwide in 2002, the vast majority - over 
four-fifths - in developing countries. The highest incidence rates were observed in Latin 
America, the Caribbean, Sub-Saharan Africa, and South and South East Asia. Cervical 
cancer tends to be less common in most of Europe, North America, Japan, Australia and 
New Zealand. The disease comprised about 4.5% of all cancers among European women in 
2002, ranking seventh most common cancer in terms of the absolute number of cases. 
The worldwide geographic variation is in part a reflection of the extent to which the Pap test 
has been available and routinely introduced as a screening tool historically, with low rates 
often in countries where cytological screening has been successful in reducing incidence (in 
some economically developed countries), and high rates in countries and areas where 
intervention has been largely absent (in most developing countries). The impact of screening 
can be readily observed by comparing the age-adjusted rates of cervical cancer in Western 
populations in the pre-screening era with those seen in developing areas today (Figure 4.1). 
Before the advent of cytological programmes in the 1960s and 1970s, the incidence in much 
of Europe, North America, and Japan was similar to that currently estimated in developing 
countries in 2002 [221]; the rates in pre-screening periods in the U.S. [84], in Northern 
Europe e.g. Denmark [169] and neighbouring German city Hamburg [169], for instance, are 
of the same order of magnitude as current incidence estimates in Eastern Africa, the region 
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presently with the highest cervical cancer rates in the world. It should also be noted that not 
all countries in Europe could be considered as low-risk in 2002. Estimated rates in Romania 
and Slovenia are, for example, three to four times those of their European counterparts, and 
they are also higher than overall rates estimated for developing countries combined (Figure 
4.1). 
Gustafsson and colleagues [221] were able to categorise the age profile of cervical cancer in 
international populations and in periods before the Pap test could have had an effect, into 
fitting one of two reference curves. Figure 4.2 demonstrates that in the absence of 
screening, the incidence of cervical cancer begins to rise around the age of 25, with risk 
rising rapidly between the ages of 30 through 40 to reach a peak rate of incidence around 
age 45-49 in many western populations, but often later in developing countries [221]. Rates 
thereafter decline, although the downward slope is of lesser magnitude than the increase 
seen in younger women. As would be expected, the age pattern profoundly changed 
following the advent of screening programmes [322]. 
Most incident cases of cervical cancer are squamous cell carcinomas. Adenocarcinomas are 
rarer, but the proportion of adenocarcinomas cases is higher in low incidence areas than 
high risk areas [323]. This may be due to the initiation of screening programmes, as 
screening by cytology is considerably more effective in preventing squamous cell cancer 
than adenocarcinoma (see 4.2.3.1). 
Mortality rates are substantially lower than incidence rates, although the geographic 
variability is similar. Some 273,000 cervical cancer deaths occurred globally in 2002 [18]. 
Reasonable prognosis is seen in low-risk higher resources settings; in the U.S., average 
five-year relative survival for all races is 73% for cases diagnosed 1995-2001 [29] and 62% 
in the European registries for cases diagnosed 1990-94 [138]. In developing countries, 
where many cases present at a relatively advanced stage, survival is fair, the most recent 
five-year estimate put at 49% [324]. Among the lowest survival figures are those in Eastem 
Europe; in Poland, the five-year survival estimate is 48% for those diagnosed in the early-
1990s [138]. 
As the disease predominantly affects relatively young women, it is a major cause of lost 
years of life in many developing regions. A recent study estimating age-weighted years of 
life lost (YLL) due to the different major causes of death found cervical cancer responsible 
for the loss of 2.3 million years of life, the biggest single cause of YLL from cancer in 
developing areas [325]. Further, the disease made a more substantial contribution to lost 
years of life than tuberculosis, maternal conditions or AIDS in Latin America, the Caribbean 
and Eastern Europe. 
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Figure 4.1: Cervical cancer age-standardised incidence rates in selected 
countries in 2002 (as reported in GLOBOCAN 2002 [263]) and in pre-screening 
populations as reported in the Volume I of CIS [18] and Dom and Cutler [84] 
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Figure 4.2: Reference. curves for the age profile of cervical cancer incidence. 
C~rves are scal~d ratios based on rates in international populations in periods 
prior to cytological screening, assigned to one of the two references types 
Adapted from Figure 4 of Gustafsson et al [221] . 
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Variations in cervical cancer incidence with respect to demographic variables such as social 
class, marital status, ethnicity and religion have long implicated a role for sexual activity. In 
1974, Beral proposed a causative role for a sexually transmitted agent on the basis of the 
similarity of cohort trends in cervical cancer and gonorrhoea infection in young women in 
England and Wales [89]. Epidemiological studies in the decades that followed showed 
consistent associations between risk and early age of initiation of sexual activity, increasing 
number of sexual partners of females or of their sexual partners, and other indicators of 
sexual behaviour [326]. The discovery of HPV type 16 emerged from its presence in the 
majority of cervical cancer biopsies in 1983 [327], and within the last 10-15 years, supported 
by the emerging molecular technology, it has been demonstrated beyond doubt that virtually 
all cases of cervical cancer harbour (as currently estimated) one of 15 oncogenic types of 
HPV DNA [310,328,329], types 16, 18,31,33,35,39,45, rf51, 52, 56, 58, 59, 68, 73 and 
82. From an update of the Bradford Hill criteria, a comprehensive evaluation of the 
association between HPV and cervical cancer has also demonstrated causality [311]. 
Previously established risk factors for cervical cancer related to sexual activity have had to 
be re-evaluated in the light of HPV as the necessary cause of cervical cancer, given that 
they may have been acting as proxies of HPV exposure or were cofactors given the 
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presence of HPV [309]. Currently, after careful adjustment of oncogenic infection, the 
residual effects of several additional factors have been noted. Recent pooled analyses of 
studies have revealed that cofactors may modify the probability of HPV exposure and 
infection, and the residual effects of high parity [330], oral contraceptive use (although effect 
of cessation is undetermined) [320,330], tobacco smoking [321,330] and Chlamydia 
trachomatis exposure [331] on cervical cancer risk have been reported. The progression of 
HPV infection to pre-invasive and invasive cervical cancer may be increased among HIV-
carriers and AIDS patients, possibly related to an absence of screening and the severity of 
immunosuppression [309]. 
4.2.2.1 Differences in main histological subtypes 
A recent meta-analysis of six case-control stUdies indicated that adenocarcinoma and 
squamous cell carcinoma share many risk factors including surrogates for persistent 
oncogenic HPV infection such as the number of sexual partners, early age of first 
intercourse, and an early age of first birth, as well as the use of oral contraceptives [332]. 
While some heterogeneity in risk factors has been noted in a U.S study [317,333,334], the 
only consistent finding across studies refers to smoking, which has been reported to 
moderately increase the risk of squamous cell carcinoma, but not adenocarcinoma 
[319,321,332,335]. 
Adenocarcinoma has been shown to be more associated with the acquisition of HPV type 18 
than squamous cell carcinoma, which in tum is more associated with HPV-16 than 
adenocarcinoma [328]. Reasons for this specificity are at present unidentified [311]. It may 
point to a lower overall prevalence of high-risk HPV DNA in adenocarcinoma compared to 
squamous cell carcinoma, as observed in a number of studies e.g. [336], indicative of a 
subset of women whom developed the disease through mechanisms unrelated to HPV 
infection. However, explanations related to artefact are probable. The testing of inadequate 
samples, sampling errors of HPV detection in biopsies, and misdassification of 
adenocarcinomas of the endometrium as of the cervix may all lead to such biased findings 
[318]. Recent studies are now estimating the proportion of adenocarcinoma harbouring high 
risk HPV types as close to 100% [318]. 
4.2.3 Cytological screening practices in Europe 
Cervical cancer is a highly preventable disease; it is detectable at a (usually prolonged) 
premalignant phase and has a suitable screening test in the Pap smear. Epidemiological 
studies have revealed that cervical cancer cases typically have been less adequately 
screened than controls (women free of the disease). Where population-based screening has 
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been implemented and routinely practiced, large declines in both cervical cancer incidence 
and mortality have been reported [193,337-339]. A recent IARC evaluation concluded that 
there was sufficient evidence that screening women aged 35 to 64 for cervical cancer 
precursors by conventional cytology every three to five years within high-quality 
programmes reduces incidence of invasive cervical cancer by at least 80% among those 
screened [309]. In spite of this, there are large variations in current screening policies in 
Europe and in organisational aspects of established programmes [308,315]. Table 4.1 
summarises, for selected countries and for regions covered by registries within countries, 
basic characteristics of the screening programmes [308]. The populations correspond to 
areas where there is long-term population-based cancer registration, and for which the data 
are considered of high quality. 
4.2.3.1 Differences in main histological subtypes 
Screening using the Pap test has been shown to effectively detect squamous cell carcinoma 
in early stages, although reports have considered it much less effective at detecting 
adenocarcinoma [314,340,341]. Recent work by Mitchell and colleagues however has 
suggested the efficacy of cytological examinations in finding adenocarcinoma has improved 
during the 1990s, and may have been responsible for some reductions in adenocarcinoma 
around this time. They observed decreases among Australian women who had a pap smear 
with endocervical material within one year, or with an increasing number of pap smears with 
an endocervical component [316]. 
It is possible that an increasing ability to detect endocervical lesions in cervical screening 
may arise from the improved diagnostic yield obtained on utilising the extended tip spatula 
or the Cervex (endocervical) brush, or a combination of both [342], as well as an 
understanding and recognition of adenocarcinoma in situ [343]. Nevertheless, in the 
Province of Florence, Italy, the extended tip spatula has been in common use since the 
1980s, and has had little impact on the increasing adenocarcinoma rates in women aged 
under 55 [344]. In a further case-control study in the same reigon, the cytobrush did not 
appear to offer any significant protection from adenocarcinoma [341]. 
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Table 4.1: Overview of screening policy* in countries and regions where cervical squamous cell carcinoma incidence trends are 
presented- reported year of onset, age range targeted and recommended screening interval 
Incidence Year of onset of organised screening Age range targeted Recommended screening interval with normal European Area Population programme, type of screening system, area (year programme began) result (years) 
covered 
Northern Denmark 1967 (achieved 90% coverage of women aged 23-59 (1986) 3 (some counties 5 years in >45 or 50) 23-59 years by 1997 [345] 
Estonia No screening programme No screening programme No screening programme 
Finland 1963 (national coverage) 30-60 (1993) 5 
Norway 1995, pilot 1992 (programme in one county 1959- 25-69 (1992) 3 1977) 
Sweden 1967-73 in different counties, Gothenburg 1977 23-60 (1999) 3 in ages 23-50; 5 in ages 51-60 
United Kingdom 1988 (national coverage) 20-64 (1988, reviewed 2003) 3-5 (currently 3 in ages 25-49 and 5 in ages 50-64) 
Eastern Czech Republic Opportunistic since 1966 (screening in two Not specified (1966) 1 districts, beginning 2004) 
Slovakia - (intention to initiate programme) 25-64 (--) 3 
Parma (1998) Parma: 25-64 (1998) 3 
Southern Italy Ragusa (No data) Ragusa: 25-64 (1996) 3 Torino (1992) Torino: 25-64 (1992) 3 
Varese (No data) Varese: 25-64 (1996) 3 
------- -
-------
Slovenia Opportunistic until 2003 20-64 (2003) 3 
~------ - ----- ------
--------
--
--~ 
--- -- ------~-
Spain Catalonia (opportunistic until 1993) Catalonia: 20-64 (1993) 3-5: Initially 2 smears 1 year apart. Then 3 years In ages 20-34 and 5 years in ages 35-64 
--~ 
- -----------_. 
Bas-Rhln (1994) Bas-Rhin: 25-65 (1990) 3 
Western France Doubs (1993) Daubs: 20-65 (1993) 3 (after 2 normal exams with 1 year interval) 
Isllre (1990) Isllre: 50-69 (1990) 3 
--
-----
- - ----
-- -- -- .-.- -- ----
Switzerland Opportunistic (no data) 18-69 (no data) 3 
-
-_._--- -~--.-- -----
• BaBed on data from the European Cervical Cancer Screening Network (ECCSN) questionnaire survey. Adapted from Table 1 of Antilla at aI, 2004 [308]. 
4.3 Review of temporal studies of cervical cancer in Europe 
4.3.1 Cervical cancer incidence and mortality 
Overall, rates of cervical cancer incidence and mortality have declined in the last 40 years in 
Western Europe [8,35]. Mortality declines predated the introduction of screening, and these 
have been ascribed loosely to factors related to increasing socioeconomic levels such as 
improvements in genital hygiene, reduced parity, and a reduction in the prevalence of 
sexually-transmitted disease [346]. More recently, the beneficial effects of cytological 
screening programmes at the population level have been quite evident. 
The most familiar to investigators studying the impact of cytological screening at the 
population level have been the temporal studies in the Nordic countries, for which high 
quality national registry incidence data have been available since the 1950s. The 
comparisons of incidence and mortality trends between the five countries enabled 
quantification of the effectiveness of screening in absolute and relative terms, given the 
contrasting national policies in relation to its implementation [193,309,338]. The declines in 
incidence were allied to the coverage and extent of the organised programmes [309], and 
were most marked in the age groups targeted by these programmes [322]. The largest 
decreases were observed in Finland, with its highly successful screening programme 
reducing cervical cancer mortality from a peak rate of 6.6 per 100,000 in the late 1960s to 
1.2 in 1991, a reduction of 80%. Respective declines of 65% and 55% were observed in 
Sweden and Denmark over the same period, countries partially covered with organised 
programmes. The decline was of a lesser order in Norway (41%), where an organised 
programme was only introduced in 1995. Opportunistic screening had increased throughout 
the period in all four countries [309]. 
Although screening in North East Scotland has been shown to be effective - a mortality 
decline of 63% was noted between 1968 and 1991 [339] -the programme was considered 
much less so in England as a result of a lack of coverage and follow-up. Since the 
introduction of an organised national programme in the late 1980s and a corresponding 
upsurge in coverage within the following five years, the re-Iaunched programme has, given 
the recent marked declines, been considered a notable success [187,347,348], with recent 
estimates suggesting the programme has prevented up to 5,000 deaths per year in England 
and Wales [349]. 
In spite of the overall declines in crude or age-adjusted incidence and mortality, increases 
have been reported among young women. The phenomenon was first described in England 
and Wales by Hill and Adelstein [350], where successive generations of women born since 
the mid-1930s were at increasingly high risk, and subsequently by others [189,351,352]. 
Similar observations have been seen elsewhere in Europe including Belgium [228,353], 
Scotland [339], Slovenia [354], Slovakia [355], Spain [356], and in several countries of 
Eastern Europe [346]. These are considered to be due to changes in sexual habits and 
increased transmission of HPV among younger generations. Even in Finland, marked 
increases in incidence in younger women (below 55 years of age) have been observed 
since 1990 [357]. A number of factors have been considered responsible including 
increased transmission of HPV [357], shortfalls in screening attendance [357], and the 
inferior quality of cytological laboratory procedures during the 1990s [358]. 
4.3.2 Squamous cell carcinoma incidence 
As squamous cell carcinoma represents the vast majority of cervical cancers, the time 
trends (and their interpretation) are usually analogous to those observed for cervical cancer 
overall. A large international study of cervical squamous cell carcinoma trends in 25 
countries by Vizcaino and colleagues found declines in incidence in younger (aged 25-49 
years) and older (aged 50-74) women in most European countries [252]. Several recent 
studies have reported trends in cervical squamous cell carcinoma in relation to the 
effectiveness of national screening programmes. A Swedish study reported little or no 
increase in risk in cervical squamous cell carcinoma in young women due to effective 
screening, and stable trends in young women with a levelling off of risk in cohorts born since 
the mid-1940s [359]. Exceptions to the decreases were observed in the international study: 
increases were seen among young women resident in the U.K., Slovenia, and Slovakia 
[252]. In the U.K., a number of recent reports have however communicated that the 
improved programme has successfully countered observed rises in rates of cervical 
squamous cell carcinoma [187,348,360]. 
4.3.3 Adenocarcinoma incidence 
Studies in the last twenty years in Finland [357], Italy [361], the Netherlands [362], Norway 
[363,364], Sweden [359,365] and the U.K. [189,366] have reported increasing rates of 
cervical adenocarcinoma relative to squamous cell carcinomas. Most noted increasing rates 
among younger women, particularly under the age of 40. As a result, adenocarcinoma may 
comprise up to 25% of cervical cancer cases in the respective Western countries [18]. 
The differential in the temporal profile of the two main subtypes of invasive cervical cancer is 
in keeping with the proposal of a relative inability of cytological screening to reduce the rates 
of invasive adenocarcinoma [18]. The Swedish study reported steady increases in period-
specific risk from 1975 to 1992, while in England and Wales, incidence rates in women 
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under 40 were reported to have reached a maximum by the late 1980s [366]. As the 
increases appear to affect relatively recent generations of women from many countries 
[253], they may reflect a changing prevalence of oncogenic types of HPV among these 
younger cohorts, the effect of which on squamous cell tumours has been diminished by 
screening programmes. 
4.4 Study I: APe trends in cervical squamous cell carcinoma incidence 
The text in this section describes an original analysis with discussion of the incidence trends 
of cervical squamous cell carcinoma in 13 European countries, with particular emphasis on 
the period and cohort effects resulting from the use of the APC model. A version of this 
section has recently been published in a peer-reviewed journal [367]. 
4.4.1 Data sources and data quality 
Registered new cases of cervical cancer and corresponding population data were extracted 
from EUROCIM [160] for women aged 30-64 (see 2.8 for details and standard inclusion 
criteria). Cervical squamous cell carcinoma was classified according to the ICO-O-2 
morphology codes 8051-8076 [131]. The time-span of available registry data in the 13 
countries varied from 15 to 45 years (Table 4.2). 
There are specific issues that concern interpretation of time trends of carcinoma of the 
cervix, including changes over time in the proportions of unspecified cervical cancer and 
unspecified cervical carcinoma, and in the prevalence of hysterectomy. Carcinomas of 
squamous cell origin coded as 'uterus unspecified' «1% of all uterine cancer cases) were 
included as cervical squamous cell carcinoma. No attempt was made to reattribute the 
unspecified carcinomas and cancers, as has been performed elsewhere [189]. The 
reasoning was that the unspecified group constituted <10% of all cervical cancer cases, and 
therefore would not materially affect the trends in cervical squamous cell carcinoma. 
There have been large variations in the prevalence of hysterectomy in European countries 
and in populations over time [368]. Hysterectomy in Europe is not as common a procedure 
as it is in the US, where over 30% of postmenopausal women may have undergone 
hysterectomy [368]. Recent evidence suggests that, adjustment for hysterectomy affects the 
magnitude and direction of trends in endometrial cancer in Finland [130] , although the 
impact on cervical cancer was less profound. The effects on trends in hysterectomy were 
not taken into account in the present analysis due to a lack of data for different countries in 
different periods and ages. The incidence of hysterectomy has been increasing in Finland 
[130], Denmark [369] and England and Wales [23], and the unadjusted trends presented 
here may underestimate the true temporal pattern in some populations. 
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-Table 4.2: Cervical squamous cell carcinoma: populations included, estimated percentage change in the regular trend, model 
characteristics and summary of the identifiable attributes of the period and cohort trends, by country within area 
ASR (0-74) Overall trend Recent trend European Country Perlod* Incldencet Person- 1993-7 (%)11 (%)' Area yearsta Per 
100,000t 95%CI 95%CI 
Northern Denmark 1979-1998 (4) 225 1,216,706 11.8 -2.4 -3.3 (-2.8 to -2.0) (-4.6 to -1.9) 
Estonia 1971-2000 (6) 99 337,550 16.7 -0.6 2.8 (-1.0 to -0.2) (0.0 to 5.8) 
Finland 1955-1999 (9) 65 1,225,829 3.1 -4.7 8.2 (-4.8 to -4.5) (3.8 to 13.4) 
Norway 1953-1997 (9) 185 933,595 11.8 -1.1 -1.2 (-1.2 to -0.9) (-2.9 to 0.6) 
Sweden 1964-1998 (7) 215 1,943,275 6.9 -4.2 -0.8 (-4.3 to -4.0) (-2.3 to 0.9) 
United Kingdom" 1978-1997 (4) 1360 11,982,152 6.9 -2.3 -5.6 (-2.5 to -2.2) (-6.0 to -5.1) 
Eastern Czech Republic 1985-1999 (3) 651 2,366,652 17.2 -0.6 -2.0 (-1.1 to-0.2) (-2.8 to -1.1) 
Slovakia 1968-1997 (6) 384 1,180,261 18.1 1.5 1.1 (1.2 to 1.8) (-0.2 to 2.6) 
Southern Italy" 1983-1997 (3) 119 1,118,959 6.3 -1.4 -0.8 (-2.5 to -0.2) (-2.9 to 1.7) 
Slovenia 1985-1999 (3) 126 475,358 14.0 3.5 5.3 (2.1 to 5.0) (2.5 to 8.5) 
Spalnc 1983-1997 (3) 72 692,076 6.1 0.7 1.0 (-0.8 to 2.4) (-1.8 to 4.2) 
Western Franced 1978-1997 (4) 115 896,132 8.0 -4.2 -3.8 (-4.8 to -3.7) (-5.5 to -1.9) 
Switzerland" 1983-1997 (3) 73 702,021 6.4 -3.7 -0.5 (-4.8 to -2.5) (-3.1 to 2.4) 
- - ---
* data available according to period of diagnosis, figure in parentheses represent number of five-year periods available In the analysis 
t average annual number of cases/person-years obtained from most recent five-year period 
II EAPC based on the trend parameter from the net drift for the whole study period (95% CI: 95% confidence Interval) 
~ EAPC based on the most recent two five-year periods (95% CI: 95% confidence Interval) 
APC Residual 
model* deviance' 
APC 12.7 
AC 34.6 
APC 78.2 
APC 69.3 
APC 71.4 
APC 51.2 
APC 9.5 
APC 38.9 
AD 14.5 
AC 5.4 
AC 9.0 
APC 24.1 
AP 20.5 
t refers to the most parsimonious final model providing a good fit: AD: Age+Drlft; AC: Age+Drlft+Cohort; AP: Age+Drlft+Perlod; APC: Age+Drlft+Perlod+Cohort 
Ref. Direction 
d.f. ' p- type 
M (mid-year) 
value' period 
trendtt 
10 0.24 I - (*) 
24 0.07 1/ 0(*) 
35 <0.05 I - (1967) 
35 <0.05 I - (1975) 
25 <0.05 I - (*) 
10 <0.05 I - (1985) 
5 0.09 I 0(*) 
20 <0.05 III/ - (1985) 
13 0.34 1111 - (*) 
6 0.49 1111 0(*) 
6 0.18 1/ 0(*) 
10 <0.05 I - (*) 
12 0.06 I - (*) 
-
Direction 
(mid-year) 
cohort 
trend~ 
+ (1949) 
+ (1936) 
+ (1945) 
0(1943) 
0(1934) 
0(1954) 
+ (1933) 
0(1945) 
+ (1938) I 
+ (1948) 
+ (1940) 
+ (1938) 
0(1938) 
0(1948) 
§ to determine the goodness-of-flt, the deviance was compared with the chi-squared distribution on the degrees of freedom determined by the model (see Appendix). p<0.05 denotes the full APC model does not yield An 
adequate fit 
"" age curve of reference type used (see Subjects and Methods) 
tt estimated direction of trends by period of diagnosis (+: positive trends, -: negative trend 0: stable trend or difficult to Interpret). Major changes In the direction noted In parentheses as the mid-year of the five-year period 
(" denotes change throughout study period) 
++ estimated direction of trends by birth cohort (-: negative trend 0: stable trend or difficult to Interpret). Major changes In the direction noted In parentheses as the mid-year of the 1 O-year birth cohort 
a aggregation of England, Scotland 
b aggregation of Florence, Varese Province, Parma Province, Ragusa Province, Turin 
c aggregation of Catalonia, Tarragona; Granada, Murcia, Navarra, Zaragoza 
d aggregation of Bas-Rhln, Caivados, Doubs, Isere, Somme, Tam 
e aggregation of Basel, Geneva, Neuchatel, St.Gall-Appenzell, Vaud, Zurich 
4.4.2 Methods: characterising age, period and cohort effects 
4.4.2.1 Evidence of a steady state age curve 
For most epithelial cancers, risk increases as a power of age [61], and this has been 
interpreted in terms of a multistage model for carcinogenesis [245,350]. Cervical cancer is 
an exception in that risk increases until around the age of menopause, and reaches a 
plateau and declines thereafter. As infection with HPV has been identified as a necessary 
aetiologic agent in cervical cancer [310,311], the underlying age pattern may be linked to the 
natural history of HPV infection and its accompanying carcinogenic mechanisms. 
Gustafsson and colleagues analysed age-specific cervical cancer incidence rates, selecting 
populations where screening activity was either minimal or had not become common [221], 
since the age distribution in post-screened populations changes markedly [322]. After 
scaling the rates to account for differing orders of magnitude, Gustafsson et at [221] found 
most populations fitted one of two reference curves (Figure 4.2). 
Reference curve type /, including Denmark, the Netherlands, Norway, Slovenia and 
Sweden, was characterised by an onset at about age 25, a rapid rise between 30 and 40 
and a peak at ages 44 to 49 years. After the peak, the decline in subsequent age groups 
was fairly rapid. Reference curve type" included Finland, and had an onset at 
approximately the same age, but a slower rise to a peak at an age around 53 years, 
followed by a decline similar to reference type I. Data from the U.K. did not fit either curve, 
probably due to the effect of large variations in risk by birth cohort distorting the cross-
sectional curves [350,352]. 
Gustafsson and colleagues showed that birth cohort trajectories could generate cross-
sectional age curves similar to both reference types dependent on the direction and 
magnitude of the birth cohort trend [221]. These curves must largely reflect cervical 
squamous cell carcinoma incidence, given that in unscreened populations in Europe, 
cervical squamous cell carcinoma comprises around 90% of all cervical neoplasms. 
4.4.2.2 Interpretation of period and cohort effects 
The relationship of cervical cancer incidence to age was assumed to be determined by the 
natural history of the disease and to be constant over time. Trends in incidence with time 
could then be partitioned into the effects of birth cohort and period of diagnosis on fixing the 
age slope using Holford's method, for which the age structures closely resembled each of 
the Gustafsson reference curves (see 4.4.2.4). 
For cervical squamous cell carcinoma, period effects can be viewed as representing the 
effects of cytological screening, given the intervention should deflect trends downwards 
across targeted age groups over the same period of time. Cohort effects are usually defined 
as proxies for changing patterns of risk attributable to iII-defined environmental causes in 
successive generations of women. For cervical cancer, they point to modifications in the 
population prevalence of persistent infection with oncogenic types of sexually-transmitted 
HPV [311,326]. 
4.4.2.3 Fitting the APe model 
Birth cohorts were obtained by subtracting age (the midpoint of five-year age band) from 
period (the central year of the five-year period of diagnosis). To distinguish the effects of 
time period and birth cohort on the time trends in each population, the full APe model of 
{3.6} was fitted according to the procedure described in 3.3.3. The goodness-of-fit of the 
APC model and its submodels, as well as tests for the overall slope and effects of period 
and cohort curvature, were obtained using the analysis of deviance of nested models, as 
suggested by Clayton and Schifflers [63,68]. 
The net drift term, reported as the EAPC, was utilised to convey the magnitude of the 
regular trend [63], as discussed in 3.4.1.1.3. A distinction was made between the overall 
trend - the net drift over the whole time period available - and the recent trend - the relative 
change in the last two five-year periods. A two-sided 9S% CI for each estimate was also 
calculated. 
The identifiability problem was highlighted by partitioning the age, period and cohort effects 
in terms of their linear and curvature component parts, according to the method of Holford 
[66] described in 3.4.2. A single solution was obtained on the basis of assumptions on the 
age slope a L ' as set out below. 
4.4.2.4 Obtaining identifiable period and cohort parameters 
The non-identifiability problem was circumvented by specifying a priori age-specific curves 
of cervical squamous cell carcinoma analogous to the reference types suggested by 
Gustafsson et al [221]. Starting with aL = 0, the APC model was refitted with age slope 
increases of 0.2% per year, until the ratio of the age parameters in the last (60-64) to first 
(30-34) strata ( j3 J / B 1 ) were equal to or greater than i) 1.S; ii) 4.9; and iii) 3.2. The first two 
ratios (hereafter referred to as type I and type II) match the ratios (and hence resemble the 
age curves) proposed by Gustafsson et al [221]. The ratio was lowered to 1.2 to obtain more 
plausible type I curves for the Czech Republic, Denmark and Sweden, since a ratio of 1.S 
produced curves showing a progressively increasing risk after age SO. A third (type 1/11) was 
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the average of the type I and type II ratios and served as an intermediate age curve. As an 
example, Figure 4.3 displays three sets of age, period and cohort effects for Slovakia 
produced by fixing the age structures to resemble types I, II and 1/11. Assuming particular 
magnitudes of the age slope from the full APC model yielded unique period and cohort 
slopes additional to the identifiable curvature of each factor. 
4.4.2.5 Presenting a single set of parameters 
As Figure 4.4 demonstrates, each age curve yielded a set of unique period and cohort 
curves differing with respect to period and cohort trends, and interpretation of the respective 
impact of screening and changing risk. A less arbitrary (but informative) final set of chosen 
parameters required an informed decision on the plausibility of the age effects, rather than 
assumptions regarding the effects of screening or changes in risk factors. 
From the three sets estimated for each country, a single set of age, period and cohort 
parameters was selected on the basis of the plausibility of the age curves and the level of 
agreement between the model parameters and the observed age, period and cohort trends. 
As well as presenting the risk patterns in terms of age, period and birth cohort effects, the 
second differences [68] acted as identifiable indicators of local departures from the linear 
trend, enabling detection of major changes (accelerations or decelerations) in the period and 
cohort trends. An attempt was also made to indirectly assess the contribution of the period 
slope (assumed to be driven by screening) to the Holford's drift, as defined in 3.4.2, 
essentially equivalent to Clayton and Schifflers' net drift described in 3.4.1.1.3. 
The age effects in each country were antilog-transformed to rates per 100,000 person-years 
to enable absolute comparisons. The period and cohort effects were reparameterised to rate 
ratios with reference points P -1 and A + P - 6 respectively, and hence the resultant 
midpoints of baseline risk were country-dependant, varying from 1990-93 for period, and 
1938-41 for birth cohort. To indirectly assess the contribution of the period slope to Holford's 
drift, a comparison of /3L with /3L + YL was made, via the specification of a L · 
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Figure 4.3: Cervical squamous cell carcinoma incidence trends, Slovakia 1968-
1997, with age reference 'type I' (dashed line), 'type II' (dotted) and type 1111 (solid) 
imposed. Age is on a rate scale. The reference points for period and cohort rate 
ratios are marked 
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Figure 4.4: Cervical squamous cell carcinoma incidence trends in 13 European 
countries for women aged 30-64. Trend based on all three reference curves of 
'type I' (dashed line), 'type II' (dotted) and type VII (solid). Age is on a rate scale. 
The reference points for period and cohort rate ratios are marked 
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Figure 4.4 cont .. 
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4.4.3 Results: description of trends 
4.4.3.1 Regular trend 
Figure 4.5 and Table 4.2 show the regular trend in each country across the whole study 
period, and within the most recent decade. There were large mean decreases in cervical 
squamous cell carcinoma in a number of Northern and Western European countries over the 
whole time period - around 4% per year in Finland (95%CI: -4.8% to -4.5%), France (95%CI: 
-4.8 to -3.7%), Sweden (95%CI: -4.3% to -4.0%) and Switzerland (95%CI: -4.8% to -2.5)%. 
Average declines of over 2% per annum were seen in Denmark (95%CI: -2.8% to -2.0%) 
and in the U.K. (95% CI: -2.5% to -2.2%). In contrast, mean annual increases have been 
observed in Slovenia of 3% per year (95%CI: 2.1% to 5.0%), and in Spain and Slovakia, 
with non-significant positive trends of 0.7% (95%CI: -0.8% to 2.4%) and 1.5% (95%CI:-
0.2% to 2.6%) per annum, respectively. 
Figure 4.5: Regular trend over the whole study period and in the last two periods: 
cervical squamous cell carcinoma incidence in 13 European countries for women 
aged 30-64, sorted by magnitude of overall trend, expressed as the EAPC. 
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For countries with a limited span of data, recent trends were of similar magnitude to the 
. 'th 
overall trends, although some interesting discrepancies emerged between countries WI 
longer periods of observation (Figure 4.5). In Sweden, the (non-significant) decline of 0.8% 
per annum (95%CI: -2.3% to 0.9%) in the 1990s was modest compared to the 4.2% (95%CI: 
-4.3% to -4.0%) decrease over the whole period (1964-1998). In Finland, the direction as 
well as the magnitude of the trend changed, with a large drop in cervical squamous cell 
carcinoma of 4% per year over several decades replaced by increases of over 8% (95%CI: 
3.8% to 13.4%) per year in the 1990s. The decrease of 5.6% (95%CI: -6.0% to -5.1%) per 
year in the U.K. between 1988 and 1997 was double that of the decline from 1978-97. 
4.4.3.2 Observed trends by age, period and cohort 
Figure 4.6 displays the observed rates versus age, period and cohort. As a result of inherent 
random variation and a combination of forces acting on the trends, there was some difficulty 
in visualising the trends and appropriating the effects to period or birth cohort. Some notable 
observations were the following: parallelism of the age-specific decreases by period of 
diagnosis in Finland from the 1960s; a similar observation in Sweden, but in successive birth 
cohorts born since the end of World War I; and substantial increases in rates in Estonia, 
Slovakia and Slovenia rates among consecutive generations born since the early-1940s. 
4.4.3.3 Period trends from the APC models 
A more comprehensible exposition of the trends is given in Figure 4.7, based on the chosen 
single set of APC model estimates for each country. In Northern European countries, there 
was clear evidence of large period-specific declines in cervical squamous cell carcinoma, 
most notably in Sweden and Finland since the mid-1960s, but also in Norway since the mid-
1970s, in the U.K., since the mid-1980s, and in Denmark throughout the study period 
available (Table 4.2). Within these countries, some indication of accelerations in the 
declining trends was seen in Norway and Sweden from the 1980s, and clearer evidence of 
an increasing trend in Finland in the 1990s. 
Estonia was an exception within Northern Europe: no trend was discernible in the period 
parameters. In France and Switzerland (Western Europe), and in Italy (Southern Europe), 
there were negative period trends in recent periods, whereas in Spain and Slovenia, no such 
trends were apparent. In Eastern Europe, the trends were slightly different: period effects 
were largely flat in the Czech Republic, but in Slovakia, a deceleration in cervical squamous 
cell carcinoma incidence was suggested, detectable from the mid-1980s. 
4.4.3.4 Birth cohort trends from the APC models 
Figure 4.7 indicates a good correspondence in the birth cohort patterns in several European 
countries. The declines in risk in generations born in the first three decades of the twentieth 
century have often been replaced by successive increases in risk in women born thereafter. 
The timing of the change varied between countries, but in each of them, the escalation of 
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risk began in generations bom in the early 1930s through to the late 1940s (Table 4.2). In 
Northem Europe, this was evident in cohort trends in Denmark and Finland, but in Estonia 
and the U.K., the generational increases started a little earlier. The increasing cohort 
parameters in Norway and Sweden were open to less inference, with a deceleration in the 
trend in the most recent generations suggested. 
In several South em and Eastem European countries, increases in risk were observed in 
women bom from around 1940 in Spain, Slovakia and Slovenia. A similar but less marked 
trend was seen in Italy that started slightly earlier, while in the Czech Republic, little change 
in risk was seen in successive cohorts. In France and Switzerland, rather constant levels of 
risk among recent generations have followed the declines observed in cohorts bom in the 
1920s and 1930s. 
4.4.3.5 The contribution of period slope to Holford's drift 
Figure 4.8 compares the contribution of the period slope to Holford's drift. The bottom left 
quadrant includes nine countries in which the downward trend in cervical squamous cell 
carcinoma is accompanied by a fall attributed to a linear period effect. The negative period 
slope took up most of the negative regular trend where the observations were reasonably 
close to the superimposed y = x line, with the extent of the period-specific reduction large in 
certain countries (e.g. Sweden and Switzerland) and minimal in others (e.g. the Czech 
Republic). Four countries were characterised by increasing regular trends (the upper 
quadrants of Figure 4.8), accompanied by period slopes of negligible magnitude. The 
increase was most notable in Slovenia. 
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Figure 4.6: Observed trends in cervical squamous cell carcinoma incidence in 13 
European countries for women aged 30-64 by region. Left to right: rates versus age 
by cohort (indices of cohorts indicated), rates versus cohort by age (midpoints of 
age groups indicated), rates versus period by age. Rates are on a logarithmic scale 
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Figure 4.6 cont.. 
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Figure 4.7: Cervical squamous cell carcinoma incidence trends in 13 European 
countries for women aged 30-64. Age is on a rate per 100,000 scale. The reference 
points for period and cohort rate ratios are marked 
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Figure 4.8: Comparison of the net drift and the contribution of the period slo alon~. Both are generated from the full APC model and expressed as the E~ . 
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4.4.4 Discussion of main findings 
There has been a major decline in the incidence of cervical squamous cell carcinoma over 
time in a number of European countries. Figure 4.8 demonstrates that in most of them, the 
decreased incidence is accompanied by a decline in the period slope, implying that it is the 
consequence of the implementation of effective cytological screening. The absolute and 
relative magnitudes of the period and cohort slopes between countries should be interpreted 
with caution as they are dependant on both the available period of observed data (in relation 
to the initiation of screening), and the initial parameterisation that yielded the particular set of 
estimates presented. 
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Nevertheless, in most of the countries in which the period slope is of lower magnitude than 
the sum of the period and cohort slopes, notably in Finland and France, there were also 
declines in risk by birth cohort during the study period. In Finland, the moderation of the 
magnitude of the period slope relative to Holford's drift could be a consequence of the 
availability of data for over a decade before screening was officially implemented, thereby 
diminishing its effect. There was almost no reduction in incidence by time period in four 
countries, implying the absence of effective screening for these women, who are at 
increasing risk in successive generations. The most obvious examples were Spain and 
Slovenia, where respective increases of 1 % and over 5% per year were observed during the 
1990s. 
In light of the results, one can broadly dichotomise the European countries in terms of their 
historical screening activity and its impact on period-specific risk, as well as in term of 
changing aetiology, as described by trends in risk according to birth cohort. 
4.4.4.1 Countries with decreases in period risk, possibly increasing cohort risks 
There is clear evidence that screening has been effective in reducing the incidence of 
cervical squamous cell carcinoma in women in Finland (at least up to the early 1990s) and 
Sweden since the 1960s, reflecting the implementation of nationally organised programmes 
in 1963 and 1964, respectively [193,359,370]. In Denmark, the incidence data go as far back 
as 1979, and the declining period trend was evident throughout. Regional screening was 
introduced in 1967 in Denmark, initially covering 40% of the population [193,371]. Screening 
was introduced in Norway in a single county (5% of the population) in the same year [193], 
and declines in cervical squamous cell carcinoma incidence by period have been occurring 
since around 1975. A coordinated screening programme has been in operation since the 
mid-1990s [372], and therefore the declines are probably a result of the increasing levels of 
opportunistic screening, at least since the time of the period decline. 
In the U.K., incidence has been falling since the 1980s, particularly so during the 1990s, 
likely a result of improvements to the National Health Service Cervical Screening 
Programme from 1988 [187,189,348,349,373,374]. Period-specific declines in risk were also 
evident throughout the study period in both France and Switzerland; in France, regional 
screening programmes were implemented in the early to mid-1990s in three of the six 
registry areas represented in this analysis. Underlying the period-specific changes in risk in 
these populations, there are changes in risk of cervical squamous cell carcinoma according 
to generation. Increasing cohort effects are most likely to be the result of changing sexual 
mores, resulting in an increased transmission of oncogenic types of HPV with corresponding 
increases in prevalence of persistent infection and dramatically increased risk [89,375,376]. 
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However, the possibility that women may have been screened differently from one cohort to 
another needs also to be considered. 
Generation-specific increases in risk were evident in Finland in women born since 1945. The 
increasing incidence among Finnish women below 55 years of age since 1990 has been 
remarked on previously, and attributed to changing sexual lifestyles and increased 
transmission of papillomaviruses in younger generations of women [357], and to shortfalls in 
screening attendance [357]. A more recent study examining several Finnish cytological 
laboratories suggested that additional explanations were possible, linked to the quality and 
criteria of lab procedures during this time [358]. In Denmark, some increases in cervical 
squamous cell carcinoma were seen in women born since 1950, while in the U.K, there were 
increases in cohorts born since the mid-1930s, as previously reported [189], although 
incidence rates in women under 55 appeared to be deflected downwards by period-related 
screening effects. Modest cohort-specific increases in risk in were observed in Sweden in 
generations born since 1940, suggested to be a consequence of organised and 
opportunistic screening efforts addressing these cohorts [359]. Further, there has been little 
or no increase in cervical squamous cell carcinoma rates in young women in this country. 
There were no cohort-specific increases in risk among recent generations of women in 
France and Switzerland. It may be that women in these countries have had different 
experiences with respect to exposure to aetiological factors than other European women. 
On the other hand, screening has been mainly opportunistic in these countries, and may 
have been accepted by successive generations of women (rather than women of all ages, at 
a given period). In this instance, screening effects on risk would appear as a cohort effect, 
and counter any underlying increase. 
4.4.4.2 Countries with minor changes in period risk, increasing cohort risks 
A decline in risk by period was small in Italy throughout the study period (1983 onwards) and 
in Slovakia since around 1985. This may reflect sporadic screening at low intensity rather 
than organised screening effects, given that the declines occurred before any regional 
screening programmes were in place in Italy, while screening policy in Slovakia is currently 
at the planning stage. In the Czech Republic, Estonia, Spain and Slovenia, there was little or 
no trend in the period slope, in accordance with the minor screening efforts in these 
countries. 
In a number of these countries there were accelerating incidence trends amongst recently 
born generations. There were large increases in cohort-specific risk in Slovenia, Slovakia 
and Spain and, to a lesser extent, in Estonia, from around 1940, and in Italy, beginning 
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slightly later. The Czech Republic was an exception, in that there appeared to be almost no 
change in the cohort-specific trends, but, as with several countries, these remain difficult to 
interpret given the short period of observation. Most disturbing are the substantial cohort-led 
increases of cervical squamous cell carcinoma in countries where no programmes are in 
place. The prime example is Slovenia, where the recent regular increase amounts to over 
5% per annum. 
4.4.4.3 Modelling concerns 
A solution to the non-identifiability problem involved considering a priori evidence of a 
constant pattern of age-specific risk over time. From a set of three candidate age curves, 
similar to those identified in unscreened populations by Gustafsson and colleagues [221], a 
fixed age slope was determined by taking into account the credibility of the age curves from 
a biological viewpoint, and on assuming the APC model was correctly specified, supporting 
evidence that the resultant period and cohort effects were not in disagreement with the 
observed age-specific trends. Although this does provide a unique solution, the true age-
specific risk cannot be directly observed, and the estimates were interpreted with 
appropriate caution. 
The model was employed primarily as a descriptive tool to interpret period- and cohort-
specific risk patterns across Europe, although the deviance statistics in Table 4.2 indicated 
the full model did not fit the data in several countries. Overdispersion, whereby the variance 
in the counts of incidence is larger than that of the Poisson assumption, is a likely 
determinant, given the large number of events being analysed at the national level [198]. 
Additionally, one may speculate that other complex factors than the effects of screening and 
changing risk patterns, such as spatial effects at the sub-national level, and heterogeneity in 
the quality or completeness of cervical cancer registration, may also have contributed. 
4.5 Study II: APe trends in cervical adenocarcinoma incidence 
Incidence trends in the other main histological subtype of cervical cancer, adenocarcinoma, 
were studied in European women in the same 13 countries, again utilising the APC model. 
However, additional complexities were anticipated in the study of adenocarcinoma trends 
that motivated a reappraisal of the methods used in presenting those for squamous cell 
carcinoma. The increasing capability to diagnose adenocarcinoma and its impact on the 
trends was a critical issue for this less common histology. Indeterminate knowledge of the 
biological age curve for adenocarcinoma, and the lack of impact of cytological screening on 
trends in Europe, had also to be considered. A version of the text in this section has been 
recently published in a peer-reviewed journal [377]. 
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4.5.1 Data sources and data quality 
Registered cases of adenocarcinoma and corresponding population data were obtained 
from EUROCIM [160] (see 2.8 for details and standard inclusion criteria). Cervical 
adenocarcinoma was classified according to the ICO-O-2 morphology codes and includes 
adenosquamous carcinoma [131]. The same countries and years were used as for the 
squamous cell carcinoma analysis (Table 4.3). To provide a broad description of the trends 
and their impact both on younger and older women, data on all subjects aged under 75 were 
analysed. 
As with the previous analysis, the rates are unadjusted for the known variations in the 
prevalence of hysterectomy in European countries over time [368]. The trends presented in 
this section therefore may be attenuated relative to the true temporal patterns upon 
adjustment for the prevalence of hysterectomy in each population. 
4.5.1.1 Increasing specificity of subtype 
As with squamous cell carcinoma, cancers of the cervix uteri with unspecified or ill-defined 
histology were not reallocated to specified histological subtypes. The prior reasoning that the 
unspecified group could not have made a sizable impact on the trends was not an 
acceptable assumption for adenocarcinoma however, given that the rates of cervix 
unspecified and the proportions of all cervical cancer combined, in some countries, was of 
the same order of magnitude as the adenocarcinoma rates (Tables 4.4 and 4.5). 
Analyses were performed on the original data on the grounds that there was insufficient 
external information on which to base a rule for reallocation. In particular, the strong 
assumption that the unspecified group represented a random sample of those subjects with 
histology specified was not considered as justified. As way of an example, in Finland, a 
sudden drop in the number of unspecified cases was observed in 1968, likely due to 
structural changes in the way pathology data was coded, with the quality of the data pre-
1968 considered of relatively poor quality in general. The Finnish data is therefore regarded 
at its most reliable if only cases coded as adenocarcinoma are included, and more recent 
trends were the focus of evaluation. The present analysis adhered to this criterion for all 13 
countries, and the evaluation of recent trends was given priority. 
170 
Table 4.3: Adenocarcinoma of the cervix: populations included in the analysis, recent age-standardised rates, the estimated 
percentage change in the regular trend, and model characteristics and characteristics of cohort trends, by country within area 
-
Annual ASR (0-74) Overall Recent trend Direction European Country Period number Person- 1993-97 trend (%)11 (%)' APC Residual dJ.' p- (Year) Area (No. of years)* yearst model* deviance' value§ Cohort of cases t per 100,000t 95%CI 95%CI trend" 
Northern Denmark 1978-1998 (21) 73 2.4 3.0 0.7 0.4 A 18.7 21 0.60 + (1945) (-0.2 to 1.5) (-0.7 to 1.6) 
Estonia 1968-2000 (33) 10 0.7 1.0 -0.6 1.0 A 35.0 35 0.47 + (1935) (-1.8 to 0.6) (-1.8 to 3.9) 
Finland 1953-1999 (45) 39 2.4 1.4 -0.2 2.6 AC 47.9 42 0.25 + (1945) (-0.6 to 0.2) (1.0 to 4.3) 
Norway 1953-1997 (45) 55 2.0 2.6 2.1 1.1 AC 36.5 42 0.71 + (1930) (1.7 to 2.5) (-0.4 to 2.7} 
Sweden 1960-1998 (39) 82 4.0 2.0 1.6 0.4 AP 40.0 36 0.30 + (--) (1.3to2) (-0.6 to 1.5) 
United KingdomS 1974-1997 (24) 591 25.1 2.2 3.2 2.4 APC 14.0 10 0.17 + (1940) (2.9 to 3.5) (1.9 to 2.8) 
Eastern Czech Republic 1985-1999 (15) 104 5.0 1.9 1.7 1.7 AD 2.6 13 1.00 + (-) (0.5 to 2.9) (0.5 to 3.0L 
Slovakia 1968-1997 (30) 53 2.6 2.1 2.0 3.4 AC 29.0 24 0.22 + (1935) (1.3 to 2.7) (1.7 to 5.11 
Southern Itall 1981-1997 (17) 37 2.1 1.4 1.5 1.6 AD 12.5 13 0.49 + (1940) (-0.7 to 3.81 (-0.8 to 4.0) 
Slovenia 1983-1999 (17) 36 1.0 3.0 4.4 4.5 AC 8.2 6 0.22 + (1940) (2.4 to 6.4) (2.4 to 6.6) 
Spainc 1980-1997 (18) 20 1.5 1.3 1.9 2.6 A 17.7 14 0.22 + (1940) (-0.6 to 4.5) (-0.2 to 5.4) 
Western Franced 1978-1997 (20) 27 1.9 1.4 0.5 -1.1 A 14.0 21 0.87 o (1945) (-2.0 to 3) (-3.1 to 1.0) 
~ - --
Swltzerland8 1981-1997 (17) 22 1.3 1.5 -1.4 0.4 A 3.6 14 1.00 0(1955) (-3.0 to 0.2) (-2.2 to 3.1) 
data available according to period of diagnosis, figure In parentheses represent number of years available In the analysis 
~~-
t average annual number of cases/person-years (latter expressed per million) obtained from most recent five-year period. ASR: truncated age-standardised rate In women aged <75 (Europe) In most recent five-year period 
II EAPC based on the trend parameter from the net drift for the whole study period 
'II EAPC based on the most recent 15-year period 
•• estimated direction of recent trends by birth cohort (+: positive trend 0: relatively stable trend or difficult to Interpret). Time In parentheses Is midyear of birth when direction al change In of trend first noted (to nearest five 
years): -- denotes change In trends not apparent 
l refers to the most parsimonious final model providing a good fit: AD: Age+Drlft: AC: Age+Drlft+Cohort: AP: Age+Drlft+Perlod: APC: Age+Drlft+Perlod+Cohort 
§ to determine goodness-of-flt, the deviance was compared with the chi-squared distribution on the degrees of freedom determined by the model (see Appendix). p<0.05 denotes the full APC model does not yield an 
adequate fit 
•• age curve of reference type used (see Subjects and Methods) 
a aggregation of England, Scotland 
b aggregation of Florence, Varese Province, Parma Province, Ragusa Province, Turin 
c aggregation of Catalonia, Tarragona: Granada, Murcia, Navarra, Zaragoza 
d aggregation of Bas-Rhln, Calvados, Doubs, Isere, Somme, Tarn 
e aggregation of Basel, Geneva, Neuchatel, SI.Gall-Appenzell, Vaud, Zurich 
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Table 4.4: Time trends in the proportions of (i) cervical adenocarcinoma; (ii) combined categories of unspecified cervical 
carcinoma and cervical unspecified cancer;(iii) cervical adenocarcinomas if all cervical cases unspecified were truly 
adenocarcinoma. Proportions expressed as percentage of all cervical cancer cases 
Unspecified cervical carcinomas and unspecified Cervical adenocarcinoma if all unspecified cervical Cervical adenocarcinoma 
cervical cancer carcinoma or unspecified cervical cancers were ~denocarcinoma __ 
European 1953-57 1963-67 1973-77 1983-87 1993-97 1953-57 1963-67 1973-77 1983-87 1993-97 1953-57 1963-67 1973-77 1983-87 1993-97 IArea Country 
Northern Denmark 12.7% 18.8% 7.5% 2.4% 20.2% 21.2% 
Estonia 5.1% 6.4% 5.6% 15.3% 8.7% 7.6% 20.4% 15.1% 13.2% 
Finland 6.1% 7.3% 11.2% 19.5% 28.4% 16.8% 26.1% 6.4% 5.1% 4.3% 22.9% 33.4% 17.60/. 24.6% 32.8% 
Norway 6.7% 6.5% 7.7% 13.7% 17.7% 11.8% 6.6% 3.7% 1.7% 2.9% 18.4% 13.1% 11.4% 15.5% 20.6% 
Sweden 6.0% 7.9% 16.8% 19.6% 7.4% 2.8% 3.2% 4.8% 13.4% 10.7% 20.0% 24.4% 
United Kingdom 8.0% 11.3% 21.0% 26.7% 17.6% 11.1% 34.7% 29.0% 32.1% 
--- -------
-- - - -----
--------
Eastern 
---
Czech Republic 7.9% 9.5% 7.4% 5.3% 15.3% 14.7% 
Slovakia 6.3% 7.7% 9.9% 23.5% 4.9% 3.9% 29.8% 12.5% 13.8% 
------
----
Southern France 10.7% 13.4% 6.6% 4.7% 17.3% 18.2% 
----- --
I~ 11.2% 16.4% 13.3% 8.2% 24.5% 24.6% 
--
----
Slovenia 12.2% 16.4% 13.1% 4.1% 25.2% 20.6% 
-- ---
---
Western Spain 11.5% 16.1% 21.8% 7.2% 33.3% 23.3% 
-
------_.-
--
Switzerland 12.9% 18.0% 1.4% 1.3% 14.3% 19.3% 
--- ----
----
-
172 
Table 4.5: Time trends in the crude rates (per 100,000 person-years) of (i) cervical adenocarcinoma; (ii) combined categories of 
unspecified cervical carcinoma and cervical unspecified cancer;(iii) cervical adenocarcinomas if all cervical cases unspecified 
were truly adenocarcinoma 
Unspecified cervical carcinomas and unspecified Cervical adenocarcinoma if all unspecified Cervical adenocarcinoma cervical carcinoma or unspecified cervical 
cervical cancer 
cancers were adenocarcinoma 
European 1953-57 1963-67 1973-77 1983-87 1993-97 1953-57 1963-67 1973-77 1983-87 1993-97 1953-57 1963-67 1973-77 1983-87 1993-97 Area Country 
Northern Denmark 3.5 4.2 2.1 0.6 5.6 4.8 
Estonia 1.6 1.7 1.6 4.8 2.3 2.2 6.5 4.0 3.8 
Finland 1.6 2.0 1.6 1.5 2.1 4.3 7.3 0.9 0.4 0.3 5.9 9.3 2.5 1.9 2.4 
Norway 1.9 2.0 2.5 3.0 3.8 3.3 2.0 1.2 0.4 0.6 5.1 4.0 3.7 3.4 4.4 
Sweden 2.1 1.7 2.8 2.9 2.6 0.6 0.5 0.7 4.7 2.3 3.3 3.6 
United Kingdom 1.7 2.6 3.2 5.8 4.0 1.7 7.5 6.5 4.9 
Eastern Czech Republic 2.4 2.8 2.3 1.5 4.7 4.3 
Slovakia 1.6 2.1 3.0 6.1 1.3 1.2 7.7 3.4 4.1 
Southern Italy 1.8 2.1 2.1 1.1 3.9 3.2 
~-
Slovenia 2.8 4.3 3.0 1.1 5.8 5.4 
Spain 1.5 1.8 2.7 0.8 4.2 2.6 
~estern France 2.3 2.0 1.4 0.7 3.7 2.7 
- ----- --
Switzerland 2.0 2.1 0.2 0.2 2.2 2.3 
_ ... _ .. ___ L. 
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4.5.2 Methods: characterising age, period and cohort effects 
Trends in adenocarcinoma incidence were analysed using the APC model; the effects of 
birth cohort and period of diagnosis were evaluated to examine the extent to which changes 
in risk in successive generations were evident, and whether the diverse cytological 
screening policies presently in Europe [308] had any recent impact in reducing 
adenocarcinoma incidence , respectively. 
An attempt was made to fix the age structure to that that was assumed for squamous cell 
carcinoma, in order to leave the period and birth cohort parameters free and thereby 
allowing an independent assessment of their effects. However, other a priori assumptions on 
the effect of period-specific risk were also examined. The first involved a similar analysis of 
the age, period and cohort effects to that carried out for squamous cell carcinoma (see 
4.5.2.2.1). The second approach analysed the temporal data at a finer resolution, in five-
year age-classes but one-year periods, the APC model smoothing the trends via cubic 
splines and the specification of knots at defined points on the age, period and cohort scales 
(see 4.5.2.2.2). 
4.5.2.1 Evidence of a steady state age curve for adenocarcinoma 
Figure 4.9 displays the trends based on the same three solutions obtained for squamous cell 
carcinoma assuming that the three alternatives for steady state age curves were also 
relevant for the representation of adenocarcinoma trends. As for squamous cell carcinoma, 
contrasting interpretations of the period and cohort effects could be made dependant on the 
particular age curve selected. Curves of reference type I tended to produce positive slopes 
for period (and accordingly, rather flat or decreasing cohorts slopes), while type II age 
curves often generated increasing positive cohort slopes, and minor or decreasing period 
slopes. 
A single set of age, period and cohort estimates is displayed in Figure 4.10, obtained by 
utilising the same reference curve as that chosen for squamous cell carcinoma, that is, on 
the basis of an equivalent ratio of the first and last age parameters, yielding three reference 
types. The imposed assumption was that the chosen biological age curve for 
adenocarcinoma was similar to that of squamous cell carcinoma, implying the selected 
curve in each country was a reasonable description of cervical cancer, regardless of 
histological subtype. Interestingly, the parameters displayed emphasises period-specific 
increases in all countries except Switzerland, with the rises evident in most countries over 
the whole period of observation. Cohort-specific increases were also apparent in most 
174 
countries, in cohorts born since the 1940s; exceptions were Sweden, the Czech Republic 
and Switzerland. 
4.5.2.2 Zero period slope as indicator of screening inefficiency 
An alternative solution applied Holford's method to fix the overall period slope to zero (see 
3.4.2.1), perhaps appropriate given the accumulated evidence of a lack of screening effect, 
at least historically. It was assumed that screening operated purely as a period effect, no 
other period-related factors were in operation, and, where effective screening was in 
operation, the effect was recent and one that would not alter the linear component of the 
period effect from its set value of zero. Holford's method still provided estimates of period 
curvature despite deactivation of the linear part of the effect. The result of a recent, relatively 
sudden ability to screen-detect adenocarcinoma (as postulated [316]) could therefore be 
observed in the non-linear period effects. Two approaches were examined, as described 
below. 
4.5.2.2.1 Trends based on standard modelling approach 
The APC model of {3.6} was utilised as before, with non-identifiability highlighted by 
partitioning the effects into their linear and curvature parts [66], with specification of J3L = 0 
resulting in aL and YL being immediately estimable. The effects were defined and 
presented in the same way as with cervical squamous cell carcinoma. 
Figure 4.11 shows the trends in age, period and cohort in which an identifiable set of 
parameter estimates was obtained on constraining the overall slope of period to zero. The 
trends, by nature of the imposed parameterisation of Holford's drift entirely to cohort, 
brought to attention the generational effects, with an underlying slope equal to its magnitude. 
The displayed trends contrast with those based on the elected squamous cell carcinoma 
curve seen in Figure 4.10. The transformation of the period slopes, from mainly positive in 
Figure 4.10 (obtained on fixing age) to zero throughout in Figure 4.11 (obtained on fixing 
period), involved a clockwise rotation of the period effects enforcing an equal but opposite 
rotation (e.g. counter-clockwise) of the cohort effects. The latter in Figure 4.11 are not only 
increaSing in most countries (in keeping with its absorption of the regular trend), but the 
trends also imply successive increases in adenocarcinoma start earlier - around 1910, or 
before, in Sweden and Norway. 
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Figure 4.9: Adenocarcinoma incidence trends in 13 European countries for 
women aged 30-64. Trend based on all three reference curves of 'type I' (dashed 
line), 'type II' (dotted) and type 1/11 (solid), as used for squamous cell carcinoma. 
Age is on a rate scale. The reference points for period and cohort rate ratios are 
marked 
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Figure 4.10: Adenocarcinoma incidence trends in 13 European countries for 
women aged 30-64. Trend based on selected reference curves used for squamous 
cell carcinoma. Age is on a rate per 100,000 scale. The reference points for period 
and cohort rate ratios are marked. Rates <2 are not shown 
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Figure 4.11: Adenocarcinoma incidence trends in 13 European countries for 
women aged 30-64. Trends obtained on constraining the overall slope of period to 
zero. Age is on a rate per 100,000 scale. The reference points for period and 
cohort rate ratios are marked. Rates <2 are not shown 
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4.5.2.2.2 Trends based on cubic spline regression 
An alternative but related presentation concerned incorporating some form of smoothing of 
the data by fitting a cubic spline to the data resolution available in EUROCIM [160]. The 
number of events and person-years corresponded to 5 year x 1 year subsets of aLexis 
diagram, and under the assumption of a constant incidence rate A , the likelihood 
contribution from each subset is proportional to a likelihood for a Poisson observation d 
with mean AY. The rates were described as a function of age, period and cohort using a 
log-linear model, with Poisson errors and a logarithmic link function, as previously. Thus for 
a given mean age a and mean date of diagnosis p (period), the mean date of birth (cohort) 
for those diagnosed (and for those at risk) was C = P - a . The number of distinct values of 
a in the dataset was 15, namely 2.5,7.5, ... ,72.5, the number of distinct values of p was 48, 
namely 1953.5,1954.5, ... ,2000.5 and hence the number of distinct values of C was 118, 
namely (1953.5 -72.5 =) 1881, 1882, ... ,1998 (= 2000.5 - 2.5). 
Country-specific drift estimates for the latest 15-year period were obtained and reported as 
the EAPC. For a more detailed description, an APC model was used for the rates A( a, p) : 
log Aa,p = f(a) + g(p) + h(c) 
with f, g and h functions each parameterised with a limited number of parameters. The 
parametric form for f, g and h was taken as cubic splines; functions that are 3rd degree 
polynomials in each of a sequence of intervals defined by a set of points (knots). The 
parameters were constrained to have Oth, 1 st and 2nd derivatives identical at the knots. 
Natural splines were used and constrained to be linear beyond the outermost (boundary) 
knots using R [209]. The knots were chosen as points on the scales for age, period and 
cohort that divided the number of recorded cases equally in the intervals between knots. To 
circumvent the identifiability problem an age-cohort model was fitted: 
log )'a,c = f(a) + h(c) 
where h is chosen so that h( co) = 0 for a reference cohort Co (in this case the 1945 cohort). 
This means that f(a) correspond to log-incidence rates in the cohort co' and h(c) , the rate-
ratio of cohort c relative to cohort Co • 
Subsequently, period effects were fitted to the residuals by using a Poisson model for D, 
but with the log of the fitted values from the age-cohort model as offset. This gives period 
effects conditional on the estimated age and cohort effects. The fitted values using this 
approach were very close to those obtained by maximum likelihood estimation in the full 
age-period-cohort model. In so doing, the secular trend was explicitly put in the cohort term 
in a well-defined way. Furthermore, the standard errors of the estimated values of f, g and 
h could be derived. The resulting period-effect was in practice very close to the "de-
trending" approach suggested by Holford [66], as used in 4.5.2.2.1. The age, period and 
cohort effects are presented together with their associated 95% CI for each of the 13 
countries (Figure 4.12), and, where informative, with the observed age-specific period and 
cohort trends in selected countries. 
4.5.2.3 Presenting a single set of parameters 
Selecting from the above presentations was a difficult task, a choice between an informative 
parameterisation on fixing to an age curve that may however be inappropriate, and a less 
informative display on fixing the period slope to zero, a marker of screening ineffectiveness. 
Trends in the period and cohort parameters based on fixing age or period gave quite 
conflicting results and different interpretations to the same datasets. 
In selecting a single approach from which to interpret the findings, the fixing of period 
approach was considered more appropriate, given that the assumption was based on 
reasonably firm evidence of a historical lack of a screening effect for adenocarcinoma. 
Further, the cohort effects obtained from such a constraint were perhaps more in keeping 
with the observed data (although their interpretation, given the variability, may itself be 
declared as arbitrary). Finally, the setting of fJL = 0 was in line with several previous U.S. 
and U.K studies [189,210,366]. Period effects were only required in the description of trends 
in Sweden and the U.K. (Table 4.3), although their lack of significance in most countries 
refers only to the non-linear component. By the inherent properties of the non-identifiability, 
strong linear period effects - like those seen in Figure 4.10 on fixing age - would have 
remained undetected using the APC model. 
Clearly, fixing the age curve, as was argued for in 4.4.2.4 for squamous cell carcinoma 
trends, would have been the best solution, leaving the period and cohort parameters 
undetermined and without any a priori judgement on their likely impact interfering with the 
display of model effects. However, knowledge of the age curve of squamous cell carcinoma 
was assumed on the grounds that it was identical to the documented reference curves 
established for cervical cancer [221], feasible, given that the histology comprised at least 
75% of cervical cancer in the populations studied. The same could not be said for the 
relatively less common adenocarcinoma, for which the knowledge of the age structure was 
more limited. Empirical evidence suggests that the peak age of incidence is in fact lower 
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than that of squamous cell carcinoma. This is discussed in the context of further 
investigations and the extensions to the considered approaches in 4.6.3. 
The results based on cubic spline smoothing (Figure 4.12) are described below in 4.5.3.4 
and 4.5.3.5. Given the random variation inherent, encompassing a smoothing effect allowing 
the available data to be analysed at a higher resolution seemed appropriate, giving a more 
appealing visualisation of the trends than the standard APC analysis involving five-year age 
groups and periods. Further, the use of splines is consistent with several other reports 
[189,210,366]. 
4.5.3 Results: description of trends 
4.5.3.1 Changing rates of adenocarcinoma relative to unspecified cases 
The rates of adenocarcinoma have tended to increase in successive decades in most 
countries studied, although trends were rather stable in Estonia, France and Sweden. In 
parallel, declines in the rates of unspecified cervical cancer and unspecified cervical 
carcinoma were observed, notably within the last two decades in Southern Europe but also 
in the U.K., Denmark and France (Table 4.4 and 4.5). The historical data from Finland, 
Norway and Sweden indicates that the rates of unknown histology were large, often 
exceeding those of adenocarcinoma from the 1950s and 1960s; but in the 1970s, 
unspecified histology rates were vastly reduced, remaining steady (and of a low order of 
magnitude) thereafter. High rates of unspecified cervical cancer/carcinoma were observed in 
Slovakia and the U.K. in the mid-1970s, although they decreased rapidly with time in 
Slovakia. In the U.K., the unspecified rate was still amongst the highest (second only to 
Estonia) in the mid-1990s. Large declines in unspecified rates were also seen in Southern 
Europe, notably in Italy and Slovenia from the mid-1980s to the mid-1990s. Conversely, the 
rates of unspecified were stable and minor in Switzerland in the same time period. 
4.5.3.2 Geographical variations in age-adjusted rates 
There was a threefold variation in the age-standardised rates of adenocarcinoma in women 
aged under 75 (Table 4.3). Rates varied from relatively low (1.3 - 1.5 per 100,000) in 
Estonia, Spain, Italy, France and Finland, through to intermediate (1.9 - 2.2) in Sweden, the 
Czech Republic, Slovakia and the U.K. The highest rates were recorded in Norway (2.6), 
Denmark (2.8) and Slovenia (3.5). 
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Figure 4.12: Age, period and cohort effects of cervical adenocarcinoma incidence 
for women aged under 75 by country within region (N Europe, panels 1-6; E 
Europe, panels 7-8; S Europe, panels 9-11; W Europe, panels 12-13). Period 
effects are estimated as residual effects of period given estimated age and cohort 
effects. Cohort effects are displayed for generations bom up to 1975. 
Corresponding 95% CI are also displayed 
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Figure 4.1~: Drift ~st~mates and corresponding 95% CI of cervical 
adenocarcinoma I~clden~e over the entire study period (in grey) and in the most 
recent 15-year period available (black) in 13 European countries in women aged 
under 75, expressed as the EAPC 
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4.5.3.3 Regular trend 
Figure 4.13 and Table 4.3 present the EAPC in each European country across the whole 
study period, and for the 15 most recent years available , based on the age-drift model. Only 
in France was a mean decline in the recent trend of adenocarcinoma observed , the annual 
change estimated at -1 .1% per year between 1983-97. 
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The mean rates of increase during the most recent 15-year period were rather modest 
(~0.5% per annum) in Denmark, Sweden and Switzerland; they were more SUbstantial in the 
majority of countries studied. Increases ranged from around 1% to 2% in Estonia and Italy, 
through to increases of 2.4% in the U.K and Spain, 2.8% in Finland, 3.4% in Slovakia, and 
4.6% in Slovenia. 
Where the span of data was limited or close to 15 years, recent trends were obviously of 
similar magnitude to the overall trend, although some discrepancies emerged in Northern 
Europe, where longer periods of data were available. In Finland and Estonia, the modest 
overall declines contrasted with recent annual increases. In Norway, Sweden and the U.K., 
the temporal changes were in opposite directions, with a reduction in the rate of increase 
observed during the most recent 15 years. 
4.5.3.4 Cohort trends from the APC models 
Figure 4.12 shows the risk of cervical adenocarcinoma in each country according to age, 
birth cohort and period of diagnosis. The particular representation of the effects indicates 
that there were generation-specific rises in almost all European populations. The increases 
varied by country in terms of both their magnitude and the time at which successive 
generations were first observed to be at increasingly higher risk of developing the disease. 
The starting point of the escalation varied from generations born in the early-1930s through 
to the mid-1940s. The risk of adenocarcinoma was elevated in women born in the mid-
1960s compared to those born in the mid-1940s, although the magnitude of the increase 
varied considerably across countries. Assuming the observed data and model specification 
are correct, Siovenian women born around 1965 had 7-8 times higher risk of 
adenocarcinoma compared to those born two decades earlier. In contrast, in France, the 
relative rate in the later birth period was only about 20% above that in women born around 
1945. 
In Northern Europe (Figure 4.12, panels 1-6), the increases were seen mainly in women 
born after around 1940, although the effect was possibly observed earlier in Norway (early-
1930s), and later in Denmark (around 1950). The largest rise in risk among recent 
generations was seen in Estonia and Finland. A lesser degree of acceleration in risk was 
seen in Sweden than elsewhere in the region. Increases were observed in the Eastern 
European countries represented (Figure 4.12, panels 7-8). 
There were also increases in risk of cervical adenocarcinoma in Southern Europe, although 
the changing rates of unspecified cancer and unspecified carcinoma call for a cautious 
interpretation. Among successive generations of Italian and Spanish women, increases from 
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around 1940 were indicated (Figure 4.12, panels 9-11). In Slovenia, consecutive cohorts 
born from around 1930 were affected, where the risk rose much more rapidly. In Western 
Europe (Figure 4.12, panels 12-13), the cohort trends in Switzerland were rather flat up to 
around 1955, with increasing risk thereafter, although the rates are based on few cases. The 
generation-specific increase among French women (from around 1945) was minor in 
comparison to other European countries. 
4.5.3.5 Period trends from the APC models 
While the assumption of a period slope of zero precluded the possibility to assess the 
magnitude of trends on this time scale, curvature, in the form of accelerations or 
decelerations in period-specific risk, were identifiable, and were noted in some countries. 
Declines in period-specific risk were most evident in the U.K., beginning around 1990 
(Figure 4.12, Panel 6), although a decline in Denmark (Figure 4.12, Panel 1) around the 
same time was also suggested, and in Sweden (Figure 4.12, Panel 5) possibly slightly 
earlier, during the late-1980s. 
4.5.3.6 Consideration of the observed trends 
The age-specific trends in Figure 4.14 indicate a stabilisation or decline in rates in women 
aged over 30 in Denmark, Sweden and the U.K., and these appear more related to period of 
diagnosis than birth cohort. Cohort-specific increases were also observed in women aged 
under 30 in Denmark and the U.K., corresponding to generations born from the mid-1960s 
onwards [377]. In contrast, the observed rates in Swedish women born after 1960 appear to 
consecutively decline, although, as a result of smoothing, the model parameters displayed in 
Figure 4.12 do not exhibit such a trend. 
4.5.4 Discussion of main findings 
This study examined temporal patterns of cervical adenocarcinoma incidence using high 
quality data from population-based cancer registries in 13 European countries. The 
interpretation of the trends is clearly complex in light of a number of plausible factors that 
may explain them. In the next sections, the relative contribution of diagnostic and coding 
artefacts, a changing distribution and prevalence of risk factors, and the impact of cytological 
screening, are assessed. 
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Figure 4.14: Observed trends in adenocarcinoma in 13 European countries for 
women aged 30-64 by region. Left to right: rates versus age by cohort (indices of 
cohorts indicated); rates versus cohort by age (midpoints of age groups 
indicated); rates versus period by age. Rates are on a logarithmic scale 
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4.5.4.1 Are increases due to increasing specificity? 
Rising cervical adenocarcinoma rates could reflect an increasing ability to diagnose the 
disease over time. A recent study from England and Wales apportioned the unspecified 
cases to adenocarcinoma or squamous cell carcinoma according to their relative proportions 
by age and period of diagnosis [189]. This approach was not taken in the present analysis, 
on the grounds that there was insufficient evidence to conclude that age and period-specific 
proportions of unspecified and specified cases were not in some way interrelated. The 
present analysis adhered to this criterion for all 13 countries, with a focus on evaluating 
recent trends. 
Caution in interpretation of cervical adenocarcinoma trends must be exercised, particularly 
where the order of magnitude of both the absolute rates of unspecified cancer/carcinoma 
and their relative rate of increase were large in comparison to those of adenocarcinoma. 
Following the alternative scenario that all unknown cases were truly adenocarcinoma, the 
recent increases in adenocarcinoma rates in Denmark, the Czech Republic, Italy, Slovenia, 
Spain and the U.K. could be explained by an increasing specificity in pathological diagnosis 
of subtype with time. The reallocation approach in a recent England and Wales study [189] 
however, yielded similar results to that of the U.K. as reported in this study, on the basis of 
the unadjusted data. 
An increasing specificity of subtype with time could at least partially explain the 
adenocarcinoma increase in Denmark. An earlier study reported proportional decreases in 
unspecified and unknown type, and increases in adenocarcinoma from the period 1943-47 
through to 1978-82. However, observed increases in adenocarcinoma rates among recent 
cohorts were also reported [378]. 
4.5.4.2 Data and modelling considerations 
The main focus has been on the description of trends by birth cohort and identification of 
deviations by period of diagnosis. To achieve a unique solution from the infinite number 
possible [68], the period slope was constrained to zero, and assumed to reflect the weI/-
documented historical inability to screen for adenocarcinoma. Other solutions, such as fixing 
the age structure, as was done for squamous cell carcinoma (4.4), were considered less 
reasonable for adenocarcinoma. There is little background knowledge regarding the latent 
age curve for adenocarcinoma, while it is possible that error may be introduced should 
segments of the age profile be over- or under-compensated by an age-related 
misc/assification of adenocarcinoma. 
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In some countries the trends are based on relatively few cases and shorter spans of data, 
this reflecting the current availability of cancer registry data of sufficient quality within 
Europe. Clearly the description of the period and cohort-specific trends is open to a more 
unequivocal interpretation for countries where registries have been longstanding and cover 
larger populations, but exdusion only to countries where cancer trends are more well-
documented would remove some of the richness of the findings in this comparison across 
European areas. 
4.5.4.3 Are the increases in risk in recent generations real? 
Recent statistically significant increases in cervical adenocarcinoma rates were observed of 
at least 2% per annum or more in Finland, the U.K., Slovakia and Slovenia. Positive but non-
significant trends of a lesser magnitude were observed in most other countries. That cervical 
adenocarcinoma is rising in recent years in Europe, particularly among young women, has 
been consistently reported in several countries [189,253,357,359,362-366,379]. Study II 
establishes that the increases in incidence in many parts of Europe referred mainly to 
generations born since the epoch 1930-45. The risk in cohorts born in the 1960s relative to 
the 1940s varied seven-fold, from high incidence in Slovenia to low incidence in France, 
where, uniquely, the risk appeared to be reasonably stable among recent generations. 
An international study of time trends of adenocarcinoma incidence 1973-91 [253] described 
increasing risk in cohorts born after the mid-1930 in England, Scotland, Denmark, Sweden, 
Slovenia and Slovakia. The trends reported here replicate these findings, although the data 
used in this study also spanned the 1990s, and found recent increases in Estonia, Spain, 
Finland, and Italy, starting in cohorts born between 1935 and 1945, countries previously 
reported to have either stable or decreasing trends by cohort. The findings for the U.K. are 
replicated by studies in England and Wales reporting generational increases in 
adenocarcinoma [189,366]. The authors found risk to be some 14 times greater in women 
born in the early 1960s relative to those born before 1935. 
Persistent infection with sexually-transmitted high-risk HPV types is established as the 
necessary cause of cervical cancer [310] and its main histological subtypes [311]. The 
widespread increases in cervical adenocarcinoma in Europe among recently-born cohorts 
reported in this study and others [189,253,362,365,366] suggest that an increasing number 
of women are becoming carriers of high-risk HPV types in many European countries. These 
cohorts may be defined by generational changes in sexual behaviour that increase the risk 
of HPV infection, among them younger age at first intercourse, increased number of sexual 
partners, and an increasing risk that each sexual partner is HPV-infected. 
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4.6 General discussion 
4.6.1 Brief summary of main findings 
These studies analysed trends in squamous cell carcinoma and adenocarcinoma of the 
cervix uteri in 13 European countries with high quality incidence data to evaluate the 
effectiveness of screening against a background of changing risk. APe models were fitted, 
and the estimated period and cohort effects were considered as primarily indicative of 
screening interventions and changing aetiology, respectively. 
4.6.1.1 Cervical squamous cell carcinoma 
In study I, a unique set of estimates was derived on fixing age slopes to one of several 
plausible age curves, under the assumption that the relation between age and cervical 
cancer incidence is biologically determined. There were period-specific declines in cervical 
squamous cell carcinoma in several countries, with the largest decrease seen in Northern 
Europe. A pattern of escalating risk in successive generations born after 1930 emerged 
across Europe. In the Western European countries, a decrease followed by a stabilisation of 
risk by cohort was accompanied by period-specific declines. In Southern Europe, stable 
period, but increasing cohort trends, were observed. Substantial changes have occurred in 
cervical squamous cell carcinoma incidence in Europe, and well-organised screening 
programmes have been highly effective in reducing the incidence of cervical squamous cell 
carcinoma. 
The beneficial effects of organised screening programmes can be deduced from the period-
specific decreases in the Nordic countries and in the U.K., which largely confirmed 
previously published results. The corresponding decline in France and Switzerland was 
consistent with the effectiveness of spontaneous screening in those countries. There were, 
however, competing generational increases in cervical squamous cell carcinoma risk in 
younger women in many countries - irrespective of their screening policy - that deserve 
particular attention. Most concerning were the future prospects in countries like Slovenia, 
where there were rapid increases in risk in successive generations of women, and where 
screening programmes are not in place, and hence a notable absence of any intervention-
related declines. 
4.6.1.2 Adenocarcinoma 
In analysing cervical adenocarcinoma trends, it was necessary to take into consideration the 
prospects of increasing specificity of subtype - the capability to diagnose the disease - and 
an inability of cytological screening to reduce cervical adenocarcinoma, against a 
background of anticipated generational increases a result of persistent HPV infection. In 
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study II therefore, APC models were fitted using Holford's method as before, but this time 
assuming a lack of screening effect by fixing the period slope to zero. 
Age-adjusted adenocarcinoma incidence rates increased throughout Europe, the rate of 
increase ranging from around 0.5% per annum in Denmark, Sweden and Switzerland to 3% 
or over in Finland, Slovakia and Slovenia. The increases first affected generations born in 
the early-1930s through to the mid-1940s, with risk invariably higher in women born in the 
mid-1960s relative to those born 20 years earlier. The magnitude of the risk ratios varied 
considerably, from around seven in Slovenia to almost unity in France. Declines in period-
specific risk were observed in the U.K., Denmark and Sweden, primarily among women 
aged over 30. 
While increasing specificity of subtype with time may have been responsible for some of the 
increases in several countries, the changing distribution and prevalence of persistent 
infection with high-risk HPV types, alongside an inability to detect cervical adenocarcinoma 
within screening programmes would accord with the temporal profile observed in Europe. 
Screening may have had at least some impact in reducing cervical adenocarcinoma 
incidence in several countries during the 1990s. 
4.6.2 Comparison of trends in adenocarcinoma and squamous cell carcinoma 
There were necessary differences in the approach to the analyses of squamous cell 
carcinoma and adenocarcinoma, as a result of the existing knowledge that could be brought 
to bear regarding the two histologies. The focus of these studies was a broad description of 
the trends of the two subtypes in Europe, and a limitation was the lack of a quantifiable and 
systematic comparison between subtypes. These themes are taken up and discussed in 
4.6.3.1 and 4.6.3.2. 
Despite this concern, some inference of the respective differences in period and cohort 
trends was possible, and Table 4.6 compares some of the key observations from the above 
stUdies. Clearly, there is tremendous variation in the ratio of squamous cell carcinoma to 
adenocarcinoma rates, and the statistic appears to be a good marker of the extent to which 
cytological screening has been a success in reducing squamous cell carcinoma, with an 
increasing degree of screening success measured by a decreasing magnitude of this ratio. 
Finland, for instance, had a very low ratio as well as a long-standing well-organised 
programme, whereas former Soviet countries had among the highest ratios, partially 
reflecting a combined effect of lesser resources and lack of provision for cytological 
screening. 
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Table 4.6: Comparisons of cervical squamous cell carcinoma and 
adenocarcino~a in 13 European .c~untries: age-adjusted rates (Europe), EAPC 
1983-97 (net drift), and charactenstlcs of period and cohort trends 
scc I AdC I scc AdC 
European Country Period Standardised 
Direction (Year) Direction (Year) 
Area (No. of years)* Rate Ratiot 'I Period trend- I Cohort trend-
! 
I 
Northern Denmark 1978-1998 (21) 4.0 I - (*) - (1990) + (1950) ! + (1945) 
Estonia 1968-2000 (33) 15.9 I 0(*) 0(*) + (1935) . 
I 
+ (1935) . 
" 
Finland 1953-1999 (45) 2.3 - (1967) 0(*) + (1945) + (1945) 
, 
I 
Norway 1953-1997 (45) 4.5 - (1975) 0(*) 0(1945) + (1930) 
Sweden 1960-1998 (39) 3.5 - (*) - (1990) 0(1935) + (-) o (1955) 
United Kingdoma 1974-1997 (24) 3.1 - (1985) - (1990) + (1935) + (1940) 
Eastern Czech Republic 1985-1999 (15) 9.2 0(*) 0(*) 0(1945) + (-) 
Slovakia 1968-1997 (30) 8.5 - (1985) 0(*) + (1935) + (1935) 
Southern ItalY' 1981-1997 (17) 4.5 - (*) 0(*) + (1945) + (1940) 
Slovenia 1983-1999 (17) 4.7 0(*) 0(*) + (1940) + (1940) 
Spainc 1980-1997 (18) 4.8 0(*) 0(*) + (1940) + (1940) 
, 
, 
Western Franced 1978-1997 (20) 5.7 - (*) 0(*) 0(1940) 0(1945) 
Switzerlande 1981-1997 (17) 4.3 - (*) 0(*) 0(1950) 0(1955) 
SCC: squamous cell carcinoma; AdC: adenocarcinoma 
• data available according to period of diagnosis, figure in parentheses represent number of years available in the analysis 
t Ratio of truncated age-standardised rates (European standard) of squamous cell carcinoma vs. adenocarcinoma, women aged 75, 1993-97 
.. estimated direction of recent trends by (+: positive trend 0: relatively stable trend or difficult to interpret). TIme in parentheses is year of birth 
when change in direction of trend first noted (to nearest five years); - denotes change in trends not apparent· denotes no change in trend 
apparent. 
a aggregation of England, Scotland 
b aggregation of Florence, Varese Province, Parma Province, Ragusa Province, Turin 
c aggregation of Catalonia, Tarragona; Granada, Murcia, Navarra, Zaragoza 
d aggregation of Bas-Rhin, Caivados, Doubs, Isere, Somme, Tarn 
e aggregation of Basel, Geneva, Neuchatel, St.GaII-Appenzell, Vaud, Zurich 
4.6.2.1 Comparisons of trends in relation to cytological screening 
The beneficial effects of organised screening programmes on reducing the incidence of 
squamous cell carcinoma may be deduced from the period-specific (non-linear) decreases 
in the Nordic countries and in the U.K. (Table 4.6), which largely confirms previously 
published results. Period-related declines were noted for eight of the same thirteen 
countries, in line with the initiation of organised screening programmes, and in France and 
Switzerland possibly consistent with the effectiveness of spontaneous screening. 
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Possible instances of a period-specific downturn in adenocarcinoma were seen in Denmark 
, 
the U.K. and Sweden, although any such screening effect was recent, during the 1990s. 
Cytological screening may thus have had a protective effect on adenocarcinoma, as 
supported by recent studies in the U.K. and Australia [316,366]. A recent Swedish study 
described a lack of screening effect, citing uniform increases in period-specific risk from 
around 1975 to 1992 [359], although the risk was in fact quite stable from 1983. In England 
and Wales, incidence has been reported to have possibly peaked in the late 1980s in young 
women (aged 25-39) [189,366]. The present analysis is in broad agreement with this finding, 
and would imply some beneficial effects of screening within the last decade, although 
substantial increases in adenocarcinoma were observed in younger women during the same 
period in the present analysis. 
4.6.2.2 Comparisons of trends in relation to risk patterns 
There is some support for the idea of homogeneity across the cohort-specific trends of each 
subtype in Europe. The cohort-specific increases in Italy, Spain, the U.K., Norway, Estonia, 
Slovakia, Finland and Slovenia in adenocarcinoma described in this study, are in 
accordance with the temporal patterns conveyed for squamous cell carcinoma, with risk of 
both subtypes accelerating among consecutive generations born in the 1930s and 1940s. 
The rapid increases in the drift estimates of adenocarcinoma noted in Finland and Slovenia 
in recent years reasonably match those observed for squamous cell carcinoma. The more 
moderate generational increases in adenocarcinoma in the Czech Republic, Sweden and 
Switzerland also largely parallel those of squamous cell carcinoma trends, as does the 
noted absence of an increase in recent generations in France of either subtype. The cohort-
specific trends are however difficult to fully interpret for countries where the span of available 
data is short. 
An increasing capability to correctly assign the histology of cervical cancer cases is unlikely 
to account for the increases in squamous cell carcinoma, which still represent the vast 
majority of cervical malignancies (75% to 90%), and may be excluded in explaining much of 
increasing adenocarcinoma trends in certain countries where the unspecified proportion was 
small relative to adenocarcinoma and/or the unspecified trends were rather stable. That 
European women born in successive generations experienced an increasing risk of both 
major histological forms of cervical cancer within the same time window - during the 1930s 
and 1940s - points to a homogeneity in the risk factors chiefly responsible for the increases, 
presumably linked to changes in sexual activity and risk of HPV infection. 
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4.6.3 Reconsideration of methods and further exploration 
The two papers published in relation to the work described in 4.4 and 4.5 in a peer-reviewed 
journal [377,380] focused on the results from a single set of parameters, the methodologies 
for which were described in 4.4.2.5 and 4.5.2.3, respectively. In circumventing the non-
identifiability problem, the estimates presented were not unique and other parameterisations 
could have been selected. However, a degree of plausibility was ascertained by bringing to 
bear external information for both squamous cell carcinoma and adenocarcinoma; the trends 
may therefore be thought of as broadly representative of the effects of screening and HPV 
infection in these countries. 
The present study used an analytical approach to the description of time trends of 
squamous cell carcinoma and adenocarcinoma to better understand the evolution of cervical 
cancer in Europe, the factors involved, and the prospects for prevention. Holford's approach 
to the problem allowed a qualitative comparison of the differences and similarities of the 
non-linear effects of period and cohort between the two histologies. Beyond the scope of the 
work presented in this chapter, are further studies that attempt to better quantify and 
reinforce some of the observations laid out here. These considerations are briefly discussed 
below. 
4.6.3.1 A more integrated approach 
There is substantial evidence that the two histological subtypes share many risk factors, with 
possible exceptions including smoking and oncogenic infection with certain HPV types. 
Assuming the histological subtypes are biologically equivalent, a more integrated approach 
might involve a joint analysis of squamous cell carcinoma and adenocarcinoma and a more 
elaborate version of the APe model. One possibility would be to collapse the data from the 
two histologies and analyse cervical cancer trends as a whole, fixing the age curves as 
previously in 4.4. A binary variable for histology could be incorporated into the model 
allowing more comparable and quantifiable answers as to whether the histological trends 
differed over time, according to period and birth cohort, and whether the introduction of 
screening changed the temporal profile. 
Ideally, one WOUld, as before, model the age effects of cervical cancer directly, leaving the 
period and cohort parameters free. It is worth noting the variability of the peak age of 
incidence noted for cervical cancer within European countries in pre-screening populations -
ranging from ages 42 to 62. Should the true age curve for cervical adenocarcinoma diverge 
from that of total cervical cancer, the possibility of wrongly attributing the period and cohort 
trends is distinct possibility. 
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A future exercise might involve introducing data on screening practices in Europe (such as 
year of implementation and estimated coverage). By explicitly including such covariates in 
the APC models, further quantification of the screening effects on incidence is possible, as is 
the prediction of the estimated numbers of cases that screening has prevented. This would 
necessarily lead to a modelling approach of further complexity however, and possibly the 
inclusion of unverifiable assumptions given the lack of reliable data regarding screening 
policies in some European countries (see 4.6.3.2). 
4.6.3.2 A more quantitative approach to the impact of screening 
An obvious public health question would be to ask, in each of the 13 countries, how many 
cases of cervical squamous cell carcinoma and adenocarcinoma has screening prevented, 
and how many will be prevented in the future. Several recent reports using data from 
England and Wales have attempted such a quantification [189,349,366]. In estimating the 
number of cases prevented in the past, one must specify an appropriate model; the age-
cohort model for instance might seem like an obvious choice for adenocarcinoma, yet Table 
4.3 indicated the terms in the models varied by country. The lack of complexity in the models 
for some countries indicates the presence of a form of non-identifiability - an inability to 
reject simpler models due to low power [381]. 
In addition, information on the historical screening processes in each country and their 
effectiveness would need to be ascertained. However - as already established [308] - it is 
problematic to determine precise data on organised screening practices. There is also a lack 
of knowledge of the amount of opportunistic screening in Europe [308]. In estimating that 
100,000 of the eight million British women born between 1951 and 1970 will be saved from 
premature death by the cervical screening programme, Peto and colleagues [349] assumed 
that opportunistic screening already accounted for 40% of the prevented deaths in England 
and Wales, before the successful call-recall system was implemented. It would be difficult to 
estimate the level with any degree of certainty for most of the countries studied, where 
rather little is known (or could be reasonably guessed) regarding its impact. The analyses in 
this chapter would imply that screening in France and Switzerland has been mainly 
opportunistic, although data on the extent of this practice are not available. Efforts to make 
future predictions would also require some assumptions on the future levels of screening 
[366]. 
4.6.3.3 Trends in HPV 
There are few studies reporting trends in HPV incidence or prevalence either overall or by 
subtype, and these have been cross-sectional in nature. Increases in the incidence and 
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seroprevalence of HPV-16 have been reported in Finland in women aged in their twenties 
[382], while in Sweden, the main increases in HPV-16 during the period 1969-89 occurred 
during the 1970s and early-1980s, in women aged under 35 [383]. It has been suggested 
that the lifetime number of sexual partners is the strongest marker for oncogenic HPV 
infection, whereas a history of condyloma is associated more with acquiring benign HPV 
types [384]. It may be of utility from a public health perspective to collect the relevant data 
and examine the prevalence and distribution of HPV and its markers in birth cohorts as a , 
means to better understand behavioural aspects that place women at a higher average risk 
of cervical cancer in certain countries relative to others. 
4.6.3.4 Influence of unspecified groups on histological trends 
The trend analyses did not take explicit account of unspecified carcinomas and cancers, 
while other analyses have reallocated this group to known proportions of histological 
subtype [189]. A comparison of the two approaches is warranted and an appraisal of the 
degree to which the trends in the unspecified group are gradual, possibly impacting on the 
period slope, undetected by the APe model. This might require exdusion to countries with 
long series of the highest quality data, such as is available in the Nordic countries. 
4.6.3.5 Comparison of incidence and mortality trends 
Given that there is an algorithm for reallocating the rubric "site unspecified" to deaths from 
either cancers of the cervix uteri or corpus uteri [312], it would be interesting to compare 
incidence and mortality trends, particularly in reference to the possible differential effects of 
screening in describing prevention or avoidance of death. Knowledge regarding the known 
improvements in treatment, both in the distant past and more recently, could help elucidate 
any observed differences in the secular trends. 
4.6.4 Future prospects for prevention 
Screening, together with changing sexual mores, largely explain the respective changes in 
period- and cohort-specific patterns in cervical squamous cell carcinoma in the European 
countries studied. The increasing risk among more recent cohorts is of obvious concern, 
particularly in countries where no screening programmes are currently in place. For cervical 
adenocarcinoma, the effects of screening, although part-enforced by the model 
specification, appeared negligible in most countries, although a downturn was observed in 
several of them where national programmes were in operation during the 1990s. This 
provides at least some confirmatory evidence that cytological screening is detecting more 
pre-invasive adenocarcinomas than in previous decades. Opportunistic screening dearly 
plays a role, but an undefined one in terms of its effectiveness. 
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The homogeneity of trends in adenocarcinoma and squamous cell carcinoma by birth cohort 
is consistent with the notion that they share a similar aetiology irrespective of the differential 
capability of screen detection. The increasing risk in successive generations of subtypes 
suggests the major driver is an increasing prevalence of persistent oncogenic HPV infection, 
and possibly, its cofactors. The observation of differing risk patterns in young cohorts in 
countries with relatively similar societal structures (the Czech Republic and Slovakia) is an 
interesting finding deserving further research. 
HPV screening for high risk HPV types - probably in combination with cytological screening 
- may maximise the possibilities of having early lesions detected and treated. Recent trials 
evaluating the efficacy of virus-like-particle vaccines in prevention of persistent infection with 
HPV types 16 and 18 in young women have been shown to be highly efficacious [385,386]. 
There is therefore some expectation that cervical cancer generally, and adenocarcinoma of 
the cervix in particular, may be preventable by HPV vaccination. Cytological screening will 
continue to play an essential role in preventing occurrences of, and deaths, from cervical 
cancer in the decades to come. There are many lower-resource countries with high rates, 
notably in Eastern Europe, where there is an unequivocal need for preventative action. 
Reaching currently unscreened groups, which are concentrated essentially in lower 
socioeconomic categories, is also an important task. 
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5 Analyses of temporal trends in endometrial cancer in Europe 
5.1 Introduction to the chapter 
This chapter aims to describe and evaluate time trends of endometrial cancer incidence and 
mortality in Europe, with an emphasis on explication of the factors responsible for the 
incidence trends with the aid of APC models. To achieve these objectives, the analysis 
involves the same high quality cancer registry data series available in the 13 European 
countries used in Chapter 4. 
The incidence and mortality observations analysed in this chapter strictly comprise cancers 
of the corpus uteri. In the follOwing text it is used interchangeably with the term "endometrial 
cancer", a longstanding practice [387] given the vast majority of cancers of the uterine 
corpus are adenocarcinomas arising from the endometrium, the epithelial cells that line the 
uterus. 
5.1.1 Why analyse trends in endometrial cancer incidence? 
Rapid increases in incidence of endometrial cancer amongst postmenopausal women 
reported in the U.S. in the early to mid-1970s [387-390] brought the substantial risk 
conferred by HRT via the intake of oestrogen to progesterone to the attention of the medical 
and scientific community, and to the public at large. No such extreme rise occurred in 
Europe at that time or thereafter. Instead, steady increases were observed in many 
countries. Some of the highest incidence rates of endometrial cancer worldwide are found in 
Europe [18], and rates vary only by a factor of two between countries [323]. 
The disease mechanisms and risk factors for endometrial cancer are more established than 
for other cancers, and surveillance of incidence trends effectively monitors the changing 
profile of the established risk determinants. Endometrial cancer has a multifactorial aetiology 
however, and one that differs according to menopausal status leaving assessment of the 
impact of specific risk factors a complicated task. In this regard, comparisons of trends 
across European populations, potentially heterogeneous with respect to the prevalence and 
distribution of certain factors that may be responsible for the neoplasm, may shed light on 
the particular components that drive trends in certain countries. 
The disease occurs predominantly after the menopause. In premenopausal women, 
endometrial cancer is relatively rare, and where data on incidence are available, observed 
trends are mainly decreasing [312]. COC provide long-lasting protection [391], as do several 
reproductive factors including high parity and a late age at first birth. In postmenopausal 
women, intake of postmenopausal oestrogens without the protective effect of progestins 
increases risk. High serum levels of endogenous oestrogens, menstrual history (early 
203 
menarche, late menopause, anovulation), nulliparity, early age at last birth, and obesity 
[392-394] may increase risk. An estimated 39% of all cases in the European Union was 
attributable to excess body weight in 1995 [395]. Smoking has been consistently reported to 
confer a decreased risk of endometrial cancer in postmenopausal women [396]. 
5.1.2 Why analyse trends in endometrial cancer mortality? 
The prevalence of endogenous hormone use in a particular country, both in terms of COC 
and HRT, is dependant on its availability, and as such, has a very different profile across 
populations, with prevalence high only in several richer countries. Mortality is an important 
indicator in establishing the contrasting risk profile of endometrial cancer in Eastern Europe 
- where long series of incidence data are unavailable in most countries. In several Eastern 
countries, five-year relative survival has been estimated to be 10-15% lower than the 78% 
European average [397]. 
As well as problems associated with using mortality as a surrogate of incidence, there are 
major problems interpreting endometrial cancer trends as a result of substantial variations in 
the accuracy of death certificates in specifying cancer of the uterus [312]. Many deaths are 
recorded as uterine cancer unspecified, rather than attributed to either cervical or corpus 
uteri cancer. A somewhat unsatisfactory practice in analysing cervix and endometrial cancer 
mortality trends involves restricting analyses to trends in subgroups considered largely 
unaffected by the problem e.g. cervical cancer in premenopausal women (few endometrial 
cancer cases) and a combination of cervix and corpus uteri trends in postmenopausal ages. 
The alternative is an aSSignment of unspecified deaths to the main sites; a recent algorithm 
was therefore used that reallocates unspecified uterine cancer deaths to cervix uteri and 
corpus uteri [312], enabling a comparison of cross-sectional trends across Europe in pre-
and postmenopausal women. 
5.1.3 Main objectives of the trends analyses 
The objectives are twofold. The first involves putting together a comprehensive synthesis of 
the major geographical and temporal variations in endometrial cancer incidence and 
mortality, with an emphasis on determining the variations in the rates of change in the age-
adjusted secular trends in pre- (aged 25-49 years) and postmenopausal (aged 50-74 years) 
women. The results are described in light of both established and postulated risk factors for 
endometrial cancer. The second aim is to examine in more detail the age-specific incidence 
trends of endometrial cancer across European countries with high quality cancer registry 
data and sufficient time series, with a view to a comparative description and interpretation of 
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the contribution of period and birth cohort effects and their relation to the risk determinants 
that drive the trends. 
5.2 Review of endometrial cancer epidemiology 
5.2.1 Descriptive epidemiology 
In 2002, almost 200,000 endometrial cancers were diagnosed worldwide [263]. The disease 
occurs mainly in Western countries, with rates high in Northern America, Europe (particularly 
Northern and Eastern Europe) and Oceania, intermediate in Southern and Central America 
, 
and predominantly low in Africa and Asia. About two-fifths of the worldwide burden of 
endometrial cancer occurs in Europe, representing one in every 18 new female cancers and 
ranking as the fourth most common neoplasm in women after breast, ovarian and colon 
cancer, and ranking above cervical and lung cancer [263]. Incidence rates are high to 
intermediate relative to other world regions, differing twofold amongst European populations 
[323]. Prognosis is relatively good - relative survival at five years in European areas covered 
by registries is between 63% and 78%, with the poorer survival estimates observed in 
several Eastern European areas [397]. The 18,000 deaths estimated in Europe per annum 
is comparatively low, ranking as the tenth most common cause of cancer death in women. 
Variations in mortality in Europe reflect both cancer incidence and survival, with variations 
between European countries suggested as a result of disparities in patient management 
[398]. Trends in survival suggesting improvements in prognosis are generally restricted to 
women over 65 [138]. 
5.2.2 Aetiology 
The epidemiology of endometrial cancer in Western countries is fairly well understood. 
Family history of endometrial cancer is associated with an increase in risk [392], while high 
parity and late age at last birth is considered to confer long-lasting protection [392]. The role 
of obesity as a risk factor in both pre- and postmenopausal women is also firmly established 
[394] and there is additional evidence - albeit limited - that physical activity has a protective 
effect [394]. 
Use of COC confers a long-lasting protection against endometrial cancer, particularly among 
long-term users [391]. HRT is an important risk factor in countries where their prescription 
has been common practice in recent decades [392]. Risk increases markedly with use of 
oestrogen-only and sequential oestrogen-progestin HRT, although it may be mitigated by 
the continuous addition of progestins [399,400]. There is also substantive evidence that 
smoking is protective [396]. The risk factors involved are discussed in more depth later in 
this chapter in relation to interpreting the results (5.4.4 and 5.5.4). 
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5.3 Review of temporal studies of endometrial cancer in Europe 
Temporal patterns of endometrial cancer came to widespread attention following the rapid 
rise in incidence amongst postmenopausal women in the U.S. in the early 1970s [387]. The 
observation of a concomitant increase in the prescription of HRT led to the hypothesis that 
high levels of oestrogens unopposed by progestins predisposed women to an elevated risk 
of endometrial cancer [399]. The subsequent prohibition of HRT with oestrogens in the U.S. 
led to prompt declines in endometrial cancer rates [401]. That the downwards trends 
continued throughout the 1980s despite an increasing HRT prescription rate in the 1980s is 
explained by the reductive or protective effect of a reduced dose of oestrogen in 
combination with added progesterone [402,403]. 
The profoundly steep rise seen in endometrial cancer was not a feature of temporal patterns 
in Europe. Instead, incidence trends in many European populations increased for several 
decades up to the early 1980s [8,404,405], with subsequent declines reported in several 
countries [152,406-409]. Widespread use of combined oestrogen-progesterone HRT from 
the 1970s onwards, together with the widespread use of combined oestrogen-progestin 
contraceptives introduced during the 1960s - which markedly reduce a women's corpus 
uteri cancer risk - have been suggested as important factors responsible for the favourable 
trends. Mortality rates have generally been shown to be decreasing with time in most 
European populations [8,405]. 
Although a number of reports have emerged from the U.S. [387,390,410,411], there have 
been relatively few such studies examining trends of endometrial cancer in European 
populations. Where they have been studied, incidence has been reported to have been 
increasing for several decades up to the early 1980s [8,404,405], while subsequently some 
declines have been reported in East Germany [408], Sweden [406], Switzerland [409] and 
England and Wales [152,407]. 
5.4 Study I: joinpoint trends in endometrial cancer in Europe 
This section describes the geographical and temporal variations in endometrial cancer 
incidence and mortality, with an emphasis on determining the variations in the rates of 
change in the age-adjusted secular trends in pre- (aged 25-49 years) and postmenopausal 
(aged 50-74 years) women via the joinpoint regression model [183]. The results are 
described in light of both established and postulated risk factors for endometrial cancer and 
their assumed prevalence and distribution in Europe. A version of this section has been 
recently published in a peer-reviewed journal [412]. 
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5.4.1 Data sources and data quality 
5.4.1.1 Incidence 
The incidence and population datasets were extracted from the EUROCIM [160] (see 2.8 for 
details and standard inclusion criteria). Table 5.1 provides details of the cancer registries 
used in this analysis. The time-span of observations in the final dataset varied from 11 to 47 
years. Incidence data pre-1960 were not considered. The analysis was restricted to the five-
year age groups comprising the age range 25-74. 
5.4.1.2 Mortality 
Mortality data coded as cancer of the cervix uteri (ICD-9 180), corpus uteri (ICD-9 182), and 
uterine cancer unspecified (ICD9 179) was extracted from the WHO mortality database (see 
2.8 for details and standard inclusion criteria). There are large variations in the accuracy of 
death certificates specifying cancer of the uterus in Europe [312], with many deaths 
recorded as uterine cancer unspecified, rather than attributed to either cervical or corpus 
uteri cancer. For some countries, the proportion is over 50% of all uterine cancer deaths, 
although there is a tendency for the proportion to decrease with calendar time [312]. 
Therefore, an algorithm proposed by Loos et al [312] was implemented that reallocates 
unspecified uterine cancer deaths to the two primary sites on the basis of age- and time-
specific distributions of cervix and corpus uteri cancer from representative populations with 
consistently high quality data. Further, the method reassigns deaths that were combined at 
the 3-digit level in ICD-8 to their original coding as corpus uteri or unspecified, allOwing 
credible time trends for corpus uteri cancer in postmenopausal women, previously 
unavailable for a number of countries [312]. The time-span of observations in the final 
dataset varied from 16 to 34 years (Table 5.2). Only mortality data from 1969 onwards were 
considered, as there was a lack of consistent data in many countries in prior years 
corresponding to the ICD-7 revision. 
5.4.1.3 Data quality 
5.4.1.3.1 Changing proportions of uterus otherwise unspecified 
There is substantial misclassification of cancer of the corpus uteri as site unspecified in 
some countries, and the reallocation procedure attempted to estimate the true rates of 
endometrial cancer by country, age and time period [312]. The algorithm dealt not only with 
problems of varying coding precision over time, but also with the combined category of 
corpus uteri and unspecified, when the data were not reported at a sufficient level of detail, 
as was common in a number of Eastern European countries. Unspecified deaths were 
reallocated on a country-specific basis, according to proportions of cervix or corpus uteri 
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from well-matching reference populations associated with high and long-term precision of 
coding. The method indicated that many of the large differences were a consequence of 
data incompleteness and could be corrected by applying the reallocation. The procedure 
was considered generally valid, at least in terms of the plausibility of the reallocated 
temporal patterns compared to those observed within populations similar in terms of socio-
economic structure and screening policies [312]. 
5.4.1.3.2 Changing rates of hysterectomy 
The prevalence of hysterectomy in the European countries must be considered in 
interpreting the geographical and temporal patterns of endometrial cancer. There are known 
to be some variations in hysterectomy rates in European populations over time [368,413]. In 
Finland for instance, the age-adjusted prevalence of hysterectomy increased from about 
13% in the late 1980s to over 20% a decade later [368]. While a number of methods have 
been proposed for correcting incidence and mortality rates of uterine cancer [368,414,415], 
hysterectomy data were not available at a sufficient level of detail to adequately present 
adjusted rates in most of these countries. A special survey has been called for to adequately 
address this issue [130]. 
The denominators in this study are thus unadjusted person-years at risk - based on the 
country and age-specific population data for all women - rather than just those with their 
uteruses intact. A lack of adjustment has the potential to seriously bias the direction and 
magnitudes of these estimates, particularly among older women. It is possible, for example, 
that the apparent levelling off of rates or even declines - seen in incidence trends in recent 
years among postmenopausal women in several Northern and Western countries - is an 
artefact of increasing population prevalence of hysterectomy [130]. Caution is also urged in 
interpreting recent mortality trends demonstrating these characteristics [130]. 
208 
Table 5.1: Endometrial cancer incidence: populations and recent stable trend in pre- and postmenopausal women 
Ages 25-49 Aaes 50-74 
European Country Period available Incident Person- Stable Stable trend Incident Person- Stable Stable trend 
Area (year span) cases . yearst period' 95%CI'II cases . yearst period' 95% CI' 
Northern Denmark 1978 - 1998 (21} 33 953,576 1978 -1998 -1.9 [-3.1, -0.7] 381 708,540 1978 - 1998 -1.1 [-1.6, -0.6] 
Estonia 1968 - 2000 (33) 16 246,027 1968 - 2000 +0.41-0.4, +1.2] 134 218,207 1968 - 2000 +1.1 [+0.8, +1.4] 
Finland 1953 - 1999 (47) 57 900,917 1953 - 1999 -0.4 [-1.1, -0.4] 470 733,776 1953 - 1999 +1.5 [+1.4, +1.Zl 
Iceland 1955 - 2000 (40) 6 47,417 1955 - 2000 -1.3 [-3.0, +0.3] 18 28,402 1955 - 2000 +1.1 [+0.2, +2.0] 
Norway 1953 - 1997 (451 52 789,483 1979 - 1997 -0.7[-2.1, +0.71 304 525,730 1978 - 2000 +2.2 [+1.8, +2.6] 
Sweden 1960 - 1998 (39) 43 1,488,299 1972 - 1998 -4.3 [-4.8, -3.8] 870 1,196,116 1985 - 1998 +1.7 [+1.1, +2.2] 
United KingdomS 1974 - 1997 (24) 317 9,885,453 1974 - 1997 -1.2 [-1.6, -0.9] 2964 6,944,200 1992 - 1997 +2.5 [+1.5, +3.51 
Eastern Czech Rep_ublic 1985 - 1999 (15) 139 1,819,411 1985 - 1999 -1.8 [-2.5, -1.0] 1152 1,459,422 1985 - 1999 +0.8[+0.2, +1.41 
Polando 1986 - 1996 (11) 72 1,018,194 1986 - 1996 -3.5 [-6.7, -0.1] 440 730,002 1986 - 1996 +3.4 [+1.0, +5.8] 
Slovakia 1968 - 1997 (30) 77 973,987 1992 -1997 -6.6 [-14.5, +2.2] 470 630,722 1973 - 1997 +1.8 [+1.5, +2.21 
Southern Ital~ 1981 -1997 (17) 56 766,773 1981 - 1997 -2.6 [-5.5, +0.41 406 753,060 1981 - 1997 -0.8 [-1.5, -0.01 
Slovenia 1983 - 1999 (17) 28 384,589 
- - 191 277,887 1983 - 1999 +2.1 [+1.3, +2.8] 
Spaino 1980 - 1997 (18) 39 659,032 1980 -1997 +0.2 [-2.0, +2.5] 285 504,290 1988 - 1997 +2.5 [+0.6, +4.5] 
Western Frances 1978 - 1997 (20) 52 741,584 1978 - 1997 -1.9 [-3.4, -0.5] 262 501,845 1978 - 1997 -0.3 [-1.0, +0.31 
Germany, Saarland 1970 - 1997 (28) 16 210,559 1970 - 1997 -2.2 [-4.2, -0.2] 116 166,488 1970 - 1997 -0.0 [-0.4, +0.4] 
Switzerland' 1981 - 1997 (17) 39 551,868 1981 - 1997 -1.6 [-3.8, +0.6] 276 451,643 1981 - 1997 -0.8 [-2.0, +0.4] 
The Netherlandsg 1986 -1997 (12) 18 329,731 1989 - 1997 -2.6 [-9.8, +5.3] 153 __ 242,837 ~6-1997 _ +0.8 [-0.3, +1.9L 
---
• number of new cases In latest year available. 
t person-years at risk (unadjusted for hysterectomy) In latest year available. 
11 EAPC based on jolnpolnt regression for the most recent period available for which authors consider the trends representative of the observed patterns; - denotes regression not possible due to sparse data, or fitted 
trends unstable. 
a aggregation of England, Scotland 
b aggregation of Cracow City, Lower Sliesla, Warsaw City 
c aggregation of Florence, Varese Province, Parma Province, Ragusa Province, Turin 
d aggregation of Tarragona; Granada, Murcia, Navarra, Zaragoza 
e aggregation of Bas-Rhln, Calvados, Doubs, Isere, Somme, Tarn 
f aggregation of Basel, Geneva, Neuchatel, St.Gall-Appenzell, Vaud, Zurich 
g aggregation of Eindhoven, Maastricht (IKL) 
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Table 5.2: Endometrial cancer mortality: populations and recent stable trend in pre- and postmenopausal women 
~ 
Ages 25-49 Ages 50-74 
European Country Period Deaths' Person- Stable period Stable trend Deaths' Person- Stable period Stable trend 
Area available yearst 95%CI' yearst 95% CI' 
(year span) 
Northern Denmark 1969 - 1999 i311 1 952,442 -1.9 [-4.5, +0.8] 1969 - 1999 67 716,716 1969 -1999 -1.2 [-1.7, -011 
Estonia 1981 - 2002 (20) 0 242,650 27 217,763 1993 - 2002 -3.9J-8.1, +0.6] 
Finland 1969 - 2002 (34) 1 880,973 -2.2 [-4.3, -0.1] 1969- 2002 62 763,982 1982 - 2002 -0.5 [-1.5, +0.6] 
Iceland 1969 - 2002 (34) 0 49,868 - - 5 27,706 - -
Ireland 1969 - 1999 (31) 4 669,300 -5.1 [-7.5, -2.5] 1969-1999 26 396,700 1969 -1999 -2.8 [-3.2, -2.3] 
Latvia 1969 - 2000 (32) 5 419,877 - - 81 378,502 1969 - 2000 +1.3 [+004, +2.1] 
Lithuania 1980 - 2002 (23) 4 633,978 - - 83 506,944 1980 - 1995 +0.1 [-1.1, +104] 
Norway 1981 - 2002 (20) 0 802,936 -0.7 [-3.2, +1.9] 1981 - 2002 63 547,974 1981 - 2002 -0.9 [-1.3, -004] 
Sweden 1969 - 2001 (33) 2 1,481,243 -2.7 [-6.0, +0.6] 1969- 2001 132 1,233,237 1987 - 2001 +0.7 [-004, +1.9] 
United Kingdom 1969 - 1999 (31) 25 10,639,800 -8.5 [-11.8, -5.1] 1985 - 1997 531 7,705,000 1969 - 1991 -1.7 [-2.2, -1.41 
Eastern Belarus 1981 - 2001 (19) 0 1,889,143 - - 262 1,419,621 1988 - 2001 +0.6 [-0.5, +1.8] 
Bulgaria 1970 - 2002 (33) 26 1,369,374 -2.7 [-704, +2.3] 1990 - 2002 162 1,263,327 1987 - 2002 -2.6 [-3.8, -1.3] 
Czech Republic 1986 - 2001 (16) 13 1,829,141 -0.3 [-4.2, +3.8] 1986- 2001 200 1,491,580 1986 - 2001 -2.0 [-2.8, -1.2] 
Hungary 1970 - 2002 (33) 14 1,831,979 -0.8 [-2.6, +1.1] 1982 - 2002 201 1,572,680 1970 - 2002 -1.6 [-1.9LJAL 
Poland 1970 - 1996 {27} 0 7,062,100 - - 678 4,581,800 1986 -1996 -1.81-2.5, -1.2] 
Republic of Moldova 1981 - 2002 (20) 13 675,023 - - 67 419,828 1981 - 2002 +1.7 [+0.2, +3.3] 
Romania 1970 - 2002 (32) 31 3,946,395 - - 246 3,031,621 1996 - 2002 -8.9 [-12.9, -4.8] 
Russia 1980 - 2002 (23) 0 27,471,229 - - 1880 20,655,545 1980 - 2000 +1.2 [+0.8, +1.5] 
Ukraine 1981 - 2000 (181 0 9,096,800 - - 1409 7,585,900 1992 - 2000 -0.6 [-1.9,+ 0.7] 
Southern Croatia 1972 - 2000 (29) 0 788,900 - - 74 684,700 1972 - 2000 -0.8 [-204, +0.9] 
Greece 1969 - 1990 (22) 4 1,887,781 -4.5 [-6.6, -2.3] 1969 - 1990 102 1,542,838 1969 - 1990 -1.3 [-1.9, -0.8] 
Italy 1972 - 2002 (31) 36 10,709,440 -4.2 [-5.3, -3.1] 1972 - 2002 777 8,738,869 1978 - 2002 -3.4 [-3.9, -2.9] 
Malta 1972 -1997 ~ 0 68,105 - - 7 ___ 54,~34 1982 - 1997 -2.6 [-6.7, __ :1"1.8] 
- - -- ----
Portugal 1972 - 1999 (28) 7 1,887,831 -3.5 [-7.1, +0.2] 1972 - 1999 128 1,440,858 1983 - 1999 -1.5 [-2.4, -0.6] 
.... 
Slovenia 1983 - 2001 (191 5 373,909 - - 36 282,585 1983 - 2001 -1.3 [-2.8, +0.3] 
Spain 1972 - 2002 (31) 16 7,559,046 -4.3l-5.4, -3.2] 1972 - 2002 492 5,391,336 1972 - 2002 -2.01 [-2.3, -111. 
-
Western Austria 1985 - 2002 (181 1 1,519,671 -4.4 [-6.0, -2.7] 1985 - 2002 102 1,095,677 1985 - 2002 -2.2 [-2.5, -1.8] 
- -. 
Belgium 1972 - 1999 (28) 5 1,864,973 -4.0 [-5.7, -2.2] 1972 - 1999 123 1,382,174 1982 -1989 -7.1 [-12.5, -1.41, 
France 1972 - 2000 (29) 26 10,698,229 -4.2 [-5.1, -3.4] 1972 - 2000 735 7,574,869 1972 -1992 -2.3 [-2.8, -1.8] 
--
Germany 1972 - 2002 (31) 37 15,083,039 - - 830 12,107,443 1991 - 2002 -2.6 [-3.8, -1.31 
Luxembourg 1972 - 2000 (29) 0 87,264 - - 1 55,207 - -
Switzerland 1985 - 2002 (18) 0 1,365,126 -5.5 [-9.0, -2.0] 1985 - 2002 73 969,158 1985 - 2002 -3.2 [-3.6, -2.8] 
The Netherlands 1969 - 2001 (33) 14 3,026,925 -3.1 [-4.7, -1.4] 1969- 2001 151 2,016,626 1969 - 2001 -2.0 [-204, -1.5] 
• number of deaths in latest year available. 
t person-years at risk (unadjusted for hysterectomy) in latest year available. 
11 EAPC based on join point regression for the most recent period available for which authors consider the trends representative of the observed patterns. - denotes regression not possible due to 
sparse data, or fitted trends unstable. 
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5.4.2 Methods: joinpoint regression 
Annual truncated age-standardised rates (TASR) of corpus uteri cancer incidence and 
mortality were calculated for women aged 25-49 and 50-74 years (hereafter pre- and 
postmenopausal are respective synonyms) using the World standard population [168]. The 
mean TASR during the period 1997-99 - or the latest three-year period if not available _ 
was calculated to provide a synopsis of geographical variations by European country. 
To present secular trends in pre- and postmenopausal women by calendar period, 
regression models [183] were fitted to the TASR for the available data in the two age groups 
by country, using the Joinpoint software package (Version 2.6) [184]. A logarithmic 
transformation of the rates and equal variance for each year were specified as options within 
the program. A maximum number of three joinpoints was specified, leading to the 
prerequisite minimum of 11 years of data required to achieve meaningful model fits. The 
program thus searched for changes in the linear trends of incidence and mortality based on 
regression models with 0, 1, 2 and 3 joinpoints, with the final model selecting the most 
parsimonious of these. Joinpoint regression can be seen as a descriptive tool for identifying 
sudden changes in the long-term trend in epochs of time, or "segments", for which rates are 
relatively stable, avoiding the need to arbitrarily select a base for estimating the direction 
and magnitude of the slope. 
The observed age-truncated rates and the fitted trends between joinpoints are shown 
graphically by country within European area. The rates are plotted on a log-transformed 2-
cycle ordinate (e.g. with a y-scale of 1 to 100), and on an abscissa covering a 40-year span 
(1960-2000), with a Y:X ratio scaled to be approximately 2:1. Presented with these 
properties, a slope of 10 degrees portrays a 1% change in the rate per annum, a rule 
proposed by Devesa et al [165] to aid visual inspection. 
The EAPC is summarised in tabular form as the best description of the most recent (and 
stable) trend by country and age group. Using the formula IOOx(exp(b)-I), b is the 
parameter estimate of the trend for the most recent segment, or for the whole available 
period, where no joinpoints were found. 
As has been recently commented [416], the estimated trend via joinpoint regression can be 
unduly influenced by the last datapoints, and additionally, some arbitrary fitted slopes can be 
anticipated for populations where large random variation is present, most notably in mortality 
trends, and trends in women aged 25-49. In presenting this data, each of the fitted trends 
from the joinpoint models was preserved in the graphical presentation, but the tabular 
display of the EAPC was limited to recent trends and those considered to provide a 
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reasonable description of the observed data. The associated 95% CI provides a gauge of 
the adequacy of the final model and the degree of random variation inherent in the observed 
rates. 
5.4.3 Results: description of trends 
5.4.3.1 Geographical variations 
There were clear variations in incidence and mortality rates, and rates among pre- and 
postmenopausal women in Europe (Figure 5.1). Endometrial cancer incidence was at least 
10 times more common in older women than in younger women in most study populations, 
with even more pronounced age ratios for mortality of up to 30-fold. Mortality rates tended to 
be four to six times lower than incidence in postmenopausal women, although more striking 
contrasts were seen in the younger women. 
Incidence rates varied threefold in premenopausal and twofold in postmenopausal women 
among the countries studied. Some consistent patterns emerged across age groups, for 
example the high rates observed in the Czech Republic and Slovakia among both pre- and 
postmenopausal women. Additionally to these countries, rates amongst women aged over 
50 were elevated in Sweden and Slovenia, but were low in France and the U.K., with the 
latter country also having the lowest incidence rate of corpus uteri cancer in premenopausal 
women. 
As with incidence, endometrial cancer mortality rates ranged approximately twofold in 
postmenopausal women. Rates varied more considerably in premenopausal women, and 
were highest in some Eastern European countries, although these estimates are based on 
small numbers in most populations. Certainly, the ranking of mortality rates among 
postmenopausal women conveys a profile more related to European area of residence than 
was seen for incidence: mortality rates were systematically higher in Eastern Europe, with 
rates in Ukraine, Latvia, Czech Republic, Russia, Belarus two to three times those seen in 
postmenopausal women in most Western European countries, where rates were generally 
low. As with incidence, very low death rates were observed in the U.K. in both age groups. 
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Figure 5.1: Truncated age-standardised endometrial cancer incidence and 
mortality rates (Europe) for the period 1997-99, in age groups 25-49 and 50-74, 
sorted by country and age. 
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5.4.3.2 Temporal variations 
Figure 5.2 describes the observed incidence and mortality rates by menopausal status for 
each country by European region, together with the corresponding linear slopes calculated 
between the joinpoints obtained from the regression analyses. Due to the coding system 
employed historically, data were unavailable in some countries for women aged under 50 
either for the whole, or a selected period. Tables 5.1 and 5.2 present the EAPC and 
corresponding 95%CI for the most recent incidence and mortality trend obtained from the 
regression, where they provided a reasonable description of the observed data. 
The majority of the trends required zero joinpoints, an indication of the slow rather linear 
changes in rates of endometrial cancer observed in European populations in the last few 
decades. Both incidence and mortality rates in premenopausal women have been uniformly 
decreasing throughout Europe. Incidence rates in this age group tended to decline by 2-4% 
per annum on average in most countries. Where sufficient numbers were available, 
corresponding falls in mortality were often more marked. The reduction in mortality in young 
women was most evident in several Western and Southern European countries, where 
decreases of 3-5% per year since the 1970s were observed. 
Secular trends in postmenopausal women were rather heterogeneous between and within 
European areas (Figure 5.2). Trends in incidence in Northern Europe (e.g. the Nordic 
countries and the U.K.) were systematically increasing annually at around 1 % to 2% on 
average, with the exception of Denmark, where a significant decline of 1 % since 1978 was 
estimated (Table 5.1), and for which the decrease was particularly evident in the 1990s. 
Some increases were also seen; in Eastern Europe, particularly Slovakia, and in Spain and 
Slovenia in the South. In Italy, rates remained stable in recent years, and a non-significant 
decrease was indicated since the 1980s. Similar plateaus or modest declines in rates were 
seen in Western Europe (France, Germany, Switzerland and the Netherlands). 
Despite the increases in incidence in women of menopausal age, in general, decreasing 
trends in mortality were seen in most countries. Although there was some variability in the 
extent of the decline, the mean reduction per annum in most European countries ranged 
from 1-2% per year (Table 5.2). In Bulgaria, Poland and Romania, the declines were 
observed somewhat later (from the mid-1980s onwards) than elsewhere, although in 
Hungary, there was a uniform annual mean decline of 1.6% since 1970. In contrast, rates in 
Belarus and Russia were relatively stable or increasing in recent years. The exception in 
Northern Europe was Sweden, where a non-significant increase in death rates was 
estimated among postmenopausal women diagnosed since around 1987. 
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Figure 5.2: Trends in age-adjusted rates (Europe) of endometrial cancer incidence 
(open symbols) and mortality (closed symbols) in ages 25-49 (triangles) and 50-74 
(circles) by country within region. Solid and dashed lines are the fitted trends 
based on joinpoint regression of ages 25-49 and 50-74, respectively. 
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5.4.4 Discussion of main findings 
This study has summarised endometrial cancer incidence and mortality rates in European 
populations by country, age group, and within country, over time. Incidence was 10 times 
higher, and mortality 10-30 times higher, amongst postmenopausal relative to 
premenopausal women. Incidence rates were relatively high across Europe, and levels 
corresponded to those seen in North America and Australia [17]. Mortality, while ranking 
much lower as a cause of cancer death than incidence, was higher in Eastern Europe, 
indicative of some disparity in early diagnosis and treatment of patients between regions, 
reflected in the lower survival estimates in some Eastern European populations relative to 
the European average [397]. 
The results presented here are in accordance with previous reports, and update and expand 
the analysis to countries where trends have not been reported. Further, the systematic 
approach utilised in this study, allowing a Europe-wide description of the contrasting 
variations in secular incidence and mortality trends, provided a useful tool to better 
understand the temporal variations in endometrial cancer, their relation to the underlying 
causes, and the development of more effective population-specific prevention strategies. 
The time trends of endometrial cancer in Europe are largely explained by our present 
understanding of the aetiology, for which several established risk factors are both highly 
prevalent in many European countries, and are most likely changing with time. 
From the 1970s, corpus uteri cancer incidence has been declining in premenopausal women 
in almost all European countries where data was available, accompanied by uniformly 
decreasing mortality trends. The observation may be explained by the long-lasting protective 
effect of GOG on endometrial cancer risk [391]. GOG became increasingly available during 
their introduction in the 1960s, and their use has become widespread among women of 
reproductive age, particularly in higher-resource countries, where long-term use is common 
[417]. Previous studies examining trends in Europe have noted the decline in endometrial 
cancer occurrence among young women [152,406-409], several attributing the observations 
to oral contraceptive use. 
Another possible contributor to the reduction in younger women may be the increasing 
number of women reproducing at later ages. Several studies have found an inverse 
association between older age at last birth and endometrial cancer risk [418-420], 
hypothesised to be due to mechanical shedding of cells that have undergone malignant 
transformation in women when they gave birth [421]. Further, the association appears 
stronger in women aged < 50 years than in older women, aged over 50 [419]. 
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In postmenopausal women, incidence trends were observed to be either increasing 
(particularly in Northern Europe) or rather stable (particularly Westem Europe). The use of 
exogenous hormones which increase endometrial cancer risk, and in particular the intake of 
postmenopausal oestrogens without progestins, considered particularly harmful, 
[394,400,422] may be responsible for the increasing rates where observed e.g. in Finland, 
Norway, Sweden and the U.K. - countries where the prevalence of HRT use has been high 
in postmenopausal women relative to other European areas. 
The addition of progestins to HRT from the late-1970s onwards has been considered an 
explanation of the rather stable trends seen in the U.S. thereafter, [394] although some 
studies have found positive associations between the use of combined oestrogen and 
progestins in HRT and endometrial cancer risk [422]. Obesity and nUlliparity may in 
combination be responsible for a large proportion of endometrial cancer in Europe: over 
one-third of all cases diagnosed in the European Union in 1995 have been estimated to be 
attributable to low fertility (36%) [19] and excess body weight (39%) [395]. Nulliparity is a 
well-established risk factor, giving a two- to three-fold increase in risk, with parity reductions 
dependant on number of children conceived [423]. Available census information from 
several European countries indicate that nUlliparity levels are increasing in a number of 
European populations, while average completed family size is decreasing. 
There is evidence that increasing energy supply is closely associated with the increases of 
overweight and obesity in many western countries [424], and these may have impacted on 
the European incidence trends amongst older women. Tretli and Magnus [425] estimated a 
potential 10% reduction in the incidence of uterine corpus cancer if obese women (women in 
the 5th quintile of the body mass population distribution) could reduce their body weight to 
within the 4th quintile. In a recent evaluation of the available evidence, IARC however 
considered that there was inadequate evidence of a reduction in risk, at least in humans, 
from intentional weight loss for any cancer site, including endometrial cancer [394]. In the 
same evaluation, physical activity was suggested as possibly preventing endometrial 
cancer, although the available evidence was considered limited. In a recent study in 
Sweden, it has been estimated that over 75% of the population attributable fraction (PAF) of 
endometrial cancer is due to the combined effect of low parity and age at first birth (PAF = 
54.5%), family history (PAF=2.1 %) and high socio-economic status (PAF = 5.9%) [426]. 
In Italy and in the Western European countries studied, relatively stable or decreasing trends 
were seen in women aged over 50. One might hypothesise as to the long-term protective 
effect of COC use in these populations, regardless of more recent or current HRT use, 
which is limited in these regions [417,427]. There are intriguing differences in the temporal 
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profile in certain countries relative to region as a whole. Endometrial cancer incidence trends 
in older women are increasing in Northern European countries with the exception of 
Denmark, where consistent decreases for at least a decade are noted. The effect of 
smoking, particularly current or recent and for high intensity or long duration expoSures, has 
been consistently reported to decrease endometrial cancer risk, at least in postmenopausal 
women [396]. The mechanisms that drive the protective association remain unclear. There 
have been substantial increases in lung cancer mortality in Danish women since the 1970s, 
a clear marker for the historical effects of increasing tobacco consumption amongst women. 
Rates recently reached a plateau (in the 1990s), but only in women aged under 60 [307]. It 
may be conjectured that the factors that have driven the rates of endometrial cancer down in 
postmenopausal women include tobacco smoking. 
The treatment of advanced breast cancer using Tamoxifen also confers an increased risk of 
endometrial cancer [428], although a Swedish study reported that the risk of endometrial 
cancer following breast cancer had not increased over time [429]. Swerdlow and colleagues 
have estimated that the use of Tamoxifen would be responsible for only about 2% of 
endometrial cancer cases in the U.K. [23]. Alternative anti-oestrogenic agents such as the 
aromatase inhibitor Anastrozole have emerged as a preferred first option for breast cancer 
treatment among premenopausal ER+ women, given the demonstration of less adverse 
effects on the endometrium five years after adjuvant therapy [430]. 
Mortality rates are decreasing in pre- and postmenopausal women in most countries. This is 
in line with previous reports on mortality rates reporting declining trends in most European 
populations [8,405]. Some exceptions are noted in this study. The decline in mortality rates 
in older women in certain Eastern European countries (and Estonia) was postponed to after 
the mid-1980s relative to elsewhere, whereas there was evidence of modest increases in 
Belarus and Russia, as well as in Sweden. 
5.5 Study II: APe trends in endometrial cancer incidence in Europe 
Study II narrows down the focus to incidence trends, with an aim to compare and contrast 
endometrial cancer trends in more depth using the longer data series available in 13 
European countries, and an examination of age, period and cohort effects using the APe 
model. A version of the text in this section has been recently published in a peer-reviewed 
journal [367]. 
5.5.1 Data sources 
The incidence data extracted as described in 5.4.1.1 was further restricted to countries for 
which registry data was available for 15 or more years. No restriction on the incidence data 
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going back in time was made, but a slightly different age range was used in this analysis 
(30-34,35-39, ... ,75-79). The final dataset incorporated 13 countries covering time spans 
from 15 to 45 years (Table 5.3). 
!a~le 5.3: Endometrial cancer: populations included in the analysis, recent 
mCldence rate and APe model fit statistics 
European Country Period* IncidenceT Person- ASRTI APC Residual dJ. § 
Area yearst modelt deviance§ I 
p-value§ 
Northern Denmark 1979-1998 (4) 535 1.5 31.8 APC 14.0 16 I 0.60 ! 
I 
Estonia 1971-2000 (6) 170 0.4 34.1 APC 43.7 32 ! 0.08 
i ! 
Finland 1955-1999 (9) 605 1.6 35.9 APC 116.8 I 56 <0.01 
Norway 1953-1997 (9) 416 1.2 33.1 APC 67.3 I 56 I 0.14 I, 
I I 
Sweden 1964-1998 (7) 1087 2.6 37.3 APC 76.0 i 
United Kingdoma 1978-1997 (4) 3765 15.5 22.8 APC I 37.1 I 
I 
Eastern Czech Republic 1985-1999 (3) 1496 3.0 44.9 APC 11.7 I 
Slovakia 1968-1997 (6) 601 1.5 41.9 APC 56.5 
Southern ltall 1983-1997 (3) 520 1.3 30.3 AP 29.3 
Slovenia 1985-1999 (3) 246 0.6 38.2 AD 16.5 
Spainc 1983-1997 (3) 285 0.7 29.4 AC 5.0 
Western Franced 1978-1997 (4) 311 0.8 27.8 A 34.5 
Switzerland8 1983-1997 (3) 291 0.7 32.7 AD 22.5 
• data available according to period of diagnosis, figure in parentheses represent number of five-year periods available in the analysis 
t average annual number of cases and person-years (per million) obtained from most recent five-year period 
I 
40 I 
! 
16 ! 
8 
32 
18 
19 
9 
30 
19 
tt truncated age-standardised rates (Europe) for ages 35-79 obtained using most recent five-year period 
:t refers to the most parsimonious final model providing a good fit: A: Age; AD: Age+Drift; AC: Age+Drift+Cohort; AP: Age+Drift+Period; APC: 
<0.01 
<0.01 
0.16 
<0.01 
0.04 
0.62 
0.83 
0.26 
0.26 
Age+Dr~+Period+Cohort 
§ to detennine the goodness-of-fit, the deviance was compared with the chi-squared distribution on the degrees offreedom (dJ.) determined by the 
model. p<O.05 indicates the full APC model does not yield an adequate fit 
a aggregation of England, Scotland 
b aggregation of Florence, Varese Province, Panna Province, Ragusa Province, Turin 
c aggregation of Catalonia, T arragon a; Granada, Murcia, Navarra, Zaragoza 
d aggregation of Bas-Rhin, Calvados, Doubs, Isere, Somme, Tam 
e aggregation of Basel, Geneva, Neuchatel, St.GaII-Appenzell, Vaud, Zurich 
5.5.2 Methods: characterising age, period and cohort effects 
Period effects denote systematic changes that affect rates in all study age groups at a given 
point in time. They often represent a data artefact or artefacts related to changes in 
completeness of registration, diagnostic practices or disease classification [60]. They can 
occur through the introduction of specific environmental factors to which all population 
members are exposed regardless of age. The launch and subsequent uptake of HRT among 
peri- and postmenopausal women during the 1960s may be a candidate in this respect. 
Cohort effects reflect changes in exposure to risk factors in successive generations. For 
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endometrial cancer, these may include the changing prevalence of COC use among young 
women, decreasing parity, and the shift towards having children at a later age. 
5.5.2.1 Fitting the APe model 
The full APC model defined in 3.3.3 was fitted to the trends. The Holford approach [66] was 
utilised with age, period and cohort effects partitioned in terms of their linear and curvature 
elements (see 3.4.2). Overall goodness-of-fit and tests for the effects of net drift and period 
and cohort curvature were obtained using the hierarchical modelling approach of Clayton 
and Schifflers [63,68]. Two approaches to providing a unique set of age, period and cohort 
trends were used in this study and are described below. 
5.5.2.2 Evidence of a steady state age curve 
A fixed age structure was constructed via the longstanding consideration that endometrial 
cancer is a consequence of the physiological action of unopposed oestrogens that increase 
the cell proliferation, opposed by progestins which instigate differentiation to a secretory 
state [393,399]. A curve describing such characteristics would require that the risk of onset 
rises steeply from premenopausal through to peri menopausal age to a peak at menopause 
and a subsequent plateau thereafter. The relationship between the age curve of endometrial 
cancer and its aetiology was first commented on by Clemmesen [431] and Lilienfeld and 
Johnson [217] and developed by Moolgavkar [246] and Pike [220,223]. Moolgavkar 
suggested the possibility of a generalised age curve and a rather stable risk in women aged 
over 60 possibly due to their low levels of ancillary oestrogens [246]. 
To obtain a single set of parameter estimates, it was therefore assumed that the steady-
state (period and cohort-adjusted) age-specific incidence curve for endometrial cancer in 
each population reflects the sensitivity of the target organ to unopposed oestrogens. Such 
an age curve was fixed for each country by choosing the age slopes {XL' for which for point 
estimates at ages 65-69, 70-74, and 75-79 were reasonably flat in each country, that is by 
selecting the estimates of {XL for which {XA - {X A-2 :::: O. 
5.5.2.3 Evidence of a generation effect 
The second assumption implied that cohort effects predominated the trends. Fixing the 
linear slope of the period effects to zero (f3L = 0) allowed the cohort slope to take up 
Holford's drift, the identifiable sum of the period and cohort slopes f3L + YL, while still 
allowing for non-linear period effects (see 3.4.2.1). The particular constraint implies that risk 
of endometrial cancer over time is mediated only by a changing distribution and prevalence 
of the known and putative risk factors in successive generations. 
5.5.2.4 Obtaining identifiable period and cohort parameters 
In addition to presenting the observed rates versus period and cohort by age, the effects of 
period and cohort are displayed on the basis of alternative parameterisations of the full APC 
model, as described in 5.5.2.2 and 5.5.2.3 above. APe models were also fitted in SUb-strata 
according to menopausal status (ages 30-54 and 55-79). However, the models generated 
did not substantially alter the results obtained for the ages 30-79, in terms of the significance 
of individual effects, the overall fit of each of the hierarchal models and the interpretation of 
the parameters from these models. The results are thus presented solely on the basis of 
incidence data covering both pre- and postmenopausal age groups. 
In presenting the model parameters, the period and cohort effects were once again 
reparameterised to rate ratios with reference points P -1 and A + P - 6 respectively. The 
reference midpoints varied from 1990 to 1993 for period, and from 1938 to 1941 for birth 
cohort. On adding together the linear and curvature components, the resulting parameters 
thus described the risk of endometrial cancer in a given generation or period of diagnosis, 
relative to a reference category that was dependant on the particular time period analysed in 
each country. 
5.5.3 Results: description of trends 
Age-adjusted rates of endometrial cancer in the most recent period available varied less 
than twofold between the 13 countries, from over 40 per 100,000 in Slovakia and the Czech 
Republic to less then 30 per 100,000 in France, Spain and the U.K. (Table 5.3). Rates were 
lowest in the U.K. (23 per 100,000). The trends in age-specific rates by birth cohort and 
period of diagnosis are rather complex (see Figure 5.3). Figure 5.4 attempts to summarise 
these data using parameters obtained from the APe model using the two constraints 
specified above. Simpler models tended to yield adequate fits to the data where fewer 
periods (3 or 4) were available. The full APe model was required elsewhere, and for some 
countries, particularly those for which the incidence data spanned a longer time period, a 
significant lack-of-fit was observed (Table 5.3). 
The interpretation of trends among the most recent cohorts is difficult given the rarity of 
events in women under the age of 45. Nevertheless, some general observations emerge 
from Figures 5.3 and 5.4, related mainly to a changing risk pattern according to menopausal 
status; both cohort and period effects were involved in risk changes in postmenopausal 
women, while in women of premenopausal age, diverse trends more orientated towards 
cohort emerged. These are described below by European region. 
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Figure 5.3: Incidence rates of endometrial cancer vs. period and cohort by age in 
13 countries by European area, women aged 30-79. Age-specific rates on the 
cohort scale are identified by the mid-year of the quinqenniums 
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Figure 5.4: Incidence rate ratios of endometrial cancer for period and cohort by 
country within region for women aged 30-79. Estimates are from the APe model. 
Solid lines assume the age curve is fixed for which a A - a A-2 ::::: 0; dashed lines 
assume the linear slope of the period effects is zero (PL = 0 ) 
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5.5.3.1 Northern Europe 
There were rather uniform increases in the incidence of endometrial cancer in women aged 
over 55 in Northern European countries except Denmark, and it is not clear from the 
observed data as to whether these upsurges may be apportioned more to generational or 
period influences (Figure 5.3). The full APe model was required in all six countries (Table 
5.3). Steady increases in risk were most evident among women born successively from the 
late 19th century and diagnosed from the early-1960s onwards. An acceleration in risk 
among Swedish women over 55 was also observed, but later, namely in generations born 
after 1915. This phenomenon was also seen in the U.K, although the available cohort data 
do not go back further than 1910. Denmark is the exception in the region; decreasing rather 
than increasing trends were seen in women aged over 55 (Figure 5.4). Cohort effects 
seemingly dominated these trends, with successive declines in risk among generations of 
women born after 1925. 
The upsurge in rates in older women contrasted with the more favourable trends seen in 
women aged under 55 in some of these countries, for which the consequence of 
generational changes were more evident (Figures 5.3 and 5.4). The modelled trends 
however implicate, depending on the assumptions specified, some importance of period 
effects, with increasing risk possibly more marked during the 1980s and 1990s in the long-
term trends in Finland and Sweden (Figure 5.4). Downwards trends were discernible in 
younger women in Sweden, Finland and the U.K., with risk decreasing among successive 
cohorts born around 1925-35. In Norway, a cohort-led decline was suggested by the model 
effects, but not unequivocally; uniform period increases were strongly indicated in Figure 
5.4, on assuming the proposed biological age curve. In Estonia, trends appeared relatively 
stable among recent cohorts. 
When attention was restricted to women of peri menopausal age (45-54), continuously 
downward trends were observed in all Northern European countries except Estonia. The 
observation may relate specifically to a declining risk in consecutive generations of women 
born after 1920 (Figures 5.3 and 5.4). Finland is the exception; there was a suggestion that 
risk of endometrial cancer is increasing in women aged under 45 born after the Second 
World War (Figures 5.3 and 5.4). 
5.5.3.2 Eastern Europe 
Trends in the Czech Republic were difficult to interpret; there were increases in women aged 
55 and over and declines in the 45-54 age groups, and these appear to follow a cohort 
pattern (Figures 5.3 and 5.4). Increasing risk is suggested among the youngest Czech 
women in the study, most notably among successive cohorts born since 1945 (Figure 5.4). 
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Uniformly increasing trends in incidence were observed in Slovakia, although it is not clear 
as to the specific importance of period or cohort-specific influences; non-linear effects of 
both types were significant (data not shown). One might consider period influences are more 
evident in view of the parallelism of the declining trends in women diagnosed during the 
1970s followed by increases thereafter (Figure 5.3), an observation supported by the 
modelled trends (Figure 5.4). 
5.5.3.3 Southern Europe 
Trends in Slovenia were similar to those described in Slovakia with uniform increases in 
incidence rates of cancer of the corpus uteri in pre- and postmenopausal women by birth 
cohort and period of diagnosis (Figures 5.3 and 5.4). The trends in Spain and Italy were 
more difficult to interpret, although increases in endometrial cancer rates were evident in 
postmenopausal women in both countries, as well as in women aged 45-54 in Spain (Figure 
5.4). 
5.5.3.4 Western Europe 
The trends in postmenopausal women in both France and Switzerland suggested the 
importance of cohort factors, with downward incidence trends seen in consecutive 
generations born after 1920 and before 1950 (Figure 5.3). These trends may be viewed as 
analogous to those observed in Denmark. The suggestion of increases in younger 
generations in France (Figure 5.4) cannot be confirmed or refuted, given the degree of 
randomness underlying these trends. 
5.5.4 Discussion of main findings 
This study has revealed the distinct patterns in the age-specific trends of cancer of the 
corpus uteri in Europe. A general profile emerged of increasing risk in postmenopausal 
women (aged over 55), and decreasing or stable trends in pre- and perimenopausal women 
(aged 30-54), particularly in Northern and Western countries. The most consistent declines 
in these regions were observed in women aged 45-54. In Southern and Eastern Europe, 
uniform increases in incidence were observed in several countries. In the majority of 
populations studied, both period and cohort effects seemed to influence the age-specific 
trends, particularly amongst women of menopausal age. 
5.5.4.1 Methodological concerns 
A number of methodological and data-related problems may have affected the results as 
reported in this analysis. Endometrial cancer is a rare event in younger women, and while 
recent trends may reveal short-term future patterns of risk, unfortunately these were 
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interpretable only in a few countries where sufficient numbers of cases were available. 
Additionally, the narrow span of period data for a number of countries (only three periods of 
incidence were available in five countries), made interpretation of the corresponding trends 
in these populations difficult. 
The modelled component of the study involved an APe analysis, and two solutions were 
presented using simple constraints that were considered plausible given our understanding 
of the biology and epidemiology of the disease. The first set of age, period and cohort 
effects obtained attempted to preserve an element of biological plausibility. The identifiability 
problem was circumvented by fixing the underlying age structure assuming that endometrial 
cancer is a consequence of the physiological action of unopposed oestrogens that increase 
the cell proliferation, opposed by progestins which instigate differentiation to a secretory 
state [399,432]. 
An alternative solution involved the simple and commonly applied assumption that the 
overall period slope was zero [107], and the changing distribution and prevalence of the 
component causes were therefore presumed to show up mainly as generational influences 
in each country. Although the drift was attributable to birth cohort only, the formulation 
allowed non-linear period effects to be considered. The estimates presented in Figure 5.4 
must however be interpreted with considerable caution, given an inherent inability to quantify 
the slopes for period and cohort. Nevertheless, the solutions obtained were based on two 
plausible assumptions: their joint examination together with the observed rates thus enabled 
an in-depth appraisal of the trends beyond the more arbitrary inferences available from an 
analysis restricted to the observed trends. 
5.5.4.2 Determinants of trends by menopausal status 
The trends provided clues as to the changing distribution of the primary risk factors, 
including use of exogenous oestrogens, reproductive factors, overweight and obesity, and 
smoking, and hence the potential for successful preventative strategies aimed at the 
population level in Europe. The text below builds on the discussion in the previous section, 
comparing the period and cohort trends with previous temporal studies and in light of the 
possible causes, according to menopausal status. 
5.5.4.2.1 Trends in postmenopausal women 
The rising trends in women aged 55 and over, as observed in many Northem and Western 
European countries, imply both period and birth cohort influences were in operation. 
Possible underlying mechanisms include temporal changes in reproductive behaviour and in 
the prevalence of overweight and obesity. Early age at menarche has been consistently 
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described as a risk factor for endometrial cancer [392]. During the last 150 years, age at 
menarche has declined at a rate of about 2-3 months per decade [433]. Completed family 
size has declined among female cohorts born during the twentieth century in most European 
countries [434]. The most substantial decreases occurred follOwing the post-war "baby 
boom"; the peak in total fertility rates in the early to mid-1960s was followed by declines in 
successive generations born after the mid-1930s [435]. Nulliparity decreased in most 
European countries for cohorts born from 1930 to 1945 [435]. In England and Wales, where 
data are available for a longer period, the decline in nulliparity began for cohorts born since 
1910 [152]. A recent study indicated that reproductive patterns may account for about half of 
the cases of endometrial cancer in Sweden in women diagnosed 1961-2002 [426], although 
the importance of reproductive behaviour on risk has been shown to decrease at older ages 
[419]. 
The use of HRT has been common in the Nordic countries and Western Europe, first during 
the 1960s containing oestrogens without the addition of progestins, and from the mid-1970s, 
as a succession of preparations combining oestrogens and progestins either sequentially, 
cyclically, or continuously [400]. Several studies confirmed a strong association between use 
of oestrogens without progestins and endometrial cancer risk [392], and a few studies also 
showed that the addition of progestins sequentially or cyclically to oestrogens increases risk 
too [436,437]. Risk increases with duration of HRT use and remains increased some years 
after cessation [400,438,439]. 
Part of the increase in risk of endometrial cancer among postmenopausal women may 
therefore be related to use of HRT in the European regions where use has been widespread 
[417]. This study reported uniform increases in endometrial cancer rates with time in 
Finland, Norway, Sweden and the U.K., and to a much lesser extent, in Estonia. In Finland 
and Norway, the cohort-specific increases began in women born towards the end of the 
nineteenth century. Exogenous oestrogens are an unlikely explanation for this trend as 
these women were aged over 65 when HRT was first introduced. Women born from 1910 
onwards would have in theory the possibility of having being exposed to HRT. Indeed the 
main acceleration in risk among postmenopausal women in Sweden is seen after 1910 and 
coincides with the market introduction in the mid-1960s, and peak of sales in the mid-1970s 
[406]. The decline in sales of oestrogens without added progestins for treatment of 
menopausal symptoms thereafter [406] might imply a decline would be observed in more 
recent cohorts born thereafter. This has not been seen however, and in Sweden, as in 
Finland, Norway and the U.K, the postmenopausal increases suggest women born from at 
least 1920 up to 1945 were at consecutively increasing risk of endometrial cancer. 
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One possible explanation relates to the prevalence of overweight and obesity, which has 
been markedly increasing in some countries [440]. Obesity, in both in pre- and 
postmenopausal ages, is a strong risk factor for endometrial cancer [394]. Indeed, 34% of 
endometrial cancers have been attributed to obesity in the US during the period 1988-1994 
and 40% in 1999-2000 [441]. Bergstrom and colleagues [395], from a meta analysis of 
papers published between 1966-97, also estimated that about 40% of cases were due to 
overweight and obesity in developed or industrialised countries. Endometrial cancer is also 
known to be more frequent among women suffering from diabetes mellitus [442-444], a 
condition closely associated with overweight, obesity and lack of physical exercise. The 
incidence of diabetes mellitus is increasing in Europe [445], as is the incidence of 
overweight and obesity [440]. Obesity-related factors probably explain at least part of the 
temporal pattern of endometrial cancer risk in postmenopausal women. This may be 
particularly the case in Southern and Eastern Europe, although fertility has also been 
declining in these countries [446]. Moreover, low levels of physical activity and high energy 
intake are increasingly commonly found in European populations and seem to increase risk 
for endometrial cancer independently of BMI [447,448]. 
Systematic declines of endometrial cancer incidence in Denmark were observed in women 
born since 1925, with no long-term increases in rates in postmenopausal women. This is at 
odds with other Northern European countries, and reverses the findings of a Danish study 
from the earlier period 1943-80 for which steady increases in all age groups was observed 
[404]. Comparisons of temporal data in Denmark with other Nordic countries regarding COC 
use and a late age at last birth reveal few dramatic differences, and therefore neither factor 
can be considered as providing a satisfactory explanation for the observation. The Danish 
trends do share some similarities however to those seen in France and Switzerland, for 
which endometrial cancer rates are also declining from around 1925. One conjecture is that 
smoking has impacted on the trends, given it is associated with a reduced risk of 
endometrial cancer, that is perhaps confined to postmenopausal women [396]. In both 
Denmark and France, trends in lung cancer mortality, a strong marker for previous tobacco 
consumption, have been uniformly increasing in successive cohorts born throughout the 
twentieth century up to 1950 [307]. Lung cancer mortality rates are highest in Denmark 
amongst the previous 15 Member State E.U., and shifted ranking from third in 1975 to first in 
1995 [307]. 
5.5.4.2.2 Trends in premenopausal women 
Systematic decreases in endometrial cancer incidence were observed in women aged 45-54 
years resident in most Northern European countries, as well as in the Czech Republic, 
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France and Italy, with successively declining risk most evident in women born between 1930 
and 1945. CDC have a well-established protective effect [392,438], even after short 
durations of use of 1-3 years [399]. They have become increasingly available in Europe from 
the 1960s onwards, and women born after about 1925 have had the opportunity to use 
them. The trends in premenopausal women were however heterogeneous; in Denmark, 
Sweden and the U.K., for instance, there were rapid declines in risk in women aged under 
45. These translate to a successively decreasing risk in women born around 1925, as has 
been reported in Sweden [406], through to the most recent cohorts born in the 1950s and 
1960s. 
A high exposure to CDC was particularly common among cohorts born after 1950. In 
England and Wales, the proportion of "ever users" of hormonal contraceptives was about 
40% for women born in the 1930s [449] compared with approximately 70% in birth cohorts 
of 1940s and 80-90% for those born in the 1950s [152]. In other European countries, the 
prevalence of use of CDC has varied, tending to be relatively high in Northern and Western 
Europe, and low in much of Southern and Eastern Europe, at least before the 1980s [417]. 
The use of hormonal contraceptives may, at least in part, be responsible for the decreases 
in incidence in several countries. Steadily increasing incidence rates of endometrial cancer 
in the Czech Republic and Slovakia in Eastern Europe, as well as in Slovenia and Spain in 
Southern Europe, have been observed both in younger and older women. An explanation for 
the endometrial cancer trends in premenopausal ages may be that women in these regions 
have failed to benefit from the protective effects of CDC due to their unavailability, or 
otherwise. Fertility has also been on the decline, although more slowly than seen elsewhere 
in Europe [446]. 
The declines seen in Sweden were not evident among premenopausal women in Finland 
and Norway. Further, there was some indication that there were increasing trends in young 
women in Finland, and possibly elsewhere (e.g. France). It is difficult to explain such a trend, 
should it be genuine. It is too early to conclude whether the observed incidence pattern 
might project itself into the future, given the underlying random variation arising from small 
numbers. 
We are not aware of major changes in routine diagnostics for endometrial cancer in Europe 
that may have impacted on the results presented. New cases of uterine cancer with subsite 
unspecified represent a small proportion of all uterine cancers in each of the populations 
studied, and over time [18,160-162]. Other than the changing population prevalence of 
hysterectomy (discussed in 5.6.2.2), one artefact that may have impacted on trends is HRT 
use in countries where its consumption is common. Women who are users of menopausal 
238 
hormones are likely to be more intensively investigated, and early precancerous or 
cancerous lesions more readily detected and reported to the cancer registries as cancers. 
5.6 General discussion 
5.6.1 Brief summary of main findings 
Study I showed that incidence and mortality rates of endometrial cancer in premenopausal 
women have been decreasing throughout Europe, with mortality declines more marked in 
Western and Southern European countries. Incidence rates among postmenopausal women 
were highest in the Czech Republic, Slovakia, Sweden and Slovenia, and lowest in France 
and the U.K. Increasing incidence trends in this age group were observed in the Nordic 
countries (except Denmark) and in the U.K. Some increases were also seen in Eastern 
(Slovakia) and Southern Europe (Spain and Slovenia), while relatively stable or modestly 
decreasing trends were observed in Italy and most Western European countries. 
Postmenopausal mortality rates were systematically higher in Eastern Europe, with death 
rates in the Ukraine, Latvia, Czech Republic, Russia, and Belarus two to three times those 
seen in Western Europe. Declining mortality trends were seen in most populations, although 
in certain Eastern European countries, the declines began rather recently, during the 1980s. 
In Belarus and Russia, recent postmenopausal death rates were stable or increasing. An 
exception in Northern Europe was Sweden, where a non-significant increase was observed. 
Study II involved an APC analysis of 13 countries, and reported that there were increasing 
trends among postmenopausal women in many Northern and Western countries. Denmark 
(and possibly France and Switzerland) were exceptions, with decreasing trends in 
postmenopausal women. In pre- and perimenopausal women, dedines were observed in 
Northern and Western Europe, most evidently in Denmark, Sweden and the U.K., affecting 
consecutive generations born after 1925. These contrast with the increasing trends 
regardless of menopausal age in some Southern and Eastern European countries, 
particularly Slovakia and Slovenia. 
These observations in combination provided evidence of changes in several established risk 
factors over time, which in turn have implications for possible primary prevention strategies. 
In postmenopausal women, changes in reproductive behaviour and prevalence of 
overweight and obesity may partially account for the observed increases, as well as HRT 
use in certain countries. Combined oral contraceptive use may be responsible for the 
declines observed among women aged under 55. While there are some prospects for 
chemoprevention in premenopausal women as oral contraceptive use becomes more 
widespread in Europe, increases in obesity, and decreases in fertility, imply that endometrial 
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cancer in postmenopausal women will become a more substantial public health problem in 
the future. 
An interesting observation was the low rates of endometrial cancer incidence (and mortality) 
among both pre- and postmenopausal women diagnosed 1997-99 in the U.K. relative to 
other European countries studied. This in part may be due to artefact, in particular as a 
result of the failure to adjust for the relatively high rates of hysterectomy recorded in the 
population. If the mean hysterectomy prevalence percentages for 1996-2000 in England and 
Wales - estimated at approximately 20% in each of the 5-year categories the age group 50-
74 [450] - were applied to the rates in Figure 5.1, the rates would be substantially larger, 
particularly among postmenopausal women. Hysterectomy-adjusted rates may have ranked 
higher in in the U.K. than in low-risk counties where the procedure has been less commonly 
practiced. One cannot exclude the possibility of underascertainment, although it seems 
unlikely that a shortfall related to diagnostic artefacts has sizably contributed to the low 
rates. One may speculate that a lower average number of routine visits to gynaecologists by 
U.K. residents, relative to other European countries, may have resulted in a lower detection 
of cases, and contributed consequently to a lower recorded rate. 
Those established protective factors against endometrial cancer that reasonably correlate 
with the observed trends in the U.K. may have played a role. Foremost is the introduction 
and increasing use of oral contraceptives, possibly affecting rates of endometrial cancer in 
successive birth cohorts from the 1920s. COC have been shown to a long-lasting protective 
effect (at least 15 years) [391], and an 80% reduction in endometrial cancer has been 
observed following 10 years of use [399]. Their long-term consumption among U.K. women 
has likely had a beneficial impact on rates in both pre- and postmenopausal age groups. 
5.6.2 Reconsideration of methods and further exploration 
5.6.2.1 Limits to joinpoint regression 
Owing to potential systematic errors in the data, excessive random variation, and particular 
nuances within the regression method, some of the EAPC may not be representative of the 
underlying endometrial cancer trends, and should be interpreted with suitable caution. An 
attempt was made to address this by reproducing in tabular form only those estimates that 
were considered to adequately represent the recent underlying trends. 
5.6.2.2 Adjusting for hysterectomy rates 
Recent evidence from Finland suggests that adjustment for hysterectomy affects the 
magnitude and direction of trends in endometrial cancer [130]. In this analysis, the effects of 
hysterectomy were not taken into account due to a lack of corresponding data in each 
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country for the requisite periods and ages. The varying prevalence of hysterectomies may 
have impacted on the trends however: the incidence of hysterectomy has been increasing in 
Finland [130], Denmark [369] and England and Wales [23], and the unadjusted trends 
presented in this chapter may have underestimated the overall time trend. As noted by 
Ewertz and Jensen [404], the assumption of a decline after the menopause used here to 
present one set of age, period and cohort trends may be artificially distorted by a dedining 
number of "susceptibles" - women who have not had a hysterectomy. The trends may have 
been more accentuated in certain countries had the rising prevalence of hysterectomy in 
these populations (particularly in recent years) been taken into account. 
5.6.2.3 Further studies 
The more in-depth APC analysis of study II gave further insight into the nature of the trends 
obtained from a stratified description of the linear trends amongst two broad age groups in 
study I. In providing a unique solution, the constraint that fixed the age curve, although 
simplistic, did retain some degree of biological plausibility. Further work would establish 
better proposals for assuming a particular age curve, possibly along the lines of research by 
Pike that could also be applied to trends in cancer of the female breast and ovary, as well as 
to the endometrium [220]. The defining epidemiological characteristic of these cancers 
appears to be a rapid deceleration in the rate of increase with age around the time of 
menopause. 
Both studies in this chapter are necessarily speculative with regards the factors that drive 
the trends, and other approaches may provide further insight. The difficulties addressing 
which of the main aetiological factors drive the trends in European populations, particularly 
in postmenopausal women, might be complemented by further study of concomitant trends 
in the population prevalence and distribution of obesity, HRT use, smoking and COC use. 
5.6.3 Future prospects for prevention 
Given the current aetiological and temporal profile of endometrial cancer, it is unlikely that 
rates of endometrial cancer will be decreasing among postmenopausal women in most 
European countries in the near future. The prevalence of obesity is increasing [424], while 
fertility rates are decreasing [446]. Trends in parity (or nulliparity) and age at last delivery, 
probably responsible for about half of the endometrial cancer cases in Europe, are not 
realistic targets for prevention. Avoiding use of postmenopausal hormones, or at least those 
drugs that clearly induce endometrial proliferation as oestrogens, would probably decrease 
endometrial cancer trends where use is widespread, such as in the Nordic countries and a 
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few Western European countries (e.g. the U.K. and Germany). The use of exogenous 
oestrogens has been rather limited in most Southern and Eastern European countries. 
The evidence for an elevated risk of endometrial cancer due to obesity is beyond doubt 
[394], and the obesity epidemic observed in Europe in the recent decades [394,424] may 
have contributed to increases in endometrial cancer incidence among postmenopausal 
women [392]. Thus, preventing obesity through weight control would probably have a 
substantial impact on endometrial cancer incidence trends over time, besides having other 
positive health impacts, such as prevention of other conditions also associated with 
endometrial cancer such as diabetes mellitus, hypertension, gallbladder disease, and most 
importantly cardio-vascular diseases. 
Reducing mortality rates, other than via a reduction in incidence, is not a simple task, 
particularly in countries where health systems face a shortage of resources, as in some 
Eastern European countries, where endometrial cancer mortality rates are systematically 
higher than in other regions. Improvements in the quality of, and access to, diagnostic and 
therapeutic services, as well as the implementation of strategies aimed at alerting women 
that vaginal bleeding after menopause is abnormal, may reduce such disparities in the 
mortality rates. 
Uniform increases were observed in rates of endometrial cancer incidence amongst the 
main risk group, postmenopausal women in most European countries studied, with Denmark 
being an important exception. Both calendar period and birth cohort effects appear to be in 
operation. The reasons for the increases in countries as diverse as Sweden and Slovakia 
may include a Europe-wide shift towards declining fertility rates and marked increases in 
overweight and obesity, although only in Sweden and several other affluent countries can 
the effects of HRT be responsible for the rising trends. In pre- and perimenopausal women, 
rates are declining in Sweden, Denmark and the U.K., mostly evidently in successive 
cohorts born since 1930. 
The downward trends in young women are presumably the result of increasing use of eoe 
in these countries, since they became available mainly to cohorts born in the mid-1920s and 
thereafter. In a number of Southern and Eastern countries (notably Slovakia), trends are 
increasing regardless of menopausal age, countries for which the lack of availability of eoe 
has offered little protection in these younger women. Prevention of endometrial cancer will 
possibly be realised in these areas as eoe use becomes increasingly widespread. The 
continuing increases in obesity and decreases in fertility however forewarns that endometrial 
cancer, as a postmenopausal disease, will become a more important public health problem 
in Europe in future years. 
242 
6 Analyses of temporal trends in testicular cancer in Europe 
6.1 Introduction to the chapter 
This chapter has two main objectives. The first involves a broad description of the time 
trends of testicular germ cell cancer incidence and testicular cancer mortality in European 
countries. From previous research on testicular cancer, generational and period-related 
influences are expected to playa major role in the respective trends of incidence and 
mortality. Of particular interest is the variability in cohort-specific patterns between countries, 
and whether there is evidence that trends in any of the study populations have reached a 
peak, or are in decline. 
The second aim is to compare the heterogeneity of generation-specific trends in the two 
major subtypes of testicular germ cell cancer, seminoma and non-seminoma, hypothesising 
that similar temporal patterns in the cohort dimension suggests a relative consistency in their 
respective aetiologies. As in the previous chapters, analyses involving the APC model and 
Holford's method of 3.4.2 are used to accomplish the objectives. 
6.1.1 Why analyse trends in testicular germ cell cancer incidence? 
Attention was first drawn to increases in testicular cancer incidence in England and Wales 
[451] and Denmark [452] half a century ago; yet the aetiology of the disease remains largely 
unexplained, in spite of having a very distinct epidemiology. Incidence trends in almost all 
European populations are characterised by rapid increases in rates of between 3% and 6% 
per annum in the last few decades [8,229,453-455], particularly in adolescent men and 
young adults [456]. The large variation in testicular cancer incidence across and within 
European countries in each population over time could point to one or several ubiquitous 
and highly prevalent environmental agents being responsible. Moreover, the factor(s) 
involved must vary in prevalence between populations, and within populations, over time. 
6.1.2 Why analyse trends in testicular cancer mortality? 
Irrespective of the increasing incidence, declining rates of mortality of the same order of 
magnitude have been observed in many of the more affluent countries of Europe, largely as 
a result of the introduction of Cisplatin therapy for advanced germ cell tumours in the 1970s, 
and the substantial progress in prognosis in younger patients [457]. The relative decline in 
death rates of testicular cancer is expected to reflect the extent of their introduction, and the 
evolution of cancer care practices within each country. 
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6.1.3 Why analyse trends in testicular seminoma and non-seminoma? 
The division of testicular germ cell cancer to seminoma and non-seminoma emerged mainly 
from the clinically distinct treatment options available for treatment of the respective 
subtypes. Pike et al on reviewing testicular cancer incidence and mortality noted the value of 
the potential subdivision of germ cell cancer into the "epidemiologically interesting" entities 
of seminoma and non-seminoma (teratoma), provided the age range was restricted to 
between 15 and 50 [186]. Both subtypes are preceded by testicular carcinoma in situ [458], 
and comparisons of their epidemiological profile would indicate that they share largely the 
same underlying causes. Despite well-documented differences in the peak age of incidence 
- non-seminoma occurs approximately a decade earlier in life than seminoma [186] - most 
stUdies have revealed little variation in risk factors between the two sub-types. In line with 
overall testiCUlar germ cell cancer incidence rates, trends in pure seminoma and non-
seminoma are increasing with calendar time in many European countries. 
6.1.4 Review of testicular cancer epidemiology 
6.1.4.1 Descriptive epidemiology 
Descriptive epidemiology has revealed considerable geographical, ethnic and temporal 
variations in incidence: at least a 30-fold variation in risk worldwide, rates ranging from 0.3 in 
Beijing, China to 12.5 in Zurich, Switzerland [18], with men of European origin in the U.S. 
having rates five times higher than their African origin counterparts [459]. Nearly 50,000 new 
cases of testicular cancer were diagnosed worldwide in 2002 [263]. The disease affects 
mainly Western populations, with rates about six times higher in developed areas relative to 
developing areas. Figure 6.1 indicates that among the highest incidence rates worldwide are 
those recorded in countries in Northern (Denmark, Norway) and Western Europe (Germany, 
Switzerland). Testicular cancer accounts for 1 % to 3% of all male cancers in Europe, but is 
the most common malignancy among young adult men aged 15-34 in most countries in the 
region [18]. 
6.1.4.2 Aetiology 
It has been hypothesised that the risk of testicular cancer is to a large extent determined 
very early in life, perhaps in-utero [460]. Several perinatal factors, including low birth weight 
[461-464], older maternal age [461,465], prematurity [462,463,465,466], low birth order 
[229,461,463-465,467] have been associated with an increased risk of testicular cancer, 
although the evidence is not entirely consistent across studies. Testicular cancer is however 
consistently associated with cryptorchidism, the most common congenital malformation of 
the male genital organs [468]. Results for perinatal risk factors have been often interpreted 
in the light of the so-called oestrogen hypothesis which postulates a carcinogenic effect due 
to an excess of sex hormones at the time of testicular differentiation [469]. Maternal life-
styles during pregnancy could also affect testicular cancer risk. Ecologic studies have 
identified maternal smoking as a possible risk factor [466], although this hypothesis has not 
found support from analytical studies [470,471]. 
Figure 6.1: Truncated (15-54) age-standardised testicular cancer incidence rates 
(World) i~ countries/regions with the highest rates globally, rates presented in 
descending order of magnitude. 
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6.1.4.2.1 Differences in main histological subtypes 
10 15 20 
Several risk factors associated with prenatal and perinatal exposures have been suggested 
for testicular cancer [461,463-466,472-475], although asides from cryptorchidism, few risk 
determinants are well-established. These in combination with other putative causal factors, 
such as low birth weight and low maternal parity, can only account for a small fraction of the 
total incidence. Numerous studies have examined aetiological differences in the two main 
clinical sub-entities of testicular germ cell cancer [186,229,461,463,476-479], most have 
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however revealed little variation in risk factors between the two sub-types and, where 
particular associations have been found, they have been inconsistent across stUdies. 
6.2 Review of temporal studies of testicular cancer in Europe 
6.2.1 Testicular germ cell cancer incidence 
As the aetiology of testicular cancer is not well understood, the underlying reasons for the 
consistent increase in incidence of between 3% to 5% per annum throughout Europe remain 
largely unknown. Improving ascertainment and better diagnostic procedures cannot account 
for the extent of the increase given the course of the disease is rapidly fatal if left untreated. 
In addition, the evidence derives mainly from a number of well-established European cancer 
registries with standardised procedures [454]. 
6.2.2 Testicular germ cell seminoma vs. non-seminoma 
The rising incidence of both seminoma and non-seminoma is unlikely to be explained by 
changes in disease classification or diagnostic activities [291,480]. The majority of temporal 
studies have reported rapid increases but similar trends between subtypes when examined 
by birth cohort [229,251,291,292,460,481]. Exceptions are a recent Canadian study that 
reported some heterogeneity in patterns of cohort-specific risk [292], while a U.S. study 
based on SEER data suggested some important temporal differences by subtype and within 
subtype by race [291]. 
6.2.3 Testicular cancer mortality 
In contrast to incidence, testicular cancer mortality has been markedly declining in a number 
of European countries since the mid-1970s, due to the introduction of platinum-based 
chemotherapy schemes [457] and best-practice tumour management [482]. Echoing these 
improvements, the pooled five-year relative survival estimate among European patients 
diagnosed in the early-1990s was over 90%, although striking differences across Europe 
were observed, with five-year survival as low as 71 % in Estonia [138,483]. The reductions in 
mortality have thus not been uniform between countries, with slower and later declines seen 
in lower resource settings [484], in accordance with the high cost of appropriate treatments, 
and possibly inadequate patient referral systems [485]. 
6.3 Study I: APe trends in testicular cancer incidence and mortality 
6.3.1 Data sources and data quality 
6.3.1.1 Incidence 
Incident cases of testicular germ cell cancer (ICD-O-2 9060-9102) were extracted from 
EUROCIM [160] for men aged 15-54 (see 2.8 for details and standard inclusion criteria). 
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Due to computation difficulties in dealing with small numbers, Estonia was not included in 
these analyses. Table 6.1 provides details of the cancer registries included in the analysis of 
incidence trends. The testicle is a visible and palpable organ, and so the origin of the tumour 
is usually evident, notably among young and middle-aged men. Hence, misclassification or 
underascertainment of registration should be minor issues relative to many other 
malignancies. A version of this section is in press in a peer-reviewed journal [486]. 
6.3.1.2 Mortality 
Testicular cancer mortality data (ICD-9 186) was extracted from the WHO mortality 
databank for men aged 15-54 (see 2.7.2 for details and standard inclusion criteria). Datasets 
spanned at least 15 years and trends in mortality prior to 1968 were excluded in order to 
focus on how the effects of improving treatment, starting 5-10 years later, subsequently 
impacted on the observed trends (see 6.3.2.1.2). Table 6.2 provides information on the 
national data from 22 countries that met the criteria: the time-span varied from three to 
seven five-year periods. Due to small numbers, Luxembourg, Malta and Slovenia were not 
included in the subsequent analyses. 
6.3.2 Methods: fitting the APe model 
Birth cohorts were obtained on subtracting the midpoints of five-year age groups (15-19,20-
24, ... ,50-54) from the corresponding five-year periods. The effects of time period and birth 
cohort were examined using the full APC model of {3.6} as described in 3.3.3. Tests for 
goodness-of-fit of the APC models, as well as the overall slope and non-linear effects of 
period and cohort were obtained using the approach of Clayton and Schifflers [63,68] (see 
3.4.1.1.3). The net drift was used to quantify the overall direction and magnitude of the time 
trend in each country. 
6.3.2.1 Obtaining identifiable period and cohort parameters 
As in the previous chapters, the non-identifiability problem was highlighted by partitioning 
the age, period and cohort effects in terms of their linear and curvature component parts, 
according to the method of Holford [66,110]. To identify plausible period and cohort effects, 
different specifications of the range of the period and cohort slopes were postulated, as 
described in general terms in 3.4.2, and outlined below for the specific study of testicular 
incidence and mortality trends, respectively. 
6.3.2.1.1 Assumptions on incidence slopes 
For incidence, the possibility of period-specific increases was respected, thus an allowance 
was made for gradual increases that would result from improving diagnostic procedures or 
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ascertainment with time. The substantial contribution of cohort influences in explaining 
testicular cancer incidence trends in Europe has been consistently demonstrated in previous 
reports [8,455,487,488], likely due to the changing prevalence and distribution of (largely 
unknown) factors that impact on the rates in successive generations. Thus it was assumed a 
priori that the overall linear slopes of period and birth cohort were positive, and specified 
scenarios for which the cohort component accounted for i) all of the regular trend; ii) half of 
the regular trend. The possible values of the cohort slopes YL were thus bounded so that 
fiL + YL < < fi I· h· fi 2 - YL - L + YL' eavlng t e penod slopes L to range from zero and half of 
Holford's drift defining the corresponding linear slopes as 0 ~ fiL ~ fiL + YL . Age 
2 
parameters were similarly bound between two estimable functions. 
6.3.2.1.2 Assumptions on slopes for mortality 
For mortality, two specifications of the period slope were postulated that mirror those for 
incidence. The first scenario attempted to capture the period-related decline in testicular 
cancer mortality due to the introduction of effective therapy and care starting, in some 
populations, in the early to mid-1970s, initially in high-resource European countries. The 
second specification took into account that the regular mortality trend related to the 
underlying incidence (and its generational influences), as well as to case-fatality. On the 
basis of these requirements, two sets of parameter estimates were presented that 
constrained the period component fiL to take either i) all of the regular trend, or ii) half of the 
. fi + Y 
regular trend. The boundary values of the penod slopes were L L ~ fiL ~ fiL + YL ' and 
2 
accordingly, the range of linear slopes for cohort YL were 0 ~ YL ~ fiL ; YL . Each 
postulation of the period slope provided an identifiable range of the age and cohort slopes. 
In 6.3.1.1 and 6.3.1.2, the effects for the individual categories of each effect were generated 
by adding together the linear and curvature components. For example, the effect for age 
group a can be expressed as aa = (a-(A+l)/2)xaL +fPa, with fPa representing the 
departures from the linear trend, and fiL and YL, the period and cohort slopes, defined as 
before [110]. 
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6.3.3 Results: description of trends 
6.3.3.1 Incidence 
There was a five-fold variation in incidence in the 12 European countries in this study (Table 
6.1), with rates ranging from around 5 per 100,000 in Spain, Finland and Italy to more than 
15 per 100,000 in Denmark and Switzerland. Increases in incidence during the period 1983-
97 were observed in all countries studied. The extent of the increase varied considerably, 
although no clear relation between the level of incidence and the magnitude of the recent 
trend was apparent (Figure 6.2). The average increases per annum varied at least six-fold 
(Table 6.1), with the most rapid inclines in Spain and Slovenia, estimated to be almost 6% 
per year on average, compared to overall increases of 1 to 2% per annum in Norway, 
Switzerland, Italy, France and Denmark. There was a suggestion of a recent peak in several 
countries, most evidently in Switzerland and Norway, during the 1990s (Figure 6.2). 
The full APC model or a submodel explained a sufficient amount of variation in each 
population (Table 6.1). Cohort effects dominated in the majority, with cohort curvature 
significantly improving the fit in 10 of the 12 countries studied, with Italy and Slovenia being 
the exceptions (Table 6.3). The age-cohort model adequately explained the variation in 
seven countries. Only in three countries (Finland, Norway and Slovakia) did non-linear 
period effects significantly improve the fit. 
Figure 6.3 shows the corresponding period and cohort risk parameters. It is evident that 
even when half of the regular trend is attributed to period of diagnosis, successive 
generational increases in risk can be seen in almost all European countries. The rises were 
fairly uniform and rapid with successive generations in Finland and the U.K, and in the 
Czech Republic and Slovakia. 
There was some evidence of a short-term dip in cohort-specific risk (regardless of the 
attribution of drift) in most European countries, affecting men born around 1940-45 in 
Denmark, Norway and possibly Sweden, and also in France, Italy, Slovenia and Spain, 
although the data are based on fewer years of observation for these countries. Rapid 
acceleration in risk followed thereafter (Figure 6.3). There was also a suggestion that 
successive generations of Swiss men, born after the early to mid-1960s, had experienced a 
steadily declining risk of testicular germ cell cancer. 
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Table 6.1: Testicular germ cell cancer incidence: populations included in the trends analysis, regular trend, and goodness-of-
fit statistics for best-fitting APe model by European area 
European Country Period available Incident Person- ASR+ Ranks Overall 
Area (# of five-year . yearst trend' cases 
periods) 
Northern Denmark 1979-1998 (4) 262 7.7 16.6 1 +1.7 
Finland 1955-1999 i9) 72 7.4 5.0 11 +4.4 
Norway 1953-1997 (9) 155 6.3 11.9 3 +2.3 
Sweden 1964-1998 (7) 206 12.1 8.4 9 +2.9 
United KingdomS 1978-1997 (4) 1359 75.4 8.6 7 +2.8 
Eastern Czech Republic 1985-1999 (3) 327 15.4 10.8 5 +4.0 
Slovakia 1968-1997 (6) 138 7.8 8.6 8 +6.8 
Southern I tall_ 1983-1997 (3) 77 6.4 5.8 10 +1.2 
Slovenia 1985-1999 (3) 68 2.9 11.3 4 +7.3 
Spainc 1983-1997 (3) 31 4.6 3.1 12 +7.7 
Western Franceo 1978-1997 (4) 103 5.8 8.6 6 +2.6 
Switzerlande 1983-1997 (3) ~ 4.2 15.9 2 +1.2 
-----
• mean annual number of Incidence cases in most recent five-year period in age group 15-54 
t mean annual male population In most recent five-year period in age group 15-54, expressed In million person-years at risk 
t: truncated (ages 15-54) age standardised rate In most recent five-year period (using European standard) 
§ ranked in descending order of ASR 
~ EAPC e.g. the net drift parameter from the Age+Drlft model 
95%CI APC 
.. 
model 
(1.2 to 2.3) AC 
(3.9 to 4.9) APC 
(2.0 to 2.6) APC 
(2.6 to 3.2) AC 
(2.5 to 3.0) AC 
i3.1 to 4.9) AC 
(6.1 to 7.6) APC 
(-0.5 to 3.0) A 
(5.0 to 9.8) AD 
(4.2 to 11.7) AC 
(1.6 to 3.6) AC 
iQ.1J() 2.4) AC 
•• refers to the most parsimonious final model providing a good fit: A: Age; AD: Age+Drift; AC: Age+Drlft+Cohort; AP: Age+Drift+Perlod; APC: Age+Drift+Perlod+Cohort 
Residual 
deviancett 
d.f.n p-valueTT 
10.1 14 0.76 
30.7 42 0.90 
41.7 42 0.48 
33.7 35 0.53 
15.0 14 0.38 
7.3 7 0.40 
28.0 24 0.26 
16.1 16 0.45 
15.4 15 0.42 
11.1 7 0.13 
6.4 14 0.96 
3.1 7 0.88 
tt to determine the goodness-of-flt, the deviance was compared with the chi-squared distribution on the degrees of freedom (d.f.) determined by the model. A p-value of <0.05 denotes the full APC model does not yield an 
adequate fit 
a aggregation of England, Scotland 
b aggregation of Florence, Varese Province, Parma Province, Ragusa Province, Turin 
c aggregation of Catalonia, Tarragona; Granada, Murcia, Navarra, Zaragoza 
d aggregation of Bas-Rhln, Calvados, Doubs, Isere, Somme, Tarn 
e aggregation of Basel, Geneva, Neuchatel, St.Gall-Appenzell, Vaud, Zurich 
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Table 6.2: Testicular cancer mortality: populations included in the trends analysis, regular trend and goodness-of-fit statistics 
for best-fitting APe model by European area 
European Country Period available Deaths Person- ASR+ Rank~ 
Area (# of five-year periods) yearst 
Northern Denmark 1969-1998 (6) 13 7.7 0.8 
Finland 1970-1999 (6) 5 7.4 0.8 
Ireland 1969-1998 (6) 4 5.2 0.8 
Norw~ 1969-1998 (6) 6 6.3 0.6 
Sweden 1969-1998 (6) 7 12.1 0.5 
---
United Kingdom 1970-1999 (6) 68 82.5 0.5 
Eastern Bulgaria 1970-1999 (6) 34 11.6 1.4 
Czech Republic 1986-2000(31 39 15.4 1.3 
Hungary 1971-2000 (6) 34 14.5 1.2 
Poland 1980-1994 (3) 114 53.4 1.0 
Romania 1981-2000J4) 48 32.5 0.9 
Southern Croatia 1986-2000 (3) 11 6.3 0.5 
Greece 1969-1998 (6) 9 14.7 0.4 
Italy 1969-199816) 46 81.2 0.4 
Portugal 1980-1999 (4) 11 14.0 0.4 
Spain 1974-1998(5) 29 57.2 0.4 
Western Austria 1971-2000 (6) 12 11.6 0.4 
Belgium 1971-1995 (5) 7 14.1 0.3 
France 1969-1998 J6) 78 82.0 0.3 
Germany 1985-1999 (3) 148 115.8 0.3 
The Netherlands 1970-1999 (6) 22 23.3 0.3 
Switzerland 1970-1994 (5) 17 10.0 0.2 
• mean annual number of deaths In most recent five-year period In age group 15-54 
t mean annual male population In most recent five-year period In age group 15-54. expressed in million person-years at risk 
+ truncated (ages 15-54) age standardised rate In most recent five-year period (using European standard) 
§ ranked In descending order of ASR 
11 EAPC e.g. the net drift parameter from the Age+Drift model 
5 
12 
22 
20 
17 
19 
1 
2 
3 
4 
6 
21 
7 
8 
9 
11 
15 
10 
13 
14 
18 
16 
Overall 95%CI 
trendll 
-4.5 (-5.0 to -4.0) 
-2.2 (-3.3 to -1.0) 
-2.6 (-3.7 to -1.4) 
-5.4 (-6.1 to -4.7) 
-4.7 (-5.4 to -4.0) 
-5.0 (-5.3 to -4.8) 
+1.0 (0.3 to 1.8) 
-3.0 (-4.5 to -1.4) 
-1.0 (-1.5 to -0.4) 
-1.5 (-2.5 to -0.4) 
-0.1 (-1.2 to 1.0) 
4.4 (-0.3 to 10.0) 
-2.5 (-3.6 to -1.4) 
-4.0 (-4.3 to -3.7) 
+2.0 (-0.7 to 5.1) 
-1.7 (-2.6 to -0.7) 
-4.0 (-4.6 to -3.5) 
-3.3 (-4.3 to -2.2) 
-2.7 (-2.9 to -2.4) 
-6.2 (-6.8 to -5.6) 
-5.1 (-5.5 to -4.6) 
-3.3 (-4.0 to -2.7) 
•• refers to the most parsimonious final model providing a good fit: A: Age; AD: Age+Drift; AC: Age+Drift+Cohort; AP: Age+Drift+Period; APC: Age+Drift+Period+Cohort 
APe Residual d.f.n p-
model 
.. 
deviancett valuett 
APC 31.4 30 0.40 
AP 39.2 42 0.59 
AP 31.1 42 0.89 
AP 47.8 42 0.25 
AP 40.1 42 0.55 
APC 29.7 24 0.19 
AP 35.5 35 0.45 
AC 8.7 7 0.27 
AC 18.2 28 0.92 
AD 24.4 15 0.06 
A 29.7 24 0.19 
A 13.0 16 0.68 
AC 33.2 28 0.23 
AP 55.2 42 0.08 
AC 22.7 14 0.06 
AD 42.0 31 0.09 
APC 29.8 30 0.48 
AD 43.5 39 0.28 
AP 45.1 42 0.34 
APC 108.3 6 <0.01 
APC 32.1 30 0.36 
AP 43.0 35 0.17 
tt to determine the goodness-of-fit. the deviance was compared with the chi-squared distribution on the degrees of freedom (dJ.) determined by the model. A p-value of <0.05 denotes the full APC model does not yield an 
adequate fI 
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Figure 6.2: Trends in truncated (15-54) age-standardised incidence and 
mortality rates (Europe) for selected countries. Rates are based on five-year 
aggregates and correspond to the period available 
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Figure 6.3: Age period cohort parameters based on assumptions on period and 
cohort slopes: incidence trends by country within European area (Panels 1-2: 
E Europe; 2-7: N Europe; 8-10: S Europe; 11-12: W Europe). Solid line: assumption of 
zero period slope (drift taken up entirely by cohort); dashed line: assumption of 
positive equal slopes for period and cohort (drift attributed equally to period and 
cohort) 
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Figure 6.3 cont .. 
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Table 6.3: Period and Cohort curvature over and above net drift (incidence) 
Period curvature Cohort curvature 
European Area Country A DevianceD A d.f.c I p-valuea 
1 
A DevianceD I A d.f.
c p-valued 
Denmark Northem 1.7 21 0.43 30.0 9 <0.01 
Finland 16.8 7 0.02 i 33.1 14 <0.01 
I Norway 18.4 7 0.01 I 57.8 i 14 <0.01 
i Sweden 2.8 5 0.72 52.1 I 12 <0.01 
United Kingdom 2.4 2 0.30 22.2 9 0.01 
Eastem Czech Republic 1.3 1 0.25 39.4 8 <0.01 I 
Slovakia 27.5 4 <0.01 I 35.7 11 <0.01 ! 
South em Italy 0.2 1 0.69 'I 12.2 8\ 0.14 i 
Slovenia 0.01 1 0.94 9.9 8 II 0.27 
Spain 1.7 1 0.20 16.1 8 0.04 
Westem France 0.4 2 0.83 19.9 9 0.02 
Switzerland 1.8 1 0.18 I 29.5 8 <0.01 
6.3.3.2 Mortality 
The ratio of testicular cancer incidence to mortality ranged from 8:1 in the Czech Republic to 
over 30:1 in Switzerland, with a clustering of rates within region more apparent than was 
noted for incidence (Table 6.2). Death rates were generally highest in Eastern and Southern 
Europe, with Bulgaria, the Czech Republic, Hungary and Poland holding the first four 
positions, and Denmark in fifth place. In further contrast to incidence, decreases in testicular 
cancer mortality were observed in 19 of the 22 populations in the most recent two decades, 
with declines of 3% to 6% seen throughout Northern and Western Europe, as well as in Italy, 
the Czech Republic and Hungary. Elsewhere in Eastern Europe (e.g. in Romania and 
Bulgaria), the magnitude of the declines were negligible (Table 6.2), while in the South, 
increases in the overall mortality trend of 2% and over 4% were observed in Portugal and 
Croatia, respectively. 
The declines in mortality rates started first in Denmark, Norway and the U.K. in the 1970s, 
followed a few years later in Sweden, Finland and France. The lower level of recent mortality 
declines in Eastern Europe partially reflects a tendency for the respective downturns to have 
occurred mainly in the last decade of observation, from the late 1980s. 
A deviance analysis of the mortality trends (Table 6.2) indicated that sub-models or the full 
APC model provided an adequate fit in every country, excepting Germany. Period and 
cohort curvature significantly improved the fit in 14 and 13 populations, respectively (Table 
6.4). Downwards trends in mortality rates were seen in most Northern and Western 
European countries (and Italy) from the mid-1970s onwards, translating (in spite of the rapid 
increases in incidence observed) to generation-specific decreases in risk of death for men 
born after 1940 (Figure 6.4). 
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The period-specific trends elsewhere in Southem Europe were difficult to interpret. The 
reduction in risk by calendar period in Greece and Spain since the 1970s led to a 
discontinuation in the increases in risk of death amongst affected birth cohorts. In contrast, 
the risk of death appeared to increase in Portugal and Croatia in consecutive cohorts bom 
after 1950. In Eastem Europe, period-specific dedines were most evident in Hungary (where 
a sufficient span of data was available) and the Czech Republic. The dedines in Bulgaria 
and Romania were seen at least a decade later than in Northem Europe, with cohort-
specific declines suggested only in Romania, and only among generations bom recently. 
Table 6.4: Period and Cohort curvature over and above net drift (mortality) 
Period curvature Cohort curvature 
I 
European Area Country 11 Devianceb 11 dJ.c p-valueQ 11 DevianceD ! 11 d.f.C p-valueo 
Northern Denmark 21.9 5 <0.01 34.6 12 i <0.01 : 
Finland I i 18.5 5 ': <0.01 I 13.9 12 0.31 
Ireland 
51 
I 
23.0 <0.01 11.6 12 0.48 
Norway 26.1 5 <0.01 21.5 12 0.04 
Sweden 35.2 5 <0.01 i 23.5 12 0.02 
United Kingdom 35.3 4 I <0.01 ! 81.3 11 <0.01 
Eastern Bulgaria 15.5 4 <0.01 15.3 11 0.17 I 
Czech Republic 0.4 1 0.55 I 19.1 8 0.01 
Hungary 18.0 4 <0.01 ! 88.7 11 <0.01 
Poland i 0.18 I 2.9 1 0.09 i 11.4 8 
Romania 8.8 2; 0.01 12.9 9 0.17 
Southern Croatia 0.4 1 I 0.54 4.7 8 0.79 I 
Greece 1.3 4 0.86 21.5 11 0.03 
Italy 48.5 51 <0.01 17.9 12 0.12 
Portugal 1.2 2 0.56 18.9 9 0.03 
Spain 7.5 3 0.06 I 10.1 10 0.43 
Westem Austria 44.4 5 <0.01 34.3 12 <0.01 
Belgium 5.6 4 0.23 5.7 11 0.89 
France 85.5 5 <0.01 32.2 12 <0.01 j 
Germany 1.3 1 0.25 ! 48.6 8 <0.01 I 
! I The Netherlands 20.5 5! <0.01 I 28.4 12 I <0.01 , 
Switzerland 40.2 41 <0.01 29.3 11 I <0.01 " 
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Figure 6.4: Age period cohort parameters based on assumptions on period slope: 
mortality trends by country within European area (Panels 1-5: E Europe; 6-11: 
N Europe; 12-16: S Europe; 17-22: W Europe). Solid line: assumption of zero cohort 
slope (drift taken up entirely by period); dashed line: assumption of positive equal 
slopes for period and cohort (drift attributed equally to period and cohort) 
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6.3.4 Discussion of main findings 
This study described the temporal patterns of testicular germ cell cancer incidence and 
testicular cancer mortality in European countries, with particular reference to the importance 
of cohort effects (on incidence trends) and period effects (on mortality trends). Similar multi-
country analyses of incidence in Europe have been compiled previously [453,455], although 
this report extended the analysis to 12 countries, including several in Southern and Eastern 
Europe. The variability in the geographical and temporal patterns within Europe was 
extensive: a five-fold variation in incidence rates was observed as well as a steady rise in 
incidence across populations that varied from 1 % to 6% per annum. Rates rose most rapidly 
in low- to intermediate-risk countries, particularly in Spain and Slovenia. Switzerland was the 
exception to the increasing profile; rates have been extremely high but stable over several 
decades [489]. 
A feature of this study was the suggestion of recent declines in testicular cancer among 
recent cohorts in certain high-risk populations. It can be speculated that a levelling off of 
incidence in such countries may represent a mature phase in the epidemic, relative to lower-
risk countries for which the testiCUlar cancer phenomenon might be considered to be at an 
early phase, with further increases anticipated in forthcoming years. 
Regardless of temporal and geographical disparities, the age-incidence curves of testicular 
cancer are well-known to be largely invariate, implying that the age window of susceptibility 
to strong determinants of testicular cancer is likely equivalent in different populations [460]. 
One of the strongest lines of evidence relates to the importance of factors acting prenatally 
or early in life that may initiate the process of testicular carcinogenesis. The strong causes 
involved in the development of carcinoma in situ, the precursor lesion of all germ cell 
tumours [490], appear identical to the strong causes of testicular cancer [460]. 
Carcinoma in situ most probably occurs during the first trimester of pregnancy, and the 
associations between testicular cancer, genital malformations and prenatal factors suggest 
that the strong causes of carcinoma in situ and, subsequently, of testicular cancer, act 
prenatally. Increased oestrogen exposure in utero has been related to increasing 
abnormities in the development and functioning of the testis [491], and a number of prenatal 
and peri-natal exposure-related factors have been implicated for testicular cancer in 
analytical studies. 
Asides from congenital malformations, of which cryptorchidism is the strongest and most 
consistent determinant [468,492,493], certain prenatal factors have been reported in 
epidemiological studies with some consistency. These include premature birth 
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[462,463,465,466], low birthweight [461-465], high birthweight [463,464], neonatal jaundice 
[464], exogenous oestrogen use [462,466], older maternal age [461,465] and first born 
[461,463-465,467]. Other factors have been suggested: smoking during pregnancy 
[470,494], subfertility [229,495], exposure to viral infections [496] and a sedentary lifestyle 
[497]. 
As has been consistently demonstrated [8,229,455,488], generational influences appeared 
largely responsible for the increasing incidence trends in Europe. Cohort curvature 
significantly improved the fit in all countries, except Italy and Slovenia, where age and age-
drift models already provided a reasonable fit, respectively, possibly because of a lack of 
power to reject these simpler models [381]. Trends in Finland, Norway and Slovenia 
required the full APC model, indicative of some period curvature being in operation in 
addition to the cohort effects. Birth cohort effects can be viewed as a consequence of the 
changing prevalence of the risk determinants of the disease in successive generations, and 
generational increases of testicular germ cell tumour are in accordance with the known 
biology of the disease, with possibly a role for external environmental factors mediated 
through exposure of the developing male embryo [498]. The sharp rise in incidence 
observed around the onset of puberty implies a role of male sex hormones in the 
progression of germ cell tumours. 
A reduced incidence amongst a specific cohort born during World War II was observed in a 
number of countries, particularly in Denmark and Norway, as has been reported previously 
[229,251,455,460,488]. It has been hypothesised that an altered supply of provisions in 
Denmark [460,488] may have impacted on consumption of a variety of foodstuffs and other 
commodities during the German military occupation. Interestingly, the pattern was also seen 
around the same time in Sweden, as previously reported [455], and in Italy, Slovenia, 
France and Switzerland. In Spain, a cohort with minimum risk was also identified, but at 
least a decade later, in the late-1950s. In the remaining countries (Finland, the U.K., 
Slovakia and the Czech Republic), no such break in the generational increases was evident. 
That the observation arises in many European countries suggests that modifications in 
lifestyle, possibly brought about by a war-related supply restriction at this time, were strong 
determinants of the disease, and that they acted very early in life, given the transitory nature 
of the phenomenon [460,488]. If a dietary factor is involved, this would probably concern an 
alteration in maternal diet affecting offspring prenatally or postnatally. A recent study 
hypothesised that the mycotoxin Ochratoxin A, a contaminator of stored foods such as 
cereals and coffee, may be a causal factor [499]. 
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Despite the increases in incidence, decreasing mortality trends of between 3% and 6% per 
annum were observed throughout Northern and Western Europe, and in Italy, the Czech 
Republic and Hungary. The starting point and the rate of decrease in each country appears 
closely related to the dramatic improvements in survival of young and middle-aged patients, 
following the introduction of Cisplatin as a therapeutic agent for advanced germ cell tumours 
[457]. Notable declines were first observed in Denmark, Norway and the U.K in the early-
1970s, followed soon after by Sweden, Finland and France. Further developments of 
Cisplatin-based regimens, improvements in tumour imaging and surgical interventions of 
residual disease, together with a multidisciplinary approach to cancer care, have all 
contributed to the declining mortality trends in the 1970s and 1980s [500]. Thus, in spite of a 
generation-specific increase in incidence, the risk of death has been on the decline in 
generations of men born after 1940 in higher resource countries. 
In several Eastern European countries, where death rates are currently among the highest 
in Europe, the rate of decrease was of a relatively low order of magnitude, in part due to a 
later decline around the mid- to late-1980s, at least a decade after Northern and Western 
Europe. The notable success of chemotherapy in terms of a reduction in mortality were thus 
not uniformly seen across Europe, and slower and later declines in some lower resource 
countries appear to be primarily due to the high cost of appropriate treatment as well as 
inadequate patient management. Of particular and immediate concern were the increases in 
testicular cancer mortality in Portugal and Croatia of 2% and over 4% per annum 
respectively. The cohort analysis clearly shows that the risk of death from testicular cancer 
has increased among men born in these countries since 1950. 
Regarding the presentation of APC effects, the setting of a slope to a particular value should 
be ideally founded on biological or epidemiological evidence, as has been a major theme in 
this thesis in recommending and practising particular methods of APC analysis. Although an 
erroneous choice will induce a bias in all of the effects [107], selecting a range of slopes 
leaves some margin for error, allowing the researcher to contrast the age, period and cohort 
effects, based on their particular preference(s) for the fixed slope, with other less plausible 
specifications [107]. 
The approach used here in presenting APC estimates was predisposed a priori towards a 
cohort-based approach in analysing trends in testicular germ cell cancer incidence, given 
that knowledge of the epidemiology and the biological mechanisms point to the importance 
of generational influences on disease occurrence. Unique estimates of the period and cohort 
effects were presented in two ways, firstly on assuming a period slope of zero, implying birth 
cohort influences were entirely responsible for the time trend. Secondly, by acknowledging 
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the possibility of some increases in rates across all age groups over a period of time, and 
attributing the regular trend equally to period and cohort slopes. The underlying risk factors 
responsible remain elusive for testicular cancer, though the extent of variation in the 
increases perhaps lends some support to the idea of an epidemic in different phases in 
different countries. 
For mortality, a priori evidence suggested that the presentation of trends should incorporate 
the well-known benefits from treatment, which should show up as period-related effects. 
Mirroring the approach to incidence, it was assumed firstly that the regular trend was a result 
of period influences, setting the cohort slope to zero. A second set of presented estimates 
accounted for the possibility of generational influences related to disease occurrence; the 
regular trend was then apportioned evenly to the slopes of period and cohort, as it was for 
incidence. Advances in therapy and the management of testicular cancer since the mid 
1970s have led to large declines in mortality in some European countries, despite the 
unabated increases in incidence. More disturbing in lower resource countries has been the 
apparently slower progress towards delivery of optimal care reflected in the time trends of 
mortality. In countries like Bulgaria and Romania, the first beneficiaries of therapy appear to 
be men born - rather than diagnosed - in the era of this major breakthrough in oncology. 
6.4 Study II: comparison of incidence trends in the main subtypes by cohort 
The main objective of this study was to test the hypothesis that testicular seminoma and 
non-seminoma trends in successive generations largely conform to the same temporal 
patterns, implying that they share the same prevalence and distribution of the main risk 
factors in operation. A version of this section has been submitted to a peer-reviewed journal 
(see Appendix 1). 
6.4.1 Data sources 
Data were obtained from the EUROCIM [160] (see 2.8 for details and standard inclusion 
criteria). The main histological grouping, germ cell tumours (ICD-O codes 9060-91 02), 
generally comprising 95% to 99% of all testicular cancers in men under age 60, was 
abstracted for analysis, as were the subtypes seminoma (9060-9064) and non-seminoma 
(including embryonal carcinoma (9070-9073), malignant teratoma (9080-9085, 9102), 
choriocarcinoma (9100-9101), and mixed tumours}. The dataset was restricted to the age 
group 15-54, to provide a well-defined grouping for the study of trends of histological 
subtypes of germ cell cancers [186]. 
Given the relative paucity of incident cases after stratifying germ cell cancers into seminoma 
and non-seminoma, countries with less than an average of five cases per period in any age 
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stratum were excluded. Eight countries were included in the final analyses (Table 6.5). 
Palpable availability of the testicle together with standardised therapeutic approaches and 
primary inguinal orchiectomy provides the basis for the high proportion of histologically 
verified tumours in most European countries [131]. 
6.4.2 Methods: fitting the APC model 
To allow a systematic evaluation of the histological trends across countries, the results are 
presented using the full APe model, and the non-identifiability problem highlighted as 
previously using assumptions based on the method of Holford [66]. 
6.4.2.1 Characterising the cohort effects 
As underlined in study I of this section, the major contribution of cohort effects has been 
consistently demonstrated in previous reports describing the increasing incidence of 
testicular cancer with time in Europe [8,229,455,488]. Birth cohort effects may be considered 
the consequence of a changing prevalence of known and/or putative risk factors for both 
subtypes in successive generations. It was therefore assumed a priori that cohort effects 
predominated and the period slopes of both seminoma and non-seminoma were on average 
of zero magnitude. The cohort effects were presented as incidence rate ratios with country-
specific reference cohort c = A + P - 7 . Due to small numbers in the cells comprising the 
youngest and oldest cohorts, the corresponding birth cohort effects were not displayed in the 
accompanying figure. 
6.4.3 Results: description of trends 
Figure 6.5 compares, using a scatter plot, the age-truncated (ages 15-54) standardised 
rates (European standard) of seminoma and non-seminoma in eight countries for diagnoses 
1994-96. Rates of seminoma tended to be about a third higher than non-seminoma, but 
there is a clear relationship between the absolute magnitude of the two, with rates of 
seminoma increasing proportionally with rates of non-seminoma in low risk (e.g. Italy, 
France) through to intermediate risk (Czech Republic, Norway) to high-risk countries 
(Denmark and Switzerland). 
265 
Figure 6.5: Truncated age-standardised rates (Europe) of sem·lno 
.  d l' ma versus non-
semmoma m men age 5-54 and diagnosed 1994-96 in eight European t . 
(CR: Czech Republic; 0: Denmark; F: France; I: Italy; N: Norway. Sw . S c~n ~es 
Swi: Switzerland; UK: United Kingdom) , e. wen, 
o 
..-
COCO 
I 
-.::t 
0) 
~,... -
0::: 
C/) 
« co -
ttl 
E 
o CL{)-
E 
Q) 
C/) ..... _ 
" ., 
N -
2 
.0 
• Swi 
.N 
• CR 
Swe. • F 
I I I 
3 4 5 6 7 8 9 10 
Non-seminoma ASR 1994-6 
There were clear increases in the incidence of both histologies with calendar period in each 
European country, with the magnitude of the slopes of seminoma and non-seminoma 
comparable across populations (Figure 6.6). The overall ranking of rates between countries 
was also retained over time. A notable feature of the trends was the observed decline in 
non-seminoma rates in some but not all countries in the last five-year period, concerning 
diagnoses in the 1990s. This pattern was seen in highest-risk countries, Switzerland and 
Denmark as well as in Norway, Italy and Sweden, but not in the Czech Republic and the 
U.K. In France, non-seminoma trends appear to have reached a plateau during the latest 
period. 
No such declines were observed in the seminoma trends (Figure 6.6). The relative 
proportions of seminoma and non-seminoma were largely similar between countries, despite 
the three-fold variation in risk. Seminoma comprised the larger share with 55% to 60% of 
germ cell cancers, leaving 40 to 45% non-seminomas (Table 6.5). The proportions of 
seminoma were slightly higher in low-risk Italy and high-risk Switzerland. 
For the seminoma trends, a sufficient amount of variation in each country was explained 
either by a model representing the linear trend adjusted for age (in France, Italy and the 
United Kingdom) or with additional cohort curvature (the Czech Republic, Denmark, Norway, 
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Sweden and Switzerland) (data not shown). The non-linear effects of cohort over and above 
the net drift provided a statistically significant contribution to the seminoma trends in four of 
the eight countries (Norway, Sweden, Denmark and the Czech Republic), and were of 
borderline significance in two (Italy and Switzerland) (Table 6.6). In contrast, period 
curvature was not required in describing the seminoma trends in any of the study 
populations. 
Figure 6.6: Truncated age-standardised rates (Europe) vs. five-year period of 
diagnosis of pure seminoma (left) and non-seminoma (right) in men aged 15-54 in 
eight European countries (CR: Czech Republic; D: Denmark; F: France; I: Italy; 
N: Norway; Swe: Sweden; Swi: Switzerland; UK: United Kingdom) 
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Table 6.5: testicular germ cell incidence: populations included in the trends 
analysis by histological subtype 
Country Calendar Person- Incidence %of Incidence 
Period' yearst (seminoma) tt germ (non-seminoma) tt cell" 
Czech Republic 1985-1999 (3) 3.1 179 54.8% 148 
Denmark 1979-1998 (4) 1.5 154 58.9% 108 
Norway 1953-1997 (9) 1.3 88 57.2% 66 
Sweden 1964-1998 (7) 2.4 116 56.4% 90 
United Kingdoma 1978-1997 (4) 15.1 792 58.3% 567 
Italy" 1983-1997 (3) 1.3 48 61.7% 30 
Francec 1978-1997 (4) 1.2 56 54.4% 47 
Switzerlandd 1983-1997 (3) 0.8 85 60.9% 55 
. data available accorchng to penod of diagnosIS. figure In parentheses represent number of five-year periods available In the arlaiyslS 
t average annual male population expressed in million person-years at risk obtained from most recent 5-year period 
tt annual number of incident cases obtained from most recent 5-year period 
II proportion based on cases in most recent 5-year period 
a aggregation of England (1978-1997). Scotland (1978-1997) 
%of 
germ 
cellI! 
, 452% 
41.1% 
42.8% 
43.6% I 
41.7% i 
38.3% i 
45.6% I 
I 
39.1% 
I 
b aggregation of Florence (1985-1997). Varese Province (1983-1997). Panna Province (1983-1997). Ragusa Province (1983-1997). Turin (1985-1997) 
c aggregation of Bas-Rhin (1978-1997). Calvados (1978-1997). Doubs (1978-1997). lsere (1979-1997). Somme (1982-1997). Tam (1982-1997) 
d aggregation of Basel (1983-1997). Geneva (1983-1997). Neuchatel (1983-1996). St.Gall-Appenzell (1983-1997). Vaud (1988-1996). Zurich (1983-1996) 
Person-
years t 
3.071.444 
1.530.603 
1.251.442 
2,426.688 
15.089.155 
1.238,491 
1.162.916 
834.828 
Table 6.6: Period and Cohort curvature over and above net drift: seminoma trends 
Period curvature Cohort curvature 
European Area Incidence Population A Deviance" A d.f.t p-value9 A Deviance" A d.f.n 
Eastern Czech Republic 3.1 1 0.08 17.5 8 
Northern Denmark 1.3 2 0.52 22.6 9 
Norway 6.2 7 0.52 60.9 14 
Sweden 5.8 5 0.32 43.7 12 
United KingdomS 0.2 2 0.88 7.0 9 
Southern ItalY' 0.2 1 0.64 15.5 8 
Western Francec 3.5 2 0.17 11.8 9 
Switzerland" 1.2 1 0.28 15.6 8 
. + + I Represents the difference In the deViance of the Age+Drift model and the Age Drift Period ~e . 
t Represents the difference in the degrees of freedom of the Age+Drift model and the. Age+Drift+Pe.riod model . 
§ to determine the goodness-{)f-fit. the change in deviance was compared with the chl-Squared dlstnbution on the change In degrees of freedom between the models 
- Represents the difference in the deviance of the Age+Drift model and the Age+Drift+Cohort ~el 
tt Represents the difference in the degrees of freedom of the Age+Drift model and the Age+Drift+Cohort model 
a aggregation of England (1978-1997). Scotland (1978-1997) .' 
b aggregation of Aorence (1985-1997). Varese Province (1983-1997). Panna Province (1983-1997). Ragusa Province (1983-1997). Tunn (1985-1997) 
c aggregation of Bas-Rhin (1978-1997). Calvados (1978-1997). Doubs (1978-1997). Isere (1979-1997). Somme (1982-1997). Tam (1982-~997) 
d aggregation of Basel (1983-1997). Geneva (1983-1997). Neuchatel (1983-1996). St.Gall-Appenzell (1983-1997). Vaud (1988-1996). Zunch (1983-1996) 
p-
valued 
0.02 
0.01 
<0.01 
<0.01 
0.63 
0.05 
0.22 
0.05 
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Figure 6.7: Incidence rate ratios of testicular germ cell seminoma (solid line) and 
non-seminoma (dashed line) by birth cohort in eight European countries, 
assuming an overall period slope of zero. The reference category (IRR=1) is 
marked as a closed circle, corresponding to birth cohort A+P-7 
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None of the population-based trends for non-seminoma suffered from a significant I ack-of-fit, 
although the required complexity of the model varied by population (data not shown). In Italy 
and Switzerland, only age effects were required, while both age and period were necessary 
in Denmark and France. Cohort curvature was necessary in explaining the non-seminoma 
incidence trends in three countries (the Czech Republic, the U.K. and Denmark) and were of 
borderline significance in Switzerland (Table 6.7). Period curvature significantly improved 
the fit of the non-seminoma trends in Norway. 
Table 6.7: Period and cohort curvature over and above net drift: non-seminoma 
trends 
Non-seminoma 
Period curvature Cohort curvature 
European Area Incidence Population A Deviance A d.f.T p-values A Deviance I A dJ.n I p-valuec 
Eastern Czech Republic 0.0 1 0.88 21.2 8 
Northern Denmark 3.6 2 0.16 16.6 9 
Norway 30.3 7 <0.01 11.8 14 
Sweden 11.0 5 0.05 15.4 12 
United Kingdoma 3.3 2 0.19 17.4 9 
Southern ItalY' 0.0 1 0.85 6.5 8 
Western Francec 1.6 2 0.45 13.0 9 
Switzeriando 0.8 1 0.38 15.6 8 
. Represents the difference In the deviance of the Age+DrifI model and the Age+DrifI+Period model 
t Represents the difference in the degrees of freedom of the Age+DrifI model and the Age+DrifI+Period model 
§ to determine the goodness~f-fit. the change in deviance was compared with the chi-squared distribution on the change in degrees of freedom between the models 
- Represents the difference in the deviance of the Age+DrifI model and the Age+DrifI+Cohort model 
tt Represents the difference in the degrees of freedom of the Age+DrifI model and the Age+DrifI+Cohort model 
a aggregation of England (1978-1997). Scotland (1978-1997) 
b aggregation of Florence (1985-1997). Varese Province (1983-1997). Parma Province (1983-1997). Ragusa Province (1983-1997). Turin (1985-1997) 
c aggregation of Bas-Rhin (1978-1997). Calvad05 (1978-1997). Daubs (1978-1997). lsere (197S-1997). Somme (1982-1997). Tam (1982-1997) 
d aggregation of Basel (1983-1997). Geneva (1983-1997). Neuchatel (1983-1996). St.Gall-Appenzell (1983-1997). Vaud (1988-1996). Zurich (1983-1996) 
0.01 
0.05 
0.62 
0.22 
0.04 . 
0.60 
0.16 
0.05 
Figure 6.7 displays the incidence rate ratios from the APC model according to birth cohort. 
The incidence trends of seminoma and non-seminoma in successive generations were 
similar, although the trends tended to be more heterogeneous in the more recently-born 
cohorts, where data was more sparse and most of the cases were non-seminomas. The 
exception was Italy, where the trends in histology diverged in generations born after 1945. In 
Switzerland, there was a strong indication of cohort-specific declines in both seminoma and 
non-seminoma rates in consecutive cohorts born since the 1960s. Finally, there was also 
some indication of a plateau in rates of both subtypes in recent generations born in France 
and Denmark, but the observation was more apparent for seminoma. 
6.4.4 Discussion of main findings 
This study provided broad support for the hypothesis that generation-specific trends in 
testicular seminoma and non-seminoma conform to largely the same temporal patterns, 
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implying that they also share important aetiological factors. Trends in pure seminoma and 
non-seminoma were increasing with calendar time in most of the countries studied, although 
there were recent plateaus or minor declines in cross-sectional age-adjusted rates of non-
seminoma in Denmark and Switzerland. Declines in incidence rates of both subtypes were 
also evident among recent birth cohorts in the latter country. 
The importance of birth cohort effects in this study was in accordance with many prior 
reports of combined or subtype-stratified testicular cancer trends in Europe [8,229,455,488], 
the U.S. [459] and Canada [292,481]. Non-linear cohort effects significantly improved the fit 
of the APC model in six countries for both subtypes, indicating the importance of 
generational influences, while period curvature was not required in the majority. Further (as 
was seen in study I for testicular germ cell cancer trends overall), short-term attenuations of 
increasing risk in men born around 1940-45 were evident in Denmark (for both histologies) 
and Norway (seminoma only), and less unequivocally, in Sweden and France, but for both 
subtypes. Such observations have been reported previously for incidence trends in the 
Scandinavian countries, not only for testicular cancer trends in general but also for both 
subtypes [251,455,460,488,501]. In Denmark, the temporary irregularity has been 
hypothesised to be at least partially a result of specific events (e.g. dietary changes or 
tobacco consumption) at the time of German occupation during the Second World War 
[460]. The similarity of the subtype trends implies such a wartime effect would act in an 
identical manner on seminoma and non-seminoma. 
The observed lag of approximately 10 years in the age at peak incidence of subtypes has 
been consistently reported in Western populations, with non-seminoma peaking earlier, in 
men aged in their late twenties [186]. The differential age profile may perhaps reflect that 
non-seminoma is more aggressive and rapidly-growing than seminoma at diagnosis; the 
proportion of metastatic to localised tumours is often higher for non-seminoma than 
seminoma [460]. Any departure from the steady increases in testicular cancer over time is 
therefore likely to occur for non-seminomas some years ahead of seminoma. This appears 
as an artefact of analysis on the period scale that is absent on the birth cohort scale. With a 
narrow time window of susceptibility to exposures earlier in life, and a biologically constant 
time to diagnosis, all temporal changes in rate-limiting exposures should appear as cohort 
effects. 
Some evidence of a plateau in the cohort-specific risk of both types was observed amongst 
recent cohorts in some populations (Czech Republic, Denmark and France), although it is 
unknown whether there will be declines subsequently. With the exception of Italy, the 
subtype trends followed a rather similar generational course, and the homogeneity parallels 
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several previous observations reported for temporal variations in testicular germ cell 
incidence. The period-specific decline in non-seminoma (but not seminoma) seen in 
Switzerland in the 1990s, is in agreement with reports describing trends in the Vaud region 
[502]. However, the observation in this study of a diminution in risk, evident since the mid-
1960s, in both histologies in consecutive Swiss cohorts, adds weight to the hypothesis that 
only a delay of around a decade in the clinical manifestation of cancer distinguishes 
seminoma from non-seminoma. 
In the unavoidable presence of non-identifiability of the three effects - the linear 
interdependency arising from cohort being entirely defined in terms of period and age-
analysing and interpreting parameter estimates via the APe model is inherently problematic. 
In circumventing the problem using Holford's method [66], and setting the period component 
of Holford's drift to zero in each country, it has been assumed that the rising regular trend is 
exclusively the result of a birth cohort phenomenon, and that there are no diagnostic or 
coding artefacts that would lead to increases or decreases in rates with calendar time. The 
prominence paid to the operation of cohort effects would seem a reasonable assumption 
given that carcinogenic development of both seminoma and non-seminoma is likely 
mediated through early-in-life or in utero exposures [458,460]. If left untreated, testicular 
cancer is highly fatal, and diagnostic or coding artefacts seem unlikely to be responsible for 
much of the rapid rises in the regular trend [186]. 
Diagnostic changes in one or both subtypes cannot be entirely excluded however. In Italy, 
the cohort effects, in discordance with other countries, diverge after the late 1940s. The 
recent seminoma:non-seminoma incidence ratio is unusually high in Italy, while the trends in 
non-seminoma are rather flat. Non-linear period effects, a potential indicator of sudden 
temporal changes related to artefact, were non-significant for either subtype, although a lack 
of power to reject simpler models [381] cannot be discounted. 
It is worth considering the possibility that artefactual changes were in operation but these 
influences were gradual, occurring throughout the study period. Such linear changes in 
period cannot be tested or quantified and would go undetected in the APe analysis. If such 
a linear component was present, and if the magnitude of the period slopes differed between 
subtypes, adjustment, were it possible, may have provided more consistency between 
cohort effects for seminoma and non-seminoma in Italy, in line with the APe trends seen 
elsewhere. 
The observations in study II are in broad agreement with a number of previous studies 
examining cohort trends in the two main subtypes. Using a varying level of analytic 
sophistication, a general consensus has emerged of increasing trends of similar magnitude 
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by subtype, based on European reports in Denmark [460], Norway [251], England and 
Wales [503] and more recently in a number of Northern European countries [229], as well as 
from reports in Canada (Ontario) [481] and the U.S. (Connecticut) [459]. 
One study found increasing trends between 1963 and 1984 in Scotland for both histologies, 
with non-seminoma increasing more rapidly than seminoma. [504] Some differences in 
trends in the subtypes have been found by two recent studies analysing testicular cancer 
data up to 1998 in the U.S. [291], and up to 1995 in Canada [292]. In the U.S. study (based 
on SEER data), non-seminoma reached a plateau in white men, with seminoma:non-
seminoma ratios of 50:50 in the mid-1970s comparing with 60:40, some 20 years later [291]. 
The Canadian study reported that subtype trends differed by age and by birth cohort. Using 
a method analogous to the present study, the authors suggested that there were distinct 
cohort patterns in aggregated data from Ontario, Saskatchewan, and British Columbia [292]. 
The subtype trends they plotted from the APC model were however not dissimilar in 
successive cohorts born after 1920, and could in fact be interpreted as indicators of 
homogeneity in the seminoma and non-seminoma trends. 
Further evidence that the subtypes share the same aetiological factors comes from several 
analytical studies examining pre- and perinatal exposures and the risk of testicular cancer. A 
Danish study [461] argued that seminoma and non-seminoma have similar causes, finding 
that while cryptorchidism, birth weight and maternal age were all independent risk factors for 
testicular cancer, only the latter differed by subtype, with higher maternal age being more 
strongly associated with seminoma. Recent studies in Canada [466], the U.S. [467] and 
Sweden [475] have generally upheld the hypothesis of a similar aetiology; despite markers 
of high oestrogen levels consistently increasing the risk of germ cell cancer, little evidence of 
heterogeneity on stratification by histological group have emerged. 
Some studies have reported statistically significant differences in risk factors for seminoma 
and non-seminoma, but these have not been found consistently across studies. Thus, 
Sabroe and Olsen [465] found elevated risks of seminoma in Danish men of a lower birth 
order, while a Swedish study [463] reported that markers of oestrogen during pregnancy, 
higher maternal age, higher placental weight and lower parity affected seminomas, and 
factors related to neonatal growth retardation, specifically lower maternal age and lower 
placental weight, increased the risk of non-seminoma. In a U.K study, a history of sexually-
transmitted disease and participation in certain sports was linked to a higher risk of non-
seminoma cancer [479]. The impact of socio-economic status on testicular cancer is not 
conclusive, although men belonging to higher socio-economic groups are often reported to 
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be at higher risk of testicular cancer relative to less privileged groups [505,506]. As with 
other variables, the risk estimates tend not however to be consistent by subtype [506]. 
Difficulties in achieving sufficient statistical power to detect truly significant effects in 
analytical studies make such investigations problematic, while the multiple testing of 
candidate risk factors increases the likelihood of finding statistically Significant effects by 
chance. In parallel, statements as to the degree of homogeneity of seminoma and non-
seminoma trends must be equivocal, given that the identifiability problem precludes the 
possibility to present and compare unique estimates of the cohort trends. Nevertheless, on 
assuming that only generational influences operate, the incidence trends are rather similar in 
this time dimension for most European countries studied, indicating that the subtypes shared 
largely the same distribution of causal factors within a number of diverse populations. Where 
the subtype trends substantially diverged (in Italy), it may be worth investigating whether 
they may be explained by the presence of linear period effects, implicating reasonably 
steady changes in diagnostic or coding artefacts with calendar time. 
This study provides further evidence of the aetiological similarity of testicular seminoma and 
non-seminoma. The importance of birth cohort coincided with the view that, given a short 
time interval of susceptibility to exposures earlier in life and a biologically constant time to 
diagnosis, all temporal changes in rate-limiting exposures should appear as generational 
effects. Trends in seminoma and non-seminoma conform to largely the same temporal 
patterns on this scale, implying that they share important aetiological factors. 
6.5 General discussion 
6.5.1 Brief summary of main findings 
Study I profiled testicular cancer incidence and mortality across Europe, and the effects of 
age, period and generational influences using APC modelling. A five-fold variation in 
incidence rates was observed and with average increases in incidence ranging from around 
6% per annum (Spain and Slovenia) to 1 % to 2% (Norway). 
In contrast, declines in testicular cancer mortality of 3-6% per annum were observed in the 
1980s and 1990s for the majority of 22 countries studied, particularly within Northern and 
Western Europe. The mortality trends in several European countries were however rather 
stable (Romania and Bulgaria) or increasing (Portugal and Croatia). Short-term attenuations 
in increasing cohort-specific risk of incidence were indicated among men born between 
1940-45 in seven European countries. In Switzerland, successive generations born from the 
mid 1960s may have experienced a steadily declining risk of disease occurrence. 
Study II compared generation-specific trends in eight European countries, hypothesising that 
similar temporal patterns by birth cohort implied seminoma and non-seminoma had a largely 
comparable aetiology. Using the APC model, the focus was on cohort effects assuming zero 
period slope. Despite uniform overall increases by calendar period, declining rates of non-
seminoma, but not pure seminoma, were observed in the majority of countries during the 
1990s. The subtype trends were however largely analogous on a birth cohort scale. Notable 
observations were a decline in rates of both subtypes among recent birth cohorts in 
Switzerland, and a short-term wartime effect in several countries, involving an attenuation of 
increasing risk of both subtypes in men born 1940-5. Departures from the steady increases 
in testicular cancer over time were likely to occur for non-seminoma some years ahead of 
seminoma on a period scale. 
6.5.2 Reconsideration of methods and further exploration 
Presentation of the APC effects in this chapter relied on the assumption that the regular 
increase in incidence of testicular cancer and its subtypes was entirely a birth cohort 
phenomenon, reasonable perhaps, given the aforementioned biological and epidemiological 
evidence supporting its role. Another approach would have been to restrict the age slope to 
a value that provided a suitable age structure, analogous to the methods used to describe 
cervical squamous cell carcinoma trends in Chapter 4. 
Testicular germ cell cancer occurs most commonly among men aged 20-34, incidence rates 
increasing after the onset of puberty and declining after the age of 35 years. Rather 
homogenous age curves are seen in different populations in cancer diagnosed under the 
age of 60, irrespective of the ethnicity of the population or the magnitude of its incidence 
rates [453,454]. This characteristic may provide a platform to obtain a unique solution to the 
APC model on assuming - instead of a period slope of zero - a particular age slope that 
provides an age curve that closely resembles that what might be considered a reference 
curve for testicular cancer. If the uniformity of age curves in different European populations 
can be demonstrated, the results could be pooled (analogous to Gustafsson's scaled 
incidence ratios for cervical cancer [221], and a ratio of two age points that are reasonably 
constant across populations measured. One potential problem is the prospect of a wide 
range of age slopes seemingly providing biologically plausible age distributions for testis 
cancer, leading to a correspondingly wide selection of possible period and cohort 
parameters. 
In parallel to the possibilities for modelling trends in the main histological subtypes of 
cervical cancer as outlined in 4.6.3.1, trends in seminoma and non-seminoma could also be 
examined within a single framework. Seminoma and non-seminoma have distinct age-
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distributions, with seminoma typically occurring 10 years later in life than the faster-growing 
and more aggressive non-seminoma [186]. Other than the different age at peak incidence 
however, the age curves are similar and potentially one may assume that seminoma and 
non-seminoma have the same age profile. An alternative approach to presenting the cohort 
effects would be to estimate a single age slope that reasonably characterises the age 
structure of both subtypes, thereby allowing a comparison of birth cohort trends that is 
independent of assumptions on the linear trends in period of diagnosis. 
6.5.3 Future prospects for testicular cancer prevention 
Epidemiological studies of testicular cancer will continue to be fundamental in gaining insight 
into a disease with few known causal determinants, and at present, little scope for primary 
prevention. While the underlying risk factors remain elusive, the temporal and geographical 
variability in testicular cancer occurrence may point to an epidemic in different phases in 
different countries - the result of country-specific differences in the prevalence of one or 
several ubiquitous and highly prevalent environmental determinants of the disease. 
Advances in treatment have led to major declines in testicular cancer mortality in many 
European countries from the mid-1970s, which has translated to cohorts of men at 
successively lower risk of death from the disease. Slower progress in the delivery of optimal 
care is however evident from the mortality trends in several lower-resource countries in 
Southern and Eastern Europe. In these countries, it appears that men born - rather than 
diagnosed - in the mid-1970s will be among the first recipients of appropriate therapy for the 
disease. 
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7 Conclusions 
This thesis has critically reviewed graphical and analytical approaches to temporal analyses 
of cancer rates and provided a broad set of recommendations to inform a detailed analysis 
of cancer trends across Europe. The introductory chapter made the case for the utility of the 
study of temporal analyses, and in particular, the role of birth cohort analyses. This 
emphasis on the established benefits of such investigations was appropriate given that 
subsequent chapters were devoted to outlining the complexities that threaten to obscure 
interpretation. 
One has to contend with the numerous grey areas that constitute research in this area. An 
obvious concern is the possible distortion of cancer trends by data artefact, and the 
difficulties getting a handle on the extent of its impact. In terms of methodology, this thesis 
paid particular prominence to a critical assessment of the numerous graphical and statistical 
approaches at hand; some broad guidelines were provided, with particular reference to 
fitting and presenting effects from the APe model. 
The methodological review focussed on the role of the model in the analysis of trends and 
the specific methods available to deal with the identifiability problem. In recent years, APe 
analyses have become standard in studying cancer trends. That a diverse range of 
techniques are applied in practice reflects the numerous proposals purporting to circumvent 
the problem. This heterogeneity in methods may in part be hypothesis-driven, but it also 
exposes the difficulties achieving consensus where there is an intrinsic inexactness in any 
given solution. 
The wide range of available methods and an absence of a unique solution may facilitate 
ambiguity in the analysis and presentation. The observations and recommendations put an 
emphasis on clear and consistent graphical approaches and APe analyses that borrowed 
some form of biological or epidemiological support in providing one or more solutions. For 
this and other reasons, Holford's approach was particularly recommended, and employed in 
relation to several lines of external support to describe trends of cervical, endometrial and 
testiCUlar cancer in Europe. 
The final remarks revisit the main objectives of this thesis. The methods of analysis using 
APe models are considered once more in 7.1; the utility of the model, with respect to the 
stUdies assembled in later chapters are reviewed in 7.2. Finally, the question of what 
constitutes a systematic analysis of cancer trends is addressed in 7.3. 
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7.1 The guiding principle in APe modelling 
In their 1997 investigation of the utility of three APC approaches to NHL incidence trends 
, 
McNally et al comment that "several methods of analysing age, period and cohort effects are 
available [although there is] no general agreement as to which is most appropriate" [227]. 
Both Clayton and Schifflers [68] and Holford have however unanimously identified methods 
that they consider inappropriate. Rephrasing the concluding comments by Clayton and 
Schifflers in their second APC paper, "[the] relationship between age, period and cohort 
implies the search for methods that bypass identifiability problem is both futile and pointless" 
[68]. In a similar vein, Holford states that "some current methods are completely arbitrary 
and only serve to obscure the real limitations in summarising time trends for disease" [107]. 
Clearly then, the purely mathematical solutions outlined in 3.4.4 provide only arbitrary 
interpretations; they are informed by algebraic rather than biological properties. 
On the opposite end of the spectrum of solutions, non-identifiability may be resolved by the 
explicit introduction of detailed information regarding the biological basis of the disease. 
Multistage models have important applications in this area, particularly for cancers where, 
through advances in the understanding of molecular biology, the processes of 
carcinogenesis is more established, as they are for cancers of the lung [507] and large 
bowel [248]. Understanding of the disease process is however limited for many cancer 
forms, and ascertaining reasonable description of period and cohort trends, weak proxies as 
they are for their respective underlying determinants, need be achieved via other 
approaches. 
Analyses should highlight rather than hide the identifiability problem. Estimable functions 
represent an honest and informative way to better understand temporal influences. Clayton 
and Schifflers advocate regular trend estimation and the search for identifiable functions. 
These ideas complement Holford's proposal that partitions the non-identifiable linear 
components and their identifiable curvature. This approach is flexible in that one can readily 
place the drift component with cohort or period explicitly and rather precisely. By specifying 
plausible assumptions regarding the linear trends of one time component, or by specifying a 
range of credible values, the nature of the identifiability problem is emphasised; presenting a 
range of solutions effectively steers the description, and the search for explanation, away 
from over-interpretation. 
Selecting one set of effects would necessarily be arbitrary were it that specific information on 
the possible artefactual, biological and epidemiological factors involved were lacking. If 
however external knowledge from these sources can be brought to bear in support of a 
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particular choice of just one slope, all slopes are determined and, on adding curvature 
terms, provides a unique description of the age, period and cohort effects. 
7.2 The utility of APe models in practice 
Six Europe-wide studies of age, period and cohort trends in three cancers formed a major 
part of this thesis. The techniques used were informed by the recommendations in 3.5 
(Table 7.1). Graphical deSCriptions of the observed trends involved C by A and P by A 
descriptions, and joinpoint regression was used to convey the recent trends in endometrial 
cancer incidence and mortality. Five of the studies focussed on APC modelling as an aid to 
graphical approaches in providing clues as to the underlying determinants. Recent and past 
estimates of the net drift were presented as per the recommendations. 
Table 7.1: Specific methods applied to site-specific studies and relevant section 
where topic is discussed 
Main recommendations for Cervix Cervix Endometrium Endometrium Testis Testis 
temporal analyses Study I Study II Study I Study II Study I Study II 
Observed rates vs. period and o (4.4.3.2) 0(4.5.3.6) 0(5.4.3.2) 0(5.5.3) 0(6.3.3) 
cohort by age. Apply rules for 
presentation (0) 
0(5.4.2 and 
Joinpoint regression (3.2.3.2) 5.4.3.2) 
APC modelling to aid graphical 0(4.4.2 and 0(4.5.2 and 0(5.5.2 and 0(6.3.2 0(6.4.2 
approaches (3.3) 4.4.3) 4.5.3) 5.5.3) and 6.3.3) and 6.4.3) 
Recent and past estimates of 0(4.4.3) 0(4.5.3) 0(5.5.3) 0(6.3.2) 
net drift (3.4.1.1.3) 
Use of Holford's approach and 0(4.4.2) 0(4.5.2.2) 0(5.5.2) 0(6.3.2) 0(6.4.2) 
external biological information 
to provide unique solution 
(3.4.2) 
Second differences (3.4.3.1) 0(4.4.2.5) 
Spline regression (3.4.5.5) 0(4.5.2.2.2) 
Holford's approach required speculation with regards the slope of one effect. Where 
possible, the age slope was fixed; reasonable assumptions were introduced regarding the 
characteristics of the underlying age curves that were in keeping with the possible 
underlying biological mechanisms for the cancer under study. Such an approach was a 
prerequisite in investigating the trends of cervical squamous cell carcinoma incidence. By 
fixing the age slope to a value that produced well-documented unique age curves-
assumed to follow the natural history of HPV infection - it was hypotheSised that the period 
279 
! 
and cohort parameters from the determined APC models would reflect the impact of 
screening and changing sexual behaviour, respectively. 
Increasing risk in successive generations born after 1930 emerged in most European 
countries (possible exceptions being the Czech Republic, France, Sweden, and 
Switzerland), but well-organised screening programmes have been highly effective in 
reducing the overall incidence of cervical squamous cell carcinoma. Disconcertingly, cervical 
screening programmes have still not been implemented in certain European countries where 
rapid increases in risk in successive generations of women have been observed. 
In providing a broad description of the trends and the separate impact of screening vs. HPV 
infection, the analytic approach worked reasonably well in providing an informative and 
realistic solution, but remains an arbitrary one, by definition. Two age curves with ages at 
peak incidence five years apart could provide rather different interpretations of the resulting 
period and cohort effects. There were difficulties in obtaining plausible age curves in some 
countries, related both to random variation associated with the underlying rates, and the 
short span of data available and the subsequent trends were less informative. 
For cervical adenocarcinoma, there was less evidence for a steady stage age curve; instead 
the observation that screening had historically failed to detect pre-invasive disease of the 
adenocarcinoma subtype was considered, and an assumption of a period slope of zero was 
specified in the APC model. While increasing specificity over time of cervical cancer 
subtypes may have been responsible for some of the increases, the trends implicated both a 
changing prevalence of persistent infection with high-risk HPV types as well as the inability 
to detect cervical adenocarcinoma within screening programmes. Screening may have had 
a recent impact in reducing cervical adenocarcinoma incidence in the U.K., Denmark and 
Sweden during the 1990s. 
Trends in endometrial cancer incidence also involved APC analyses and attempt to preserve 
an element of biological plausibility. In the presentation of one set of trends, the age slope 
was fixed to an age curve that was reasonably flat for the ages 65-69,70-74, and 75-79 
under the hypothesis that endometrial cancer increases with age were a consequence of 
unopposed oestrogens; and when opposed by progestins, at around the menopausal age, a 
large reduction and stability in risk of endometrial cancer follows. Although the assumption 
was plausible, the method was rather simplistic, and it was considered appropriate to 
compare the method with a solution assuming the changes in risk involved cohort 
influences, obtained on assuming a period slope of zero. 
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Trends in the observed rates - in combination with the two solutions from the APC model _ 
provided evidence of changes in several established risk factors over time. In 
postmenopausal women, changes in HRT use (where prevalent), reproductive behaviour 
and prevalence of overweight and obesity may have partially accounted for the observed 
increases. CDC use may have been responsible for declines observed among 
premenopausal women in more affluent European countries, but increases in obesity and 
decreases in fertility in Europe implies endometrial cancer will become a more common 
neoplasm among women of postmenopausal age in the future. 
Age, period and cohort effects of testicular germ cell cancer incidence were presented using 
Holford's method on assuming the regular trend was taken up birth cohort, in line with 
biological and empirical evidence pointing to generational in utero or early in life influences 
as the major causes of cancer of the testes. It was still considered necessary however to 
simultaneously provide solutions that attributed half of the drift to period. For testicular 
cancer mortality, the introduction of effective treatment from the 1970s would have likely 
impacted on the increasing incidence in consecutive generations as a period effect. An 
approach to providing a solution or solutions was not easy to configure, but one intuitive 
solution was to take the converse of the approach to incidence -a period trend was first 
assumed, but a second solution allocated Holford's drift equally to period and cohort. 
Geographical and temporal variations were apparent in testicular cancer incidence, but the 
average increases in rates of between 2% and 5% per year were in contrast with the 
corresponding declines in mortality, particularly in richer European countries. Short-term 
attenuations in increasing cohort-specific risk of incidence were indicated among men born 
between 1940-45 in seven European countries, with successive generations born from the 
mid-1960s possibly at a steadily declining risk of testicular germ cell cancer occurrence in 
Switzerland. 
A more focussed study compared generation-specific trends of the main histological 
subtypes of testicular germ-cell cancer, hypothesising that analogous trends by birth cohort 
implied seminoma and non-seminoma had a largely similar aetiology. Cohort effects were 
again assumed to dominate, and a zero period slope fixed in the APC model. The subtype 
trends were indeed rather comparable on a cohort scale. It was speculated that on a period 
scale, departures from the uniform increases in testis cancer overall would occur for the 
more aggressive non-seminomas some years ahead of seminoma. 
Each of these chapters closed with a discussion of approaches that might be considered in 
future studies, and this thesis does not pretend to provide a definitive analysis of trends by 
age, period and cohort for these sites. This work may be seen as analytic in terms of the 
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modelling strategies, but it remains necessarily descriptive in its interpretation. Each of the 
studies hopefully will act as a template for further developments that tailor APC analyses 
towards the inclusion of pertinent biological and epidemiological information, where 
available. More systematic and quantifiable approaches to APC modelling are certainly 
warranted. These may have particular application in the study of subtypes of both cervical 
and testicular cancer, for which a shared aetiology seems likely, as was outlined in Chapters 
5 and 6 respectively. The final section deals with the possibilities of achieving a truly 
systematic approach to time trend analyses of cancer rates. 
7.3 The utility of systematic approaches in practice 
An integrated approach to data collection, analysis and presentation facilitates comparison 
and objective interpretation; insights into cancer may be derived from the variability in trends 
between and within subgroups. In this thesis, the need for a systematic approach to data 
collection, analysis and presentation was considered from the outset, and the intention was 
to systematically analyse trends both in terms of the populations and cancers under 
investigation. In reality however, only the analyses across countries could be considered as 
systematic: there was consistency in aspects of the collection of data (inclusion criteria), 
analysis (single methodology) and presentation (uniform graphical and tabular descriptions). 
Controlling these analyses across populations for a given disease is necessary if one is to 
critically compare temporal variations in different populations and interpret these differences 
in terms of the factors that may have produced the observations. The temporal analyses did 
not however impose such a limitation on analyses across the three cancer sites. In part, this 
reflected a requirement to adapt methods to answer research hypotheses that were specific 
to the cancer under investigation. More fundamentally, a customised approach to these 
analyses reflected the importance of bringing to bear external information on the biology or 
epidemiology specific to the cancer under study. Given the heterogeneous nature of the 
disease entities that comprise the cancer types under study, it would have been 
inappropriate to do otherwise. 
It is worth considering previous large studies examining broad groups of cancers in one or 
more populations and assessing the degree to which a systematic approach can be applied 
in practice. Two compilations of time trends of incidence and mortality of multiple sites 
published 1993-94 varied substantially in this respect [8,113]. Coleman and colleagues 
published a strictly systematic attempt at the analysis of worldwide trends of the major 
cancers in four continents [8], with a consistent APC modelling approach and presentation 
undertaken by five authors. The results, although comprehensive and comparable, were 
highly processed, and may have suffered from a lack of basic description of the observed 
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data, and the absence of tailored analyses specific to particular cancer types and/or 
populations. Dealing as it did with over 2000 sub-analyses however, the study demonstrates 
a very understandable motive for a strictly systematic approach: the need to efficiently 
process large amounts of information. 
The editorial process in the monograph by Doll et al allowed considerably more flexibility; 
each chapter was left to a designated cancer-specific expert or experts to decide on the 
selection of data, the presentation format and interpretation [113]. The result of which was a 
rather disparate set of studies on cancer-specific trends: very different approaches to the 
graphical and statistical display of trends were provided in each chapter, yet this often 
enabled a much more detailed exposition of the trends of specific cancers, centred around 
the authors' hypotheses and interests. 
Several publications have examined cancer incidence and mortality trends in one country 
using relatively systematic but more descriptive approaches [23,208]. One interesting 
initiative by Rouch et al was to provide sets of parameter estimates for each subgroup 
analysis as an Appendix, thus enabling the interested reader to reconstruct the trends 
according to a different set of model constraints [208]. Others have published brief 
descriptive reviews of mortality trends in Europe [508] using a specific APC modelling 
technique [120]. 
Some of the inconsistencies in the Doll et al monograph are perhaps also embedded in the 
work in this thesis; the analytic components of the six studies that comprise Chapters 4 to 6 
are neither consistent between cancer sites, subtype or the measure investigated 
(incidence, mortality), as seen in Table 7.1. The underlying importance attached to 
addressing biological and epidemiological evidence on a site-by-site basis may explain 
some of the disparity. In the sprit of the Doll et al book, the work in this thesis also involved 
numerous collaborators in three cancer-specific working groups (see Appendix 2). Although 
the aims and methods were set out a priori (by the first author), collaboration naturally 
allowed constructive comments, opinions and ideas that may have altered certain aspects of 
the analysis and presentation of the data. 
This work has then raised the question of whether a single methodological approach can be 
applied to multiple cancer sites. It is clearly problematic to make a systematic approach 
given that a temporal analysis of two cancer sites may differ in a number of respects. The 
analyses in this thesis incorporated (where informative) trends in the major histological 
subtypes. For cervical cancer, differences in screen detection and (possibly) aetiology drive 
the need for stratification. For testicular germ cell cancer the main subtypes appear to be 
similar; confirmation was sought on the basis of cohort trends in different countries. 
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Hypotheses based on existing knowledge will drive the type of temporal analyses necessary 
to answer them, and these must reflect the possible artefacts, major risk factors, 
interventions and prospects for prevention; these clearly differ considerably between cancer 
sites, anatomical subsites and histological subtypes, and so forth. 
The utility of temporal analyses and their application to the study of cancer is evident from 
the hundreds of pivotal time trends studies published over the last 50 years, and such 
investigations will continue to be of fundamental value in the next half century. This thesis 
provides a small contribution to maintaining this outlook. It has reviewed and recommended 
graphical and statistical approaches to the analysis of cancer trends, and applied these in 
practice. One may hope, if not antiCipate, that these will be given due consideration in future 
studies of time trends. In particular, optimal returns from the APC model will require a shift of 
emphasis from ambiguous choices of presentation, to those that consider what is known 
regarding the cancer in question. Our ever-expanding understanding of the biology and 
epidemiology of the disease should certainly provide for this necessary change from 
arbitrariness to enlightenment. 
Appendix 1: Peer-reviewed articles published as a result of this research 
Chapter 4: Cervical cancer 
Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, M011er H, Hakama M, Parkin DM. 
Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing 
risk and the effects of screening. Cancer Epidemiol Biomarkers Prey 2005;14(3):677-86. 
Bray F, Carstensen B, M011er H, Zappa M, Primic Zakelj M, Lawrence G, Hakama M, 
Weiderpass E. Incidence trends in adenocarcinoma of the cervix in 13 European countries, 
Cancer Epidemiol Biomarkers Prey, 2005;14(9). 
Chapter 5: Endometrial cancer 
Bray F, Loos A, Oostindier M, Weiderpass E. Geographical and temporal variations in 
cancer of the corpus uteri: incidence and mortality in pre- and post-menopausal women in 
Europe, IntJ Cancer;117(1):123-31. 
Bray F, M011er H, dos Santos Silva I, Weiderpass E. Endometrial cancer incidence trends in 
Europe: underlying determinants and prospects for prevention. Cancer Epidemiol 
Biomarkers Prey, 2005;14(5):1132-42. 
Chapter 6: Testicular cancer 
Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, M011er H. Trends in testicular cancer 
incidence and mortality in Europe: continuing increases in incidence but further declines in 
mortality. Int J Cancer, in press. 
Bray F, Richiardi L, Ekbom A, Forman 0, Pukkala E, Cuninkova M, M011er H. Do testicular 
seminoma and non-seminoma share the same aetiology? Evidence from age-period-cohort 
analysis of incidence trends in eight European countries. Cancer Epidemiol Biomarkers 
Prey, in press. 
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Appendix 2: Declaration and acknowledgement of co-investigators 
The research was undertaken whilst F Bray embarked on a collaborative time trends project 
at the International Agency for Research on Cancer (IARC), Lyon, France. The research 
was part of the objectives of Comprehensive Cancer Monitoring Project (CaMon) project 
funded by the European Commission, Agreement No. 812.327599 (2001 CVG3 - 512), 
involving analysis of time trends of incidence of, and mortality from specific cancers in 
Europe. 
The research undertaken in the Chapters 1 through 3 was constructive in establishing the 
methodology in the time trends project. The analysis and interpretation of time trends in 
Chapter 4 through 6 are the consequence of F Bray applying the main outcomes and 
conclusions of these chapters to provide original analyses of European incidence and 
mortality data for the three cancers specified. These three chapters formed the basis of six 
papers disseminated in peer-reviewed journals by a collaborative writing groups that 
consisted of an IARC secretariat, enlisted cancer registry personnel, and a senior 
epidemiologist who acted as coordinator of the activity. F Bray was substantially involved in 
the planning, analysis and interpretation stages of each paper, and wrote the first and 
subsequent drafts leading to submission and the publications cited in Appendix 1. 
The three chapters and the articles are a product of a successful collaboration with 
numerous researchers in each of the Working Groups and the European cancer registries 
whom contributed not only their incidence data, but also expert commentary on the final 
draft of the manuscript: 
Cervical Cancer Working Group 
Marc Arbyn 
Bendix Carstensen 
Anja Loos 
Gill Lawrence 
Peter McCarron 
Henrik M011er 
Maja Primic Zakelj 
Elisabete Weiderpass Vainio 
Max Parkin 
Matti Hakama 
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Endometrial Cancer Working Group 
Isabel dos Santos Silva 
Anja Loos 
Henrik Moller 
Mariette Oostindier 
Elisabete Weiderpass Vainio 
Testicular Cancer Working Group 
Lorenzo Richiardi 
Eero Pukkala 
Anders Ekbom 
David Forman 
Martina Cuninkova 
Henrik Moller 
The European Network of Cancer Registries (Director in parentheses) 
Czech Republic - Czech National Cancer Registry, Prague (Dr Marie Jechova) 
Denmark - Danish Cancer Registry, Copenhagen (Dr Hans H. Storm) 
Estonia - Estonian Cancer Registry, Tallinn (Dr Tiiu Aareleid) 
Finland - Finnish Cancer Registry, Helsinki (Dr Timo Hakulinen) 
France - Registre Bas Rhinois des Cancers, Strasbourg (Dr Michel Velten), Registre 
General des Tumeurs du Calvados, Caen (Dr J. Mace-Lesech), Registre des Tumeurs du 
Doubs, Besan9Qn (Dr Arlette Danzon), Registre du Cancer de I'Isere, Meylan (Dr Franc;ois 
Menegoz), Registre du Cancer de la Somme, Amiens (Mme Nicole Raverdy), Registre des 
Cancers du Tarn, Albi (Dr Martine Sauvage) 
Germany - Saarland Cancer Registry SaarbrOcken (Mr Hartwig Ziegler) 
Iceland - Icelandic Cancer Registry, Reykjavik (Dr Laufey Tryggvadottir) 
Italy - Registro Tumori Toscano, Florence (Dr Eugenio Paci), Registro Tumori Lombardia 
(Provincia di Varese), Milan (Dr Paolo Crosignani), Registro Tumori della Provincia di Parma 
(Dr Vincenzo De Lisi), Registro Tumori della Provincia di Ragusa, Ragusa (Dr Rosario 
Tumino), Piedmont Cancer Registry, Turin (Dr Roberto Zanetti) 
The Netherlands - Eindhoven Cancer Registry, Eindhoven (Dr Jan Willem Coebergh), 
Maastricht Cancer Registry, Maastricht (Dr Miranda Dirx) 
Norway - Cancer Registry of Norway, Oslo (Dr Fmydis Langmark) 
Poland - Cracow Cancer Registry, Cracow (Dr Jadwiga Rachtan), Lower Silesian Cancer 
Registry, Wroclaw (Mr Jerzy Blaszczyk), Warsaw Cancer Registry, Warsaw (Dr Maria 
Zwierko) 
Slovakia - National Cancer Registry of Slovak Republic, Bratislava (Dr Ivan Plesko) 
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Slovenia - Cancer Registry of Slovenia, Ljubljana (Dr Maja Primic-Zakelj) 
Spain - Tarragona Cancer Registry, Reus (Dr Jaume Galceran), Registro de Cancer de 
Granada, Granada (Dr Carmen Martinez Garcia), Registro de Cancer de Murcia, Murcia (Dr 
Carmen Navarro Sanchez), Registro de Cancer de Navarra, Pamplona (Dr E. Ardanaz 
Aicua), Zaragoza Cancer Registry, Zaragoza (Dr Carmen Martos Jimenez) 
Sweden - Swedish Cancer Registry, Stockholm (Dr Lotti Barlow) 
Switzerland - Krebsregister Basel-Stadt und Basel-Land, Basle (Dr Gernot Jundt), Registre 
Genevois des Tumeurs, Geneva (Dr Christine Bouchardy), Registre Neuchatelois des 
Tumeurs, Neuchatel (Dr Fabio Levi), Krebsregister St Gallen Appenzell, St Gallen (Dr 
Thomas Fisch), Registre Vaudois des Tumeurs, Lausanne (Dr Fabio Levi), 
KantonalzOrcherisches Krebsregister, ZOrich (Dr Nicole Probst) 
United Kingdom - National Cancer Intelligence Centre, London (Dr Mike Quinn), Scottish 
Cancer Intelligence Unit, Edinburgh (Dr David Brewster) 
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Appendix 3: R Program and graphical output: Holford's zero period slope 
#set directory and bring in data and R functions 
setwd ("c: /ttdata/bladder. it") 
library (Epi) 
source ("C: /ttprogs/tt. R") 
bladder<-read. table ("bladder. txt" ,header=T) 
# calculate cohort, and specify age, period and cohorts as factors 
bladder<-transform(bladder,cohort = period - age) 
bladder<-transform(bladder, A=factor(age) , P=factor(period) , C=factor(cohort)) 
attach (bladder) 
# index age, period and cohort such that sum of effects is zero 
sumzero_a<-((age-min(age))/S+l) - mean((age-min(age))/S+l) 
sumzero-p<-((period-min(period))/S+l) - mean((period-min(period))/S+l) 
sumzero_c<-((cohort-min(cohort))/S+l) - mean((cohort-min(cohort))/S+l) 
# calculate number of levels for age, period and cohort 
max_a<-max((age-min(age))/S+l) 
max-p<-max((period-min(period))/S+l) 
max_c<-max((cohort-min(cohort))/S+l) 
# fit APC models using orthogonal contrasts with period and cohort slopes both included 
pc_APC<- glm(D/Y-sumzero-p+sumzero_c+C(A,contr.orth,how.many=max_a-
2) +C(P,contr.orth,how.many=max-p-2)+C(C,contr.orth,how.many=max_c-2), 
family=poisson,weights=Y) 
rep1<-report.coef(pc~PC,round=2,exp=FALSE) 
#get "true" slopes from relationship between biased ones 
#extract biased period and cohort slopes from the model 
biased_slope-p<-(report.coef(pc_APC,subset="sumzero-p",exp=FALSE)) [1] 
biased_slope_c<-(report.coef(pc_APC,subset="sumzero_c",exp=FALSE)) [1] 
#assume "true" period slope is equal to .. zero 
#so v now determined .. 
# .. and can be used to obtain "true" cohort slope 
true_slope_c <- biased_slope_c - v 
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# still need to obtain "true" age slope, same procedure but with age and cohort slopes 
estimated in APe model 
ap_APC<-glm(D/Y-sumzero_a+sumzero-p+C (A, contr. orth, how. many=max a-
2)+C(p,contr.orth,how.many=max-p- 2 )+C(C,contr.orth,how.many=max-C-2), 
family=poisson,weights=Y) -
rep2<-report.coef(ap_APC,round=2,exp=FALSE) 
biased_slope_a<-(report.coef(ap_APC,subset="sumzero_a",exp=FALSE)) [1] 
true_slope_a <- biased_slope_a - v 
#Overall curvature obtained by applying, for each effect, the design matrix, orthogonal to 
Holford drift, to the regression parameters 
ACURv<-contr.orth(max_a)%*%as.matrix(report.coef(pc_APC,Subset="A,",exp=FALSE) [,I]) 
PCURV<-contr.orth(max-p) %*%as.matrix (report.coef (pc_APC, sub set="P,",exp=FALSE) [,I]) 
CCURv<-contr.orth(max_c)%*%as.matrix(report.coef(pc_APC,subset="C,",exp=FALSE) [,I]) 
#individual categories of each effect found by adding together corresponding linear and 
curvature components 
effect_a=true_slope_a*sort(unique(sumzero_a))+ACURV 
effect-p=true_slope-p*sort(unique(sumzero-p))+PCURV 
effect_c=true_slope_c*sort(unique(sumzero_c))+CCURV 
#table of 3 x 2 graphs, top is observed, bottom is effects based on assumed slope of one 
effect 
bl.rate <- tapply( D, list(age,period), sum) / tapply( Y, list(age,period), sum 
part mfrow=c(2,3) ) 
rateplot( bl.rate*10 A6, at=10A(-1:3), labels=c(0.l,l,10,100,1000),which="AP" 
rateplot( bl.rate*10 A6, at=10 A(-1:3), labels=c(0.l,l,10,100,1000),which="PA" 
rateplot( bl.rate*10 A6, at=10 A(-1:3), labels=c(0.l,l,10,100,1000),which="CA" 
xa<-sort(unique(age)) 
plot (xa, effect_a, "1", ylab="Age effect", xlab="Age") 
xp<-sort(unique(period)) 
plot (xp,effect-p, "l",ylab="Period effect", xlab="Period",ylim range(effect_c), 
title ("assuming period slope = 0")) 
xc<-sort(unique(cohort)) 
plot (xc,effect_c, "l",ylab="Cohort effect", xlab="Cohort", ylim range(effect_c)) 
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Graphical output from R on running above program. Bladder cancer incidence data in men 
in Italy 1955-79 (source: Clayton and Schiffflers, 1987). Top: observed rates vs. age by 
period (left), vs. period by age (middle) vs. cohort by age (right). Bottom: on assuming a 
period slope of zero, APC model effects for age (left), period (middle), cohort (right) NB 
contr.orth was written in R by Dr Bj0rn M011er [205] after Holford [66]. 
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